WO2002026727A2 - Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai - Google Patents

Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai Download PDF

Info

Publication number
WO2002026727A2
WO2002026727A2 PCT/US2001/025465 US0125465W WO0226727A2 WO 2002026727 A2 WO2002026727 A2 WO 2002026727A2 US 0125465 W US0125465 W US 0125465W WO 0226727 A2 WO0226727 A2 WO 0226727A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
carbons
compound
pharmaceutically acceptable
acceptable base
Prior art date
Application number
PCT/US2001/025465
Other languages
French (fr)
Other versions
WO2002026727A3 (en
Inventor
Jayasree Vasudevan
Alan T. Johnson
Liming Wang
Dehua Huang
Roshantha A. Chandraratna
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Priority to AU2001286478A priority Critical patent/AU2001286478B2/en
Priority to JP2002531111A priority patent/JP2004509955A/en
Priority to EP01965927A priority patent/EP1322631A2/en
Priority to AU8647801A priority patent/AU8647801A/en
Priority to CA002423919A priority patent/CA2423919A1/en
Publication of WO2002026727A2 publication Critical patent/WO2002026727A2/en
Publication of WO2002026727A3 publication Critical patent/WO2002026727A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention is directed to providing, preparing and using compounds which inhibit the enzyme cytochrome P450RAI. More particularly, the present invention is directed to selecting and preparing compounds which inhibit the enzyme cytochrome P450RAI, many of which are derivatives of phenylacetic or heteroarylacetic acid, and using said compounds for treatment of diseases and conditions which are normally treated by retinoids .
  • retinoid-like activity Compounds which have retinoid-like activity are well known in the art, and are described in numerous United States and other patents and in scientific publications. It is generally known and accepted in the art that retinoid-like activity is useful for treating animals ofthe mammalian species, including humans, for curing or alleviating the symptoms and conditions of numerous diseases and conditions.
  • compositions having a retinoid-like compound or compounds as the active ingredient are useful as regulators of cell proliferation and differentiation, and particularly as agents for treating skin-related diseases, including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hype ⁇ roliferative disorders ofthe skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin.
  • skin-related diseases including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hype ⁇ roliferative disorders ofthe skin, ec
  • Retinoid compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers ofthe breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas ofthe mucous membranes and in the treatment of Kaposi's sarcoma.
  • premalignant and malignant hyperproliferative diseases such as cancers ofthe breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas ofthe mucous membranes and in the treatment of
  • retinoid compounds can be used as agents to treat diseases ofthe eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other comeopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA).
  • PVR proliferative vitreoretinopathy
  • TPA tissue plasminogen activator
  • retinoid compounds include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as Minoxidil R , diseases associated with the immune system, including use ofthe present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rej ection and facilitation of wound healing, including modulation of chelosis.
  • HPV human papilloma virus
  • various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's
  • Retinoid compounds have relatively recently been also discovered to be useful for treating type II non-insulin dependent diabetes mellitus (NIDDM).
  • NIDDM non-insulin dependent diabetes mellitus
  • Several compounds having retinoid-like activity are actually marketed under appropriate regulatory approvals in the United States of America and elsewhere as medicaments for the treatment of several diseases responsive to treatment with retinoids.
  • Retinoic acid (RA) itself is a natural product, biosynthesized and present in a multitude of human and mammalian tissues and is known to play an important rule in the regulation of gene expression, tissue differentiation and other important biological processes in mammals including humans.
  • a catabolic pathway in mammals, including humans, of natural retinoic acid includes a step of hydroxylation of RA catalyzed by the enzyme Cytochrome P450RAI (retinoic acid inducible).
  • Cytochrome P450RAI retinoic acid inducible
  • novel compounds of Formulas 1 through 8 are used as inhibitors of the enzyme cytochrome P450RAI to treat diseases and conditions which are normally responsible to treatment by retinoids, or which are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid. These novel compounds are shown by Formulas 1
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • X is O, S or NR where is H, alkyl of 1 to 6 carbons or benzyl;
  • Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I;
  • Z is -C ⁇ C-, where
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, ftiryl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • X is O, S or NR where R is H, alkyl of 1 to 6 carbons or benzyl; Z is -C ⁇ C-, where n' is an integer having the value 1 - 5,
  • Rj is independently H or alkyl of 1 to 6 carbons;
  • p is an integer having the values of 0 to 4;
  • R 2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;
  • R 3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl;
  • m is an integer having the values 0 to 4;
  • R 5 is H, alkyl of 1 to 6 carbons, fluorosubstituted alkyl of 1 to 6 carbons, benzyl, or lower alkyl or halogen substituted benzyl;
  • n is an integer having the values of 0 to 4, and
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, f ⁇ ryl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 1 to 6 carbons, Cl, Br, or I;
  • Z is -C ⁇ C-, -(CR ⁇ CR !
  • R j is independently H or alkyl of 1 to 6 carbons;
  • p is an integer having the values of 0 to 5;
  • R 2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;
  • R 3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl;
  • m is
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • X j is 1 -imidazolyl, or lower alkyl or halogen substituted 1 -imidazolyl, OR, SR, NRRg where R is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzy
  • Z is -C ⁇ C-, where n' is an integer having the value 1 - 5,
  • Rx is independently H or alkyl of 1 to 6 carbons
  • R 2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons
  • R 3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl
  • m is an integer having the values 0 to 2
  • 4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen
  • o is an integer having the values of 0 to 4
  • R 6 is H, lower alkyl, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloal
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • X is O, S or NR where R is H, alkyl of 1 to 6 carbons, C g-trialkylsilyl or benzyl;
  • Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I;
  • Ri is independently H or alkyl of 1 to 6 carbons;
  • R 2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;
  • R 3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl;
  • m is an integer having the values 0 to 3 ;
  • R 7 is H
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • X 2 is 1 -imidazolyl, lower alkyl or halogen substituted 1 -imidazolyl, OR 7 , SR 7 or NRR 7 where R is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substitute
  • R j is independently H or alkyl of 1 to 6 carbons;
  • R 2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;
  • R 3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl;
  • m is an integer having the values 0 to 3;
  • R 7 is H
  • n is an integer having the values of 0 to 4
  • R 8 is H, alkyl of 1 to 6 carbons, -CH 2 0(Ci. 6 -alkyl), or a cation of a pharmaceutically acceptable base.
  • the novel compounds used in the method of treatment ofthe present invention are also shown in Formula 7
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, F, Cl, Br, or I;
  • Z is -C ⁇ C-, where n' is an integer having the value 1 - 5, -CO-NR r , NR r CO-,
  • A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R 2 groups;
  • X 3 is S, or O, C(R j ) 2 , or CO;
  • Yj is H, lower alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons, benzyl, lower alkyl substituted cycloalkyl of 3 to 6 carbons;
  • Z is -C ⁇ C-, where n' is an integer having the value 1 - 5
  • R ! is independently H or alkyl of 1 to 6 carbons
  • R 2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF 3 , fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons
  • R 3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, CF 3 , fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl
  • m is an integer having the values 0 to 2
  • Y j is cycloalkyl, when Y 1 is not cycloalkyl then X 3 is O or S and n is 1 , when Y 1 is not cycloalkyl then X 3 is CO, and n is 1, when Y l is not cycloalkyl then X 3 is CO and the moiety A is substituted with at least one F group.
  • novel compounds of Formula 1 through Formula 8 as well as the previously known compounds disclosed below in the specification are used for the prevention or treatment of diseases and conditions in mammals, including humans, those diseases or conditions that are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid. Because the compounds act as inhibitors of the breakdown of retinoic acid, the invention also relates to the use ofthe compounds of Formula 1 through Formula 8 in conjunction with retinoic acid or other retinoids.
  • retionoids are useful for the treatment of skin-related diseases, including, without limitation, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders ofthe skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin.
  • the retinoids are also useful for the prevention and treatment of metabolic diseases such as type II non- insulin dependent diabetes mellitus (NIDDM) and for prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers ofthe breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas ofthe mucous membranes and in the treatment of Kaposi's sarcoma.
  • metabolic diseases such as type II non- insulin dependent diabetes mellitus (NIDDM)
  • cancerous and precancerous conditions including, premalignant and malignant hyperproliferative diseases such as cancers ofthe breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, laryn
  • Retinoids can also be used as agents to treat diseases ofthe eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other comeopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA).
  • PVR proliferative vitreoretinopathy
  • TPA tissue plasminogen activator
  • retinoids include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as Minoxidil R , diseases associated with the immune system, including use ofthe present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rej ection and facilitation of wound healing, including modulation of chelosis.
  • HPV human papilloma virus
  • various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease
  • This invention also relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising one or more compounds of Formula 1 through Formula 8 or one or more of the previously known compounds disclosed below in the specification, in admixture with a pharmaceutically acceptable excipient, said formulation being adapted for administration to a mammal , including a human being, to treat or alleviate the conditions which were described above as treatable by retinoids, or which are controlled by or responsive to the organism's native retinoic acid.
  • These formulations can also be co-administered with retinoids to enhance or prolong the effects of medications containing retinoids or ofthe organism's native retinoic acid.
  • the present invention also relates to a method of providing a compound which is an inhibitor ofthe enzyme cytochrome P450RAI, wherein the method of providing the cytochrome P450RAI inhibitory compound comprises: identifying a compound that has activity as a retinoid in any ofthe art recognized assays which demonstrate retinoid-like activity, the retinoid compound having a formula such that it includes a benzoic acid, benzoic acid ester, naphthoic acid, naphthoic acid ester or heteroaryl carboxylic acid or ester moiety, with a partial structure of -A(R 2 )-(CH 2 ) n -COOR 8 where the symbols are defined as in Formulas 1 through 8, and where n is 0, and selecting a compound that is a homolog of the previously identified retinoid compound where in the formula of the homolog n is 1 or 2, preferably 1.
  • Said homolog if it is not a previously known compound can be prepared by homologation procedures well known to the synthetic organic chemist, such as for example the well known Arndt-Eistert synthesis.
  • said homologs can be prepared by any of the applicable synthetic processes illustrated below for the preparation of the novel compounds of Formulas 1 through 8 wherein the symbol n represents the integral 1 (one).
  • BRIEF DESCRIPTION OF THE DRAWING FIGURE Figure 1 is a schematic representation ofthe P450RAI cell based assay utilized to evaluate the ability ofthe compounds ofthe invention to inhibit the Cytochrome P450RAI enzyme.
  • Figure 1 shows a schematic diagram ofthe P450RAI-1 cell based assay.
  • P45 ORAL 1 stably transfected HeLa cells are maintained in 100 millimolar tissue culture dishes in Modified Eagle's Medium (MEM) containing 10 % Fetal Bovine Serum (FBS) and 100 ⁇ g/ml hygromycin. Exponentially growing cells are harvested by incubating in trypsin.
  • MEM Modified Eagle's Medium
  • FBS Fetal Bovine Serum
  • IC 50 values obtained in this assay for several previously known compounds the cythochrome P450RAI inhibitory activity of which has been discovered in accordance with the present invention are disclosed in Table 1A below.
  • Assays of Retinoid-like or Retinoid Antagonist and Inverse Agonist-like Biological Activity Assays described below measure the ability of a compound to bind to, and/or activate various retinoid receptor subtypes. When in these assays a compound binds to a given receptor subtype and activates the transcription of a reporter gene through that subtype, then the compound is considered an agonist of that receptor subtype.
  • a compound is considered an antagonist of a given receptor subtype if in the below described co-tranfection assays the compound does not cause significant transcriptional activation of the receptor regulated reporter gene, but nevertheless binds to the receptor with a K d value of less than approximately 1 micromolar.
  • the ability ofthe compounds to bind to RAR ⁇ , RAR ⁇ , RAR ⁇ , RXR ⁇ , RXR ⁇ and RXR y receptors, and the ability or inability ofthe compounds to activate transcription of a reporter gene through these receptor subtypes can be tested.
  • Table # refers to Table 2 through 9 provided below where the compound is identified with reference to a corresponding specific formula of Formulas 9 through 16.
  • Table 1A below provides data similar to those provided in Table 1, for certain previously known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI. These compounds are shown by Formula A through O and have compounds numbers 201 through 247. TABLE 1A
  • TOPICAL SKT-N IRRITATION TESTS As is known the topical retinoid all-trans-retinoic acid (ATRA) and oral retinoids such as 13-cis RA and etretinate are known to induce substantial skin irritation in humans. This irritation is a direct result of activation of the RAR nuclear receptors. Analysis of retinoid topical irritation is also a highly reproducible method of determining in vivo retinoid potency.
  • the SKH1- hrBR or hairless mouse provides a convenient animal model of topical irritation, since retinoid-induced skin flaking and abrasion can be readily scored by eye (Standeven et al, "Specific antagonist of retinoid toxicity in mice.” Toxicol. Appl.
  • mice Female hairless mice (Crl:SKHl-ArBR), 5-7 weeks old, were obtained from Charles River Breeding Labs (Wilmington, MA). Animals were about 6 weeks old at the start ofthe experiments. Food (Purina Rodent Chow 5001) and reverse osmosis water were provided ad libitum. Mice were housed individually throughout the dosing period. In some experiments, mice that fit within a defined weight range, e.g. , 21 -25g, were selected from the available stock and then randomly assigned to the various treatment groups, using body weight as the randomization variable. The compounds to be tested were dissolved in acetone for application o the backs of the mice.
  • mice were treated topically on the back in a volume of 4.0 ml/kg (0.07- 0.12ml) adjusted daily so as to deliver a fixed dose of test compound per g body weight. Doses are disclosed as nmol/25g. Unless indicated otherwise, mice were treated with retinoids once daily on days 1 through 5 and observed on days 2, 3, 4, 5, 6, 7 and 8. The mice were weighed daily and the dorsal skin was graded daily using separate semi-quantitative scales to determine flaking and abrasion. These flaking and abrasion scores were combined with weight change (if any) to create a cutaneous toxicity score (Blackjack score). Cutaneous Toxicity Score A visual grading scale was used for characterizing topical irritation on a daily basis. The grading scale used is as follows:
  • Topical Toxicity Score The flaking and abrasion observations were combined with body weight observations to calculate a single, semiquantitative topical or cutaneous "toxicity score" as detailed below.
  • the toxicity score also known as “blackjack score” since the theoretical maximum is 21) takes into account the maximal severity, and the time of onset of skin flaking and abrasions and the extent of weight between the first and last days ofthe experiment. Below are listed the seven numerical components ofthe toxicity score and an explanation of how those values are combined to calculate the toxicity score. 1. Flaking-Maximal Severity: Highest flaking score attained during observation period. 2.
  • Flaking-Day of Onset of grade 2 or worse 0 - > 8 days 1 - day 8 2 - day 6 or 7 3 - day 4 or 5 4 - day 2 or 3 3.
  • Flaking- Average Severity Flaking severity scores are summed and divided by the number of observation days. 4.
  • Abrasion-Maximal Severity Highest abrasion score attained during observation period. 5.
  • Abrasion- Average Severity Abrasion severity scores are summed and divided by the number of observation days . 7.
  • Flaking onset score (2) and average severity score (3) are summed and divided by two. The quotient is added to the maximal severity score (1).
  • Composite flaking scores are calculated for each individual animal in a group, averaged, and rounded to the nearest integer. Values can range from 0-9.
  • Calculation of Composite Abrasion Score Abrasion onset score (5) and average severity score (6) are summed and divided by two. The quotient is added to the maximal severity score (4).
  • Composite abrasion scores are calculated for each individual animal in a group, averaged and rounded to the nearest integer. Values can range from 0- 8.
  • Toxicity Score Composite flaking score, composite abrasion score, and systemic toxicity score are summed to give the "toxicity score.” Toxicity scores are calculated for each individual animal in a group, averaged, and rounded to the nearest integer. Values can range from 0-21 and are expressed in Table IB below as the mean ⁇ SD ofthe values for a group. Calculation of Percentage Change in Body Weight The body weight at the time ofthe last weighing (day 8, 11, or 12) was subtracted from the initial body weight. The difference was divided by the initial body weight, multiplied by 100%>, and rounded to the nearest integer. Values were calculated for each individual animal and the mean and standard deviation for each group are shown. TABLE IB
  • the compounds used in the methods of treatment of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and numerous other considerations.
  • it will generally be preferred to administer the drug topically though in certain cases such as treatment of severe cystic acne or psoriasis, oral administration may also be used.
  • Any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be used. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania.
  • the compounds could also be administered as a powder or spray, particularly in aerosol form.
  • the drug may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral administration.
  • the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as extended release formulation for deposit under the skin or intramuscular injection.
  • medicaments can be added to such topical formulation for such secondary pu ⁇ oses as treating skin dryness; providing protection against light; other medications for treating dermatoses; medicaments for preventing infection, reducing irritation, inflammation and the like.
  • Treatment of dermatoses or any other indications known or discovered to be susceptible to treatment by retinoic acid-like compounds, or to control by naturally occurring retinoic acid will be effected by administration ofthe therapeutically effective dose of one or more compounds used in accordance with the instant invention.
  • a therapeutic concentration will be that concentration which effects reduction ofthe particular condition, or retards its expansion.
  • the compound potentially may be used in prophylactic manner to prevent onset of a particular condition.
  • a useful therapeutic or prophylactic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, no single concentration will be uniformly useful, but will require modification depending on the particularities of the disease being treated. Such concentrations can be arrived at through routine experimentation. However, it is anticipated that in the treatment of, for example, acne, or similar dermatoses, that a formulation containing between 0.01 and 1.0 milligrams per milliliter of formulation will constitute a therapeutically effective concentration for total application. If administered systemically, an amount between 0.01 and 5 mg per kg of body weight per day would be expected to effect a therapeutic result in the treatment of many diseases for which these compounds are useful.
  • alkyl refers to and covers any and all groups which are known as normal alkyl and branched-chain alkyl. Unless specified otherwise, lower alkyl means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and 3 to 6 carbons for lower branch chained alkyl groups.
  • a pharmaceutically acceptable salt may be prepared for any compound used in accordance with the invention having a functionality capable of forming a salt, for example an acid functionality.
  • a pharmaceutically acceptable salt is any salt which retains the activity ofthe parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered.
  • Pharmaceutically acceptable salts may be derived from organic or inorganic bases. The salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, sodium, potassium, calcium, and magnesium.
  • Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules.
  • salts are those formed with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid. Any of a number of simple organic acids such as mono-, di- or tri- acid may also be used. Some compounds used in accordance with the present invention may have trans and cis (E and Z) isomers.
  • a bond drawn with a wavy line indicates that the carbon to which the bond is attached can be in any ofthe applicable possible configurations.
  • General Synthetic Methodology The novel compounds used in accordance with the invention are encompassed by the general Formulas 1 through 8 provided above.
  • the previously known compounds the cytochrome P450RAI activity of which has been discovered in accordance with the present invention are identified below, and references are provided which enable their preparation by one of ordinary skill in the art of synthetic organic chemistry.
  • a linker or tethering group designated Z covalently connects an aromatic or heteroaromatic moiety designated A(R 2 )-(CH 2 ) n -COOR 8 and another cyclic moiety which in accordance with these formulas is a substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety.
  • the group X 4 represents a reactive group, which is suitable for coupling the X 4 .A(R 2 )-(CH 2 ) n -COOR 8 compound to a derivative ofthe substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety so that as a result ofthe coupling the linker or tether moiety Z is formed.
  • the group X 4 is a leaving group such as halogen, or trifluoromethanesulfonyloxy, or a group capable of participating in a Wittig or Homer Emmons reaction.
  • the group X 4 is an ethynyl group capable of undergoing a coupling reaction with a leaving group (such as a halogen or a trifluoromethanesulfonyloxy group) attached to the substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety.
  • a leaving group such as a halogen or a trifluoromethanesulfonyloxy group
  • the group X 4 can also represent an OH or an NH 2 group that forms an ester (COO) or amide (CONH) linker, respectively, when reacted with an activated carboxyl derivative ofthe substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety.
  • Examples for the compounds of formula X 4 A(R 2 )-(CH 2 ) n -COOR 8 are provided in the specific examples below.
  • X 4 group is halogen
  • ethyl 4-iodobenzoate ethyl 6-iodonicotinate, ethyl 5-iodoruran-3 -carboxylate, ethyl 5-iodothio ⁇ hen-3-earboxylate, ethyl 5-iodofuran-2-carboxylate, ethyl 5- iodothiophen-2-carboxylate, and analogous halogenated derivatives ofthe respective pyridazine, pyrazine and other heteroaryl carboxylic acid esters.
  • analogous aryl and and heteroaryl hydroxyl compounds and amines wherein the halogen ofthe above-listed compounds is replaced by OH or NH 2 respectively, also serve as additional examples for the reagents ofthe formula X 4 -A(R 2 )-(CH 2 ) ⁇ -COOR 8 .
  • X 4 is OH or NH 2 , respectively.
  • a derivative ofthe substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety is synthesized first, having a covalently attached X 5 group.
  • the X s group reacts with the X 4 group of the reagent X 4 -A(R 2 )-(CH 2 ) n -COOR 8 to form the linker designated Z in Formulas 1 through 8.
  • the X 5 group is one that is capable of participating in a catalyzed coupling reaction, (such as an ethynyl group when X 4 is a leaving group), or a leaving group (such as halogen or trifluoromethanesulfonyloxy when X 4 is an ethynyl group) , or an activated carboxylic acid function (when X 4 is OH or NH 2 ).
  • the X 5 group can also be an OH, SH or NH 2 group when the X 4 group is an activated carboxylic acid function.
  • substituted phenyl substituted tetrahydronaphthalene
  • substituted chroman substituted thiochroman
  • tetrahydroquinoline substituted thiochroman
  • tetrahydroquinoline substituted thiochroman
  • tetrahydroisoquinoline intermediates having an X 5 functionality are provided below, and are also available in the chemical scientific and patent literature.
  • the substituted phenyl, tetrahydronaphthalene, chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety ofthe novel compounds used in accordance with the invention are derivatized in a manner to include the specific substituents (such as for example the cycloalkyl substituents) encompassed within the scope ofthe invention, either before or after the - A(R 2 )-(CH 2 ) n -COOR 8 moiety has been attached and the linker Z has formed, as illustrated by the below described specific examples.
  • the -(CH 2 ) n -COOR 8 moiety ofthe compounds of Formulas 1 through 8 can be modified in order to obtain still further novel compounds.
  • One such modification is saponification of compounds where the R 8 group is an alkyl or -CH 2 0(C 1 . 6 -alkyl) group.
  • Another modification is esterification of the carboxylic acid function when the R 8 group is H or a cation.
  • Such saponification and esterification reactions are well known in the art and within the skill ofthe practicing organic chemist.
  • Still another modification ofthe compounds used in accordance with the invention (or of the intermediates X 4 - A(R 2 )-(CH 2 ) n -COOR 8 , or of precursors to these intermediates) is the homologation ofthe (CH 2 ) n group.
  • the synthetic procedure of homologation that may be utilized for providing a compound having the partial structure of -A(R 2 )-(CH 2 ) n -COOR 8 where n is 1, or 2 (one or two), preferably 1 (one), can be one of the several known procedures of homologation of carboxylic acids or esters, such as the Arndt-Eistert procedure that is described inter alia in March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, pages 809-810, McGraw-Hill Publishers, 1968, inco ⁇ orated herein by reference.
  • the homologs ofthe partial structure of -A(R 2 )-(CH 2 ) complicat-COOR 8 are synthesized in accordance with the synthetic schemes disclosed herein in connection with the preparation of the novel compounds .
  • SPECIFIC EMBODIMENTS With reference to the symbol A in Formulas 1 through 8, the preferred novel compounds used in accordance with the present invention are those where A is phenyl, naphthyl, pyridyl, thienyl or furyl. Even more preferred are compounds where A is phenyl. As far as substitutions on the A (phenyl) and A (pyridyl) groups are concerned, compounds are preferred where the phenyl group is 1,4 (para) substituted and where the pyridine ring is 2,5 substituted.
  • R 8 group H lower alkyl of 1 to 3 carbons, and -CH 2 0(C 1 . 6 -alkyl) groups are preferred, as well as the pharmaceutically acceptable salts ofthe free acids when R 8 is H.
  • the lower alkyl and -CH 2 0(C 1 . 6 -alkyl) groups ethyl and OCH 2 CH 3 , respectively, are presently most preferred.
  • the linker Z is attached to the 6 position in Formula 1, to the 4 position in Formula 2, to the 6 position in Formula 3, to the 6 position in Formula 4, to the 4 position in Formula 5, to the 4 position in Formula 6, to the 6 position in Formula 7, and to the 6 position in Formula 8.
  • the Rj group substituting the non-aromatic rings in Formulas 1, 3, 4, 7 and 8 is preferably alkyl, more preferably alkyl of 1 to 3 carbons, and most preferably methyl.
  • the R x group substituting the cyclopropane ring in Formulas 1, 2, 3 and 7 is preferably non-existent (p is 0), or is alkyl of 1 to 3 carbons, even more preferably methyl.
  • the X group in Formulas 1 and 5 is preferably O, and in Formula 2 X is preferably O or NR.
  • the Xj group in Formula 4 is preferably 1 -imidazolyl, substituted 1- imidazolyl, or NRR 6 , where R 6 is preferably cyclopropyl or branched-chain alkyl.
  • the X 2 group in Formula 6 is preferably 1 -imidazolyl or substituted 1 -imidazolyl.
  • the Y group is preferably H, lower alkyl of 1 to 3 carbons, cycloalkyl, lower alkyl substituted cycloalkyl, or halogen. Among these, H, Cl, and cyclopropyl are most preferred.
  • the Y j group of Formula 8 is preferably H, lower alkyl of 1 to 3 carbons, cycloalkyl, or lower alkyl substituted cycloalkyl. Among these H, ethyl and cyclopropyl are presently most preferred.
  • the most preferred novel compounds used in accordance with the invention are disclosed in Tables 2 through 9 with reference to Formulas 9 through 16.
  • the preferred compounds shown in Table 3 with reference to the more specific Formula 10 are within the scope of Formula 2; the preferred compounds shown in Table 4 with reference to the more specific Formula 11 are within the scope of Formula 3; the preferred compounds shown in Table 5 with reference to the more specific Formula 12 are within the scope of Formula 4; the preferred compounds shown in Table 6 with reference to the more specific Formula 13 are within the scope of Formula 5; the preferred compounds shown in Table 7 with reference to the more specific Formula 14 are within the scope of Formula 6; the preferred compounds shown in Table 8 with reference to the more specific Formula 15 are within the scope of Formula 7, and the preferred compounds shown in Table 9 with reference to the more specific Formula 16 are within the scope of Formula 8.
  • the compounds used in accordance with the invention can be synthesized by applying the general synthetic methodology described above, and by such modifications of the hereinafter described specific synthetic routes which will become readily apparent to the practicing synthetic organic chemist in light of this disclosure and in view of general knowledge available in the art.
  • the hereinafter disclosed specific reaction schemes are directed to the synthesis of exemplary and preferred compounds used in accordance with the invention. Whereas each ofthe specific and exemplary synthetic routes shown in these schemes may describe specific compounds only within the scope of one or two ofthe general Formulas 1 through 8, the synthetic processes and methods used therein are adaptable within the skill ofthe practicing organic chemist and can be used with such adaptation for the synthesis of compounds used in accordance with the invention which are not specifically described herein as examples.
  • Reaction Scheme 1 discloses a presently preferred synthetic route to certain intermediates or reagents having the general formula X 4 -A(R 2 )-CH 2 ) n - COOR 8 , where the symbol A represents a di-, or tri-substituted phenyl moiety. These intermediates are utilized in the synthesis ofthe novel compounds used in accordance with the invention.
  • Reaction Scheme 3 discloses presently preferred synthetic routes to obtain exemplary and preferred novel tetrahydronaphthalene compounds within the scope of Formula 4 where X j represents a dialkyl substituted nitrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 4 discloses presently preferred synthetic routes to obtain exemplary and preferred novel isoquinoline compounds within the scope of Formula 3 where the symbol Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 5 discloses presently preferred synthetic routes to obtain exemplary and preferred novel chroman compounds within the scope of Formula 8 where the symbol Yj represents hydrogen, Z is an ethynyl moiety or an ester (COO) fimction, and A is a substituted phenyl moiety.
  • TPAP tetrarn-propyl ammonium peruthenate
  • Reaction Scheme 6 discloses presently preferred synthetic routes to obtain other exemplary and preferred novel chroman compounds within the scope ofFormula 8 where the symbol Y x represents a cyclopropyl group, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 7 discloses presently preferred synthetic routes to obtain exemplary and preferred novel chroman compounds within the scope of Formula 1 where the symbol X represents oxygen (O), Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 8 discloses presently preferred synthetic routes to obtain other exemplary and preferred novel chroman compounds within the scope ofFormula 1 where the symbol X represents oxygen (O), Y represents a cyclopropyl group, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 9 discloses presently preferred synthetic routes to obtain exemplary and preferred novel tetrahydroquinoline compounds within the scope ofFormula 1 where the symbol X represents an alkyl substituted nitrogen (alkyl-N), Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Schemes 10 and 11 disclose presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 2 where the symbol X represents oxygen (O), Rg is alkyl or benzyl, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 12 discloses presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 2 where the symbol Rs-X represents an alkyl, dialkyl, benzyl or dibenzyl substituted nitrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Schemes 13 and 14 disclose presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope ofFormula 6 where the symbol X 2 represents a (1 -imidazolyl) moiety, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • R i-propyl intermediate 97
  • R i-propyl intermediate 104
  • R t-butyl intermediate 106
  • R t-butyl
  • TBS t-butyldimethylsilyl
  • Reaction Scheme 16 discloses presently preferred synthetic routes to obtain exemplary and preferred novel tetrahydronaphthalene compounds within the scope ofFormula 4 where the symbol X x represents a (1- imidazolyl) moiety, Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 17 discloses presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 6 where the symbol X 2 represents a 1-methyl-cyclopropoxy moiety, Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • Reaction Scheme 18 discloses presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 5 where the symbol X represents oxygen (O), Y represents a tertiar -buty ] group, Z is an ethynyl moiety and A is a substituted phenyl moiety.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
  • Compound 201 is described as compound 4 in United States Patent No. 4,980,369 inco ⁇ orated herein by reference.
  • Compounds 202, 210, and 215 are described in United States Patent No. 4,810,804 inco ⁇ orated herein by reference.
  • Compound 215 is example 12 of Patent No. ,4810,804.
  • Compound 238 is described in United States Patent No. 5,089,509 inco ⁇ orated herein by reference (see Claim 5 of Patent No. 5,089,509).
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base.
  • R 8 is H or a cation of a pharmaceutically acceptable base.
  • Compound 240 is described and can be made in accordance with the teachings of United States Patent Nos. 5,089,509, ,5,602,130 or 5,348,972 all of which are inco ⁇ orated herein by reference.
  • Still other known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula C where R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
  • R 10 CH 3j
  • R ⁇ CF 3
  • R 12 F
  • X 6 CH.
  • Compound 206 R 8 is H or a cation of a pharmaceutically acceptable base
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 10 CH 3j
  • n CH 3j
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 10 CH 3>
  • R ⁇ Cl
  • R 12 F
  • X 6 N.
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 10 CH 3
  • R ⁇ H
  • R 10 CH 3
  • R 10 CH 3
  • R n CF 3 CF 2
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 10 CH 3
  • R n CF 3 CF 2
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 10 CH 3)
  • R ⁇ CH 3 CH 2
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 10 F and X 6 CH
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 10 CH 3j
  • X 6 CH.
  • Compounds 203 - 206, 220, 221, 224 - 228 and 247 - 254 are described and can be made in accordance with the teachings of United States Patent No. 5,675,024 which is inco ⁇ orated herein by reference.
  • Compound 205 is compound or example 14
  • Compound 225 is compound or example 10
  • Compound 228 is compound or example 32 in Patent No. 5,675,024.
  • Compound 220 is also described in United States Patent No. 5,965,606, inco ⁇ orated herein by reference.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 H
  • R 14 CH 3 .
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 H
  • R 12 F
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 H
  • Compound 207 is described (as compound 7) in United States Patent No. 5,489,584 inco ⁇ orated herein by reference.
  • Compound 232 is described (as compound 42) in United States Patent No.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C ⁇ 6 -alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 H
  • R 15 tertiary-butyl
  • R 16 OH
  • R 17 Cl
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 H
  • R 15 tertiary-butyl
  • R 16 OCH 3
  • R 17 tertiary-butyl
  • R 12 H
  • R 15 1-adamantyl
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 H
  • R 15 tertiary-butyl
  • R 16 OH
  • R 17 tertiary-butyl
  • R 12 F
  • R 15 tertiary-butyl
  • R 16 OH
  • R 17 H.
  • Compound 211 is described and can be made in accordance with the teachings of United States Patent No. 5,202,471
  • Compound 235 is described and can be made in accordance with the teachings of United States Patent No. 5,498,795. The specification of Patent Nos.
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 F
  • R 15 tertz ⁇ ry-butyl
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 12 F
  • R 15 tertiary-butyl
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 ⁇ (C ⁇ 6 -alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • Compounds 217 is described (as example or compound 4) and can be made in accordance with the teachings of United States Patent Nos. 4,739,098 the specification of which is inco ⁇ orated herein by reference.
  • Compounds 219 is described (as compound 2) and can be made in accordance with the teachings of United States Patent Nos. 5,688,957, the specification of which is inco ⁇ orated herein by reference.
  • Compound 212 and Compound 229 can be made in accordance with the teachings of United States Patent Nos. 4,739,098 and in case of Compound 212 also in accordance with United States Patent No. 5,426,118, with such modifications ofthe synthetic procedures which will be readily apparent to those skilled in the art.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 - 6 -alkyl), or a cation of a pharmaceutically acceptable base.
  • R 8 is H or a cation of a pharmaceutically acceptable base.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base.
  • R 8 is H or a cation of a pharmaceutically acceptable base.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C ⁇ 6 -alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
  • R 8 is H or a cation of a pharmaceutically acceptable base
  • Compounds 237 and 246 are described and can be made in accordance with the teachings of United States Patent Nos. 5,675,024 and 5,856,490.
  • Compound 237 is compound or example 2 of Patent No. 5,675,024.
  • the specification of United States Patent No. 5,856,490 is inco ⁇ orated herein by reference.
  • Additional known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula K where R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C
  • R 8 is H or a cation of a pharmaceutically acceptable base.
  • Compound 231 is described (as compound 2) in United States Patent No , 5,006,550, the specification of which is inco ⁇ orated herein by reference.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base.
  • R 8 is H or a cation of a pharmaceutically acceptable base.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C I . 6 -alkyl), or a cation of a pharmaceutically acceptable base.
  • R 8 is H or a cation of a pharmaceutically acceptable base.
  • R 8 generally represents H, alkyl of 1 to 6 carbons, -CH 2 0(C 1 . 6 -alkyl), or a cation of a pharmaceutically acceptable base.
  • R 8 is H or a cation of a pharmaceutically acceptable base.
  • Compound 247 is described in the publication by Winum et al. II Farmaco, 1997, Vol. 52, 1, ⁇ 39-42, inco ⁇ orated herein by reference.
  • the P450RAI inhibition data of this compound are provided in Table 1A, and the cutaneous toxicity score (blackjack score) ofthe compound in the topical skin irritation tests provided above, are disclosed in Table IB.
  • Methyl-2-fluoro-4-iodo benzoate (Reagent G) A solution of 2-fluoro-4-iodo toluene (5g, 26.6mmol) in pyridine (2mL) and water (20mL) was treated with potassium permanganate (16.6g, 105mmol) and heated at 150°C overnight. The reaction mixture was then cooled to room temperature and filtered and the filtrate was extracted with hexane. The aqueous phase was acidified with 10% hydrochloric acid and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo.
  • Ethyl-2-fluoro-4-trifluoromethylsulfonyloxy-benzoate (Intermediate 6)
  • a stirred, cooled (ice bath) solution of ethyl-2-fluoro-4-hydroxy- benzoate (Intermediate 5, 0.368g, 2mmol) and 2,6-di-tert-butyl-4-methyl- pyridine (0.81 g, 8mmol) in 8mL of dichloromethane was treated with trifluoromethanesulfonic anhydride (O.lg, 4mmol). The reaction mixture was allowed to warm to ambient temperature and stirred overnight.
  • Ethyl-2-fluoro-4-trimethylsilanylethynyl-benzoate (Intermediate 7)
  • a solution of ethyl-2-fluoro-4- trifluoromethylsulfonyloxy-benzoate (Intermediate 6, 1.82g, 6mmol) in triethyl amine (12mL) and anhydrous tetrahydrofuran (30mL) was treated with copper(I)iodide (0.12g, 0.6mmol) and sparged with argon.
  • GENERAL PROCEDURE A 7-Methoxy- 1.1 -dimethyl- 1.2.3.4- tetrahydronaphthalene (Intermediate 8)
  • IM titanium tetrachloride
  • IM dimethyl zinc
  • 2M dimethyl zinc
  • 5mL a solution of 7-methoxy- 1 - tetralone (1.76g, lOrnmol) in anhydrous dichloromethane (5mL) was cannulated into the reaction mixture and the resulting solution was allowed to warm to ambient temperature and stirred overnight.
  • reaction mixture was then cooled to -40°C and cautiously quenched with methanol (1 lmL). It was diluted with dichloromethane and saturated aqueous ammonium chloride solution. The phases were separated and the aqueous phase was extracted with dichloromethane (x2mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to the title compound (1.75g, 92%) as an oil.
  • GENERAL PROCEDURE B 6-Methoxy-4.4-dimethyl-1.2.3.4- tetrahydronaphthalene- 1 -one (Intermediate 9)
  • a solution of 7-methoxy- 1 , 1 -dimethyl- 1 ,2,3 ,4-tetrahydronaphthalene (Intermediate 8, 1.65g, 8.7 mmol) in 7.5mL of glacial acetic acid was cooled to 0°C and treated with a solution of chromium trioxide (2g, 20mmol) in 8mL of acetic acid and 7mL of water. The reaction mixture was then allowed to warm to ambient temperature and stirred overnight. It was diluted with water and extracted with diethyl ether (x2).
  • 6-Hydroxy-4.4-dimethyl- 1.2.3.4-tetrahvdronaphthalene- 1 -one (Intermediate 10)
  • a stirred, cooled (-78°C) solution of 6-methoxy-4,4-dimethyl-l ,2,3,4- tetrahydronaphthalene- 1 -one (Intermediate 9, 0.8, 3mmol) under argon was treated with a IM solution of boron tribromide (lOmL).
  • the reaction mixture was allowed to warm to ambient temperature and stirred overnight.
  • the reaction mixture was cooled to -78°C, quenched and diluted with saturated aqueous sodium bicarbonate solution and the aqueous phase was extracted with dichloromethane (x2).
  • GENERAL PROCEDURE C 4.4-Dimethyl-6-trifluoromethylsulfonyloxy- 1.2.3.4-tetrahvdronaphthalene- 1 -one (Intermediate 11)
  • GENERAL PROCEDURE D 4.4-Dimethyl-6-trimethylsilanyl-ethvnyl- 1,2.3.4-tetrahydronaphthalene-l-one (Intermediate 12)
  • Trimethylsilyl acetylene (0.85mL, 6mmol) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (0.25g, 0.36mmol).
  • the resulting reaction mixture was heated at 70°C for 17h. It was then cooled to ambient temperature, diluted with diethyl ether and filtered over a bed of celite. The filtrate was evaporated vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent to afford the title compound (0.28g, 72%).
  • GENERAL PROCEDURE E 6-Ethynyl-4.4-dimethyl- 1.2.3.4- tetrahydronphthalene- 1 -one (Intermediate 13)
  • a solution of 4,4-dimethyl-6-frimethylsilanylethynyl- 1 ,2 ,3 ,4- tetrahydronaphthalene-1-one (Intermediate 12, 0.28g, 1.03mmol) in methanol (lOmL) was treated with potassium carbonate (0.74g, 5.35mmol) and stirred at ambient temperature for 4h. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with diethyl ether (x2).
  • GENERAL PROCEDURE F 4-(8.8-Dimethyl-5-oxo-5.6.7.8-tetrahvdro- naphthalene-2-yl-ethynyl)-benzoic acid ethyl ester (Intermediate 14)
  • a solution of 6-ethynyl-4,4-dimethyl- 1 ,2,3 ,4-tetrahydronaphthalene- 1 - one (Intermediate 13, 0.23g, l.lmmol) and ethyl-4-iodo benzoate (Reagent A, 0.36g, 1.3mmol) in triethyl amine (7mL) and anhydrous tetrahydrofuran (3mL) was treated with copper(I)iodide (0.114g, 0.6mmol) and sparged with argon for 5 minutes.
  • GENERAL PROCEDURE I 4-[f5-Cyclopropyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahydro-naphthalene-2yl-ethynyl1-benzoic acid (Compound 3, General Formula 4)
  • a solution of 4-[(5-cyclopropyl-methyl-amino)-8,8- dimethyl-5,6,7,8-tetrahydro-naphthalene-2-ylethynyl]-benzoic acid ethyl ester (Compound 2, 0.065g, 0.158mmol) in ethanol (ImL) and tetrahydrofuran (ImL) was treated with IM aqueous sodium hydroxide solution (ImL) and heated at 80°C for lh.
  • GENERAL PROCEDURE J 4-[f8.8-Dimethyl-5-oxo-5.6.7.8-tetrahvdro- na ⁇ hthalene-2-yl-ethynv - ⁇ henyl]-acetic acid (Compound 5, General Formula 8)
  • a solution of 4-[(8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro-na ⁇ hthalene- 2-ylethynyl)-phenyl]-acetic acid methyl ester (Compound 4, 0.1 g, 0.28mmol) in a mixture of methanol (2mL), tetrahydrofuran (3.5mL) and water (1.5mL) was treated with lithium hydroxide monohydrate (0.1 lg, 2.62mmol) and the resulting reaction mixture was stirred at ambient temperature for 3h.
  • GENERAL PROCEDURE K 8.8-Dimethyl-5.6.7.8-tetrahydro-naphthalene-l- one-2-carboxylic acid-4-( ⁇ ert-butoxycarbonylmethyDphenyl ester Compound 19, General Formula 8)
  • a solution of 4,4-dimethyl-6-trifluoromethylsulfonyloxy- 1 ,2,3 ,4- tetrahydronaphthalene- 1 -one (Intermediate 11, 0.14g, 0.434mmol), t-butyl-4- hydroxy-phenyl acetate (Reagent E, 0.14g, 0.673mmol), palladium acetate (0.054g, 0.24mmol) and l,3-bis(diphenyl ⁇ hos ⁇ hino)propane (0.082g, 0.2mmol) in a mixture of dimethylsulfoxide (ImL), 1,2-dichloroethane (1.5mL) and triethyl amine (
  • 6-Methoxy-4,4-dimethyl- 1.2.3.4-tetrahvdro-isoquinoline (Intermediate 18)
  • a solution of 6-methoxy-4,4-dimethyl- 1 ,2,3 ,4-tetrahydro-isoquinoline- 1-one (Intermediate 17, 3.5g, 17mmol) in lOOmL of anhydrous tetrahydrofuran was treated with lithium aluminum hydride (1.3g, 34.25mmol) in small portions and the resulting suspension was refluxed for 3 hours under argon.
  • reaction mixture was then cooled in an ice bath and cautiously quenched with saturated aqueous sodium sulfate solution and the resulting slurry was filtered and the filter-cake washed well with ethyl acetate.
  • the filtrate and washings were evaporated in vacuo to a brown oil which was dissolved in chloroform, the solution was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound (3.2g, -100%).
  • 6-Methoxy-4.4-dimethyl- 1.2.3.4-tetrahydro-isoquinoline-2-carbaldehvde (Intermediate 19)
  • a solution of 6-methoxy-4,4-dimethyl- 1 ,2,3 ,4-tetrahydro-isoquinoline (Intermediate 18, 3.2g, 16.7mmol) in anhydrous dichloromethane (40mL) was treated with formic acid (ImL, 26.5mmol) followed l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.9g, 20.34mmol) and the resulting solution was stirred at ambient temperature overnight.
  • 6-Hydroxy-4.4-dimethyl- 1.2.3 ⁇ 4-tetrahydro-isoquinoline-2-carbaldehyde (Intermediate 20) A stirred, cooled (-78°C) solution of 6-methoxy-4,4- dimethyl- 1,2, 3, 4-tetrahydro-isoquinoline-2-carbaldehyde (Intermediate 19, 3.26g, 15mmol) in anhydrous dichloromethane (15mL) was treated with IM solution of boron tribromide in dichloromethane (50mL) stirred at ambient temperature for 3h.
  • reaction mixture was allowed to warm to -20°C over 1.5h, quenched with saturated aqueous ammonium chloride solution and extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound as an oil (O.lg, 94%).
  • GENERAL PROCEDURE L [4-f2.2.4.4-Tetiamethyl-chroman-6-yl-ethvnyr) phenyl] acetic acid (Compound 28, General Formula 8)
  • 6-Bromo-4.4-dimethyl-chroman-2-one A solution of 3-methyl-but-2-enoic acid 4-bromo-phenyl ester (7g, 27.6mmol) in anhydrous dichloromethane (200mL) was cooled (ice bath) and treated with aluminum chloride (6.6g, 49.6mmol) and the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution and extracted with diethyl ether (x2).
  • 6-Bromo-2.2.4.4-tetramethyl-chroman A solution of 4-bromo-2-(3-hydroxy- 1 , 1 ,3-trimethyl-butyl)-phenol (l .lg, 3.92mmol) and ⁇ -toluene sulfonic acid (0.744g, 3.92mmol) in benzene (20mL) was refluxed overnight. The reaction mixture cooled to ambient temperature, filtered on silica gel and washed with 10% ethyl acetate in hexane.
  • GENERAL PROCEDURE M 6-Bromo-2.2.4.4-tetramethyl-chroman-8- carbaldehyde (Intermediate 30)
  • a stirred, cooled (ice bath) solution of 6-bromo-2,2,4,4-tetramethyl chroman, (0.5g, 1.865mmol) in anhydrous dichloromethane (5mL) was treated with a IM solution (1.86mL, 1.86mmol) of titanium tetrachloride in dichloromethane followed by ⁇ , ⁇ -dichloro methyl ether (0.214g, 1.865mmol) .
  • the reaction mixture was allowed to warm to ambient temperature for 4h.
  • GENERAL PROCEDURE N 6-Bromo-8-vinyl -2.2.4.4-tetramethyl- chroman (Intermediate 31)
  • a solution of methylidene triphenyl phosphorane [generated from methyl triphenylphosphonium bromide (7g, 20mmol) and (11.8mL, 19mmol) of a 1.6M solution of n-butyl lithium in hexanes ] was added 6-bromo-2,2,4,4- tetramethyl chroman- 8-carbaldehyde (Intermediate 30, 0.52g, 1.75mmol).
  • GENERAL PROCEDURE O 6-Bromo-8-cvclopropyl-2.2.4.4-tetramethyl chroman (Intermediate 32) A stirred, cooled (-30°C) solution of 6-bromo-8-vinyl-2,2,4,4- tetramethyl chroman (Intermediate 31, 0.37g, 1.26mmol) in diethyl ether was treated with a solution of diazomethane in diethyl ether and catalytic amount of palladium (I ⁇ )acetate ( ⁇ 30mg).
  • GENERAL PROCEDURE P 6-Bromo-4.4-dimethyl-2-methylene chroman (Intermediate 35)
  • a stirred, cooled (ice bath) solution of 6-bromo-4,4-dimethyl-chroman- 2-one available in accordance with U.S. Patent No. 5,399,561 inco ⁇ orated herein by reference (lg, 3.92mmol) in 8mL of anhydrous tetrahydrofuran was treated with a 0.5 M solution of ⁇ -chloro- ⁇ -methylene- [bis(cyclopentadienyl)titanium]dimethylaluminum (Tebbe reagent) in toluene (8.23mL, 4.12mmol).
  • reaction mixture was poured into ice-water mixture containing 50mL of IM sodium hydroxide and extracted with hexane.
  • the hexane extract was washed with brine (xl), filtered over a bed of celite and evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using hexane as the eluent to afford the title compound (0.74g, 74%) as a clear oil.
  • GENERAL PROCEDURE R 2.2.4.4-Tetramethyl-chroman-6-carboxylic acid (Intermediate 39)
  • a stirred, cooled (-78°C) solution of 6-bromo-2,2,4,4-tetramethyl chroman ( 1.2g, 4.47mmol) in 15mL of anhydrous tetrahydrofuran was treated with a 1.7M solution of tert-butyl lithium solution in pentane ( 5.27mL, 8.9mmol).
  • carbon dioxide generated from dry ice was bubbled into the reaction mixture. The reaction mixture was allowed to warm to ambient temperature.
  • reaction mixture was diluted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using ethyl acetate as the eluent to afford the title compound as a white solid (l.lg, 92%) .
  • reaction mixture was subjected to flash column chromatography over silica gel (230-400 mesh) using 5-10% ethyl acetate in hexane as the eluent to afford the title compound (O.lg, 55%).
  • 6-Bromo-8-ethyl-2.2.4.4-tetramethyl chroman (Intermediate 46) A stirred, cooled (ice bath) solution of 8-acetyl-6-bromo-2,2,4,4- tetramethyl chroman (Intermediate 45, 0.95g, 3. lmmol) in trifluoroacetic acid ( 1 OmL) was treated with triethy lsilane ( 1 OmL) and the resulting reaction mixture was allowed to warm to ambient temperature and stirred overnight. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with hexane (x2).
  • 6-Bromo-4,4-dimethyl- 1.2.3.4-tetrahydro-quinoline- 1 -carbaldehyde (Intermediate 50)
  • a solution of 6-bromo-4,4-dimethyl- 1 ,2,3 ,4-tetrahydroquinoline, available in accordance with United States Patent No. 5,089,509, the specification of which is inco ⁇ orated herein by reference (1.8g, 7.5mmol) in 1 OmL of formic acid was refluxed for 3h.
  • the reaction mixture was then cooled to ambient temperature and poured into ice-cold saturated aqueous sodium bicarbonate solution and extracted with diethyl ether (x2).
  • 6-Bromo- 1 -cyclo ⁇ ropyl-4.4-dimethyl- 1.2.3.4-tetrahvdroquinoline (Intermediate 51)
  • a stirred, cooled (0°C) solution of 6-bromo-4,4-dimethyl- 1 ,2,3 ,4- tetrahydro-quinoline-1-carbaldehyde (Intermediate 50, 21.8, 6.7mmol) in anhydrous tetrahydrofuran (20mL) under argon was treated with titanium tetra--5O- ⁇ ropoxide (2.15mL, 7.39mmol) followed by 3M solution of ethyl magnesium bromide in diethyl ether (5.6mL, 16.8mmol) and the reaction mixture was then heated at 50°C overnight.
  • reaction mixture was stirred for 1 hour at the same temperature and then cooled to room temperature. Ice was added cautiously to the solid, followed by ⁇ 200mL of iced water. The reaction mixture was then extracted with ether (x2) and dichloromethane (xl) and the combined organic phase was dried over anhydrous magnesium sulfate and evaporated in vacuo to yield a brown solid. The solid was treated with hexane-dichloromethane and filtered to afford 1.7g of product. The mother liquor was evaporated and purified by flash column chromatography on silica gel (230-400 mesh) to afford 2.9g of the title compound as a solid (total 72%).
  • Method A The carboxylic acid was combined with a solution ofthe desired alcohol and concentrated sulfuric acid (20 to 1 v/v) and the resulting mixture or solution (0.75 to 1.0 M) heated to reflux overnight. The solution was cooled to room temperature, diluted with EtjO, and washed with H 2 0, saturated aqueous NaHC0 3 , and saturated aqueous NaCl before being dried over MgS0 4 . Concentration ofthe dry solution under reduced pressure afforded the desired carboxylic ester of sufficient purity to be used directly in the next reaction.
  • Method B To a solution (0.67 to 1 ,0M) ofthe carboxylic acid in acetone was added 1.1 equivalents of the desired alkyl halide and 1.0 equivalents of solid potassium carbonate. The resulting mixture was heated to reflux for 2h and then allowed to stir at room temperature overnight. The mixture was filtered and the filtrate concentrated under reduced pressure. The product was isolated from the residue by column chromatography using silica gel as the solid phase.
  • Method C A solution (IM) ofthe carboxylic acid in thionyl chloride was heated at reflux until analysis of a reaction aliquot by IR spectroscopy showed the absence ofthe aryl carboxylic acid carbonyl band ( 1705 - 1680 cm "1 ).
  • the solution was cooled to room temperature and concentrated under reduced pressure to give the crude acyl chloride.
  • the acyl chloride was dissolved in CH 2 C1 2 and the resulting solution (0.5 to 0.75M) treated with 1.1 equivalents the desired alcohol and 2.0 equivalents of pyridine. After stirring overnight at room temperature the solution was diluted with Et ⁇ O and washed with H 2 0, 10% aqueous HCl, saturated aqueous NaHC0 3 , and saturated aqueous NaCl before being dried over Na 2 S0 4 . Concentration ofthe dry solution under reduced pressure followed by column chromatography afforded the desired ester.
  • GENERAL PROCEDURE 1 preparation of Enol ethers : A solution (0.35 M) ofthe aryl ester in anhydrous THF was cooled to 0 °C and treated with 1.0 equivalents of Tebbe's Reagent ([ ⁇ -chloro- ⁇ - methylene[bis(cyclopentadienyl)titanium]-dimethylaluminum] 0.5 M in toluene). After 30 minutes the solution was warmed to room temperature and stirred for 30 minutes before being carefully added to a 0.1 N NaOH solution at 0 °C. This mixture was treated with hexanes and the solids removed by filtration through a pad of Celite.
  • GENERAL PROCEDURE 2 (cvclopropanation ofthe enol ethers): To a solution (0.3 M) ofthe enol ether in anhydrous Et 2 0 was added 2.0 equivalent of Et 2 Zn (as a solution in hexanes) and 2.0 equivalents of CH 2 I 2 .
  • Ethyl 4-[4-(l-methoxycyclo ⁇ ro ⁇ yl)-phenylethynyl]-benzoate (Compound 67, General Formula 2) Using General Procedure F; l-ethynyl-4-(l-methoxycyclopropyl)- benzene (Intermediate 61, 100.0 mg, 0.47 mmol) and ethyl-4-iodo benzoate (Reagent A, 141.0 mg, 0.51 mmol) in triethyl amine (6 mL) was treated with copper(I)iodide (30.0 mg, 0.16 mmol) and sparged with argon for 5 minutes.
  • Methyl 4-[4-(l-methoxycvclo ⁇ ro ⁇ yl)- ⁇ henylethvnyl]- ⁇ henyl -acetate (Compound 68, General Formula 2) Using General Procedure F; 1 -ethynyl-4-( 1 -methoxycyclopropyl)- benzene (Intermediate 61, 120.0 mg, 0.56 mmol) and methyl-(4-iodo ⁇ henyl)- acetate (Reagent B, 154.0 mg, 0.56 mmol) in triethyl amine (6 mL) was treated with copper(I)iodide (35.0 mg, 0.19 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenyl ⁇ hosphine)palladium(II) (66.0 mg, 0.094 mmol).
  • the resulting reaction mixture was heated to 70 °C for 5 days.
  • the title compound (250.0 mg, 98%) was isolated by chromatography (0 - 3% EtOAc - hexanes) as an orange oil.
  • Ethyl 4-[4-( 1 -isopropoxycyclopropyl)-phenylethynyl]-benzoate (Compound 71, General Formula 2) Using General Procedure F; l-ethynyl-4-(l-isopropoxycyclopropyl)- benzene (Intermediate 66, 114.0 mg, 0.57 mmol) and ethyl-4-iodo benzoate (Reagent A, 731.0 mg, 0.63 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (36.0 mg, 0.19 mmol) and sparged with argon for 5 minutes.
  • Methyl ⁇ 4-[4-(l-iso ⁇ ro ⁇ oxycvclopropylV ⁇ henylethvnyll- ⁇ henyll-acetate (Compound 72, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -isopropoxy cyclopropyl)- benzene (Intermediate 66, 95.0 mg, 0.45 mmol) and methyl-(4-iodophenyl)- acetate (Reagent B, 131.0 mg, 0.45 mmol) in triethylamine (6 mL) was treated with copper(I)iodide (30.0 mg, 0.16 mmol) and sparged with argon for 5 minutes .
  • Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (37.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (150.0 mg, 83%) was isolated by chromatography (0 - 3% EtOAc - hexanes) s a pale-yellow oil.
  • ⁇ NMR (CDC1 3 ) ⁇ : 7.21 (3H, m), 7.09 - 7.01 (6H, m), 4.18 (2H, s), 1.07 (2H, m), 0.79 (2H, m), 0.02 (9H, s).
  • Ethyl 4- [4-( 1 -benzyloxycyclopropylVphenylethynyl] -benzoate (Compound 75, General Formula 2) Using General Procedure F; 1 -ethynyl-4-(l -benzyloxycyclopropyl)- benzene (Intermediate 71, 60.0 mg, 0.24 mmol) and ethyl-4-iodo benzoate (Reagent A, 72.0 mg, 0.26 mmol) in triethylamine (4 mL) was treated with cop ⁇ er(I)iodide (17.0 mg, 0.09 mmol) and sparged with argon for 5 minutes.
  • Methyl ⁇ 4- [4-( 1 -benzyloxy cyclopropylVphenylethynyl] -phenyl ⁇ -acetate (Compound 76, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)- benzene (Intermediate 71, 60.0 mg, 0.20 mmol) and methyl-(4-iodophenyl)- acetate (Reagent B, 66.0 mg, 0.24 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (15.0 mg, 0.08 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (70.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (300.0 mg, 89%) was isolated by chromatography (0 - 2% EtOAc - hexanes). ⁇ NMR (CDC1 3 ) ⁇ : 7.34-7.13 (8H, m), 4.24 (2H, s), 2.52 (3H, s), 1.20 (2H, m), 0.88 (2H, m), 0.25 (9H, s).
  • Ethyl 4-[4-(l-benzyloxycvclopropylV3-methyl-phenylethynyl]-benzoate (Compound 79, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)-3- methyl-benzene (Intermediate 76, 90.0 mg, 0.34 mmol) and ethyl-4-iodo benzoate (Reagent A, 95.0 mg, 0.34 mmol) in triethylamine (6 mL) was treated with copper(I)iodide (23.0 mg, 0.12 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenyl ⁇ hosphine) ⁇ alladium(II) (70.0 mg, 0.1 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (250.0 mg, 91%) was isolated by chromatography (0 - 3% EtOAc - hexanes).
  • Ethyl 4-[4-( 1 -isopropoxycyclopropyl)-3-methyl-phenylethynyl]-benzoate (Compound 83, General Formula 2) Using General Procedure F; 4-ethynyl- 1 -( 1 -isopropoxy cyclopropyl)-3 - methyl-benzene (Intermediate 81, 80.0 mg, 0.13 mmol) and ethyl-4-iodo benzoate (Reagent A, 100.0 mg, 0.36 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (25.0 mg, 0.13 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis- (triphenylphosphine)palladium(II) (63.0 mg, 0.09 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (220.0 mg, 81%) was isolated by chromatography ( 1 -2% EtOAc - hexanes) .
  • Eth y l 4-[4-[l-(2.2-dimethylpropyloxy)-cyclopropyl]-3-methyl-phenylethynyl]- benzoate (Compound 87, General Formula 2) Using General Procedure F; 4-ethynyl-l-[l-(2,2-dimethylpropyloxy)- cyclopropyl]-3-methyl-benzene (Intermediate 85, 75.0 mg, 0.31 mmol) and ethyl-4-iodo benzoate (Reagent A, 86.0 mg, 0.31 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (21.0 mg, 0.11 mmol) and sparged with argon for 5 minutes.
  • Methyl l4- 4-ri-(2.2-dimethylpropyloxyVcyclopropyll-3-methyl- phenylethynyl]-phenyl ⁇ -acetate (Compound 88, General Formula 2) Using General Procedure F; 4-ethynyl- 1 -[ 1 -(2,2-dimethylpropyloxy)- cyclo ⁇ ropyl]-3-methyl-benzene (Intermediate 85, 75.0 mg, 0.31 mmol) and methyl-(4-iodophenyl)-acetate (Reagent B, 86.0 mg, 0.31 mmol) in triethylamine (6 mL) was treated with copper(I)iodide (21.0 mg, 0.11 mmol) and sparged with argon for 5 minutes.
  • Ethyl 4-[4-(l-benzyloxycyclopro ⁇ ylV3-ethyl-phenylethynyl]-benzoate (Compound 91, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)-3- ethyl-benzene (Intermediate 90, 90.0 mg, 0.33 mmol) and ethyl-4-iodo benzoate (Reagent A, 100.0 mg, 0.36 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (21.0 mg, 0.11 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(tri ⁇ henyl ⁇ hos ⁇ hine) ⁇ alladium(II) (75.0 mg, 0.11 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (320.0 mg, 99%) was isolated by chromatography (0 - 2% EtOAc - hexanes) as an orange oil.
  • Ethyl 4-[4-(l-isopropoxycyclopropyl)-3-ethyl-phenylethynyl]-benzoate (Compound 95, General Formula 2) Using General Procedure F; 4-ethynyl- 1 -( 1 -isopropoxy cy clopropyl)-3 - ethyl-benzene (Intermediate 95, 108.0 mg, 0.47 mmol) and ethyl-4-iodo benzoate (Reagent A, 130.0 mg, 047 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (30.0 mg, 0.16 mmol) and sparged with argon for 5 minutes .
  • Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (38.0 mg, 0.05 mmol).
  • the resulting reaction mixture was heated to 95 °C for 5d.
  • the title compound 200.0 mg (99%), was isolated by chromatography (0 - 2% EtOAc - hexanes) as an orange oil.
  • Ethyl 4-r4-(l-ethoxycyclopro ⁇ y -3-isopropyl- ⁇ henylethvnvn-benzoate (Compound 99, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2- isopropylbenzene (Intermediate 103, 50.0 mg, 0.22 mmol) and ethyl-4-iodo benzoate (Reagent A, 60.0 mg, 0.22 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (14.0 mg, 0.07 mmol) and sparged with argon for 5 minutes.
  • Meth y l 4-r4- ( l-ethoxycvclopropyl -3-isopro ⁇ yl-phenylethvnyl]-phenyl ⁇ - acetate (Compound 100, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2- isopropylbenzene (Intermediate 103, 120.0 mg, 0.52 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 150.0 mg, 0.52 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (32.0 mg, 0.17 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (40.0 mg, 0.06 mmol).
  • the resulting reaction mixture was heated to 95 °C for 18 hours.
  • Ethyl 4- 4-(l-ethoxycyclo ⁇ ropylV3-tert-butyl-phenylethynyll-benzoate (Compound 103, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2-tert- butylbenzene (Intermediate 112, 70.0 mg, 0.30 mmol) and ethyl-4-iodo benzoate (Reagent A, 85.0 mg, 0.30 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (19.0 mg, 0.01 mmol) and sparged with argon for 5 minutes.
  • Methyl ( 4-r4- ( l-ethoxycvclopropylV3-tert-butyl- ⁇ henylethynyl]-phenyll- acetate (Compound 104, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2-tert- butylbenzene (Intermediate 112, 95.0 mg, 0.39 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 108.0 mg, 0.39 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (25.0 mg, 0.13 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis(triphenyl ⁇ hosphine) ⁇ alladium(II) (48.0 mg, 0.06 mmol).
  • the resulting reaction mixture was heated to 70 °C for 5days.
  • the title compound (80.0 mg, 75%) was isolated by chromatography (0 - 10% EtOAc - hexanes) as an orange oil.
  • Ethyl 4-[4-(l-propylamino-cyclopropyl)-phenylethvnyl]-benzoate (Compound 107, General Formula 2) Using General Procedure F; [l-(4-ethynyl ⁇ henyl)-cyclo ⁇ ro ⁇ yl]- propylamine (Intermediate 120, 38.0 mg, 0.19 mmol) and ethyl-4-iodo benzoate (Reagent A, 58.0 mg, 0.21 mmol) in triethyl amine (6 mL) was treated with copper(I)iodide (8.0 mg, 0.04 mmol) and sparged with argon for 5 minutes.
  • Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (35.0 mg, 0.05 mmol).
  • the resulting reaction mixture was heated to 70 °C for 5d.
  • the title compound was isolated by chromatography (0 - 3% EtOAc - hexanes).
  • Ethyl 4-[4-(l-dipropylamino-cyclopropyl)-phenylethynyl]-benzoate (Compound 109, General Formula 2) Using General Procedure F; [l-(4-ethynylphenyl)-cyclopropyl]- dipropylamine (Intermediate 123, 34.0 mg, 0.16 mmol) and ethyl-4-iodo benzoate (Reagent A, 59.0 mg, 0.21 mmol) in triethyl amine (6 mL) was treated with cop ⁇ er(I)iodide (13.0 mg, 0.07 mmol) and sparged with argon for 5 minutes.
  • Ethyl 4- [4-( 1 -benzylamino-cyclopropyl)-phenylethynyl] -benzoate (Compound 111, General Formula 2) Using General Procedure F; benzyl-[l-(4-ethynylphenyl)-cyclopropyl]- amine (Intermediate 127, 65.0 mg, 0.27 mmol) and ethyl-4-iodo benzoate (Reagent A, 68.0 mg, 0.27 mmol) in triethyl amine (8 mL) was treated with copper(I)iodide (16.0 mg, 0.08 mmol) and sparged with argon for 5 minutes.
  • Ethyl 4T4-( 1 -dibenzylamino-cvclo ⁇ ropylVphenylethvnyl]-benzoate (Compound 113, General Formula 2) Using General Procedure F; dibenzyl-[l-(4-ethynyl ⁇ heny ⁇ )- cyclopro ⁇ yl]-amine (Intermediate 129, 40.0 mg, 0.12 mmol) and ethyl-4-iodo benzoate (Reagent A, 60.0 mg, 0.22 mmol) in triethylamine (5 mL) was treated with co ⁇ per(I)iodide (8.0 mg, 0.04 mmol) and sparged with argon for 5 minutes.
  • Benzyl- 1 -(4-ethvnyl ⁇ henylV cyclopropyl]-methylamine (Intermediate 132) Using General Procedure E; benzyl- [ 1 -(4-trimethylsilanylethynyl- ⁇ henyl)-cyclopropyl]-methylamine (Intermediate 131, 80.0 mg, 0.24 mmol) in methanol (5 mL) was treated with potassium carbonate (80.0 mg, 0.59 mmol) and stirred overnight at ambient temperature. The crude alkyne (60 mg, 99%) was used directly in the next reaction.
  • Ethyl 4- ⁇ 4-f 1 -(benzyl-methylamino -cyclopropyl]- ⁇ henylethynyl ⁇ -benzoate (Compound 115, General Formula 2) Using General Procedure F; benzyl-[l -(4-ethynyl ⁇ henyl)-cyclopropyl]- methylamine (Intermediate 132, 70.0 mg, 0.28 mmol) and ethyl-4-iodo benzoate (Reagent A, 77.0 mg, 0.28 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (18.0 mg, 0.10 mmol) and sparged with argon for 5 minutes.
  • Ethyl 4-(4-hydroxymethyl-3-methyl-phenylethynyl -benzoate (Compound 117, General Formula 6) Using General Procedure F; (4-ethynyl-2-methyl-phenyl)-methanol (Intermediate 136, 100.0 mg, 0.44 mmol) and ethyl-4-iodo benzoate (Reagent A, 125.0 mg, 0.45 mmol) in triethyl amine (4 mL) was treated with copper(I)iodide (29 mg, 0.15 mmol) and sparged with argon for 5 minutes.
  • Eth y l 4- 4-bromomethyl-3-methyl-phenylethynylVbenzoate (Intermediate 137)
  • a solution of ethyl 4-(4-hydroxymethyl-3-methyl-phenylethynyl)- benzoate (Compound 117, 130.0 mg, 0.44 mmol) and triphenylphosphine (150.0 mg, 0.57 mmol) in 5 mL CH 2 C1 2 was cooled to 0 °C and N- bromosuccinimide (101.0 mg, 0.57 mmol) was added in 5 portions over 20 minutes. The solution was warmed to 25 °C and stirred for 17 hours. The reaction was quenched by the addition of dilute aqueous NaHC0 3 .
  • Ethyl 4-(4-imidazol- 1 -yl-methyl-3-methyl-phenylethynyl -benzoate (Compound 118, General Formula 6)
  • a solution of imidazole (30.0 mg, 0.44 mmol) in 2 mL DMF was treated with NaH (11.0 mg, 0.44 mmol) and heated to 90 °C.
  • a solution of ethyl 4-(4-bromomethyl-3 -methyl-phenylethynyl)-benzoate (Intermediate 137, 120.0 mg, 0.34 mmol) in 2 mL DMF was added and stirring at 90 °C continued for 1 hour.
  • the solution was cooled to room temperature and concentrated under reduced pressure.

Abstract

Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.

Description

METHODS OF PROVIDING AND USING COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI BACKGROUND OF THE INVENTION 1. Cross-Reference to Related Application This application is a continuation-in-part of application serial number 09/651,235, filed August 29, 2000. 2. Field of the Invention The present invention is directed to providing, preparing and using compounds which inhibit the enzyme cytochrome P450RAI. More particularly, the present invention is directed to selecting and preparing compounds which inhibit the enzyme cytochrome P450RAI, many of which are derivatives of phenylacetic or heteroarylacetic acid, and using said compounds for treatment of diseases and conditions which are normally treated by retinoids . BACKGROUND ART Compounds which have retinoid-like activity are well known in the art, and are described in numerous United States and other patents and in scientific publications. It is generally known and accepted in the art that retinoid-like activity is useful for treating animals ofthe mammalian species, including humans, for curing or alleviating the symptoms and conditions of numerous diseases and conditions. In other words, it is generally accepted in the art that pharmaceutical compositions having a retinoid-like compound or compounds as the active ingredient are useful as regulators of cell proliferation and differentiation, and particularly as agents for treating skin-related diseases, including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hypeφroliferative disorders ofthe skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin. Retinoid compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers ofthe breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas ofthe mucous membranes and in the treatment of Kaposi's sarcoma. In addition, retinoid compounds can be used as agents to treat diseases ofthe eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other comeopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA). Other uses for retinoid compounds include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as MinoxidilR, diseases associated with the immune system, including use ofthe present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rej ection and facilitation of wound healing, including modulation of chelosis. Retinoid compounds have relatively recently been also discovered to be useful for treating type II non-insulin dependent diabetes mellitus (NIDDM). Several compounds having retinoid-like activity are actually marketed under appropriate regulatory approvals in the United States of America and elsewhere as medicaments for the treatment of several diseases responsive to treatment with retinoids. Retinoic acid (RA) itself is a natural product, biosynthesized and present in a multitude of human and mammalian tissues and is known to play an important rule in the regulation of gene expression, tissue differentiation and other important biological processes in mammals including humans. Relatively recently it has been discovered that a catabolic pathway in mammals, including humans, of natural retinoic acid includes a step of hydroxylation of RA catalyzed by the enzyme Cytochrome P450RAI (retinoic acid inducible). Several inhibitors of CP450RAI have been synthesized or discovered in the prior art, among the most important ones ketoconazole, liarozole and Rl 16010 are mentioned. The chemical structures of these prior art compounds are provided below. It has also been noted in the prior art, that administration to mammals, including humans, of certain inhibitors of CP-450RAI results in significant increase in endogeneous RA levels, and further that treatment with CP450RAI inhibitors, for example with liarozole, gives rise to effects similar to treatment by retinoids, for example amelioration of psoriasis.
Figure imgf000005_0001
Rl 16010
Figure imgf000005_0002
J AROZOLE
The following publications describe or relate to the above-summarized role of CP450RAI in the natural catabolism of RA, to inhibitors of CP-450RAI and to in vitro and in vivo experiments which demonstrate that inhibition of CP450RAI activity results in a increases endogeneous RA levels and potential therapeutic benefits: Kuijpers, et al, "The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin", British Journal of Dermatology. (1998) 139: pp 380-389. Kang, et al. , "Liarozole Inhibits Human Epidermal Retinoid Acid 4- Hydroxylase Activity and Differentially Augments Human Skin Responses to Retinoic Acid and Retinol In Vivo", The Journal of Investigative Dermatology, (August 1996) Vol. 107, No. 2: pp 183-187. VanWauwe, et al, "Liarozole, an Inhibitor of Retinoic Acid Metabolism, Exerts Retinoid-Mimetic Effects in Vivo", The Journal of Pharmacology and Experimental Therapeutics. (1992) Vol. 261, No 2: pp 773-779. De Porre, et al. , "Second Generation Retinoic Acid Metabolism Blocking Agent (Ramba) Rl 16010: Dose Finding in Healthy Male Volunteers" , University of Leuven, Belgium, pp 30. Wauwe, et al, "Ketoconazole Inhibits the in Vitro and in Vivo Metabolism of AU-rrαns-Retinoic Acid", The Journal of Pharmacology and Experimental Therapeutics. (1988) Vol. 245, No. 2: pp 718-722. White, et al, "cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26)*", Jhe Journal of Biological Chemistry. (1997) Vol. 272, No. 30, Issue of July 25 pp 18538-18541. Hanzlik, et al, "Cyclopropylamines as Suicide Substrates for Cytochromes P450RAI", Journal of Medicinal Chemistry (1979), Vol. 22, No. 7, pp 759- 761. Ortiz de Montellano, "Topics in Biology - The Inactivation of Cytochrome P450RAI", Annual Reports in Medicinal Chemistry. (1984), Chapter 20, pp 201-210. Hanzlik, et al. "Suicidal Inactivation of Cytochrome P450RAI by Cyclopropylamines> Evidence for Cation-Radical Intermediates", J. Am. Chem. Soc. (1982), Vol. 104, No. 107, pp. 2048-2052. In accordance with the present invention several previously known and several new compounds are utilized as inhibitors of CP450RAI to provide therapeutic benefit in the treatment or prevention ofthe diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. The perceived mode of action of these compounds is that by inhibiting the enzyme CP450RAI that catabolyzes natural RA, endogenous RA level is elevated to a level where desired therapeutic benefits are attained. The chemical structures of certain previously known compounds which have been discovered to be inhibitors ofthe enzyme CP450RAI are provided in the descriptive portion of this application for patent. The chemical structures ofthe novel compounds which are used in the methods of treatment in accordance with the invention are summarized by Formulas 1 through 8 in the Summary Section of this application for patent. Based on these chemical structures the following art is of interest as background to the novel structures. U.S. Patent Nos. 5,965,606; 6,025,388; 5,773,594; 5,675,024; 5,663,347; 5,045,551; 5,023,341; 5,264,578; 5,089,509; 5,616,712; 5,134,159; 5,346,895; 5,346,915; 5,149,705; 5,399,561; 4,980,369; 5,015,658; 5,130,335; 4,740,519; 4,826,984; 5,037,825; 5,466,861; WO 85/00806; EP 0 130,795; DE 3316932; DE 3708060; Dawson, et al. "Chemistry and Biology of Synthetic Retinoids", published by CRC Press. Inc.. (1990), pages 324-356; are of interest to compounds of Formula 1. U.S. Patent Nos. 5,965,606; 5,534,641; 5,663,357; 5,013,744; 5,326,898; 5,202,471; 5,391,753; 5,434,173; 5,498,795; 4,992,468; 4,723,028; 4,855,320; 5,563,292; WO 85/04652; WO 91/16051; WO 92/06948; EP 0 170 105; EP 0 286 364; EP 0 514269; EP 0 617 020; EP 0 619 116; DE 3524199; Derwent JP6072866; Dawson, et al. "Chemistry and Biology of Synthetic Retinoids", published by CRC Press. Inc.. 1990, pages 324-356; are of interest to compounds of Formula 2. Dawson, et al. "Chemistry and Biology of Synthetic Retinoids", published by CRC Press. Inc.. (1990), pages 324-356; is of interest to compounds of Formula 3. U.S. Patent Nos. 5,965,606; 5,773,594; 5,675,024; 5,663,347; 5,023,341; 5,264,578; 5,089,509; 5,149,705; 5,130,335; 4,740,519; 4,826,969; 4,833,240; 5,037, 825; 5,466,861; 5,559,248; WO 85/00806; WO 92/06948; WO 95/04036; WO 96/05165; EP 0 098 591; EP 0 170 105; EP 0 176 034; EP 0 253,302; EP 0 303 915; EP 0 514 269; EP 0 617 020; EP 0 619 116; EP 0 661 259; DE 3316932; DE 3602473; DE 3715955; UK application GB 2190378; Eyrolles et al, J. Med. Chem.. (1994), 37, 1508-1517; Graupner et al. Biochem. and Biophysical Research Communications. (1991), 1554- 1561; Kagechika, et al, J. Med. Chem.. (1988), 31, 2182-2192; Dawson, et al. "Chemistry and Biology of Synthetic Retinoids", published by CRC Press, Inc.. (1990), pages 324-356; are of interest to compounds of Formula 4. U.S. Patent Nos. 5,965,606; 6,025,388; 5,534,641; 5,663,357; 5,013,744; 5,326,898; 5,202,471; 5,391,753; 5,434,173; 5,498,795; 4,992,468; 5,723,028; 4,855,320; 5,563,292; WO 85/04652; WO 91/16051; WO 92/06948; EP 0 170 105; EP 0 286 364; EP 0 514 269; EP 0 617 020; EP 0 619 116; DE 3524199; Derwent JP6072866; Dawson, et al. "Chemistry and Biology of Synthetic Retinoids", published by CRC Press. Inc.. ( 1990), pages 324-356; are of interest to compounds of Formula 5. U.S. Patent Nos. 5,965,606; 6,025,388; 5,534,641; 5,663,357; 5,013,744; 5,326,898; 5,202,471; 5,391,753; 5,434,173; 5,498,795; 4,992,468; 5,723,028; 4,855,320; 5,563,292; WO 85/04652; WO 91/16051; WO 92/06948; EP 0 170 105; EP 0 286 364; EP 0 514269; EP 0 617 020; EP 0 619 116; DE 3524199; Derwert JP6072866; Dawson, et al. "Chemistry and Biology of Synthetic Retinoids", published by CRC Press. Inc.. ( 1990), pages 324-356; are of interest to compounds of Formula 6. U.S. Patent Nos. 6,048,873; 5,663,347; 5,045,551; 5,023,341; 5,739,338; 5,264,578; 5,089,509; 5,616,712; 5,399,561; 4,826,984; 5,037,825; EP 0 130 795; DE 3316932; Dawson, et al "Chemistry and Biology of Synthetic Retinoids", published by CRC Press. Inc.. (1990), pages 324-356; are of interest to compounds of Formula 7. U.S. Patent Nos. 5,965,606; 5,998,471; 5,773,594; 5,675,024; 5,663,347; 5,045,551; 5,023,341; 5,264,578; 5,134,159; 5,346,895; 5,346,915; 5,149,705; 5,399,561; 4,980,369; 5,130,335; 4,326,055; 4,539,154; 4,740,519; 4,826,969; 4,826,984; 4,833,240; 5,037,825; 5,466,861; 5,559,248; WO 85/00806; WO 92/06948; WO 95/04036; WO 96/05165; EP 0 098 591; EP 0 130 795; EP 0 176 034; EP 0 253 302; EP 0 303 915; EP 0 514269; EP 0 617 020; EP 0 619 116; EP 0 661 259; DE 3316932; DE 3602473; DE 3708060; DE 3715955; U.K. application GB 2190378; Eyrolles et al, J. Med. Chem.. (1994), 37 1508, 1517; Graupner et al, Biochem. and Biophysical Research Communications. (1991) 1554-1561; Kagechika, et al, J. Med. Chem.. (1988), 31, 2182-2192; Dawson, et al "Chemistry and Biology of Synthetic Retinoids", published by CRC Press. Inc.. (1990), pages 324-356; are of interest to compounds of Formula 8. Prior art which is of interest as background to the previously known compounds that have been discovered in accordance with the present invention to be inhibitors of cytochrome P450RAI, is identified together with the identification of these known compounds . SUMMARY OF THE INVENTION In accordance with the present invention novel compounds of Formulas 1 through 8 are used as inhibitors of the enzyme cytochrome P450RAI to treat diseases and conditions which are normally responsible to treatment by retinoids, or which are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid. These novel compounds are shown by Formulas 1
Figure imgf000010_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X is O, S or NR where is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I; Z is -C≡C-,
Figure imgf000010_0002
where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-; -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 4; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 2; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base. The novel compounds used in the method of treatment ofthe present invention are also shown in Formula 2
Figure imgf000012_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, ftiryl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups;
X is O, S or NR where R is H, alkyl of 1 to 6 carbons or benzyl; Z is -C≡C-,
Figure imgf000012_0002
where n' is an integer having the value 1 - 5,
-CO-NRr,
NRrCO-,
-CO-0-,
-0-CO-,
-CS-NRr,
NRrCS-,
-CO-S-,
-S-CO-,
-N=N-; Rj is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 4; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 4; R5 is H, alkyl of 1 to 6 carbons, fluorosubstituted alkyl of 1 to 6 carbons, benzyl, or lower alkyl or halogen substituted benzyl; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base. The novel compounds used in the method of treatment ofthe present invention are also shown in Formula 3
Figure imgf000013_0001
Formula 3 wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, fύryl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 1 to 6 carbons, Cl, Br, or I; Z is -C≡C-, -(CR^CR!)-.. where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 5; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base. The novel compounds used in the method of treatment of the present invention are also shown in Formula 4
Figure imgf000015_0001
Formula 4 wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; Xj is 1 -imidazolyl, or lower alkyl or halogen substituted 1 -imidazolyl, OR, SR, NRRg where R is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I;
Z is -C≡C-,
Figure imgf000015_0002
where n' is an integer having the value 1 - 5,
-CO-NRr,
NRrCO-,
-CO-0-,
-0-CO-,
-CS-NRr,
NRrCS-,
-CO-S-,
-S-CO-,
-N=N-;
Rx is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; 4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; R6 is H, lower alkyl, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, with the proviso that when Y is H, A is phenyl and Xj is OH then n is 1 to 4. The novel compounds used in the method of treatment of the present invention are also shown in Formula 5
Figure imgf000016_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X is O, S or NR where R is H, alkyl of 1 to 6 carbons, C g-trialkylsilyl or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I; Z is -C≡C-, -(CR^CR!)--' where n1 is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-O-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Ri is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 3 ; R7 is H, alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons or lower alkyl substituted cycloalkyl of 1 to 6 carbons; n is an integer having the values of 1 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base. The novel compounds used in the method of treatment of the present invention are also shown in Formula 6
Figure imgf000018_0001
Formula 6 wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X2 is 1 -imidazolyl, lower alkyl or halogen substituted 1 -imidazolyl, OR7, SR7 or NRR7 where R is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I; Z is -C≡C-, -(CR^CRj),.. where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 3; R7 is H, alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons or Cι_6-trialkylsilyl. n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(Ci.6-alkyl), or a cation of a pharmaceutically acceptable base. The novel compounds used in the method of treatment ofthe present invention are also shown in Formula 7
Figure imgf000019_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, F, Cl, Br, or I; Z is -C≡C-,
Figure imgf000020_0001
where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 5; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base. The novel compounds used in the method of treatment of the present invention are also shown in Formula 8
Figure imgf000021_0001
Formula 8 wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X3 is S, or O, C(Rj)2, or CO; Yj is H, lower alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons, benzyl, lower alkyl substituted cycloalkyl of 3 to 6 carbons;
Z is -C≡C-,
Figure imgf000021_0002
where n' is an integer having the value 1 - 5
-CO-NRr.
NRrCO-,
-CO-0-,
-0-CO-,
-CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; R! is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, the compound meeting at least one of the provisos selected from the group consisting of: Yj is cycloalkyl, when Y1 is not cycloalkyl then X3 is O or S and n is 1 , when Y1 is not cycloalkyl then X3 is CO, and n is 1, when Yl is not cycloalkyl then X3 is CO and the moiety A is substituted with at least one F group. In accordance with the invention the novel compounds of Formula 1 through Formula 8 as well as the previously known compounds disclosed below in the specification are used for the prevention or treatment of diseases and conditions in mammals, including humans, those diseases or conditions that are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid. Because the compounds act as inhibitors of the breakdown of retinoic acid, the invention also relates to the use ofthe compounds of Formula 1 through Formula 8 in conjunction with retinoic acid or other retinoids. In this regard it is noted that retionoids are useful for the treatment of skin-related diseases, including, without limitation, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders ofthe skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin. The retinoids are also useful for the prevention and treatment of metabolic diseases such as type II non- insulin dependent diabetes mellitus (NIDDM) and for prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers ofthe breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas ofthe mucous membranes and in the treatment of Kaposi's sarcoma. Retinoids can also be used as agents to treat diseases ofthe eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other comeopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA). Other uses for retinoids include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper pituitary function, including insufficient production of growth hormone, modulation of apoptosis, including both the induction of apoptosis and inhibition of T-Cell activated apoptosis, restoration of hair growth, including combination therapies with the present compounds and other agents such as MinoxidilR, diseases associated with the immune system, including use ofthe present compounds as immunosuppressants and immunostimulants, modulation of organ transplant rej ection and facilitation of wound healing, including modulation of chelosis. This invention also relates to a pharmaceutical formulation comprising one or more compounds of Formula 1 through Formula 8 or one or more of the previously known compounds disclosed below in the specification, in admixture with a pharmaceutically acceptable excipient, said formulation being adapted for administration to a mammal , including a human being, to treat or alleviate the conditions which were described above as treatable by retinoids, or which are controlled by or responsive to the organism's native retinoic acid. These formulations can also be co-administered with retinoids to enhance or prolong the effects of medications containing retinoids or ofthe organism's native retinoic acid. The present invention also relates to a method of providing a compound which is an inhibitor ofthe enzyme cytochrome P450RAI, wherein the method of providing the cytochrome P450RAI inhibitory compound comprises: identifying a compound that has activity as a retinoid in any ofthe art recognized assays which demonstrate retinoid-like activity, the retinoid compound having a formula such that it includes a benzoic acid, benzoic acid ester, naphthoic acid, naphthoic acid ester or heteroaryl carboxylic acid or ester moiety, with a partial structure of -A(R2)-(CH2)n-COOR8 where the symbols are defined as in Formulas 1 through 8, and where n is 0, and selecting a compound that is a homolog of the previously identified retinoid compound where in the formula of the homolog n is 1 or 2, preferably 1. Said homolog, if it is not a previously known compound can be prepared by homologation procedures well known to the synthetic organic chemist, such as for example the well known Arndt-Eistert synthesis. Alternatively, said homologs can be prepared by any of the applicable synthetic processes illustrated below for the preparation of the novel compounds of Formulas 1 through 8 wherein the symbol n represents the integral 1 (one). BRIEF DESCRIPTION OF THE DRAWING FIGURE Figure 1 is a schematic representation ofthe P450RAI cell based assay utilized to evaluate the ability ofthe compounds ofthe invention to inhibit the Cytochrome P450RAI enzyme. BIOLOGICAL ACTIVITY, MODES OF ADMINISTRATION P450RAI-1 Cell-Based Inhibitor Assay: Figure 1 shows a schematic diagram ofthe P450RAI-1 cell based assay. P45 ORAL 1 stably transfected HeLa cells are maintained in 100 millimolar tissue culture dishes in Modified Eagle's Medium (MEM) containing 10 % Fetal Bovine Serum (FBS) and 100 μg/ml hygromycin. Exponentially growing cells are harvested by incubating in trypsin. Cells are then washed with IX Phosphate Buffered Saline (PBS) and plated in a 48-well plate at 5 XI 05 cells in 0.2 ml MEM medium containing 10 % FBS and 0.05 μCi [3H]-RA in the presence or absence of increasing concentrations ofthe test compounds. The compounds are diluted in 100% DMSO and then added in triplicate wells at either 10, 1 or 0.1 μM final concentration. As a positive control for RA metabolism inhibition, cells are also incubated with ketoconazole at 100, 10 and 1 μM. Cell are incubated for 3 hours at 37°C. The retinoids are then extracted using the procedure of Bligh et al. (1959) Canadian Journal of Biochemistry 37, 911-917, modified by using methylenechloride instead of chloroform. The publication Bligh et al (1959) Canadian Journal of Biochemistry 37, 911-917 is specifically incoφorated herein by reference. The water soluble radioactivity is quantified using a β- scintillation counter. IC50 values represent the concentration of inhibitor required to inhibit a\\-trans-RA metabolism by 50 percent and are derived manually from log-transformed data. The IC50 values obtained in this assay for several novel compounds used in accordance with the invention are disclosed in Table 1 below. The IC50 values obtained in this assay for several previously known compounds the cythochrome P450RAI inhibitory activity of which has been discovered in accordance with the present invention, are disclosed in Table 1A below. Assays of Retinoid-like or Retinoid Antagonist and Inverse Agonist-like Biological Activity Assays described below measure the ability of a compound to bind to, and/or activate various retinoid receptor subtypes. When in these assays a compound binds to a given receptor subtype and activates the transcription of a reporter gene through that subtype, then the compound is considered an agonist of that receptor subtype. Conversely, a compound is considered an antagonist of a given receptor subtype if in the below described co-tranfection assays the compound does not cause significant transcriptional activation of the receptor regulated reporter gene, but nevertheless binds to the receptor with a Kd value of less than approximately 1 micromolar. In the below described assays the ability ofthe compounds to bind to RARα, RARβ, RARγ, RXRα, RXRβ and RXRy receptors, and the ability or inability ofthe compounds to activate transcription of a reporter gene through these receptor subtypes can be tested. As far as specific assays are concerned, a chimeric receptor transactivation assay which tests for agonist-like activity in the RARα, RARβ, and RARγ, receptor subtypes, and which is based on work published by Feigner P. L. and Holm M. (1989) Focus, 112 is described in detail in United States Patent No. 5,455,265. The specification of United States Patent No. 5,455,265 is hereby expressly incoφorated by reference. The numeric results obtained with several preferred novel compounds used in accordance with the invention in this assay are shown below in Table 1. These data demonstrate that generally speaking the compounds of Formulas 1 through 8, are not agonists (or only weak agonists) of RAR retinoic receptors, and also that they do not bind, or in some cases bind only weakly to RAR retinoid receptors. A holoreceptor transactivation assay and a ligand binding assay which measure the antagonist/agonist like activity of the compounds used in accordance with the invention, or their ability to bind to the several retinoid receptor subtypes, respectively, are described in published PCT Application No. WO W093/11755 (particularly on pages 30 - 33 and 37 - 41) published on June 24, 1993, the specification of which is also incoφorated herein by reference. A detailed experimental procedure for holoreceptor transactivations has been described by Heyman et al. Cell 68, 397 - 406, (1992); Allegretto et al. J. Biol. Chem. 268, 26625 - 26633, and Mangelsdorf et al The Retinoids: Biology, Chemistry and Medicine, pp 319 - 349, Raven Press Ltd., New York, which are expressly incoφorated herein by reference. The results obtained in this assay are expressed in EC50 numbers, as they are also in the chimeric receptor transactivation assay. The results of ligand binding assay are expressed in Kd numbers. (See Cheng et al. Biochemical Pharmacology Vol. 22 pp 3099-3108, expressly incoφorated herein by reference.) The results if the ligand binding assay for several preferred novel compounds used in accordance with the invention are included in Table 1. In the holoreceptor transactivation assay, tested for RXRα, RXRβ, and RXRT receptors, the novel compounds are, generally speaking, entirely devoid of activity, demonstrating that the novel compounds do not act as RXR agonists.
TABLE 1
Figure imgf000028_0001
Figure imgf000029_0001
90 NA NA NA
0.95 >10K >10K >10K
94 NA NA NA
>10 >10K >10K >10K
93 4821 20 10
(114) (39) (55) >10
3450 554 358
NA 11 NA
(36) 0.55
9148 2815 >10K
NA 363 NA (96) 0.4
10K 3781 25K
86 NA NA NA
1.4
>10K >10K >10K
85 976 3.5 2.5 (60) (77) (65) >10 1861 240 302
98 NA NA NA
0.8
13 NA 3.2 116 (6.6) (9) 3.1
10 57 0.3 6 (146) (86) (94) 0.7
36
0.033
13K 4896 492
38
0.025
10K 5317 2884
Figure imgf000031_0001
Figure imgf000032_0001
!The "Table #" refers to Table 2 through 9 provided below where the compound is identified with reference to a corresponding specific formula of Formulas 9 through 16.
Table 1A below provides data similar to those provided in Table 1, for certain previously known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI. These compounds are shown by Formula A through O and have compounds numbers 201 through 247. TABLE 1A
Figure imgf000033_0001
Figure imgf000034_0001
TOPICAL SKT-N IRRITATION TESTS As is known the topical retinoid all-trans-retinoic acid (ATRA) and oral retinoids such as 13-cis RA and etretinate are known to induce substantial skin irritation in humans. This irritation is a direct result of activation of the RAR nuclear receptors. Analysis of retinoid topical irritation is also a highly reproducible method of determining in vivo retinoid potency. The SKH1- hrBR or hairless mouse provides a convenient animal model of topical irritation, since retinoid-induced skin flaking and abrasion can be readily scored by eye (Standeven et al, "Specific antagonist of retinoid toxicity in mice." Toxicol. Appl. Pharmacol.. 138:169-175, (1996); Thacher, et al, "Receptor specificity of retinoid-induced hypeφlasia. Effect of RXR-selective agonists and correlation with topical irritation". J. Pharm. Exp. Ther.. 282:528- 534, (1997)). As is demonstrated below the topical application of P450RAI inhibitors in accordance with the present invention also causes an increase in the endogenous levels of ATRA that results in ATRA-induced irritation in skin of hairless mice. The attached data table discloses the retinoid-mimetic effects of some P450RAI inhibitor compounds in accordance with the present invention on the skin of hairless mice. Methods Female hairless mice (Crl:SKHl-ArBR), 5-7 weeks old, were obtained from Charles River Breeding Labs (Wilmington, MA). Animals were about 6 weeks old at the start ofthe experiments. Food (Purina Rodent Chow 5001) and reverse osmosis water were provided ad libitum. Mice were housed individually throughout the dosing period. In some experiments, mice that fit within a defined weight range, e.g. , 21 -25g, were selected from the available stock and then randomly assigned to the various treatment groups, using body weight as the randomization variable. The compounds to be tested were dissolved in acetone for application o the backs of the mice. Mice were treated topically on the back in a volume of 4.0 ml/kg (0.07- 0.12ml) adjusted daily so as to deliver a fixed dose of test compound per g body weight. Doses are disclosed as nmol/25g. Unless indicated otherwise, mice were treated with retinoids once daily on days 1 through 5 and observed on days 2, 3, 4, 5, 6, 7 and 8. The mice were weighed daily and the dorsal skin was graded daily using separate semi-quantitative scales to determine flaking and abrasion. These flaking and abrasion scores were combined with weight change (if any) to create a cutaneous toxicity score (Blackjack score). Cutaneous Toxicity Score A visual grading scale was used for characterizing topical irritation on a daily basis. The grading scale used is as follows:
Figure imgf000036_0001
Topical Toxicity Score The flaking and abrasion observations were combined with body weight observations to calculate a single, semiquantitative topical or cutaneous "toxicity score" as detailed below. The toxicity score (also known as "blackjack score" since the theoretical maximum is 21) takes into account the maximal severity, and the time of onset of skin flaking and abrasions and the extent of weight between the first and last days ofthe experiment. Below are listed the seven numerical components ofthe toxicity score and an explanation of how those values are combined to calculate the toxicity score. 1. Flaking-Maximal Severity: Highest flaking score attained during observation period. 2. Flaking-Day of Onset of grade 2 or worse: 0 - > 8 days 1 - day 8 2 - day 6 or 7 3 - day 4 or 5 4 - day 2 or 3 3. Flaking- Average Severity: Flaking severity scores are summed and divided by the number of observation days. 4. Abrasion-Maximal Severity: Highest abrasion score attained during observation period. 5. Abrasion-Day of Onset of grade 2 or worse: Same scale as (2) above. 6. Abrasion- Average Severity: Abrasion severity scores are summed and divided by the number of observation days . 7. Systemic Toxicity (weight loss): 0 - <lg
1 - 1 to 2g
2 - 2 to 4g
3 - 4 to 6g
4 - >6g or dead Calculation of Composite Flaking Score Flaking onset score (2) and average severity score (3) are summed and divided by two. The quotient is added to the maximal severity score (1). Composite flaking scores are calculated for each individual animal in a group, averaged, and rounded to the nearest integer. Values can range from 0-9. Calculation of Composite Abrasion Score Abrasion onset score (5) and average severity score (6) are summed and divided by two. The quotient is added to the maximal severity score (4). Composite abrasion scores are calculated for each individual animal in a group, averaged and rounded to the nearest integer. Values can range from 0- 8. Calculation of Toxicity Score Composite flaking score, composite abrasion score, and systemic toxicity score are summed to give the "toxicity score." Toxicity scores are calculated for each individual animal in a group, averaged, and rounded to the nearest integer. Values can range from 0-21 and are expressed in Table IB below as the mean ± SD ofthe values for a group. Calculation of Percentage Change in Body Weight The body weight at the time ofthe last weighing (day 8, 11, or 12) was subtracted from the initial body weight. The difference was divided by the initial body weight, multiplied by 100%>, and rounded to the nearest integer. Values were calculated for each individual animal and the mean and standard deviation for each group are shown. TABLE IB
Figure imgf000039_0001
Modes of Administration The compounds used in the methods of treatment of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and numerous other considerations. Thus, in the treatment of dermatoses, it will generally be preferred to administer the drug topically, though in certain cases such as treatment of severe cystic acne or psoriasis, oral administration may also be used. Any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be used. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania. For topical application, the compounds could also be administered as a powder or spray, particularly in aerosol form. If the drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable for oral administration. For intravenous or intraperitoneal administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as extended release formulation for deposit under the skin or intramuscular injection. Other medicaments can be added to such topical formulation for such secondary puφoses as treating skin dryness; providing protection against light; other medications for treating dermatoses; medicaments for preventing infection, reducing irritation, inflammation and the like. Treatment of dermatoses or any other indications known or discovered to be susceptible to treatment by retinoic acid-like compounds, or to control by naturally occurring retinoic acid will be effected by administration ofthe therapeutically effective dose of one or more compounds used in accordance with the instant invention. A therapeutic concentration will be that concentration which effects reduction ofthe particular condition, or retards its expansion. In certain instances, the compound potentially may be used in prophylactic manner to prevent onset of a particular condition. A useful therapeutic or prophylactic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, no single concentration will be uniformly useful, but will require modification depending on the particularities of the disease being treated. Such concentrations can be arrived at through routine experimentation. However, it is anticipated that in the treatment of, for example, acne, or similar dermatoses, that a formulation containing between 0.01 and 1.0 milligrams per milliliter of formulation will constitute a therapeutically effective concentration for total application. If administered systemically, an amount between 0.01 and 5 mg per kg of body weight per day would be expected to effect a therapeutic result in the treatment of many diseases for which these compounds are useful. In some applications pharmaceutical formulations containing the CP- 450RAI inhibitory compounds may be co-administered with formulations containing retinoids. In such cases the dose of the cytochrome P450RAI inhibitors compounds is in the range of 0.01 and 5 mg per kg body weight per day. GENERAL EMBODIMENTS AND SYNTHETIC METHODOLOGY Definitions The term alkyl refers to and covers any and all groups which are known as normal alkyl and branched-chain alkyl. Unless specified otherwise, lower alkyl means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and 3 to 6 carbons for lower branch chained alkyl groups. A pharmaceutically acceptable salt may be prepared for any compound used in accordance with the invention having a functionality capable of forming a salt, for example an acid functionality. A pharmaceutically acceptable salt is any salt which retains the activity ofthe parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered. Pharmaceutically acceptable salts may be derived from organic or inorganic bases. The salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, sodium, potassium, calcium, and magnesium. Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules. Where there is a nitrogen sufficiently basic as to be capable of forming acid addition salts, such may be formed with any inorganic or organic acids or alkylating agent such as methyl iodide. Preferred salts are those formed with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid. Any of a number of simple organic acids such as mono-, di- or tri- acid may also be used. Some compounds used in accordance with the present invention may have trans and cis (E and Z) isomers. Unless specific orientation of substituents relative to a double bond or a ring is indicated in the name ofthe respective compound, and/or by specifically showing in the structural formula the orientation ofthe substituents relative to the double bond or ring the invention covers trans as well as cis isomers. Some ofthe compounds used in accordance with the present invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms. The scope ofthe present invention is intended to cover all isomers per se, as well as mixtures of cis and trans isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well. A bond drawn with a wavy line indicates that the carbon to which the bond is attached can be in any ofthe applicable possible configurations. General Synthetic Methodology The novel compounds used in accordance with the invention are encompassed by the general Formulas 1 through 8 provided above. The previously known compounds the cytochrome P450RAI activity of which has been discovered in accordance with the present invention are identified below, and references are provided which enable their preparation by one of ordinary skill in the art of synthetic organic chemistry. In each of these formulas a linker or tethering group designated Z covalently connects an aromatic or heteroaromatic moiety designated A(R2)-(CH2)n-COOR8 and another cyclic moiety which in accordance with these formulas is a substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety. Generally speaking a compound such as X4-A(R2)-(CH2)n-COOR8 is commercially available, or can be made in accordance with the chemical literature, or with such modification of known chemical processes which are within the skill ofthe practicing organic chemist. The group X4 represents a reactive group, which is suitable for coupling the X4.A(R2)-(CH2)n-COOR8 compound to a derivative ofthe substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety so that as a result ofthe coupling the linker or tether moiety Z is formed. In many instances the group X4 is a leaving group such as halogen, or trifluoromethanesulfonyloxy, or a group capable of participating in a Wittig or Homer Emmons reaction. In some instances the group X4 is an ethynyl group capable of undergoing a coupling reaction with a leaving group (such as a halogen or a trifluoromethanesulfonyloxy group) attached to the substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety. The group X4 can also represent an OH or an NH2 group that forms an ester (COO) or amide (CONH) linker, respectively, when reacted with an activated carboxyl derivative ofthe substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety. Examples for the compounds of formula X4A(R2)-(CH2)n-COOR8 are provided in the specific examples below. Further examples where the X4 group is halogen are ethyl 4-iodobenzoate, ethyl 6-iodonicotinate, ethyl 5-iodoruran-3 -carboxylate, ethyl 5-iodothioρhen-3-earboxylate, ethyl 5-iodofuran-2-carboxylate, ethyl 5- iodothiophen-2-carboxylate, and analogous halogenated derivatives ofthe respective pyridazine, pyrazine and other heteroaryl carboxylic acid esters. The analogous aryl and and heteroaryl hydroxyl compounds and amines, wherein the halogen ofthe above-listed compounds is replaced by OH or NH2 respectively, also serve as additional examples for the reagents ofthe formula X4-A(R2)-(CH2)π-COOR8. In these examples X4 is OH or NH2, respectively. Still further in accordance with the general synthetic methodology to provide the compounds of Formulas 1 through 8 a derivative ofthe substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety is synthesized first, having a covalently attached X5 group. The Xs group reacts with the X4 group of the reagent X4-A(R2)-(CH2)n-COOR8 to form the linker designated Z in Formulas 1 through 8. The X5 group is one that is capable of participating in a catalyzed coupling reaction, (such as an ethynyl group when X4 is a leaving group), or a leaving group (such as halogen or trifluoromethanesulfonyloxy when X4 is an ethynyl group) , or an activated carboxylic acid function (when X4 is OH or NH2). The X5 group can also be an OH, SH or NH2 group when the X4 group is an activated carboxylic acid function. Specific examples for substituted phenyl, substituted tetrahydronaphthalene, substituted chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline intermediates having an X5 functionality are provided below, and are also available in the chemical scientific and patent literature. Generally speaking, for reagents and reactions covalently joining a substituted tetrahydronaphthalene, substituted chroman, thiochroman, or tetrahydroquinoline intermediate with a substituted aryl or heteroaryl group, such as X4-A(R2)-(CH2)n-COOR8, to form a compound including the linker designated Z, reference is made to United States Patent Nos. 5,648,503 ; 5,723,666 and 5,952,345 the specification of each of which are expressly incoφorated herein by reference. The substituted phenyl, tetrahydronaphthalene, chroman, thiochroman, tetrahydroquinoline or tetrahydroisoquinoline moiety ofthe novel compounds used in accordance with the invention are derivatized in a manner to include the specific substituents (such as for example the cycloalkyl substituents) encompassed within the scope ofthe invention, either before or after the - A(R2)-(CH2)n-COOR8 moiety has been attached and the linker Z has formed, as illustrated by the below described specific examples. The -(CH2)n-COOR8 moiety ofthe compounds of Formulas 1 through 8 can be modified in order to obtain still further novel compounds. One such modification is saponification of compounds where the R8 group is an alkyl or -CH20(C1.6-alkyl) group. Another modification is esterification of the carboxylic acid function when the R8 group is H or a cation. Such saponification and esterification reactions are well known in the art and within the skill ofthe practicing organic chemist. Still another modification ofthe compounds used in accordance with the invention (or of the intermediates X4- A(R2)-(CH2)n-COOR8, or of precursors to these intermediates) is the homologation ofthe (CH2)n group. The latter can be accomplished, for example, by the well known Arndt-Eistert method of homologation, or other known methods of homologation. The previously known compounds which have been discovered to be inhibitors of cythochrome P450RAI and which are used in accordance with the present invention are made, generally speaking, pursuant to the teachings of a patent or publication which is identified in connection with each of the known compounds. These patents or publications are incoφorated by reference in the present specification. The synthetic procedure of homologation that may be utilized for providing a compound having the partial structure of -A(R2)-(CH2)n-COOR8 where n is 1, or 2 (one or two), preferably 1 (one), can be one of the several known procedures of homologation of carboxylic acids or esters, such as the Arndt-Eistert procedure that is described inter alia in March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, pages 809-810, McGraw-Hill Publishers, 1968, incoφorated herein by reference. Alternatively the homologs ofthe partial structure of -A(R2)-(CH2)„-COOR8 are synthesized in accordance with the synthetic schemes disclosed herein in connection with the preparation of the novel compounds . SPECIFIC EMBODIMENTS With reference to the symbol A in Formulas 1 through 8, the preferred novel compounds used in accordance with the present invention are those where A is phenyl, naphthyl, pyridyl, thienyl or furyl. Even more preferred are compounds where A is phenyl. As far as substitutions on the A (phenyl) and A (pyridyl) groups are concerned, compounds are preferred where the phenyl group is 1,4 (para) substituted and where the pyridine ring is 2,5 substituted. (Substitution in the 2,5 positions in the "pyridine" nomenclature corresponds to substitution in the 6-position in the "nicotinic acid" nomenclature.) In the presently preferred novel compounds used in accordance with the invention either there is no R2 substituent on the A group, or the R2 substituent is preferably a fluoro group that is preferably located on the aromatic carbon adjacent (ortho) to the carbon bearing the -(CH2)n- COOR8 group. As far as the -(CH2)n-COOR8 is concerned the use of novel compounds is preferred where n is 0, 1 or 2, and even more preferred where n is 1. In Formulas 5 and 8 only compounds where n is 1 or 2 are preferred, with n=l being most preferred. For the R8 group H, lower alkyl of 1 to 3 carbons, and -CH20(C1.6-alkyl) groups are preferred, as well as the pharmaceutically acceptable salts ofthe free acids when R8 is H. Among the lower alkyl and -CH20(C1.6-alkyl) groups ethyl and OCH2CH3, respectively, are presently most preferred. The linker group Z in all ofthe novel compounds used in accordance with the invention is preferably ethynyl (-C≡C-), ester (CO-O), ethenyl, (-CR-! =CRr) or amide (CONR^. Among these the ethynyl (-C≡C-) and ester (CO-O) linkers are most preferred. Moreover, preferably the linker Z is attached to the 6 position in Formula 1, to the 4 position in Formula 2, to the 6 position in Formula 3, to the 6 position in Formula 4, to the 4 position in Formula 5, to the 4 position in Formula 6, to the 6 position in Formula 7, and to the 6 position in Formula 8. These positions are indicated by arabic numerals in Formulas 1 through 8. The Rj group substituting the non-aromatic rings in Formulas 1, 3, 4, 7 and 8 is preferably alkyl, more preferably alkyl of 1 to 3 carbons, and most preferably methyl. The Rx group substituting the cyclopropane ring in Formulas 1, 2, 3 and 7 is preferably non-existent (p is 0), or is alkyl of 1 to 3 carbons, even more preferably methyl. The X group in Formulas 1 and 5 is preferably O, and in Formula 2 X is preferably O or NR. The Xj group in Formula 4 is preferably 1 -imidazolyl, substituted 1- imidazolyl, or NRR6, where R6 is preferably cyclopropyl or branched-chain alkyl. The X2 group in Formula 6 is preferably 1 -imidazolyl or substituted 1 -imidazolyl. The X3 group in Formula 8 is preferably O or C=0. The Y group is preferably H, lower alkyl of 1 to 3 carbons, cycloalkyl, lower alkyl substituted cycloalkyl, or halogen. Among these, H, Cl, and cyclopropyl are most preferred. The Yj group of Formula 8 is preferably H, lower alkyl of 1 to 3 carbons, cycloalkyl, or lower alkyl substituted cycloalkyl. Among these H, ethyl and cyclopropyl are presently most preferred. The most preferred novel compounds used in accordance with the invention are disclosed in Tables 2 through 9 with reference to Formulas 9 through 16. The compounds specifically shown in Tables 2 through 9 are carboxylic acids, but it should be understood that the use ofthe corresponding C1.3alkyl esters, methoxymethyl (OCH2CH3) esters and of pharmaceutically acceptable salts ofthe acids shown in these tables is also highly preferred. It should also be apparent that the preferred compounds shown in Table 2 with reference to the more specific Formula 9 are within the scope of Formula 1. Similarly, the preferred compounds shown in Table 3 with reference to the more specific Formula 10 are within the scope of Formula 2; the preferred compounds shown in Table 4 with reference to the more specific Formula 11 are within the scope of Formula 3; the preferred compounds shown in Table 5 with reference to the more specific Formula 12 are within the scope of Formula 4; the preferred compounds shown in Table 6 with reference to the more specific Formula 13 are within the scope of Formula 5; the preferred compounds shown in Table 7 with reference to the more specific Formula 14 are within the scope of Formula 6; the preferred compounds shown in Table 8 with reference to the more specific Formula 15 are within the scope of Formula 7, and the preferred compounds shown in Table 9 with reference to the more specific Formula 16 are within the scope of Formula 8.
Figure imgf000049_0001
Formula 9
TABLE 2
Figure imgf000049_0002
Figure imgf000050_0001
TABLE 3
Figure imgf000050_0002
Figure imgf000051_0002
Figure imgf000051_0001
Formula 11
TABLE 4
Figure imgf000051_0003
Figure imgf000052_0001
Formula 12
TABLE 5
Figure imgf000052_0002
Figure imgf000053_0001
TABLE 6
Figure imgf000053_0002
Figure imgf000054_0001
Formula 14
TABLE 7
Figure imgf000054_0002
Figure imgf000055_0001
TABLE 8
Figure imgf000055_0002
Figure imgf000056_0001
Formula 16
TABLE 9
Figure imgf000056_0002
The compounds used in accordance with the invention can be synthesized by applying the general synthetic methodology described above, and by such modifications of the hereinafter described specific synthetic routes which will become readily apparent to the practicing synthetic organic chemist in light of this disclosure and in view of general knowledge available in the art. The hereinafter disclosed specific reaction schemes are directed to the synthesis of exemplary and preferred compounds used in accordance with the invention. Whereas each ofthe specific and exemplary synthetic routes shown in these schemes may describe specific compounds only within the scope of one or two ofthe general Formulas 1 through 8, the synthetic processes and methods used therein are adaptable within the skill ofthe practicing organic chemist and can be used with such adaptation for the synthesis of compounds used in accordance with the invention which are not specifically described herein as examples. Reaction Scheme 1 discloses a presently preferred synthetic route to certain intermediates or reagents having the general formula X4-A(R2)-CH2)n- COOR8, where the symbol A represents a di-, or tri-substituted phenyl moiety. These intermediates are utilized in the synthesis ofthe novel compounds used in accordance with the invention.
Figure imgf000058_0001
N 1S1BBSS,. AWJBN, CClt NaCN,EtOHH20 CN
Figure imgf000058_0002
Figure imgf000058_0003
intermediate 1 intermediate 2
Figure imgf000058_0004
intermediate 4 icte 5
Figure imgf000058_0005
H3 t
COOH H3d XBJ COOBit
HO »«-
HO
PhCH3, 8(fC reagent E
Figure imgf000058_0006
FhCH,, SϋPc reagent F
REACπON SCHEME 1
Figure imgf000059_0001
reagent G
Figure imgf000059_0002
intermediate 2 reagent H
EtOH, Hβ04
Figure imgf000059_0003
Figure imgf000059_0004
intermediate 4 reagent I
REACΗON SCHEME 1 CONTINUED
Reaction Scheme 2 discloses presently preferred synthetic routes to obtain exemplary and preferred novel tetrahydronaphthalenone compounds within the scope of Formula 8 where the the symbol X3 represents a C=0 group, Z represents an ethynyl moiety or a -COO- (ester) function, and A is a substituted phenyl moiety. Reaction Scheme 3 discloses presently preferred synthetic routes to obtain exemplary and preferred novel tetrahydronaphthalene compounds within the scope of Formula 4 where Xj represents a dialkyl substituted nitrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 4 discloses presently preferred synthetic routes to obtain exemplary and preferred novel isoquinoline compounds within the scope of Formula 3 where the symbol Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 5 discloses presently preferred synthetic routes to obtain exemplary and preferred novel chroman compounds within the scope of Formula 8 where the symbol Yj represents hydrogen, Z is an ethynyl moiety or an ester (COO) fimction, and A is a substituted phenyl moiety.
Figure imgf000061_0001
intermediate 8 intermediate 9
Figure imgf000061_0002
intermediate 10 intermediate 11
C
Figure imgf000061_0003
intermediate 12 intermediate 13
Figure imgf000061_0004
intermediate 14 n = 0 X=HR = CH3CH2 Compomd4 n = 1 X =HR = CH3 Compound5 «=i X=H Compound 14 «=I X = F R= CH3CH2 Compound IS n=lX = F
Figure imgf000061_0005
1. Pd(OAc)2> dppp, EDC, NEt3> CO
Figure imgf000062_0002
Figure imgf000062_0001
Figure imgf000062_0003
intermediate 11 Compound 20 reagent E 2. CFsCOOH, CH2Cl2
BEACΗON CHEME 2 CONTINUED
Figure imgf000063_0001
intermediate 14 n = 0 X=H R = CH3CH2 Compound 3 n — Q X = H Compound4 11 =1 X =HR = CH3 Compound 8 n = l X =H Compound 9 n = 0 X =FR = CH3CH2 Compound 13 n = 0 X = F CompoundU n=l X = FR= CH3CH2 Compound 18 n = l X = F
Figure imgf000063_0002
intermediate 12 intermediate 29
Figure imgf000063_0003
Compound 25 Compound 26
REACTION SCHEME 3 63
1
Figure imgf000064_0001
i •nt -ermed ji-a.-t.e 1 I T 7 mtermediate 18
Figure imgf000064_0002
\ 1 intermedi e 22 intermediate 23
Figure imgf000064_0003
14
TPAP= tetrarn-propyl ammonium peruthenate
15 NMO — N-methylmorpholine N-oodde reference 1 Tomita etaL J. Chem, Soc. (c), 1969, 183-188 15 reference 2 Chqpiinslά et aL Angew. Chem Int Edit. Engl, 1996, 35, 413-414
17
REACπON SCHEME 4 18
19
20
21
22
23
Figure imgf000065_0001
intermediate 27 Compound21X=F R = CH3CH2 Compomtd23X=H R = CH3
UOHH20, MeOHTHF:H20
Figure imgf000065_0002
Compound 22 X = F Compound 24 X=H
REACΩON SCHEME 4 CONTINUED
Figure imgf000066_0001
U. S. Patent Nos. 5,045,551 and 5,616,597 Compound 29 X = F n = 0 R = CH3 Compound 31 X = F n =l R = CH3CH2
Figure imgf000066_0002
Compound 30 X = Fn = 0 Compound32 X = Fn=l
l. SOCl2, benzene
Figure imgf000066_0003
2. pyridine, intermediate 39 reagent E
Figure imgf000066_0004
Compoimd 46
REACπON SCHEMES
Reaction Scheme 6 discloses presently preferred synthetic routes to obtain other exemplary and preferred novel chroman compounds within the scope ofFormula 8 where the symbol Yx represents a cyclopropyl group, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 7 discloses presently preferred synthetic routes to obtain exemplary and preferred novel chroman compounds within the scope of Formula 1 where the symbol X represents oxygen (O), Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 8 discloses presently preferred synthetic routes to obtain other exemplary and preferred novel chroman compounds within the scope ofFormula 1 where the symbol X represents oxygen (O), Y represents a cyclopropyl group, Z is an ethynyl moiety and A is a substituted phenyl moiety.
Figure imgf000068_0001
intermediate 32 intermediate 33
Figure imgf000068_0002
intermediate 34
Compound 33 X=Hn = 0R = CH3CH2 Compound 35 X=H n = l R = CH3 Compound 37 -V = «=1 Λ = CH3C&
Figure imgf000068_0003
Compound 34 X=H n = 0 Compound 36 X=H n=l Compound 38 X=F n = l
BEACπON SCHEME 6
Figure imgf000069_0001
K2C03,MeOH
Figure imgf000069_0002
Figure imgf000069_0003
intermediate 37 intermediate 38
Figure imgf000069_0004
Compound 39 X=Hn = 0 Λ = CH3CH2 Compound41X=Hn=l R = CH3 Compound 43 X=F n = 0 R = CH3
Figure imgf000069_0005
Compound 40 X=H n = 0 Compound42 X=H n=l Compound 44 X = F n =0
REACπON SCHEME 7
Figure imgf000070_0001
ititennedide 36 intermediate 40 intermediate 41
Figure imgf000070_0002
intermediate 43 intermediate 42
Figure imgf000070_0003
intermediate 44
Compound47 X=H n=l R = CH3 Compound49 X = F n = l R = CH3 Compound 51 X=H n = 0 Λ = CH3CH2 Compound S3 X = F n = 0 R = CH3
Figure imgf000070_0004
Compoimd 48 X ~H n =l CompoundSO X=F n=l Compound 52 X =H n = 0 Compoimd 54 X = F n = 0
REACπON SCHEME 8 Reaction Scheme 9 discloses presently preferred synthetic routes to obtain exemplary and preferred novel tetrahydroquinoline compounds within the scope ofFormula 1 where the symbol X represents an alkyl substituted nitrogen (alkyl-N), Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Schemes 10 and 11 disclose presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 2 where the symbol X represents oxygen (O), Rg is alkyl or benzyl, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 12 discloses presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 2 where the symbol Rs-X represents an alkyl, dialkyl, benzyl or dibenzyl substituted nitrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Schemes 13 and 14 disclose presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope ofFormula 6 where the symbol X2 represents a (1 -imidazolyl) moiety, Z is an ethynyl moiety and A is a substituted phenyl moiety.
Figure imgf000072_0001
intermediate 54 mtermediate 55
TiiOIr1)* EtMgBr
THF, Ether
Figure imgf000072_0002
intermediate 56 intermediate 57
Figure imgf000072_0003
Compound 65
Figure imgf000072_0004
Compound 66
REACTION SCHEME 9
Figure imgf000073_0001
intermediate 63 R =H R'=i-propyl intermediate 59 R = H R'=Me intermediate 68 R =H R'=benzyl intermediate 64 i- = H R'=i-propyl intermediΛe 73 R =Me R'= benzyl intermediate 69 R- H R'= benzyl intermediate 78 R =Me R'=i-propyl intermediate 74 i? = Me R'= benzyl intermediate 83 R 'Me R'=neopentyl intermediate 79 i? = Me R'=i-propyl intermediate 87 R --Et R'= benzyl intermediate 84 R- Me R'=neopentyl intermediate 92 R --Et R'=i-propyl intermeditέe 88 R = Et R'= benzyl intermediate 93 R = Et R'*=i-propyl
REACπON SCHEME 10
Figure imgf000074_0001
intermediate 61 R=H R'=Me intermedirte 66 R=H R'=i-propyl intermediate 71 R=H R'= benzyl Compound 69 n = 0 R =H R'=methyl intermediate 76 R=Me R'= benzyl Compound 70 n =l R =j_-" R'=metlψl intermediate 81 R=Me R'=i-propyl Compound 73 n = 0 R =H R'^i-propyl intermediate 85 R=Me R'=neopentyl Compound 74 n = l R =H R'=i-propyl intermediate 90 R = Et R'= benzyl Compoimd 77 n = 0 R =H R'^benzyl intermediate 95 R = Et R'^i-propyl Compound 78 n =l R =H R' -benzyl Compound 81 « = -. R =Me R'= benzyl Compound 82 n = l R =Me R'= benzyl Compound 85 « = 0 R =Me R'=i-propyl Compound 86 n =l R =Me R'=i-propyl Compoimd 89 « = 0 R - ■■ Me R'=neopenfyl Compound 90 n = l R =Me R'=neopentyl Compound 93 n = 0 R = Et R'= benzyl Compound 94 n = l R -Et R'= benzyl Compound 97 n = 0 R -Et R'=i-propyl Compound 98 n =l R = Et R'=i-pwpyl
REACπON SCHEME 10 CONTINUED
Figure imgf000075_0002
Tebbe Reagent
Figure imgf000075_0001
R = i-propyl intermediate 97 R = i-propyl intermediate 104 R= t-butyl intermediate 106 R = t-butyl
Figure imgf000075_0003
intermediate 98 R= i-propyl intermediate 99 R = i-propyl intermediate 107 R= t-butyl intermediate 108 R = t-butyl
Figure imgf000075_0004
TBAF=tetra-n-butyl ammonium fluoride
Figure imgf000075_0005
REACπON SCHEME 11
Figure imgf000076_0001
Figure imgf000076_0002
Figure imgf000076_0003
irtermediate 118 R=H, R'= n-propyl intermediate 116 or intermediate 121 R = n-propyl, R'= n-propyl
CH3CH2CHO, NaCNBH3 itermediate 124 R=H, R'= benzyl intermediate 125 R = benzyl, R'= benzyl
Figure imgf000076_0004
intermediate 130
Figure imgf000076_0005
intermediate 118 R=H, R'= n-propyl intermediate 120 R=H, R'= n-propyl intermediate 121 R = n-propyl, R'= n-propyl intermediate 123 R = -propyl, R' = -propyl intermediate 124 R=H, R'=benzyl intermediate 127 R=H, R'= benzyl intermediate 125 intermediate 129 R = benzyl, R,=s benzyl R = benzyl, R'= benzyl intermediate 130 R= methyl, R'= benzyl intermediate 132 R = methyl R'= benzyl
Figure imgf000076_0006
REACπON SCHEME 12
Figure imgf000077_0001
Figure imgf000077_0002
interme ate 136
Figure imgf000077_0004
Br ntermeiate 37
Figure imgf000077_0003
Figure imgf000077_0005
intermediate 141
REACTION SCHEME 13
Figure imgf000078_0001
intermediate 143 intermediate 146
Figure imgf000078_0002
intermediate 152 intermediate 153 n = 0 R = ethyl intermediate 154 n = l R = methyl
Figure imgf000078_0003
intermediate 155 n ~ 0 R= ethyl intermediate 156 n=l R = methyl
TBS=t-butyldimethylsilyl
Figure imgf000078_0004
REACπON SCHEME 14 Reaction Scheme 15 disclose presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 6 where X2 represents an alkyl and cyclopropyl substituted nitrogen (X2 = (alkyl,cycloalkyl)N) , Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 16 discloses presently preferred synthetic routes to obtain exemplary and preferred novel tetrahydronaphthalene compounds within the scope ofFormula 4 where the symbol Xx represents a (1- imidazolyl) moiety, Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 17 discloses presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 6 where the symbol X2 represents a 1-methyl-cyclopropoxy moiety, Y represents hydrogen, Z is an ethynyl moiety and A is a substituted phenyl moiety. Reaction Scheme 18 discloses presently preferred synthetic routes to obtain exemplary and preferred novel phenyl compounds within the scope of Formula 5 where the symbol X represents oxygen (O), Y represents a tertiar -buty] group, Z is an ethynyl moiety and A is a substituted phenyl moiety.
Figure imgf000080_0001
intermediate 158
B
Figure imgf000080_0002
2.K2C03,MeOH intermediate 159 intermediate 161
Figure imgf000080_0003
REACTION SCHEME 15
Figure imgf000081_0001
intermediate 13 n = 0 R=Et Compoimd 4 n —1 R=Me
Figure imgf000081_0002
n = 0 R=Et Compound 135 n ~l R=Me Compound 137 n = l Compound 139 n = 0
REΛ CΩON SCHEME 16
Figure imgf000082_0001
Compound 141
REACTION SCHEME 17
H
Figure imgf000083_0001
3. K2C03, MeOH intermediate 169
Figure imgf000083_0002
Compound 142 R=H Compound 143 R=H Compound 144 R = F Compound 145 R = F
REACΗON SCHEME 18
Certain known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula A where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000084_0001
In Compound 201 X5 = O, X6 = CH, n = 0, R8 = H or a cation of a pharmaceutically acceptable base and R10 = CH3.
In Compound 202 X5 = S, X6 = CH, n = 1, R8 = H or a cation of a pharmaceutically acceptable base and R10 = H.
In Compound 210 X5 = S, X6 = CH, n = 2, R8 = H or a cation of a pharmaceutically acceptable base and R10 = H.
In Compound 215 X5 = S, X6 = CH, n = 0, R8 = H or a cation of a pharmaceutically acceptable base and R10 = H.
In Compound 238 X5 = S, X6 = N, n = 0, R8 = H or a cation of a pharmaceutically acceptable base, R10 = H.
Compound 201 is described as compound 4 in United States Patent No. 4,980,369 incoφorated herein by reference. Compounds 202, 210, and 215 are described in United States Patent No. 4,810,804 incoφorated herein by reference. Compound 215 is example 12 of Patent No. ,4810,804. Compound 238 is described in United States Patent No. 5,089,509 incoφorated herein by reference (see Claim 5 of Patent No. 5,089,509).
Other known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula B where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
Figure imgf000085_0001
Specifically in Compound 240 R8 is H or a cation of a pharmaceutically acceptable base. Compound 240 is described and can be made in accordance with the teachings of United States Patent Nos. 5,089,509, ,5,602,130 or 5,348,972 all of which are incoφorated herein by reference. Still other known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula C where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000086_0001
In Compound 203 R8 is H or a cation of a pharmaceutically acceptable base,
R10 = CH3; Rn = Cl, R12 = F and X6 = CH.
In Compound 204 R8 is H or a cation of a pharmaceutically acceptable base,
R10 = C Ru = cyclopropyl, Rϊ2 = F and X6 = CH.
In Compound 205 R8 is H or a cation of a pharmaceutically acceptable base,
R10 = CH3j Rπ = CF3, R12 = F and X6 = CH.
In Compound 206 R8 is H or a cation of a pharmaceutically acceptable base,
R10 = CH3CH2, Rπ = Br, R12 = F and X6 = CH.
In Compound 220 R8 is H or a cation of a pharmaceutically acceptable base,
R10 = CH3j Rn = CH3j R12 = F and X6 = CH.
In Compound 221 R8 is H or a cation of a pharmaceutically acceptable base,
R10 = CH3> Rπ = Cl, R12 = F and X6 = N.
In Compound 224 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3; R = phenyl, Ri2 = F and X6 = CH. In Compound 225 R8 is H or a cation of a pharmaceutically acceptable base, R10 = H Ru = Br R12 = F and X6 = CH. In Compound 226 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3> R„ = OCH3) Rj2 = F and X6 = CH. In Compound 227 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3; Rn = CH3j R12 = H and X6 = CH. In Compound 228 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3 Rπ = H R12 = F and 6 = CH. In Compound 247 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3; Rπ - Br R12 = F and X6 = CH. In Compound 248 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3; Rn = CF3CF2, R12 = F and X6 = CH. In Compound 249 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3) Rπ = CH3 CH2, R12 = F and X6 = CH. In Compound 250 R8 is H or a cation of a pharmaceutically acceptable base, R10
Figure imgf000087_0001
F and X6 = CH. In Compound 251 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3 Rπ = (l-methyl)cyclopropylf R12 = F and X6 = CH. In Compound 252 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3j Rπ
Figure imgf000087_0002
R12 = F and X6 = CH. In Compound 253 R8 is H or a cation of a pharmaceutically acceptable base, R-io = CH3 Rπ = (2,2-difluoro)cyclopropyl) R12 = F and X6 = CH. In Compound 254 R8 is H or a cation of a pharmaceutically acceptable base, R10 = CH3j Rn = (cyclopropy^methy^ R12 = F and X6 = CH. Compounds 203 - 206, 220, 221, 224 - 228 and 247 - 254 are described and can be made in accordance with the teachings of United States Patent No. 5,675,024 which is incoφorated herein by reference. (Compound 205 is compound or example 14, Compound 225 is compound or example 10, and Compound 228 is compound or example 32 in Patent No. 5,675,024. Compound 220 is also described in United States Patent No. 5,965,606, incoφorated herein by reference.
Still other known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula D where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000088_0001
In Compound 207 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, the two R13 groups jointly represent an oxo (=0) function and R14 = CH3.
In Compound 208 R8 is H or a cation of a pharmaceutically acceptable base,
R12 = H, R13 = H and R14 = CH3.
In Compound 216 R8 is H or a cation of a pharmaceutically acceptable base,
R12 = H, R13 = CH3 and R14 = CH3.
In Compound 218 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, R13 = CH3 and R14 = H. In Compound 230 R8 is H or a cation of a pharmaceutically acceptable base, R12 = F, R13 = CH3 and 14 = CH3. In Compound 232 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, one ofthe R13 groups is H, the other is OH and R14 = CH3. Compound 207 is described (as compound 7) in United States Patent No. 5,489,584 incoφorated herein by reference. Compound 232 is described (as compound 42) in United States Patent No. 5,654,469 incoφorated herein by reference. Compounds 208, 216 and 218 are described in the publication by Chandraratna el al. J. Eur. J. Med. Chem., Suppl. to Vol. 30, 1995, 506s- 517s. Compound 230 can also be made in accordance with the teachings of the publication by Chandraratna el al. J. Eur. J. Med. Chem., Suppl to Vol. 30, 1995, 506s-517s, incoφorated herein by reference, or by such modification ofthe synthetic procedures of this reference which will be readily apparent to those skilled in the art. Still further known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula E where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(Cμ6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000089_0001
In Compound 209 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, R15 = tertiary-butyl, R16 = OH and R17 = Cl. In Compound 211 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, R15 = tertiary-butyl, R16 = OCH3 and R17 = tertiary-butyl. In Compound 214 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, R15 = 1-adamantyl, R16 = OCH3 and R17 = H. In Compound 235 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, R15 = tertiary-butyl, R16 = OH and R17 = tertiary-butyl. In Compound 236 R8 is H or a cation of a pharmaceutically acceptable base, R12 = F, R15 = tertiary-butyl, R16 = OH and R17 = H. Compound 211 is described and can be made in accordance with the teachings of United States Patent No. 5,202,471, and Compound 235 is described and can be made in accordance with the teachings of United States Patent No. 5,498,795. The specification of Patent Nos. 5,202,471 and 5,498,795 are incoφorated herein by reference. Compounds 209, 214 and 236 can also be made in accordance with the teachings of United States Patent Nos. 5,202,471 and 5,498,795 with such modifications ofthe synthetic procedures which will be readily apparent to those skilled in the art. Still more known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula F where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(CI.6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000091_0001
In Compound 222 R8 is H or a cation of a pharmaceutically acceptable base, R12 = F, R15 = tertzαry-butyl, R16 = CH3CH20 and R17 = I. In Compound 223 R8 is H or a cation of a pharmaceutically acceptable base, R12 = F, R15 = tertiary-butyl, R16 = CH3CH20 and R17 = Br.
Compounds 222 and 223 are described and can be made in accordance with the teachings of United States Patent Nos. 5,663,357 and 5,917,048, the . specifications of which are incoφorated herein by reference.
Yet more known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula G where R8 generally represents H, alkyl of 1 to 6 carbons, -CH2θ(Cμ6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000092_0001
In Compound 212 R8 is H or a cation of a pharmaceutically acceptable base,
R12 = H, X6 = CH and X7 = (CH3)2C.
In Compound 217 R8 is H or a cation of a pharmaceutically acceptable base,
R12 = H, X6 = CH and X7 - CH2.
In Compound 219 R8 is H or a cation of a pharmaceutically acceptable base,
R12 = H, X6 = CH and X7 = S.
In Compound 229 R8 is H or a cation of a pharmaceutically acceptable base,
R12 = F, X6 = CH and X7 = CH2.
In Compound 244 R8 is H or a cation of a pharmaceutically acceptable base,
R12 = H, X6 = N and X7 = CH2.
Compounds 217 is described (as example or compound 4) and can be made in accordance with the teachings of United States Patent Nos. 4,739,098 the specification of which is incoφorated herein by reference. Compounds 219 is described (as compound 2) and can be made in accordance with the teachings of United States Patent Nos. 5,688,957, the specification of which is incoφorated herein by reference. Compound 212 and Compound 229 can be made in accordance with the teachings of United States Patent Nos. 4,739,098 and in case of Compound 212 also in accordance with United States Patent No. 5,426,118, with such modifications ofthe synthetic procedures which will be readily apparent to those skilled in the art. The specification of United States Patent No. 5,426, 118 is incoφorated herein by reference. Compound 244 is described (as compound or example 7) and can be made in accordance with the teachings of United States Patent Nos. 4,923,884, the specification of which is incoφorated herein by reference.
Still more known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula H where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1-6-alkyl), or a cation of a pharmaceutically acceptable base.
Figure imgf000093_0001
Specifically in Compound 245 R8 is H or a cation of a pharmaceutically acceptable base.
Compounds 245 is described and can be made in accordance with the teachings of United States Patent Nos. 4,923,884. Further known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula I where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
Figure imgf000094_0001
Specifically in Compound 242 R8 is H or a cation of a pharmaceutically acceptable base.
Compound 242 is described in the publication by Bernard et al. Biochem. Biophys. Res. Commun., 1992, Vol. 186, 977-983, incoφorated herein by reference.
Still more known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula J where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(Cμ6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000095_0001
Formula J
In Compound 237 R8 is H or a cation of a pharmaceutically acceptable base,
Figure imgf000095_0002
In Compound 246 R8 is H or a cation of a pharmaceutically acceptable base, R12 = H, R18 = OH and R19 = F.
Compounds 237 and 246 are described and can be made in accordance with the teachings of United States Patent Nos. 5,675,024 and 5,856,490. Compound 237 is compound or example 2 of Patent No. 5,675,024. The specification of United States Patent No. 5,856,490 is incoφorated herein by reference. Additional known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula K where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C|.6-alkyl), or a cation of a pharmaceutically acceptable base.
Figure imgf000096_0001
Specifically in Compound 231 R8 is H or a cation of a pharmaceutically acceptable base.
Compound 231 is described (as compound 2) in United States Patent No, 5,006,550, the specification of which is incoφorated herein by reference.
Still more known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula L where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
Figure imgf000097_0001
Specifically in Compound 243 R8 is H or a cation of a pharmaceutically acceptable base.
Compound 243 is described (as example or compound 7) in United States Patent No. 5,130,335, the specification of which is incoφorated herein by reference.
Still more known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula M where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, and where the other variables have the following specific values:
Figure imgf000098_0001
In Compound 233 R8 is H or a cation of a pharmaceutically acceptable base, R15 = 1-adamantyl and R16 = OH.
In Compound 234 R8 is H or a cation of a pharmaceutically acceptable base, R15 = 1-adamantyl and R16 = OCH3.
Compounds 233 and 234 are described in the publication by Shroot et¬ al. J. M. EP 199636 (1986) incoφorated herein by reference.
Further known compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula N where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(CI.6-alkyl), or a cation of a pharmaceutically acceptable base.
Figure imgf000099_0001
Specifically in Compound 241 R8 is H or a cation of a pharmaceutically acceptable base.
Compound 241 is described in the publication by Dawson et al. J. Med. Chem., 1983, Vol. 26, 1653-1656. incoφorated herein by reference.
Still further compounds which have been discovered in accordance with the present invention to be useful as inhibitors of cytochrome P450RAI are shown by Formula O where R8 generally represents H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
Figure imgf000100_0001
Form ula O
Specifically in Compound 247 R8 is H or a cation of a pharmaceutically acceptable base. Compound 247 is described in the publication by Winum et al. II Farmaco, 1997, Vol. 52, 1, ρ39-42, incoφorated herein by reference.
The P450RAI inhibition data of this compound are provided in Table 1A, and the cutaneous toxicity score (blackjack score) ofthe compound in the topical skin irritation tests provided above, are disclosed in Table IB.
SPECIFIC EXAMPLES OF NEW COMPOUNDS 4-Hvdroxy phenyl acetic acid-t-butyl ester (Reagent E) A stirred suspension of 4-hydroxy-ρhenyl acetic acid (0.152g, immol) in anhydrous toluene (5mL) was heated at 80°C and N,N-dimethyl formamide- di-t-butyl acetal (lmL, 4.17mmol) was added when the solution became homogenous. After 0.5h, the reaction mixture was cooled to ambient temperature and the volatiles were distilled off in vacuo. The residue was diluted with water and extracted with diethyl ether (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 16% ethyl acetate in hexane as the eluent to afford the title compound as a solid (0.1 lg, 56%). Η-NMR (300 MHz, CDCl3):δ 1 ,44(s, 9H), 3.45(s, 2H), 6.55(s, IH), 6.69(d, J = 8.8Hz, 2H), 7.06(d, J = 8.5Hz, 2H). 3-Hydroxy phenyl acetic acid-r-butyl ester (Reagent F) A stirred suspension of 3-hydroxy-phenyl acetic acid (1.52g, lOmmol) in anhydrous toluene (20mL) was heated at 80°C and N,N-dimethyl formamide-di-t-butyl acetal (9.6mL, 40mmol) was added when the solution became homogenous. After 0.5h, the reaction mixture was cooled to ambient temperature and the volatiles were distilled off in vacuo. Th residue was diluted with water and extracted with diethyl ether (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 16% ethyl acetate in hexane as the eluent to afford the title compound as a solid ( 1.17g, 56%) . Η-NMR (300 MHz, CDCl3):δ 1.47(s, 9H), 3.49(s, 2H), 6.30(s, IH), 6.70-6.79 (m, 2H), 6.8 l(d, J = 7.6Hz, IH), 7.16(t, J = 7.7Hz, IH). Methyl-2-fluoro-4-iodo benzoate (Reagent G) A solution of 2-fluoro-4-iodo toluene (5g, 26.6mmol) in pyridine (2mL) and water (20mL) was treated with potassium permanganate (16.6g, 105mmol) and heated at 150°C overnight. The reaction mixture was then cooled to room temperature and filtered and the filtrate was extracted with hexane. The aqueous phase was acidified with 10% hydrochloric acid and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The residue was dissolved in 20mL of methanol, treated with concentrated sulfuric acid ( lmL) and refluxed overnight. The volatiles were distilled off in vacuo and the residue was dissolved in diethyl ether, washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to an oil. Flash column chromatography over silica gel (230-400 mesh) using 10% ethyl acetate in hexane as the eluent afforded the title compound as an oil (0.26g, 5%). Η NMR (300 MHz, CDC13): δ 7.60 (m, 4H), 3.93 (s, 3H). Ethyl-2-fluoro-4-hydroxy benzoate (Reagent I) A solution of 2-fluoro-4-hydroxy benzoic acid (Intermediate 4, 3g, 19.2mmol) in ethanol (65mL) and benzene (90mL) was treated with concentrated sulfuric acid ( 1.5mL) and heated at reflux overnight using a Dean-Stark water trap. The volatiles were distilled off in vacuo and the residue was diluted with water and diethyl ether. The phases were separated and the organic phase was washed with saturated aqueous sodium bicarbonate (xl), water (xl) and brine (xl), dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound as a solid (3.07g, 86%). Η-NMR (300 MHz, CD3COCD3): δ 1.34 (t, J= 7.1Hz, 3H), 4.32 (q, J= 7.1Hz, 2H), 6.66(dd, J = 2.6, 10.9Hz, IH), 6.76 (dd, J= 2.3, 8.5Hz, IH), 7.83(d, J= 8.4Hz, IH), 9.91 (s, IH). Ethyl-2-fluoro-4-trifluoromethylsulfonyloxy-benzoate (Intermediate 6) A stirred, cooled (ice bath) solution of ethyl-2-fluoro-4-hydroxy- benzoate (Intermediate 5, 0.368g, 2mmol) and 2,6-di-tert-butyl-4-methyl- pyridine (0.81 g, 8mmol) in 8mL of dichloromethane was treated with trifluoromethanesulfonic anhydride (O.lg, 4mmol). The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The reaction mixture was subjected to flash column chromatography over silica gel (230- 400 mesh) using 5-10%> ethyl acetate in hexane as the eluent to afford the title compound (0.53g, 85%). Η-NMR (300 MHz, CDC13): δ 1.41 (t, J= 7.3Hz, 3H), 4.42 (q, J= 7.1Hz, 2H), 7.12-7.20(m, 2H), 8.08(t, J= 8.3Hz, IH). Ethyl-2-fluoro-4-trimethylsilanylethynyl-benzoate (Intermediate 7) A solution of ethyl-2-fluoro-4- trifluoromethylsulfonyloxy-benzoate (Intermediate 6, 1.82g, 6mmol) in triethyl amine (12mL) and anhydrous tetrahydrofuran (30mL) was treated with copper(I)iodide (0.12g, 0.6mmol) and sparged with argon. Dichlorobis(triphenylphosphine)palladium(II) (0.43g, 0.6mmol) was added followed by (trimethylsilyl) acetylene (3.6mL, 24mmol) and the resulting reaction mixture was heated at 70°C overnight. It was then cooled to ambient temperature, diluted with diethyl ether and filtered over a bed of celite. The filtrate was evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent to afford the title compound as an orange oil (1.5g, quantitative). Η-NMR (300 MHz, CDCl3):δ 0.011 (s, 9H), 1.13(t, J= 7.1Hz, 3H), 4.13 (q, J = 7.1Hz, 2H), 6.93-7.02(m, 2H), 7.07 (s, IH), 7.61(t, J= 7.9Hz, IH). Ethyl-4-ethvnyl-2-fluoro benzoate (Reagent D) A solution of ethyl-2-fluoro-4-trimethylsilanylethynyl-benzoate (Intermediate 7, 1.5g, 6mmol) in ethanol (16mL) was treated with potassium carbonate (1.485g, 10.74mmol) and stirred overnight at room temperature. The reaction mixture was then diluted with water and extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford an orange oil. Flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent afforded the title compound ( 1 g, 86%) . Η-NMR (300 MHz, CDCl3):δ 1.39 (t, J= 7.1Hz, 3H), 3.26 (s, IH), 4.39 (q, J = 7.1Hz, 2H), 7.22-7.33 (m, 2H), 7.88(t, J= 7.7Hz, IH). Methyl-4-iodo-ρhenyl acetate (Reagent B) A solution of 4-iodo phenyl acetic acid (5g, 19mmol) in methanol was treated with concentrated sulfuric acid (0.5mL) and refluxed overnight. The volatiles were distilled off in vacuo and the residue was dissolved in ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent to afford the title compound as a clear oil (5g, 95%). Η NMR (300 MHz, CDC13): δ 7.63 (d, 2H, J= 8.5Hz), 7.01 (d, 2H, J= 8.0Hz), 3.67 (s, 3H), 3.55 (s, 2H). 2-Fluoro-4-iodo-phenyl acetonitrile (Intermediate 2) A solution of 2-fluoro-4-iodo-benzyl bromide (Intermediate 1 , 2.56g, 8.15mmol) in ethanol (55mL and water (lOmL) was treated with sodium cyanide (2.15g, 43.86mmol) and refluxed for 0.5h. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with diethyl ether (x2). The combined organic extract was washed with water (xl) and brine (xl), dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound as a pale yellow solid (2.05g, 96%). Η-NMR (300 MHz, CDC13): δ 3.71(s, 3H), 7.16(t, J= 8.2Hz, IH), 7.45(dd, J = 1.7, 9.1Hz, IH), 7.51(dd, J= 1.5, 8.2Hz, IH). 2-Fluoro-4-iodo-phenyl acetic acid (Intermediate 3) A solution of 2-fluoro-4-iodo-ρhenyl acetonitrile (Intermediate 2, 2.05g, 7.83mmol) in ethanol (50mL and water (15mL) was treated with potassium hydroxide (3.4g, 60.7mmol) and refluxed for 4h. The volatiles were distilled off in vacuo and the residue was diluted with water and poured into cold, dilute hydrochloric acid and the precipitated solid was filtered. The solid was dissolved in diethyl ether, and the organic solution was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound a pale yellow solid (1.75g, 79%). Η-NMR (300 MHz, CDCl3):δ 3.64 (s, 2H), 6.98(t, /= 7.9Hz, IH), 7.25-7.46 (m, 2H), 9.60-10.40(br s, IH). Ethyl-2-fluoro-4-iodo-ρhenyl acetate (Reagent C) A solution of 2-fluoro-iodo-ρhenyl acetic acid (Intermediate 3, 1.75g, 6.22mmol) in ethanol (50mL) and benzene (lOOmL) was treated with concentrated sulfuric acid (1.4mL) and heated at reflux overnight using a Dean-Stark water trap. The volatiles were distilled off in vacuo and the residue was diluted with water and diethyl ether. The phases were separated and the organic phase was washed with saturated aqueous sodium bicarbonate (xl), water (xl) and brine (xl), dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5%-10% ethyl acetate in hexane as the eluent to afford the title compound as a pale yellow solid (1.4g, 73%). 'H-NMR (300 MHz, CDC13): δ 1.25 (t, J= 7.1Hz, 3H), 3.60 (s, 2H), 4.16 (q, J = 7.1Hz, 2H), 6.99(t, J = 8.0Hz, IH), 7.39-7.44(m, 2H). Methyl-2-fluoro-4-iodo-phenyl acetate (Reagent H) A solution of 2-fluoro-4-iodo-phenyl acetonitrile (Intermediate 2, 3g, 11.45mmol) in methanol (50mL) and benzene (50mL) was treated with p- toluene sulfonic acid (2.5g, 13.15mmol) and heated at reflux overnight using a Dean-Stark water trap. The volatiles were distilled off in vacuo and the residue was diluted with water and diethyl ether. The phases were separated and the organic phase was washed with saturated aqueous sodium bicarbonate (xl), water (xl) and brine (xl), dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 6% ethyl acetate in hexane as the eluent to afford the title compound as a colorless oil (2.7g, 80%). Η-NMR (300 MHz, CDC13): δ 3.62 (s, 2H), 3.70 (s, 3H), 6.99(t, J = 7.9Hz, IH), 7.39-7.45(m, 2H). GENERAL PROCEDURE A: 7-Methoxy- 1.1 -dimethyl- 1.2.3.4- tetrahydronaphthalene (Intermediate 8) A stirred, cooled (-40°C) solution of titanium tetrachloride in anhydrous dichloromethane (IM, 20mL) under argon, was treated with a solution of dimethyl zinc (2M, 40mL) in toluene. After 0.5h, a solution of 7-methoxy- 1 - tetralone (1.76g, lOrnmol) in anhydrous dichloromethane (5mL) was cannulated into the reaction mixture and the resulting solution was allowed to warm to ambient temperature and stirred overnight. The reaction mixture was then cooled to -40°C and cautiously quenched with methanol (1 lmL). It was diluted with dichloromethane and saturated aqueous ammonium chloride solution. The phases were separated and the aqueous phase was extracted with dichloromethane (x2mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to the title compound (1.75g, 92%) as an oil. Η-NMR (300 MHz, CDCl3):δ 1.33(s, 6H), 1.67-1.71(m, 2H), 1.79-1.90(m, 2H), 2.75(t, J = 6.2Hz, 2H), 3.83(s, 3H), 6.72(dd, J = 2.6, 8.3Hz, IH), 6.93(d, J = 2.6Hz, IH), 7.02(d, J = 8.3Hz, IH). GENERAL PROCEDURE B: 6-Methoxy-4.4-dimethyl-1.2.3.4- tetrahydronaphthalene- 1 -one (Intermediate 9) A solution of 7-methoxy- 1 , 1 -dimethyl- 1 ,2,3 ,4-tetrahydronaphthalene (Intermediate 8, 1.65g, 8.7 mmol) in 7.5mL of glacial acetic acid was cooled to 0°C and treated with a solution of chromium trioxide (2g, 20mmol) in 8mL of acetic acid and 7mL of water. The reaction mixture was then allowed to warm to ambient temperature and stirred overnight. It was diluted with water and extracted with diethyl ether (x2). The combined organic phase was washed with water (xl), saturated aqueous sodium bicarbonate (xl) and brine (xl), dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound (1.64g, 93%) as a yellow oil. 'H-NMR (300 MHz, CDCl3):δ 1.34(s, 6H), 1.96(t, J = 7.1Hz, 2H), 2.64(t, J = 7.1Hz, 2H), 3.83(s, 3H), 6.77(dd, J = 2.6, 8.7Hz, IH), 6.83(d, J = 2.5Hz, IH), 7.98(d, J = 8.7Hz, IH). 6-Hydroxy-4.4-dimethyl- 1.2.3.4-tetrahvdronaphthalene- 1 -one (Intermediate 10) A stirred, cooled (-78°C) solution of 6-methoxy-4,4-dimethyl-l ,2,3,4- tetrahydronaphthalene- 1 -one (Intermediate 9, 0.8, 3mmol) under argon was treated with a IM solution of boron tribromide (lOmL). The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The reaction mixture was cooled to -78°C, quenched and diluted with saturated aqueous sodium bicarbonate solution and the aqueous phase was extracted with dichloromethane (x2). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to an oil. Flash column chromatography over silica gel (230-400 mesh) using 30% ethyl acetate in hexane as the eluent afforded the title compound (0.3g, 52%) as a yellow viscous oil. Η-NMR (300 MHz, CDCl3):δ 1.33(s, 6H), 1.97(t, J = 6.8Hz, 2H), 2.7 l(t, J = 6.7Hz, 2H), 6.81(dd, J = 2.3, 8.5Hz, IH), 6.94(d, J = 2.3Hz, IH), 7.98(d, J = 8.7Hz, IH), 9.35(s, IH). GENERAL PROCEDURE C: 4.4-Dimethyl-6-trifluoromethylsulfonyloxy- 1.2.3.4-tetrahvdronaphthalene- 1 -one (Intermediate 11) A stirred, cooled (0°C) solution of 6-hydroxy-4,4-dimethyl- 1 ,2,3 ,4- terahydronaphthalene-1-one (Intermediate 10, 0.3g, l.όmmol) in anhydrous dichloromethane (lOmL) was treated with 4-(dimethylamino)pyridine (0.36g, 3.27mmol) followed by 2-[N,N'-bis(frifluoromethylsulfonyl)amino]-5- chloropyridine (0.79g, 2mmol). After stirring at ambient temperature for 0.75h, the reaction mixture was diluted with dichloromethane and washed with water (xl). The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to an oil. Flash column chromatography over silica gel (230-400 mesh) using 8-10% ethyl acetate in hexane as the eluent afforded the title compound (0.462g, 90%) as an off-white solid. Η-NMR (300 MHz, CDC13): δ 1.36(s, 6H), 2.01(t, J = 6.8Hz, 2H), 2.70(t, J = 6.7Hz, 2H), 7.15(dd, J = 2.5, 8.7Hz, IH), 7.28(d, J = 2.4Hz, IH), 8.06(d, J = 8.7Hz, IH). GENERAL PROCEDURE D: 4.4-Dimethyl-6-trimethylsilanyl-ethvnyl- 1,2.3.4-tetrahydronaphthalene-l-one (Intermediate 12) A solution of 4,4-dimethyl-6-trifluoromethylsulfonyloxy- 1,2,3,4- tetrahydronaphthalene- 1 -one (Intermediate 11, 0.46g, 1.43mmol) in triethyl amine (3mL) and anhydrous tetrahydrofuran (8mL) was treated with copper(I)iodide (O.lg, 0.53mmol) and sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.85mL, 6mmol) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (0.25g, 0.36mmol). The resulting reaction mixture was heated at 70°C for 17h. It was then cooled to ambient temperature, diluted with diethyl ether and filtered over a bed of celite. The filtrate was evaporated vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent to afford the title compound (0.28g, 72%). Η-NMR (300 MHz, CDC13): δ 0.26(s, 9H), 1.36(s, 6H), 1.99(t, J = 6.8Hz, 2H), 2.69(t, J = 6.7Hz, 2H), 7.35(dd, J = 1.7, 8.2Hz, IH), 7.49 (unresolved d, IH), 7.93(d, J = 8.1Hz, IH). GENERAL PROCEDURE E: 6-Ethynyl-4.4-dimethyl- 1.2.3.4- tetrahydronphthalene- 1 -one (Intermediate 13) A solution of 4,4-dimethyl-6-frimethylsilanylethynyl- 1 ,2 ,3 ,4- tetrahydronaphthalene-1-one (Intermediate 12, 0.28g, 1.03mmol) in methanol (lOmL) was treated with potassium carbonate (0.74g, 5.35mmol) and stirred at ambient temperature for 4h. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with diethyl ether (x2). The combined organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound (0.19g, 89%) as an oil that solidified on standing. Η-NMR (300 MHz, CDCl3):δ 1.33(s, 6H), 1.96(t, J = 6.8Hz, 2H), 2.67(t, J = 6.8Hz, 2H), 3.25(S, IH), 7.33(dd, /= 1.5, 8.1Hz, IH), 7.49 (d, J = 1.5Hz, IH), 7.13(d, J = 8.1Hz, IH). GENERAL PROCEDURE F: 4-(8.8-Dimethyl-5-oxo-5.6.7.8-tetrahvdro- naphthalene-2-yl-ethynyl)-benzoic acid ethyl ester (Intermediate 14) A solution of 6-ethynyl-4,4-dimethyl- 1 ,2,3 ,4-tetrahydronaphthalene- 1 - one (Intermediate 13, 0.23g, l.lmmol) and ethyl-4-iodo benzoate (Reagent A, 0.36g, 1.3mmol) in triethyl amine (7mL) and anhydrous tetrahydrofuran (3mL) was treated with copper(I)iodide (0.114g, 0.6mmol) and sparged with argon for 5 minutes. Dichlorobis(triρhenylphosphine)palladium(II) (0.23g, 0.33mmol) was added and the reaction mixture was stirred overnight at room temperature. It was diluted with diethyl ether and filtered over a bed of celite. The filtrate was evaporated in vacuo to a brown oil that was subjected to flash column chromatography over silica gel (230-400 mesh) using 6-7% ethyl acetate in hexane as the eluent to afford the title compound (0.29g, 72%) as a pale brown solid. Η-NMR (300 MHz, CDC13): δ 1.3(t, J = 7.1Hz, 3H), 1.37(s, 6H), 1.80 (t, J = 6.8Hz, 2H), 2.69(t, J = 6.8Hz, 2H), 4.35(q, J = 7.1Hz, 2H), 7.40(dd, J = 1.5, 8.2Hz, IH), 7.51 (d, J = 1.6Hz, IH), 7.57 (d, J = 8.3Hz, 2H), 7.96(d, J = 8.2Hz, IH), 7.99(d, J = 8.5Hz, 2H). GENERAL PROCEDURE G 4-f5-Cvclopropylamino-8.8-dimethyl-5,6,7.8- tetrahvdro-naphthalene-2yl-ethvnylVbenzoic acid ethvl ester (Compound 1, General Formula 4) A solution of 4-(8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro-naρhthalene-2- ylethynyl)-benzoic acid ethyl ester (Intermediate 14, 0.14g, 0.4mmol) in 3mL of dichloromethane and 2mL of acetonitrile was treated with cyclopropyl amine(lmL, 14.45mmol). After 5 minutes, acetic acid (ImL) was added followed by sodium cyanoborohydride (0.13g, 2mmol) . The reaction was stirred overnight at ambient temperature. It was then diluted with water and saturated aqueous sodium carbonate solution and extracted with dichloromethane (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to an oil. Flash column chromatography over silica gel (230-400 mesh) using 20% ethyl acetate in hexane as the eluent afforded the title compound (O.lg, 62%) as a pale yellow solid. Η-NMR (300 MHz, CDC13): δ 0.30-0.60(m, 4H), 1.28(s, 3H), 1.35 (s, 3H), 1.30(t, J = 7.1Hz, 3H), 1.55-1.61(m, IH), 1.83-2.05(m, 3H), 2.25 (quintet, J = 3.0 Hz, lH), 3.80 (t, J = 4.9Hz, lH), 4.39(q, J = 7.1Hz, 2H), 7.27-7.36(m, 2H), 7.52 (s, IH), 7.55(d, J = 8.3Hz, 2H), 8.03(d, J = 8.5Hz, 2H). GENERAL PROCEDURE H 4-rf5-Cyclopropyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahydro-naphthalene-2-ylethynyl]-benzoic acid ethyl ester (Compound 2, General Formula 4) A solution of 4-(5-cyclopropylamino-8,8-dimethyl-5,6,7,8-tetrahydro- naρhthalene-2-ylethynyl)-benzoic acid ethyl ester (Compound 1, 0.064g, O.lόmmol) in acetone (2mL) was treated with potassium carbonate (0.6g, 4.34mmol) and methyl iodide (ImL, 16mmol) and stirred overnight at ambient temperature. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with dichloromethane (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford the title compound (0.065g, 99%). 'H-NMR (300 MHz, CDC13): δ 0.28-0.49 (m, 4H), 1.21(s, 3H), 1.26 (s, 3H), 1.33 (t, / = 7.1Hz, 3H), 1.58-1.73 (m, 2H), 1.83-1.89 (m, 2H), 2.02-2.08 (m, IH), 2.06 (s, 3H), 3.88 (t, J = 8.1Hz, IH), 4.32(q, J = 7.1Hz, 2H), 7.20(d, J = 7.8Hz, IH), 7.41 (s, IH), 7.46 (d, J = 7.8Hz, IH), 7.52(d, J = 8.4Hz, 2H), 8.03(d, J = 8.3Hz, 2H). GENERAL PROCEDURE I: 4-[f5-Cyclopropyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahydro-naphthalene-2yl-ethynyl1-benzoic acid (Compound 3, General Formula 4) A solution of 4-[(5-cyclopropyl-methyl-amino)-8,8- dimethyl-5,6,7,8-tetrahydro-naphthalene-2-ylethynyl]-benzoic acid ethyl ester (Compound 2, 0.065g, 0.158mmol) in ethanol (ImL) and tetrahydrofuran (ImL) was treated with IM aqueous sodium hydroxide solution (ImL) and heated at 80°C for lh. The volatiles were distilled off in vacuo and the residue was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford a solid that was washed with dichorornethane and dried to afford the title compound (0.029g, 38%) as a white solid. Η-NMR (300 MHz, CD3COCD3): δ 0.35-0.5 l(m, 4H), 1.26(s, 3H), 1.29 (s, 3H), 1.60-1.82(m, 2H), 1.88-2.02(m, 2H), 2.02-2.15 (m, IH), 2.10 (s, 3H), 3.93 (t, J = 8.0Hz, IH), 7.26(dd, J = 1.5, 8.2Hz, IH), 7.51 (d, J = 1.5Hz, IH), 7.52(d, J = 8.2Hz, IH), 7.62(d, J = 8.5Hz, 2H), 8.02(d, J = 8.2Hz, 2H). 4-rr8.8-Dimethyl-5-oxo-5.6.7.8-tetrahydro-naphthalene-2-yl-efhvnylVρhenyl]- acetic acid methyl ester (Compound 4, General Formula 8) Following general procedure F and using 6-ethynyl-4,4-dimethyl- 1,2,3,4-tetrahydronaphthalene-l-one (Intermediate 13, 0.312g, 1.5mmol), 4- iodo phenyl acetic acid methyl ester (Reagent B, 0.50g, 1.8mmol), triethyl amine (7mL), anhydrous tetrahydrofuran (3mL), copper(I)iodide (0.04g, 0.2mmol) and dichlorobis(friρhenylρhosρhine)ρalladium(II) (0.15g, 0.213mmol) followed by flash column chromatography over silica gel (230- 400 mesh) using 16-20% ethyl acetate in hexane as the eluent, the title compound was obtained as a pale yellow solid (0.42g, 76%). Η-NMR (300 MHz, CDCl3):δ 1.42(s, 6H), 2.04(t, J = 6.7Hz, 2H), 2.74(t, J = 6.7Hz, 2H), 3.66(s, 2H), 3.71(s, 3H), 7.29 (d, J = 8.2Hz, 2H), 7.43(dd, J = 1.5, 7.9Hz, IH), 7.52 (d, J = 8.2Hz, 2H), 7.57 (d, J = 1.5Hz, IH), 8.00(d, J = 8.2Hz, IH). GENERAL PROCEDURE J: 4-[f8.8-Dimethyl-5-oxo-5.6.7.8-tetrahvdro- naρhthalene-2-yl-ethynv -ρhenyl]-acetic acid (Compound 5, General Formula 8) A solution of 4-[(8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro-naρhthalene- 2-ylethynyl)-phenyl]-acetic acid methyl ester (Compound 4, 0.1 g, 0.28mmol) in a mixture of methanol (2mL), tetrahydrofuran (3.5mL) and water (1.5mL) was treated with lithium hydroxide monohydrate (0.1 lg, 2.62mmol) and the resulting reaction mixture was stirred at ambient temperature for 3h. The volatiles were distilled off in vacuo and the residue was diluted with water and dilute hydrochloric acid and extracted with ethyl acetate (x3). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford the title compound as a pale yellow solid (0.088g, 92%). Η-NMR (300 MHz, CDC13): δ 1.41(s, 6H), 2.02(t, J = 6.7Hz, 2H), 2.74(t, J = 6.8Hz, 2H), 3.68(s, 2H), 7.28 (d, J = 8.2Hz, 2H), 7.42(dd, J = 1.5, 8.2Hz, IH), 7.52 (ά, J = 8.2Hz, 2H), 7.56 (d, J = 1.5Hz, IH), 7.99(d, J = 8.2Hz, IH). 4-["(5-(Cyclopropyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahydro-naphthalene-2-yl- ethynyl)-ρhenyl]-acetic acid methyl ester (Compound 6, General Formula 4) Following general procedure G and using 4-[(8,8-dimethyl-5-oxo- 5,6,7, 8-tetrahydro-naphthalene-2-yl-ethynyl)-phenyl]-acetic acid methyl ester (Compound 4, 0.2g, 0.54mmol), dichloromethane (4mL), acetonitrile(2mL), cyclopropyl amine(lmL, 14.45mmol), acetic acid (lmL)and sodium cyanoborohydride (0.16g, 2.54mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 30% ethyl acetate in hexane as the eluent the title compound was obtained as a pale yellow oil (0.22g, 99%). Η-NMR (300 MHz, CDC13): δ 0.38-0.60 (m, 4H), 1.26(s, 3H), 1.33(s, 3H), 1.50-1.59(m, IH), 1.79-2.10 (m, 3H), 2.25(m, IH), 3.63(s, 2H), 3.69(s, 3H), 3.79(t, J = 4.8Hz, IH), 7.20-7.32 (m, 4H), 7.47(s, IH), 7.58(d, J = 8.2Hz, 2H). 4-[T5-(Cycloρropyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahvdro- naρhthalene-2-yl-ethynylVphenyl]-acetic acid methyl ester (Compound 7, General Formula 4) Following general procedure H and using 4-[(5-(cyclopropyl-amino)- 8,8-dimethyl- 5,6,7,8-tetrahydro-naphthalene-2-ylethynyl)-phenyl]-acetic acid methyl ester (Compound 6, 0.15g, 0.37mmol), acetone (5mL), potassium carbonate (l.lg, 7.95mmol) and methyl iodide (ImL, 16mmol), the following work-up was used. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with dichloromethane (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford the title compound (0.148g, 97%). Η-NMR (300 MHz, CDC13): δ 0.38-0.58(m, 4H), 1.27(s, 3H), 1.31 (s, 3H), 1.68-1.81(m, 2H), 1.85-1.98(m, 2H), 2.08-2.15 (m, IH), 2.12 (s, 3H), 3.62(s, 2H), 3.69(s, 3H), 3.94 (t, J = 7.9Hz, IH), 7.24(d, J = 8.2Hz, IH), 7.24 (d, J = 8.2Hz, 2H), 7.44-7.5 l(m, 4H). 4-r("5- Cvclopropyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahvdro- naphthalene-2-yl-ethynyl)-phenyl]-acetic acid (Compound 8, General Formula 4) Following general procedure J and using 4-[(5-(cyclopropyl-methyl- amino)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalene-2ylethynyl)-phenyl]- acetic acid methyl ester (Compound 7, 0.148g, 0.357mmol), methanol (2mL), tetrahydrofuran (4mL), water (ImL) and lithium hydroxide monohydrate (0.25g, 5.95mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 30-75% ethyl acetate in hexane as the eluent, the title compound was obtained as a white solid (0.08g, 56%). 'H-NMR (300 MHz, CDC13): δ 0.52-0.54(m, 2H), 0.68-0.70(m, 2H), 1.27(s, 3H), 1.29(s, 3H), 1.63-1.80(m, 2H), 1.95-2.17(m, 2H), 2.19-2.24(m, IH), 2.24(s, 3H), 3.60(s, 2H), 4.18(t, J = 7.7Hz, IH), 7.24(dd, J = 1.5, 8.2Hz, IH), 7.26 (d, J = 8.2Hz, 2H), 7.43 (d, J = 8.2Hz, IH), 7.47(s, IH), 7.47(d, J = 8.2Hz, 2H), 10.37(br s, IH). 2-Fluoro-4-[(8.8-dimethyl-5-oxo-5.6.7.8-tetrahvdro-naρhthalen-2-yl- ethynyljbenzoic acid ethyl ester (Compound 9, General Formula 8) A solution of 4,4-dimethyl-6-trifluromethylsulfbnyloxy-l,2,3,4- tetrahydronaphthalene- 1 -one (Intermediate 11, 0.3g, 0.9mmol), copper(I)iodide (0.057g, 0.3mmol) and ethyl-2-fluoro-4-ethynyl-benzoate (Reagent D, 0.44g, 2.27mmol) in triethyl amine (2mL) and tetrahydrofuran (3mL) was sparged with argon for 5 minutes and treated with dichlorobis(triphenylphosphine)palladium(II) (0.135g, 0.192mmol) and stirred at room temperature overnight and then refluxed for 2h. It was then cooled to ambient temperature, diluted with diethyl ether and filtered over a bed of celite. The filtrate was evaporated in vαcuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 10- 15% ethyl acetate in hexane as the eluent to afford the title compound as a yellow solid (0.22g, 67%). Η-NMR (300 MHz, CDC13): δ 1.38 (t, J = 7.0Hz, 3H), 1.39(s, 6H), 2.01(t, J = 6.7Hz, 2H), 2.71(t, J = 6.7Hz, 2H), 4.37(q, J= 7Hz, 2H), 7.28(dd, J= 0.9, 10Hz, IH), 7.34(dd, J= 0.9, 8.2Hz, IH), 7.41 (dd, J = 1.5, 8.2Hz, IH), 7.57(d, J = 0.9Hz), 7.90(t, J= 7.9Hz, IH), 7.93 (d, J= 7.9Hz, IH). 2-Fluoro-4-(8.8-dimethyl-5-oxo-5.6.7.8-tetrahvdro-naρhthalen-2yl-ethynylV benzoic acid (Compound 10, General Formula 8) A solution of 2-fluoro-4-(8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro- naρhthalen-2-ylethynyl)benzoic acid ethyl ester (Compound 9, 0.1 g, 0.274mmol) in ethanol(4mL), methanol (2mL) and tetrahydrofuran (2mL) was treated with IM aqueous sodium hydroxide solution and heated at 70°C for lh. The volatiles were distilled off in vacuo and the residue was diluted with water and dilute hydrochloric acid and extracted with ethyl acetate (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford a solid that was recrystallized from hot aqueous acetonitrile to afford the title compound (0.025g, 27%). Η-NMR (300 MHz, CDC13): δ 1.43(s, 6H), 2.05(t, J = 6.9Hz, 2H), 2.76(t, J = 6.9Hz, 2H), 7.26-7.47(m, 3H), 7.60(d, J = 1.1Hz, IH), 7.99-8.05(m, 2H). 4- 5-("Cycloρropyl-aminoV8.8-dimethyl- 5.6.7.8-tefrahydro-naphthalene-2-yl- ethvnyll-2-fluoro-benzoic acid ethyl ester (Compound 11, General Formula 4) Following general procedure G and using 2-fluoro-4-(8,8-dimethyl-5- oxo-5,6,7,8-tetrahydro-naphthalene-2-ylethynyl)-benzoic acid ethyl ester (Compound 9, 0.132g, 0.3mmol), dichloromethane (4mL), acetonifrile(2mL), cyclopropyl amine(lmL, 14.45mmol), acetic acid (lmL)and sodium cyanoborohydride (0.18g, 2.86mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 16-20% ethyl acetate in hexane as the eluent, the title compound was obtained as a pale yellow oil (O.lg, 82%). Η-NMR (300 MHz, CDCl3):δ 0.36-0.54 (m, 4H), 1.27(s, 3H), 1.33(s, 3H), 1.40(t, J= 7.0Hz, 3H), 1.54-1.61(m, 2H), 1.82-2.05 (m, 2H), 2.26(m, IH), 3.79 (t, J = 4.9Hz, IH), 4.39(q, J= 7.1Hz, 2H), 7.26-7.50(m, 4H), 7.87(s, IH), 7.92 (t, J= 7.9Hz, IH). 4-[5-(Cvcloproρyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahydro- naρhthalene-2-yl-ethvnyll-2-fluoro benzoic acid ethyl ester (Compound 12, General Formula 4) Following general procedure H and using 4-[5-(cycloρroρyl-mefhyl- amino)-8,8-dimethyl- 5,6,7,8-tetrahydro-naphthalene-2-ylethynyl]-2-fluoro- benzoic acid ethyl ester (Compound 11, O.lg, 0.246mmol), acetone (4mL), potassium carbonate (0.917g, 6.63mmol) and methyl iodide (0.8mL, 1 lmmol), the following work-up was used. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with dichloromethane (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to an oil. Flash column chromatography over silica gel (230-400 mesh) using 8-10% ethyl acetate in hexane as the eluent afforded the title compound as a pale yellow oil (0.102g, 98%). Η-NMR (300 MHz, CDC13): δ 0.39-0.62 (m, 4H), 1.29(s, 3H), 1.34(s, 3H), 1.42(t, J= 6.9Hz, 3H), 1.65-1.82(m, 2H), 1.85-2.02 (m, 2H), 2.02-2.10(m, IH), 2.15(s, 3H), 3.97(t, J = 7.7Hz, IH), 4.42(q, J- 7.0Hz, 2H), 7.28-7.36 (m, 3H), 7.59(s, IH), 7.55(d, J = 7.9Hz, 2H), 7.92 (t, J= 7.5Hz, IH). 4-r5-(Cvcloϋropyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahydro- naρhthalene-2-yl-ethvnyll-2-fluoro benzoic acid (Compound 13, General Formula 4) Following general procedure I and using 4-[(5-cycloρropyl-methyl- amino)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalene-2-ylethynyl]-2-fluoro- benzoic acid ethyl ester (Compound 12, 0.102g, 0.23mmol), ethanol (4mL) and IM aqueous sodium hydroxide solution (2mL) followed by flash column chromatography over silica gel (230-400 mesh) 30% ethyl acetate in hexane as the eluent, the title compound was obtained as an off-white solid(0.015g, 16%). 'H-NMR (300 MHz, CDC13): δ 0.54-0.65 (m, 4H), 1.29 (s, 3H), 1.32 (s, 3H), 1.68-1.83 (m, 2H), 1.97-2.05 (m, 2H), 2.18-2.25 (m, IH), 2.25 (s, 3H), 4.13 (t, J = 6.7Hz, IH), 7.26-7.30 (m, 2H), 7.34 (dd, J = 1.5, 7.9Hz, IH), 7.48 (d, J = 1.8Hz, IH), 7.60 (d, J = 8.5Hz, IH), 7.95 (t, J = 7.9Hz, IH). [2-Fluoro-4-(8.8-dimethyl-5-oxo-5.6.7.8-tetrahvdro-naphthalene-2-yl- ethynylVphenyll acetic acid ethyl ester (Compound 14, General Formula 8) Following general procedure F and using 6-ethynyl-4,4-dimethyl- 1 ,2,3,4-tetrahydro-naρhthalene-l-one (Intermediate 13, 0.298g, 1.43mmol), 2-fluoro-4-iodo phenyl acetic acid ethyl ester (Reagent C, 0.44g, 1.43mmol), triethyl amine (Intermediate 13, 3mL), anhydrous tetrahydrofuran (7mL), copper(I)iodide (0.04g, 0.2mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.15g, 0.213mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 14-16% ethyl acetate in hexane as the eluent, the title compound was obtained as an oil (0.43g, 77%). Η-NMR (300 MHz, CDC13): δ 1.26(t, /= 7.2Hz, 3H), 1.41(s, 6H), 2.04(t, J = 6.7Hz, 2H), 2.74(t, J = 6.7Hz, 2H), 3.68(s, 2H), 4.18(q, J= 7.1Hz, 2H), 7.23- 7.57(m, 4H), 7.59 (d, J = 1.5Hz, IH), 7.99(d, J = 7.9Hz, IH). r2-Fluoro-4-r8.8-dimethyl-5-oxo-5.6.7.8-tetrahvdro-naρhthalene-2-yl- ethvny phenyll -acetic acid (Compound 15, General Formula 8) Following general procedure J and using [2-fluoro-4-(8,8-dimethyl-5- oxo-5,6,7,8-tetrahydro-naphthalene-2-ylethynyl)phenyl]acetic acid methyl ester (Compound 14, 0.18g, 0.48mmol), methanol (4mL), tetrahydrofuran (8mL), water (2mL) and lithium hydroxide monohydrate (0.2g, 4.76mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 50- 100% ethyl acetate in hexane as the eluent, the title compound was obtained as a dirty white solid (0.068g, 41%). Η-NMR (300 MHz, CDC J: δ 1.41(s, 6H), 2.03(t, J = 6.7Hz, 2H), 2.74(t, J = 6.8Hz, 2H), 3.73(s, 2H), 7.24-7.32(m, 3H), 7.42(dd, J= 1.5, 7.9Hz, IH), 7.56 (s, IH), 7.99(d, J = 7.9Hz, IH), 9.40-10.00 (br s, IH). [4-('5-rCvcloproρyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahvdro-naphthalene-2-yl- ethvnylV2-fluoro-ρhenyl] acetic acid ethyl ester (Compound 16, General Formula 4) Following general procedure G and using [2-fluoro-4-(8,8-dimethyl-5- oxo-5,6,7,8-tetrahydro-naphthalene-2-ylethynyl) phenyljacetic acid ethyl ester (Compound 14, 0.258g, 0.68mmol), dichloromethane (4mL), acetonitrile(2mL), cyclopropyl amine(lmL, 14.45mmol), acetic acid (lmL)and sodium cyanoborohydride (0.266g, 4.23mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 16-20-25% ethyl acetate in hexane as the eluent , the title compound was obtained as a pale yellow oil (0.21g, 73%). Η-NMR (300 MHz, CDCl3):δ 0.35-0.54 (m, 4H), 1.25(t, J= 7.1Hz, 3H), 1.26(s, 3H), 1.32(s, 3H), 1.53-1.64(m, IH), 1.82-2.05 (m, 3H), 2.21-2.28(m, lH), 3.65(s, 2H), 3.78(t, J = 5.0Hz, IH), 4.17(q, J= 7.1Hz, 2H), 7.19-7.41 (m, 5H), 7.47(d, J = 1.5Hz, IH). r4-r5- Cvclopropyl-methyl-amino -8.8-dimethyl-5.6.7.8-tetrahvdro- naρhthalene-2-yl-ethvnyl -2-fluoro-phenyll-acetic acid ethyl ester (Compound 17, General Formula 8) Following general procedure H and using [4-((5-cyclopropyl-amino)- 8,8-dimethyl- 5 ,6,7,8-tetrahydro-naphthalene-2ylethynyl)-2-fluoro- phenyl]acetic acid ethyl ester (Compound 16, 0.21 g, 0.5mmol), acetone (5mL), potassium carbonate (1.13g, 8.17mmol) and methyl iodide (0.5mL, 8mmol), the following work-up was used. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with dichloromethane (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford an oil. Flash column chromatography over silica gel (230-400 mesh) using 8% ethyl acetate in hexane as the eluent afforded the title compound (0.15g, 69%). Η-NMR (300 MHz, CDC13): δ 0.39-0.53(m, 4H), 1.27(s, 3H), 1.31 (s, 3H), 1.66-1.81(m, 2H), 1.89-2.05(m, 2H), 2.08-2.13 (m, IH), 2.13 (s, 3H), 3.62(s, 2H), 3.94 (t, J = 8.0Hz, IH), 4.16(q, J= 7.1Hz, 2H), 7.20-7.29(m, 4H), 7.44(d, J = 1.5Hz, IH), 7.51 (d, J= 8.2Hz, IH). [4-('5-rCvcloproρyl-methyl-aminoV8.8-dimethyl- 5.6.7.8-tetrahvdro- naphthalene-2-yl-ethvnyl -2-fluoro-phenyl]-acetic acid (Compound 18, General Formula 4) Following general procedure J and using [4-(5-(cyclopropyl-methyl- amino)-8,8-dimethyl- 5,6,7,8-tetrahydro-naphthalene-2-ylethynyl)-2-fluoro- phenyl]-acetic acid ethyl ester (Compound 17, 0.025g, 0.059mmol), methanol (ImL), tetrahydrofuran (ImL), water (0.5mL) and lithium hydroxide monohydrate (0.060g, 1.43mmol), the title compound was obtained as a white solid (0.023g, 95%). Η-NMR (300 MHz, CDCl3):δ 0.52-0.54(m, 2H), 0.68-0.70(m, 2H), 1.27(s, 3H), 1.29(s, 3H), 1.63-1.80(m, 2H), 1.95-2.17(m, 2H), 2.19-2.24(m, IH), 2.24(s, 3H), 3.60(s, 2H), 4.18(t, J = 7.7Hz, IH), 7.19-7.28(m, 4H), 7.45 (d, J = 1.5Hz, IH), 7.49(d, J = 8.2Hz, IH), 8.80-9.20(br s, IH). GENERAL PROCEDURE K: 8.8-Dimethyl-5.6.7.8-tetrahydro-naphthalene-l- one-2-carboxylic acid-4-(ϊert-butoxycarbonylmethyDphenyl ester Compound 19, General Formula 8) A solution of 4,4-dimethyl-6-trifluoromethylsulfonyloxy- 1 ,2,3 ,4- tetrahydronaphthalene- 1 -one (Intermediate 11, 0.14g, 0.434mmol), t-butyl-4- hydroxy-phenyl acetate (Reagent E, 0.14g, 0.673mmol), palladium acetate (0.054g, 0.24mmol) and l,3-bis(diphenylρhosρhino)propane (0.082g, 0.2mmol) in a mixture of dimethylsulfoxide (ImL), 1,2-dichloroethane (1.5mL) and triethyl amine (ImL) was heated at 70°C under an atmosphere of carbon monoxide overnight. The volatiles were distilled of in vacuo and the residue was diluted with water and extracted with diethyl ether (x3). The combined organic extract was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 15% ethyl acetate in hexane as the eluent to afford the title compound (0.1 lg, 53%). Η-NMR (300 MHz, CDC13): δ 1.44(s, 3H), 1.44(s, 9H), 1.46 (s, 3H), 2.07(t, J = 6.9Hz, 2H), 2.76(t, J =* 6.8Hz, 2H), 3.55(s, 2H), 7.17 (d, J = 8.5Hz, 2H), 7.35(d, J = 8.5Hz, 2H), 8.05-8.13(m, 2H), 8.25 (d, J = 1.5Hz, IH). 8.8-Dimethyl-5-oxo-5.6.7.8-tetrahvdro-naphthalene-2-carboxylic acid-4- (carboxymethyDphenyl ester (Compound 20, General Formula 8) A solution of 8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro-naphthalene-2- carboxylic acid 4-(tert-butoxycarbonylmethyl)phenyl ester (Compound 19, 0.11 g, 0.229mmol) in dichloromethane (2mL) was treated with trifluoroacetic acid (0.85mL and stirred at ambient temperature for 2.5h. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with ethyl acetate (x3). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford a solid which was subjected to flash column chromatography over silica gel (230-400 mesh) using ethyl acetate as the eluent to afford the title compound (0.024g, 25%). 'H-NMR (300 MHz, CDC13): δ 1.46 (s, 6H), 2.08(t, J = 6.7Hz, 2H), 2.80(t, J = 6.7Hz, 2H), 3.70(s, 2H), 7.20(d, J = 8.5Hz, 2H), 7.37(d, J = 8.5Hz, 2H), 8.08(dd, J = 1.4, 8.2Hz, IH), 8.14 (d, J = 8.2Hz, IH), 8.24 (d, J = 1.2Hz, IH). 5-Methoxy-3.3-dimethyl-indane (Intermediate 15) Following general procedure A and using titanium tetrachloride (5.5mL,50mmoL), anhydrous dichloromethane (80mL), 2M solution dimethyl zinc (50mL) in toluene and a solution of 6-methoxy-indane- 1 -one (4.05g, 25mmol) in dichloromethane (lOmL) the title compound was obtained as an oil (3.13g, 71%). Η-NMR (300 MHz, CDCl3):δ 1.37 (s, 6H), 2.04(t, J = 7.2Hz, 2H), 2.94(t, J = 7.2Hz, 2H), 3.89(s, 3H), 6.82(d, J= 2.1Hz, IH), 7.28(dd, J= 2.1, 7.0Hz, IH), 7.35 (d, J = 7.0Hz, IH). 5-Methoxy-3.3 -dimethyl-indane- 1 -one (Intermediate 16) Following general procedure B and using 5-methoxy-3,3-dimethyl indane (Intermediate 15, 3.13g, 17.78mmol) in 20mL of glacial acetic acid and a solution of chromium trioxide (3.91g, 39.1mmol) in 20mL of acetic acid and 20mL of water the title compound was obtained as a viscous yellow oil (3.3g, 97%). Η-NMR (300 MHz, CDCl3):δ 1.37 (s, 6H), 2.54 (s, 2H), 3.87(s, 3H), 6.86- 6.87 (m, 2H), 7.60 (d, J = 7.0Hz, IH). 6-Methoxy-4.4-dimethyl- 1.2.3.4-tetrahydro-isoquinoline- 1 -one (Intermediate 17) A solution of 5-methoxy-3,3-dimethyl-indane-l-one (Intermediate 16, 3.3g, 17.4mmol) in benzene (50mL) was treated with concentrated sulfuric acid (lOmL) and heated to 60°C. Sodium azide (1.95g, 30mmol) was added in small portions and after the addition was complete, the reaction mixture was heated further for 4h. It was then cooled, diluted with water and extracted with chloroform (x3). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound as a brown solid (3.5g, quantitative by weight). Η-NMR (300 MHz, CDC13): δ 1.31 (s, 6H), 3.28 (s, 2H), 3.83(s, 3H), 6.78 (d, J = 2.6Hz, IH), 6.82(dd, J = 2.6Hz, 8.5Hz, IH), 7.59 (s, IH), 8.02 (d, J= 8.2Hz, IH). 6-Methoxy-4,4-dimethyl- 1.2.3.4-tetrahvdro-isoquinoline (Intermediate 18) A solution of 6-methoxy-4,4-dimethyl- 1 ,2,3 ,4-tetrahydro-isoquinoline- 1-one (Intermediate 17, 3.5g, 17mmol) in lOOmL of anhydrous tetrahydrofuran was treated with lithium aluminum hydride (1.3g, 34.25mmol) in small portions and the resulting suspension was refluxed for 3 hours under argon. The reaction mixture was then cooled in an ice bath and cautiously quenched with saturated aqueous sodium sulfate solution and the resulting slurry was filtered and the filter-cake washed well with ethyl acetate. The filtrate and washings were evaporated in vacuo to a brown oil which was dissolved in chloroform, the solution was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound (3.2g, -100%). Η-NMR (300 MHz, CDC13): δ 1.27 (s, 6H), 2.22 (s, IH), 2.84 (s, 2H), 3.79 (s, 3H), 3.95 (s, 2H), 6.68(dd, J = 2.4Hz, 8.3Hz,lH), 6.86(d, J = 2.4Hz, IH), 6.91 (d, J= 8.3Hz, IH). 6-Methoxy-4.4-dimethyl- 1.2.3.4-tetrahydro-isoquinoline-2-carbaldehvde (Intermediate 19) A solution of 6-methoxy-4,4-dimethyl- 1 ,2,3 ,4-tetrahydro-isoquinoline (Intermediate 18, 3.2g, 16.7mmol) in anhydrous dichloromethane (40mL) was treated with formic acid (ImL, 26.5mmol) followed l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.9g, 20.34mmol) and the resulting solution was stirred at ambient temperature overnight. It was then diluted with chloroform and washed with water (xl) and brine (xl), dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound as pale brown viscous oil (3.26g, 90%). 'H-NMR (300 MHz, CDC13): δ 1.28 (s, 6H), 3.32 (s, 0.7H), 3.54 (s, 0.3H), 3.79(s, 3H), 4.54 (s, 0.3H), 4.66(s, 0.7H), 6.71(dd, / = 2.6Hz, 8.2Hz, IH), 6.85-6.97(m, IH), 7.02-7.27(m, IH), 8.15(s, 0.7H), 8.34(s, 0.3H), 8.40-8.80 (br s, IH). 6-Hydroxy-4.4-dimethyl- 1.2.3 ■4-tetrahydro-isoquinoline-2-carbaldehyde (Intermediate 20) A stirred, cooled (-78°C) solution of 6-methoxy-4,4- dimethyl- 1,2, 3, 4-tetrahydro-isoquinoline-2-carbaldehyde (Intermediate 19, 3.26g, 15mmol) in anhydrous dichloromethane (15mL) was treated with IM solution of boron tribromide in dichloromethane (50mL) stirred at ambient temperature for 3h. It was then cooled again to 78°C and quenched carefully with saturated aqueous sodium carbonate solution, diluted with water and the aqueous phase was extracted with ethyl acetate (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford the title compound as a solid foam (3g, 99%). Η-NMR (300 MHz, CDC13): δ 1.23 (s, 6H), 3.31 (s, 0.7H), 3.54 (s, 0.3H), 4.51 (s, 0.3H), 4.64 (s, 0.7H), 6.70-6.75(m, IH), 6.84-6.90(m, 2H), 7.50- 7.80(br s, IH), 8.12(s, 0.7H), 8.32(s, 0.3H). 2-Cvcloproρyl-6-hydroxy-4.4-dimethyl - 1.2.3.4-tetrahvdro-isoquinoline (Intermediate 21) A stirred, cooled (0°C)solution of 6-hydroxy-4,4-dimethyl- 1 ,2,3 ,4- tetrahydro-isoquinoline-2-carbaldehyde (Intermediate 20, 2.3g, 11.2 lmmol) in anhydrous tetrahydrofuran (40mL) under argon was treated with titanium tetra-z'so-propoxide (8.28mL, 28mmoι) followed by 3M solution of ethyl magnesium bromide in diethyl ether (18.7mL) and the reaction mixture was then heated at 55°C overnight. It was then cooled in an ice-bath, quenched with saturated aqueous ammonium chloride solution and extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford a yellow oily solid. Flash column chromatography over silica gel (230-400 mesh) using 10-20% ethyl acetate in hexane as the eluent afforded the title compound as a pale yellow solid (1.55g, 63%). 'H-NMR (300 MHz, CD3COCD3): δ 0.016-0.16(m, 4H), 0.847 (s, 6H), 1.37 (m, IH), 2.20(s, 2H), 3.25 (s, 2H), 6.22(dd, J= 2.4, 8.2Hz, IH), 6.41(d, = 2.6Hz, IH), 6.47(d, J= 8.2Hz, IH), 7.62(s, IH). 2-Cvclopropyl-4.4-dimethyl-6-trifluoiOmethylsulfonyloxy- 1.2.3 ,4-tetrahvdro- isoquinoline (Intermediate 22) Following general procedure C and using 2-cyclopropyl-6-hydroxy-4,4- dimethyl- 1, 2,3, 4-tetiahydro-isoquinoline (Intermediate 21, 1.5g, 6.9mmol) in anhydrous dichloromethane (30mL), triethyl amine (1.5mL, 10.39mmol) and [N,N'-bis(trifluoromethylsulfonyl)amino]-5-chloroρyridine (2.75g, 7mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 8% ethyl acetate in hexane as the eluent the title compound was obtained (2.23g, 92%) as oil. Η-NMR (300 MHz, CDC13): δ 0.42-0.54(m, 4H), 1.25(s, 6H), 1.76(m, IH), 2.62(s, 2H), 3.74(s, 2H), 6.98(dd, J = 2.3, 8.4Hz, IH), 7.16(d, J = 8.2Hz, IH), 7.14(d, J = 2.3Hz, IH). Ethyl-2-cyclopropyl-4.4-dimethyl- 1.2.3.4-tetrahydroisoquinoline-6- carboxylate (Intermediate 23) Following general procedure K and using 2-cyclopropyl-4,4-dimethyl- 6-trifluoromethylsulfonyloxy- 1 ,2,3 ,4-tetrahydro-isoquinoline (Intermediate 22, 1.6g, 4.6mmol), palladium acetate (0.127g, 0.56mmol), 1,3- bis(diphenylphosphino)propane (0.160g, 0.39mmol), dimethylsulfoxide (2mL), 1,2-dichloroethane (5mL), triethyl amine (2mL) , ethanol (5mL) and an atmosphere of carbon monoxide followed by flash column chromatography over silica gel (230-400 mesh) using 10% ethyl acetate in hexane as the eluent the title compound was obtained as an oil (lg, 79%). Η-NMR (300 MHz, CDCl3):δ 0.44-0.54(m, 4H), 1.27(s, 6H), 1.38 (t, J = 7Hz, 3H), 1.73(m, IH), 2.62(s, 2H), 3.76(s, 2H), 4.35 (q, J = 7.1Hz, 2H), 7.04(d, J = 7.9Hz, IH), 7.74 (dd, J = 1.7, 7.9Hz, IH), 7.97(d, J = 1.8Hz, IH). 2-Cvcloρropyl-6-hydroxymethyl-4.4-dimethyl- 1.2.3.4-tetrahvdroisoquinoline (Intermediate 24) A stirred cooled (-78°C)solution of ethyl-2-cyclopropyl-4,4-dimethyl- 1,2,3,4-tetrahydro isoquinoline-6-carboxylate (Intermediate 23, lg, 3.66mmol) in anhydrous dichloromethane (20mL) under argon was treated with a IM solution of di-ώo-butyl aluminum hydride in dichloromethane (lOmL) and the reaction mixture was warmed to -20°C over lh. It was then quenched with saturated aqueous ammonium chloride solution and diluted with dichloromethane and filtered over a bed of celite. The phases were separated and the aqueous phase was extracted with dichloromethane (xl). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford the title compound as a viscous oil (0.74g, 87%). Η-NMR (300 MHz, CDC13): δ 0.45-0.53(m, 4H), 1.25(s, 6H), 1.72-1.82(m, 2H), 2.61(s, 2H), 3.73(s, 2H), 4.61 (d, J = 5Hz, 2H), 6.98(d, J = 7.9Hz, IH), 7.07 (dd, J = 1.5, 7.6Hz, IH), 7.27(s, IH). 2-Cycloρroρyl-4.4-dimethyl- 1.2.3.4-tetrahvdroisoquinoline-6-carbaldehvde (Intermediate 25) A solution of 2-cyclopropyl-6-hydroxymethyl-4,4-dimethyl- 1 ,2,3 ,4- tetrahydroisoquinoline (Intermediate 24, 0.74g, 3.2mmol) in dichloromethane (lOmL) and acetonitrile (2.5mL) was treated sequentially with 4A° molecular sieves powder (1.06g), tetra-n-propyl ammonium perruthenate (0.050g, 0.14mmol) and N-methyl moφholine N-oxide ( 1.1 g, 9. δmmol) . After stirring at ambient temperature for 0.5h, it was diluted with 5mL of hexane and subjected to flash column chromatography over silica gel (230-400 mesh) using 10% ethyl acetate in hexane as the eluent to afford the title compound as an oil (0.27g, 37%). Η-NMR (300 MHz, CDCl3):δ 0.44-0.56(m, 4H), 1.30(s, 6H), 1.79(m, IH), 2.66(s, 2H), 3.82(s, 2H), 7.17(d, J = 7.9Hz, IH), 7.60 (dd, J = 1.6, 7.9Hz, IH), 7.82(d, J = 1.8Hz, IH), 9.95 (s, IH). 6-(2.2-Dibromo-vinylV2-cyclopropyl-4.4-dimethyl-1.2.3.4- tetrahydroisoquinoline (Intermediate 26) A stirred, cooled (ice-bath) solution of triphenyl phosphine (0.53g, 2mmol) in anhydrous dichloromethane was treated with carbon tetrabromide (0.35g, lmmol) under argon. After 0.5h, a solution of 2-cyclopropyl-4,4- dimethyl- 1 ,2,3 ,4-tetrahydroisoquinoline-6-carboxaldehyde (Intermediate 25, 0.13g, 0.57mmol) in dichloromethane (2mL) was cannulated into the reaction mixture. After 1.5h between 0°C and 10°C, the reaction mixture was subjected to flash column chromatography over silica gel (230-400 mesh) using 3-5%o ethyl acetate in hexane as the eluent to afford the title compound as a viscous, pale yellow oil (0.18g, 82%). Η-NMR (300 MHz, CDCl3):δ 0.49-0.57(m, 4H), 1.31 (s, 6H), 1.80(m, IH), 2.67(s, 2H), 3.77(s, 2H), 7.04(d, J = 7.9Hz, IH), 7.29 (dd, J = 1.7, 7.9Hz, IH), 7.49 (s, IH), 7.50(d, J = 1.7Hz, IH). 2-Cvclopropyl-6-ethvnyl-4.4-dimethyl-1.2.3.4-tetrahvdroisoquinoline (Intermediate 27) A stirred, cooled (-78°C) solution of 6-(2,2-dibromo-vinyl)-2- cycloρroρyl-4,4-dimethyl- 1 ,2,3 ,4-tetrahydroisoquinoline-6-carboxaldehyde (Intermediate 26, 0.18g, 0.47mmol) in tetrahydrofuran (2mL) was treated with 1.6M solution of n-butyl lithium (0.6mL, 0.96mmol) under argon. The reaction mixture was allowed to warm to -20°C over 1.5h, quenched with saturated aqueous ammonium chloride solution and extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford the title compound as an oil (O.lg, 94%). Η-NMR (300 MHz, CDCl3):δ 0.47-0.55(m, 4H), 1.28(s, 6H), 1.77(m, IH), 2.63(s, 2H), 3.05(s, IH), 3.67(s, 2H), 6.98(d, J = 7.6Hz, IH), 7.26 (dd, J = 1.5, 7.9Hz, IH), 7.46(d, J = 1.5Hz, IH). [4-(2-Cyclopropyl-4.4-dimethyl- 1.2.3.4-tetrahydro-isoquinolin-6-yl-ethvnylV 2-fluoro-phenyll-acetic acid ethyl ester (Compound 21, General Formula 3) Following general procedure F and using 2-cyclopropyl-6-ethynyl-4,4- dimethyl- 1 ,2,3 ,4-tetrahydro-isoquinoline(Intermediate 27, 0.13g, 0.571mmol), 2-fluoro-4-iodo phenyl acetic acid ethyl ester (Reagent C, 0.16g, 0.52mmol), triethyl amine (0.8mL), anhydrous tetrahydrofuran (2mL), copper(I)iodide (0.051g, 0.27mmol) and dichlorobis(triphenylphosphine)palladium(II) (O.lg, 0.14mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 10% ethyl acetate in hexane as the eluent, O.lg of the title compound was obtained as an oil. It was further purified by preparative normal phase HPLC on a partisil- 10 silica column using 10% ethyl acetate in hexane as the mobile phase (0.055g, 24%). Η-NMR (300 MHz, CDCl3):δ 0.42-0.5 l(m, 4H), 1.26(t, J= 7.3Hz, 3H), 1.27(s, 6H), 1.75(m, IH), 2.61(s, 2H), 3.66(s, 2H), 3.74(s, 2H), 4.18 (q, J= 7.3Hz, 2H), 6.97 (d, J = 7.9Hz, IH), 7.20-7.29(m, 4H), 7.45(d, J = 1.5Hz, IH). |"4-f 2-C vcloproρyl-4.4-dimethyl- 1.2.3.4-tetrahvdro-isoquinolin-6-yl-ethvnyl - 2-fluoro-phenyll -acetic acid (Compound 22, General Formula 3) Following general procedure J and using [4-(2-cyclopropy 1-4,4- dimethyl- 1 ,2,3 ,4-tetrahydro-isoquinolin-6-ylethynyl)-2-fluoro-phenyl]-acetic acid ethyl ester (Compound 21, 0.055g, 0.135mmol), methanol (2mL), tetrahydrofuran (4mL), water (ImL) and lithium hydroxide monohydrate (0.117g, 2.97mmol) the title compound was obtained as a pale yellow solid foam (0.040g, 78%). 'H-NMR (300 MHz, CDC13): δ 0.52-0.65(m, 4H), 1.27(s, 6H), 1.84(m, IH), 2.71(s, 2H), 3.61(s, 2H), 3.85(s, 2H), 6.98(d, J = 7.9Hz, IH), 7.06 (t, J = 7.6Hz, IH), 7.17-7.25(m, 3H), 7.43(d, J = 1.2Hz, IH), 8.60-9.00(br s, IH). |"4-(2-Cvclopropyl-4.4-dimethyl- 1.2.3.4-tetrahvdro-isoquinolin-6-yl-ethynyl - phenyl] -acetic acid methyl ester (Compound 23, General Formula 3) Following general procedure F and using 2-cyclopropyl-4,4-dimethyl- 6-ethynyl-l,2,3,4-tetrahydro-isoquinoline(Intermediate 27, 0.13g, 0.571mmol), 4-iodo phenyl acetic acid methyl ester (Reagent B, 0.16g, 0.58mmol), triethyl amine (0.5mL), anhydrous tetrahydrofuran (2mL), copper(I)iodide (0.04g, 0.21mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.12g, 0.17mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 10% ethyl acetate in hexane as the eluent, 0.05g ofthe title compound was obtained as an oil. It was further purified by preparative normal phase HPLC on a partisil- 10 silica column using 10% ethyl acetate in hexane as the mobile phase (0.01 g, 6%). 'H-NMR (300 MHz, CDC13): δ 0.42-0.58(m, 4H), 1.29(m, 6H), 1.79(m, IH), 2.64(s, 2H), 3.67(s, 3H), 3.72(s, 2H), 3.77(s, 2H), 7.09 (d, J = 7.9Hz, IH), 7.28(dd, J = 1.5, 7.9Hz, IH), 7.36 (d, / = 7.9Hz, 2H), 7.50 (d, J = 1.6Hz, IH), 7.51(d, J = 7.9Hz, 2H). [4-(2-Cycloρropyl-4.4-dimethyl-1.2.3.4-tetrahvdro-isoquinolin-6-yl-ethvnyl - phenyll-acetic acid (Compound 24, General Formula 3) Following general procedure J and using [4-(2-cyclopropyl-4,4- dimethyl-l,2,3,4-tetrahydro-isoquinolin-6ylethynyl)-ρhenyl]-acetic acid methyl ester (Compound 23, O.Olg, 0.027mmol), methanol (ImL), tetrahydrofuran (ImL), water (0.5mL) and lithium hydroxide monohydrate (0.042g, lmmol) the title compound was obtained as a pale yellow solid foam (0.0065g, 68%). Η-NMR (300 MHz, CDC13): δ 0.35-0.52(m, 4H), 1.24(s, 6H), 1.74(m, IH), 2.59(s, 2H), 3.64(s, 2H), 3.71(s, 2H), 7.03 (d, J = 8.2Hz, IH), 7.22(dd, J = 1.4, 7.9Hz, IH), 7.33 (d, J = 8.2Hz, 2H), 7.46 (d, J = 8.2Hz, 2H), 7.47(s, IH). 1 -(/-?o-propyl-methyl-aminoV6-trimethylsilanylethvnyl-4.4-dimethyl- 1.2.3.4- tetrahvdro-naphthalene (Intermediate 28) Following general procedure G and using a solution of 4,4-dimethyl-6- trimethylsilanylethynyl- 1 ,2,3 ,4-tetrahydro-naρhthalene 2-one (Intermediate 12, 0.2g, 0.78mmol), dichloromethane (4mL), acetonitrile (2mL), acetic acid (ImL), isopropyl amine (ImL, 11.74mmol) and sodium cyanoborohydride (0.19g, 3.02mmol), after 15days of reaction time and work up afforded an intermediate (0.14g, 60%, 0.47mmol) which was used following general procedure H along with acetone (2mL), potassium carbonate (0.6g, 4.34mmol) and methyl iodide (0.5mL, δmmol). The crude product after work up was subjected to flash column chromatography over silica gel (230-400 mesh) using 15% ethyl acetate in hexane as the eluent to afford the title compound as a pale yellow oil (0.14g, 95%). 'H-NMR (300 MHz, CDC13): δ 0.001(s, 9H), 0.85 (d, J= 6.4Hz, 6H), 0.98 (s, 3H), 1.03 (s, 3H), 1.32-1.60 (m, 4H), 1.81(s, 3H), 2.64(heptet, J= 6.4Hz, IH), 3.65 (dd, J = 6.1, 9.4Hz, IH), 6.97 (dd, J = 1.7, 7.9Hz, IH), 7.13 (d, J= 1.7Hz, IH), 7.82 (d, J = 7.9Hz, IH). 6-Ethvnyl- 1 -(t-?o-ρroρyl-methyl-amino -4.4-dimethyl- 1.2.3.4-tetrahvdro- naphthalene (Intermediate 29) Following general procedure E and using l-(methyl-z-?σ-propylamino)- 4,4-dimethyl-6-trimethylsilanylethynyl- 1 ,2,3 ,4-tetrahydro-naphthalene (Intermediate 28, 0.14g, 0.45mmol), methanol (5mL), potassium carbonate (0.61g, 4.41mmol) and ethyl acetate the title compound (0.092g, 80%) was obtained as an oil. 'H-NMR (300 MHz, CDCl3):δ l.l l(d, J= 6.4Hz, 6H), 1.23(s, 3H), 1.28(s, 3H), 1.51-1.87 (m, 4H), 2.09(s, 3H), 2.90 (heptet, J = 6.4Hz, IH), 3.00(s, IH), 3.91 (dd, J= 5.8, 10.0Hz, IH), 7.25(dd, J = 1.7, 8.2Hz, IH), 7.41 (d, J = 1.7Hz, IH), 7.70(d, J = 8.2Hz, IH). 4-[5-(/-?o-propyl-methyl-amino -8.8-dimethyl-5.6.7.8-tetrahydro-naphthalene- 2-yl-ethynyl)]-benzoic acid ethyl ester (Compound 25. General Formula 4) Following general procedure F and 6-ethynyl- 1 -(wo-propyl-methyl- amino)-4,4-dimethyl-l,2,3,4-tetrahydro-naρhthalene (Intermediate 29, 0.092g, 0.36mmol), ethyl-4-iodo benzoate (Reagent A, 0.12g, 0.48mmol), triethyl amine (ImL), tetrahydrofuran (2mL), copper(I)iodide (0.028g, 0.14mmol) and dichlorobis(triρhenylρhosphine)palladium(II) (0.075g, 0.1 lmmol) followed by flash column chromatography over silica gel (230-400 mesh) using 10-15% ethyl acetate in hexane as the eluent the title compound was obtained (0.04g, 27%). Η-NMR (300 MHz, CDC13): δ 1.12 (d, J= 6.5Hz, 6H), 1.27 (s, 3H), 1.31 (s, 3H), 1.40 (t, J = 7.0Hz, 3H), 1.62-1.89 (m, 4H), 2.10(s, 3H), 2.92 (heptet, J = 6.4Hz, IH), 3.94(dd, J = 6.1, 9.7Hz, IH), 4.38(q, J = 7.1Hz, 2H), 7.3 l(dd, J = 1.4, 8.2Hz, IH), 7.46 (d, / = 1.7Hz, IH), 7.58 (d, J = 8.2Hz, 2H), 7.75(d, J = 8.2Hz, IH), 8.01(d, J = 8.2Hz, 2H). 4-[5-(Zyg>-ρroρyl-methyl-amino -8.8-dimethyl-5.6.7.8-tetrahydro-naphthalene- 2-yl-ethynv ]-benzoic acid (Compound 26, General Formula 4) Following general procedure I and using 4-[5-(z'so-propyl-methyl- amino)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalene-2-ylethynyl)]-benzoic acid ethyl ester (Compound 25, 0.04g, O.Olmmol), ethanol (2mL), tetrahydrofuran (ImL) and IM aqueous sodium hydroxide solution (ImL) followed by recrystallization from diethylether-hexane, the title compound was obtained as an off-white solid (O.OlOg, 27%). Η-NMR (300 MHz, CDC13): δ 1.30(d, J= 6.0Hz, 6H), 1.31(s, 9H), 1.67- 1.98(m, 4H), 2.35 (s, 3H), 3.19 (heptet, J= 6.4Hz, IH), 4.36 (t, J = 7.6Hz, IH), 7.28(dd, J= 1.4, 8.2Hz, IH), 7.48 (d, J = 1.4Hz, IH), 7.55 (d, J = 8.2Hz, 2H), 7.81 (d, J = 8.2Hz, IH), 8.05 (d, J = 8.2Hz, 2H). [4-(2,2.4.4-Tetramethyl-chroman-6-yl-ethynyl phenyl] acetic acid methyl ester (Compound 27, General Formula 8) Following general procedure F and using 6-ethynyl-2,2,4,4- tetramethylchroman (synthesis described in U.S. Patent Nos. 5,045,551 and 5,616,597 incoφorated herein by reference) (0.060g, 0.28mmol), methyl-4- iodo phenyl acetate (Reagent B, 0.078g, 0.28mmol), triethyl amine (4mL), tetrahydrofuran (4mL), copper(I)iodide (0.030g, 0.16mmol) and dichlorobis(triρhenylρhosphine)ρalladium(II) (0.1 lg, 0.16mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5-10 % ethyl acetate in hexane as the eluent the title compound was obtained (0.047g, 46%). Η NMR (300 MHz, CDC13): δ 7.48-7.45 (m, 3H), 7.25-7.23 (m, 3H), 6.75 (d, IH, J= 8.2Hz), 3.70 (s, 3H), 3.62 (s, 2H), 1.84 (s, 2H), 1.36 (s, 6H), 1.35 (s, 6H). GENERAL PROCEDURE L: [4-f2.2.4.4-Tetiamethyl-chroman-6-yl-ethvnyr) phenyl] acetic acid (Compound 28, General Formula 8) A solution of [4-(2,2,4,4-tetramethyl-chroman-6-yl-ethynyl) phenyl] acetic acid methyl ester (Compound 27, 0.047g, 0.13mmol) in 5mL of methanol was treated with IM sodium hydroxide solution (2mL) and heated at 55°C for 2h. The volatiles were distilled off in vacuo and the residue was acidified with 10% hydrochloric acid and extracted with ethyl acetate (x2). The combined organic phase was washed with brine (xl), dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was purified by preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase to afford the title compound (0.034g, 82%). ]H NMR (300 MHz, CDC13): δ 7.49-7.45 (m, 3H), 7.26-7.22 (m, 3H), 6.75 (d, 1H, J= 8.2Hz), 3.65 (s, 2H), 1.84 (s, 2H), 1.36 (s, 6H), 1.35 (s, 6H). 2-Fluoro-4-r2.2.4.4-tetramethyl-chroman-6-yl-ethynyl)-benzoic acid methyl ester (Compound 29, General Formula 8) Following general procedure F and using 6-ethynyl-2, 2,4,4- tetramethylchroman (0.11 g, 0.5 lmmol), methyl-2-fluoro-4-iodo-benzoate (Reagent G, 0.14g, 0.51 mmol), triethyl amine (5mL), tetrahydrofuran( 1 OmL), copρer(I)iodide(0.030g, 0.16mmol) and dichlorobis(triphenylρhosρhine)palladium(II) (0.11 Og, 0.16mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5-10 % ethyl acetate in hexane as the eluent, the title compound was obtained (0.14g, 79%). Η NMR (300 MHz, CDC13): δ 7.82 (t, IH, J= 7.9Hz), 7.39 (d, IH, J= 1.8Hz), 7.25-7.16 (m, 3H), 6.69 (d, IH, J= 8.2Hz), 3.85 (s, 3H), 1.77 (s, 2H), 1.29 (s, 6H), 1.28 (s, 6H). 2-Fluoro-4-(2.2.4.4-tetramethyl-chroman-6-yl-ethynyl)-benzoic acid (Compound 30, General Formula 8) Following general procedure L and using 2-fluoro-4-(2,2,4,4- tetramethyl-chroman-6-yl-ethynyl)-benzoic acid methyl ester (Compound 29, 0.14g, 0.4mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by recrystallization from ethyl acetate, the title compound was obtained (0.083g, 58%). 'H NMR (300 MHz, CD3COCD3): δ 8.00 (t, IH, J= 7.8Hz), 7.63 (d, IH, J = 2.1Hz), 7.45 (dd, 1H, J= 1.5, 7.9Hz), 7.38 (dd, 1H, J= 1.5, 11.4Hz), 7.32 (dd, 1H, J= 2.1, 8.2Hz), 6.81 (d, lH, J= 8.5Hz), 1.92 (s, 2H), 1.41 (s, 6H), 1.38 (s, 6H). [2-Fluoro-4-(2.2.4.4-tetramethyl-chroman-6-yl-ethynv phenyl] acetic acid ethyl ester (Compound 31, General Formula 8) Following general procedure F and using 6-ethynyl-2,2,4,4- tetramethylchroman (0.204g, 0.95mmol), ethyl-2-fluoro-4-iodo phenyl acetate (Reagent C, 0.263g, 0.86mmol), triethyl amine, tetrahydrofuran, copper(I)iodide (0.025g, 0.13mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.075g, 0.1 lmmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5-10 % ethyl acetate in hexane as the eluent, the title compound was obtained (0.2 lg, 62%). !H NMR (300 MHz, CDC13): δ 7.46 (d, IH, /= 2.1Hz), 7.25-7.21 (m, 4H), 6.69 (d, lH, J= 8.5Hz), 4.16 (q, 2H, J= 7.1Hz), 3.65 (s, 2H), 1.82 (s, 2H), 1.35 (s, 6H), 1.35 (s, 6H), 1.24 (t, 3H, J= 7.2Hz). 2-Fluoro-4-(2.2.4.4-tetramethyl-chroman-6-yl-ethynyl) phenyl] acetic acid (Compound 32, General Formula 8) Following general procedure L and using [2-fluoro-4-(2,2,4,4- tetramethyl-chroman-6-ylethynyl) phenyl] acetic acid ethyl ester (Compound 31, 0.21g, 0.58mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by flash column chromatography over silica gel (230-400 mesh) using 50% ethyl acetate in hexane, the title compound was obtained as a solid (0.184g, 93%). !H NMR (300 MHz, CDC13): δ 11.40 (br s, IH), 7.48 (d, IH, J= 1.8Hz), 7.46- 7.16 (m, 4H), 6.76 (d, IH, J= 8.2Hz), 3.69 (s, 2H), 1.82 (s, 2H), 1.34 (s, 12H). 3-Methyl-but-2-enoic acid 4-bromo-phenyl ester: To a stirred, cooled (ice bath) suspension of sodium hydride (2.4g, lOOmmol) in anhydrous tetrahydrofuran (200mL), 4-bromo phenol (17.3g, 1 OOmmol) was added followed by 3 ,3 ,-dimethyl acryloyl chloride ( 11.14mL, 1 OOmmol). After 4hours at ambient temperature, the reaction mixture was poured into brine and extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 2% ethyl acetate in hexane as the eluent to afford the title compound (15g, 59%>). Η-NMR (300 MHz, CDCl3):δ 2.00(s, 3H), 2.23(s, 3H), 5.89(s, IH), 7.00(d, J = 8.8Hz, 2H), 7.49(d, J = 8.8Hz, 2H). 6-Bromo-4.4-dimethyl-chroman-2-one: A solution of 3-methyl-but-2-enoic acid 4-bromo-phenyl ester (7g, 27.6mmol) in anhydrous dichloromethane (200mL) was cooled (ice bath) and treated with aluminum chloride (6.6g, 49.6mmol) and the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution and extracted with diethyl ether (x2). The combined organic extract was washed woth brine (xl), dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford an oil which was purified by flash column chromatography over silica gel (230- 400 mesh) using 2.5% ethyl acetate in hexane as the eluent to afford the title compound (4.2g, 57%). 'H-NMR (300 MHz, CDCl3):δ 1.36(s, 6H), 2.62(s, 2H), 6.95(d, J = 8.5Hz, IH), 7.37(dd, J = 2.4, 8.5Hz, IH), 7.43(d, J = 2.3Hz, IH). 4-Bromo-2-("3 -hvdroxy- 1.1.3-trimethyl-butylVρhenol: A solution of 6-bromo-4,4-dimethyl-chroman-2-one (1 g, 3.92mmol) in anhydrous tetrahydrofuran (20mL) was treated with 3M solution of ethyl magnesium bromide (2.6mL) and stirred at ambient temperature for 2hours. The reaction mixture was poured into cold dilute hydrochloric acid and extracted with ethyl acetate (x2). The combined organic extract was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to afford a residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using 10% ethyl acetate in hexane as the eluent to afford the title compound as a pale yellow solid (l.lg, 100%). 'H-NMR (300 MHz, CDCl3):δ 1.14(s, 6H), 1.44(s, 6H), 2.20(s, 2H), 6.49(d, J = 8.4Hz,lH), 7.15(dd, J = 2.4, 8.5Hz, IH), 7.37(d, J = 2.4Hz, IH). 6-Bromo-2.2.4.4-tetramethyl-chroman: A solution of 4-bromo-2-(3-hydroxy- 1 , 1 ,3-trimethyl-butyl)-phenol (l .lg, 3.92mmol) and ^-toluene sulfonic acid (0.744g, 3.92mmol) in benzene (20mL) was refluxed overnight. The reaction mixture cooled to ambient temperature, filtered on silica gel and washed with 10% ethyl acetate in hexane. The filtrate and washings were evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent to afford the title compound as a pale yellow oil (0.84g, 80%). Η-NMR (300 MHz, CDCl3):δ 1.34(s, 6H), 1.35(s, 6H), 1.82(s, 2H), 6.68(d, J = 8.4Hz, IH), 7.16(dd, J = 2.7, 8.7Hz, IH), 7.37(d, J = 2.6Hz, IH). The synthesis of this compound, as described here, is in close analogy to the synthesis of 6-bromo-2,2,4,4-tetramethylthiochroman, as described in United States Patent No. 5,045,551 2.2.4.4-tetramethyl-6-("2-trimethylsily ethynyl chroman: Following general procedure D and using 6-bromo-2,2,4,4-tetramethyl chroman (0.5g, 1.87mmol), triethyl amine (5mL), anhydrous tetrahydrofuran (15mL),coρρer(I)iodide (0.107g, 0.156mmol), frimethylsilyl acetylene (1.84g, 18.7mmol) and dichlorobis(triphenylρhosρhine)palladium(II) (0.39g, 0.56mmol) the title compound was obtained as a brown oil (0.61g, 100%). !H NMR (300 MHz, CDC13): δ 7.43 (d, IH, J= 2.1Hz), 7.23 (dd, IH, J= 7.9, 2.1Hz), 6.73 (d, IH, J= 8.2Hz), 1.83 (s, 2H), 1.36 (s, 12H), 0.28 (s, 9H). 6-Ethynyl-2.2.4.4-tetramethyl chroman: Following general procedure E and using 2,2,4,4-tetramethyl-6-(2- trimethylsilyl)ethynyl chroman (0.61g, 1 ,87mmol), potassium carbonate (1.9g, 13.74mmol) and methanol the title compound was obtained (0.4g, 90%). 'H NMR (300 MHz, CDC13): δ 7.47 (d, IH, /= 2.1Hz), 7.24 (dd, IH, /= 7.9, 2.1Hz), 6.76 (d, IH, /= 8.2Hz), 3.01 (s, IH), 1.85 (s, 2H), 1.37 (s, 6H), 1.36 (s, 6H). An alternative synthesis for this compound is described in United States Patent Nos. 5,045,551 and 5,616,597 GENERAL PROCEDURE M: 6-Bromo-2.2.4.4-tetramethyl-chroman-8- carbaldehyde (Intermediate 30) A stirred, cooled (ice bath) solution of 6-bromo-2,2,4,4-tetramethyl chroman, (0.5g, 1.865mmol) in anhydrous dichloromethane (5mL) was treated with a IM solution (1.86mL, 1.86mmol) of titanium tetrachloride in dichloromethane followed by α,α-dichloro methyl ether (0.214g, 1.865mmol) . The reaction mixture was allowed to warm to ambient temperature for 4h. The reaction mixture was diluted with diethyl ether, washed with brine (xl) and dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane to afford the title compound as a yellow solid (0.52g, 94%). Η NMR (300 MHz, CDC13): δ 10.38 (s, IH), 7.72 (d, IH, J= 2.6Hz), 7.57 (d, IH, J= 2.6Hz), 1.88 (s, 2H), 1.41 (s, 6H), 1.36 (s, 6H). GENERAL PROCEDURE N: 6-Bromo-8-vinyl -2.2.4.4-tetramethyl- chroman (Intermediate 31) A solution of methylidene triphenyl phosphorane [generated from methyl triphenylphosphonium bromide (7g, 20mmol) and (11.8mL, 19mmol) of a 1.6M solution of n-butyl lithium in hexanes ] was added 6-bromo-2,2,4,4- tetramethyl chroman- 8-carbaldehyde (Intermediate 30, 0.52g, 1.75mmol). After lh the reaction mixture was diluted with hexane, washed with brine (xl), dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a clear oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 2% ethyl acetate in hexane as the eluent to afford the title compound as a clear oil (0.37g, 72%). lH NMR (300 MHz, CDC13): δ 7.46 (d, IH, J= 2.5Hz), 7.33 (d, IH, J = 2.5Hz), 7.03 (dd, 1H, J= 11.3, 17.9Hz), 5.75 (dd, 1H, J= 1.4, 17.9Hz), 5.30 (dd, IH, J= 1.4, 11.3Hz), 1.85 (s, 2H), 1.39 (s, 6H), 1.37 (s, 6H). GENERAL PROCEDURE O: 6-Bromo-8-cvclopropyl-2.2.4.4-tetramethyl chroman (Intermediate 32) A stirred, cooled (-30°C) solution of 6-bromo-8-vinyl-2,2,4,4- tetramethyl chroman (Intermediate 31, 0.37g, 1.26mmol) in diethyl ether was treated with a solution of diazomethane in diethyl ether and catalytic amount of palladium (IΙ)acetate (~30mg). The reaction mixture was allowed to warm to ambient temperature and subjected to flash column chromatography over silica gel (230-400 mesh) using 2% ethyl acetate in hexane as the eluent to afford the title compound as a clear, pale yellow oil (0.376g, 97%). !H NMR (300 MHz, CDC13): δ 7.17 (d, IH, J= 2.3Hz), 6.73 (d, IH, J= 2.6Hz), 2.19-2.16 (m, IH), 1.83 (s, 2H), 1.37 (s, 6H), 1.33 (s, 6H), 0.94-0.88 (m, 2H), 0.64-0.59 (m, 2H). 8-Cyclopropyl-6-trimethylsilanylethynyl-2.2.4.4-tetramethyl chroman (Intermediate 33) Following general procedure D and using 6-bromo-8-cycloρropyl- 2,2,4,4-tetramethyl chroman (Intermediate 32, 0.376g, 1.22mmol), (trimethylsilyl)acetylene (4mL, 28mmol), triethyl amine (3mL), anhydrous tetrahydrofuran (5mL), coρper(I)iodide (0.025g, 0.13mmol) and dichlorobis(triphenylρhosρhine)palladium(II) (0.075g, 0.1 lmmol), the title compound was obtained as an oil (0.173g, 43%). Η NMR (300 MHz, CDC13): δ 7.36 (d, IH, J= 2.2Hz), 6.90 (d, IH, J= 1.9Hz), 2.31-2.22 (m, IH), 1.96 (s, 2H), 1.49 (s, 6H), 1.46 (s, 6H), 1.05-0.88 (m, 2H), 0.78-0.72 (m, 2H), 0.37 (s, 9H). 8-Cvcloproρyl-6-ethynyl-2.2.4.4-tetramethyl chroman (Intermediate 34) Following general procedure E and using 8-cyclopropyl-6- trimethylsilanylethynyl-2,2,4,4-tetramethyl chroman (Intermediate 33, 0.17g, 0.68mmol), methanol and potassium carbonate (0.2g, 1.47mmol) the title compound was obtained as an oil (0.064g, 47%). Η NMR (300 MHz, CDC13): δ 7.38 (d, IH, J= 1.9Hz), 6.92 (d, IH, J= 1.9Hz), 3.08 (s, IH), 2.32-2.23 (m, IH), 1.96 (s, 2H), 1.50 (s, 6H), 1.46 (s, 6H), 1.05-0.99 (m, 2H), 0.77-0.72 (m, 2H). 4-(8-Cyclopropyl-2.2.4.4-tetramethyl-chroman-6-yl-ethynyl)-benzoic acid ethyl ester (Compound 33, General Formula 8) Following general procedure F and using δ-cyclopropyl-6-ethynyl- 2,2,4,4-tetramethylchroman (Intermediate 34, 0.1 g, 0.3 δmmol), ethyl-4-iodo- benzoate (Reagent A, O.lg, 0.34mmol), triethyl amine (5mL), tetrahydrofuran( 1 OmL), copper(I)iodide(0.025g, 0.13mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.075g, 0.1 lmmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5-10 % ethyl acetate in hexane as the eluent, the title compound was obtained (0.135g, 89%). Η NMR (300 MHz, CDC13): δ 8.00 (d, 2H, J= 8.2Hz), 7.55 (d, 2H, J= 8.2Hz), 7.30 (d, IH, J= 1.8Hz), 6.84 (d, IH, J= 2.0Hz), 4.38 (q, 2H, J= 6.9Hz), 2.22-2.12 (m, IH), 1.85 (s, 2H), 1.40 (t, 3H, J= 6.9Hz), 1.38 (s, 6H), 1.36 (s, 6H), 0.92-0.88 (m, 2H), 0.67-0.62 (m, 2H). 4-r8-Cyclopropyl-2.2.4.4-tetramethyl-chroman-6-yl-ethvnylVbenzoic acid (Compound 34, General Formula 8) Following general procedure L and using 4-(8-cyclopropyl-2,2,4,4- tetramethyl-chroman-6-yl-ethynyl)-benzoic acid ethyl ester (Compound 33, 0.135g, 0.34mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a solid (0.093g, 73%). Η NMR (300 MHz, CDC13): δ 11.26 (br s, IH), 8.0δ (d, 2H, J= δ.2Hz), 7.59 (d, 2H, J= δ.2Hz), 7.31 (d, IH, J= l.δHz), 6.δ5 (d, IH, J= 2.1Hz), 2.22-2.13 (m, IH), 1.85 (s, 2H), 1.38 (s, 6H), 1.36 (s, 6H), 0.95-0.87 (m, 2H), 0.68-0.63 (m, 2H). [4-(8-Cyclopropyl-2.2.4.4-tetramethyl-chroman-6-yl-ethynyl) phenyl] acetic acid methyl ester (Compound 35, General Formula 8) Following general procedure F and using δ-cyclopropyl-6-ethynyl- 2,2,4,4-tetramethylchroman (Intermediate 34, 0.096g, 0.3 δmmol), methyl-4- iodo phenyl acetate (Reagent B, 0.094g, 0.34mmol), triethyl amine (3mL), tetrahydrofuran (3mL), copρer(I)iodide (0.025g, 0.13mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.075g, 0.1 lmmol) the title compound was obtained (0.137g, 90%). Η NMR (300 MHz, CDC13): δ 7.47 (d, 2H, J= 7.9Hz), 7.29 (d, IH, J= 1.8Hz), 7.24 (d, 2H, J= 7.9 Hz), 6.82 (d, 1H, J= 2.1Hz), 3.70 (s, 3H), 3.63 (s, 2H), 2.22-2.13 (m, IH), 1.85 (s, 2H), 1.38 (s, 6H), 1.36 (s, 6H), 0.94-0.86 (m, 2H), 0.68-0.63 (m, 2H). r4-('8-Cyclopropyl-2.2.4.4-tetramethyl-chroman-6-yl-ethvnyl phenyl] acetic acid (Compound 36, General Formula 8) Following general procedure L and using [4-(8-cyclopropyl-2,2,4,4- tetramethyl-chroman-6-ylethynyl) phenyl] acetic acid methyl ester (Compound 35, 0.137g, 0.30mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a solid (0.1 lg, 80%). Η NMR (300 MHz, CDC13): δ 11.56 (br s, IH), 7.47 (d, 2H, J= 8.9Hz), 7.28 (d, IH, J= 1.9Hz), 7.23 (d, 2H, J= 8.5Hz), 6.δ2 (d, IH, J= 1.9Hz), 3.62 (s, 2H), 2.21-2.12 (m, IH), 1.83 (s, 2H), 1.36 (s, 6H), 1.34 (s, 6H), 0.93-0.82 (m, 2H), 0.72-0.62 (m, 2H). r4- 8-Cycloproρyl-2.2.4.4-tetramethyl-chroman-6-yl-ethynylV2-fluoroρhenyl1 acetic acid ethyl ester (Compound 37, General Formula 8) Following general procedure F and using 8-cyclopropyl-6-ethynyl- 2,2,4,4-tetramethylchroman (Intermediate 34, 0.096g, 0.38mmol), ethyl-2- fluoro-4-iodo phenyl acetate (Reagent C, 0.104g, 0.34mmol), triethyl amine (3mL), tetrahydrofuran (3mL), copper(I)iodide (0.020g, 0. lmmol) and dichlorobis(triphenylphosphine)palladium(II) (0.060g, 0.085mmol) the title compound was obtained (0.14g, 85%). Η NMR (300 MHz, CDC13): δ 7.31 (d, IH, J= 1.9Hz), 7.29-7.21 (m, 3H), 6.85 (d, IH, J= 1.9Hz), 4.20 (q, 2H, J= 7.1Hz), 3.68 (s, 2H), 2.24-2.14 (m, IH), 1.87 (s, 2H), 1.40 (s, 6H), 1.38 (s, 6H), 1.28 (t, 3H, J= 7.1Hz), 0.96-0.85 (m, 2H), 0.70-0.64 (m, 2H). 4-(,8-Cyclopropyl-2.2.4.4-tetramethyl-chroman-6-yl-ethynylV2-fluorophenyl] acetic acid (Compound 38, General Formula 8) Following general procedure L and using [4-(8-cyclopropyl-2,2,4,4- tetramethyl-chroman-6-yl-ethynyl)-2-fluorophenyl] acetic acid ethyl ester (Compound 37, 0.14g, 0.323mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by reverse phase HPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a solid (O.l lOg, 80%). Η NMR (300 MHz, CDC13): δ 7.2δ (d, IH, J= 2.1Hz), 7.27-7.17 (m, 3H), 6.82 (d, 1H, J= 1.8Hz), 3.70 (s, 2H), 2.21-2.11 (m, IH), 1.84 (s, 2H), 1.37 (s, 6H), 1.35 (s, 6H), 0.94-0.87 (m, 2H), 0.67-0.62 (m, 2H). GENERAL PROCEDURE P: 6-Bromo-4.4-dimethyl-2-methylene chroman (Intermediate 35) A stirred, cooled (ice bath) solution of 6-bromo-4,4-dimethyl-chroman- 2-one available in accordance with U.S. Patent No. 5,399,561 incoφorated herein by reference (lg, 3.92mmol) in 8mL of anhydrous tetrahydrofuran was treated with a 0.5 M solution of μ-chloro-μ-methylene- [bis(cyclopentadienyl)titanium]dimethylaluminum (Tebbe reagent) in toluene (8.23mL, 4.12mmol). After 10 minutes, the reaction mixture was poured into ice-water mixture containing 50mL of IM sodium hydroxide and extracted with hexane. The hexane extract was washed with brine (xl), filtered over a bed of celite and evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using hexane as the eluent to afford the title compound (0.74g, 74%) as a clear oil. Η NMR (300 MHz, CDC13): δ 7.34 (d, IH, J= 2.3Hz), 7.23 (dd, IH, J= 2.3.8.5Hz), 6.77 (d, IH, J= 8.0Hz), 4.61 (d, IH, J= 0.73Hz), 4.17 (d, IH, J= 0.73Hz), 2.33 (s, 2H), 1.27 (s, 6H). GENERAL PROCEDURE Q: 6-Bromo-3.4-dihvdro-4.4-dimethylspiro[2H- 1 - benzoρyran-2.1 '-cyclopropane] (Intermediate 36) A solution of diethyl zinc in hexane (IM, 7. ImL) was treated with diiodomethane (1.89g, 7. lmmol). After 5 minutes, a solution of 6-bromo-4,4- dimethyl-2-methylene chroman (Intermediate 35, 0.44g, 1.77mmol) in 3mL of hexane was added and the solution was refluxed for lh. The reaction mixture was then cooled to ambient temperature, diluted with hexane, washed with brine (xl), dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using hexane as the eluent to obtain the title compound (0.44g, 93%). 'H NMR (300 MHz, CDC13): δ 7.47 (d, IH, J= 2.3Hz), 7.23 (dd, IH, J= 2.3,8.5Hz), 6.70 (d, IH, J= 8.0Hz), 1.96 (s, 2H), 1.47 (s, 6H), 1.09-1.05 (m, 2H), 0.74-0.70 (m, 2H). 3.4-Dihydro-4.4-dimethyl-6-(trimethylsilanyl ethynylsρiro|"2H- 1 -benzopyran- 2.1 '-cyclopropane] (Intermediate 37) Following general procedure D and using 6-bromo-3,4-dihydro-4,4- dimethylspiro[2H- 1 -benzopyran-2, 1 '-cyclopropane] (Intermediate 36, 0.44g, 1.65mmol), triethyl amine (4mL), anhydrous tetrahydrofuran (5mL), copper(I)iodide (0.95g, 0.5mmol), trimethylsilyl acetylene (1.62g, 16.5mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.4g, 0.56mmol), the title compound was obtained as a brown oil (0.4g, 86%). Η NMR (300 MHz, CDC13): δ 7.44 (d, IH, J= 2.1Hz), 7.18 (dd, IH, J = 2.1,8.5Hz), 6.65 (d, 1H, J= 8.5Hz), 1.87 (s, 2H), 1.37 (s, 6H), 1.01-0.97 (m, 2H), 0.65-0.61 (m, 2H), 0.26 (s, 9H). 6-Ethynyl-3.4-dihydro-4.4-dimethylspiro[2H- 1 -benzopyran-2.1 '- cyclopropane] (Intermediate 38) Following general procedure E and using 3,4-dihydro-4,4-dimethyl-6- (trimethylsilanyl)ethynylspiro[2H- 1 -benzopyran-2, 1 ' -cyclopropane] (Intermediate 37, 0.4g, 1.42mmol), potassium carbonate (0.98g, 7. lmmol) and methanol, the title compound was obtained as a yellow oil (0.3g, 100%). »Η NMR (300 MHz, CDC13): δ 7.44 (d, IH, J= 2.1Hz), 7.18 (dd, IH, J= 2.1, 8.5Hz), 6.65 (d, IH, J= 8.5Hz), 2.97 (s, IH), 1.86 (s, 2H), 1.37 (s, 6H), 1.00- 0.95 (m, 2H), 0.64-0.59 (m, 2H). Benzoic acid. 4-[( .4-dihvdro-4.4-dimethylspiro[2H-l-benzopyran-2.1 '- cvclopropane]-6-yl ethvnyll-ethyl ester (Compound 39, General Formula 1) Following general procedure F and using 6-ethynyl-3,4-dihydro-4,4- dimethylspiro[2H- 1 -benzopyran-2, 1 '-cyclopropane] (Intermediate 38, 0.06g, 0.28mmol), ethyl-4-iodo-benzoate (Reagent A, 0.086g, 0.3 lmmol), triethyl amine (4mL), tetiahydrofuran(4nιL), copρer(I)iodide(0.032g, 0.17mmol) and dichlorobis(triρhenylρhosphine)ρalladium(II) (0.118g, 0.17mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5-10 % ethyl acetate in hexane as the eluent, the title compound was obtained (0.07g, 70%). Η NMR (300 MHz, CDC13): δ 8.01 (d, 2H, J= 8.2Hz), 7.56 (d, 2H, J= 8.5Hz), 7.49 (d, IH, /= 2.1Hz), 7.24 (dd, IH, J= 2.1,8.5Hz), 6.70 (d, IH, J= 8.5Hz), 4.38 (q, 2H, J= 7.1Hz), 1.89 (s, 2H), 1.40 (s, 6H), 1.40 (t, 3H, J= 7.0Hz), 1.02-0.98 (m, 2H), 0.67-0.62 (m, 2H). Benzoic acid. 4-[(3.4-dihydro-4.4-dimethylspiro[2H-l-benzopyran-2.1 '- cycloρropane]-6-yl)ethynyll- (Compound 40, General Formula 1) Following general procedure L and using benzoic acid, 4-[(3,4-dihydro-4,4- dimethylspiro[2H-l -benzopyran-2, 1 '-cyclopropane]-6-yl)ethynyl]-ethyl ester (Compound 39, 0.07g, 0.196mmol), 5mL of ethanol and IM sodium hydroxide solution (2mL) followed by preparative reverse phase ΗPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a solid (0.034g, 52%). Η NMR (300 MHz, CD3COCD3): δ 8.05 (d, 2H, J= 8.2Hz), 7.64 (d, 2H, J= 8.2Hz), 7.60 (d, IH, J= 2.1Hz), 7.28 (dd, IH, J= 2.1, 8.5Hz), 6.73 (d, IH, J= 8.5Hz), 1.95 (s, 2H), 1.43 (s, 6H), 0.96-0.92 (m, 2H), 0.74-0.71 (m, 2H). Benzeneacetic acid. 4-[f3.4-dihydro-4,4-dimethylspiro[2H-l -benzopyran-2.1 '- cycloρroρane]-6-yl)ethynyl]-methyl ester (Compound 41, General Formula 1) Following general procedure F and using 6-ethynyl-3,4-dihydro-4,4- dimethylsρiro[2H- 1 -benzopyran-2, 1 '-cyclopropane] (Intermediate 38, , 0.060g, 0.28mmol), methyl-4-iodo phenyl acetate (Reagent B, 0.078g, 0.28mmol), triethyl amine (4mL), tetrahydrofuran (4mL), copper(I)iodide (0.032g, 0.17mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.118g, 0.17mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5 % ethyl acetate in hexane as the eluent, the title compound was obtained (0.084g, 84%). Η NMR (300 MHz, CDC13): δ 7.48-7.45 (m, 3H), 7.26-7.20 (m, 3H), 6.67 (d, IH, J= 8.5Hz), 3.70 (s, 3H), 3.63 (s, 2H), 1.89 (s, 2H), 1.40 (s, 3H), 1.40 (s, 3H), 1.01-0.97 (m, 2H), 0.67-0.61 (m, 2H). Benzeneacetic acid. 4-[r3.4-dihvdro-4.4-dimethylspiror2H-l-benzoρyran-2. - cycloρropane]-6-yl)ethvnyl]- (Compound 42, Formula 1) A solution of benzeneacetic acid, 4-[(3,4-dihydro-4,4- dimethylspiro[2H-l-benzopyτan-2, -cyclopropane]-6-yl)ethynyl]-methyl ester (Compound 41, 0.084g, 0.24mmol) in 5mL of methanol was treated with IM sodium hydroxide solution (2mL) and heated at 55°C for 2h. The volatiles were distilled off in vacuo and the residue was acidified with 10% hydrochloric acid and extracted with ethyl acetate (x2). The combined organic phase was washed with brine (xl), dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was purified by preparative reverse phase ΗPLC using 10% water in acetonitrile as the mobile phase to afford the title compound (0.080g, 100%). Η NMR (300 MHz, CD3COCD3): δ 7.49-7.46 (m, 3H), 7.25 (d, 2H, J= 8.2Hz), 7.22 (dd, IH J= 2.1,8.5Hz), 6.68 (d, IH, J= 8.5Hz), 3.66 (s, 2H), 1.88 (s, 2H), 1.44 (s, 6H), 1.01-0.97 (m, 2H), 0.67-0.61 (m, 2H). 2-Fluoro-benzoic acid. 4-[(3.4-dihydro-4.4-dimethylspiro[2H- 1 -benzopyran- 2.1' -cyclopropane] -6-yl)ethynyl] -methyl ester (Compound 43, General Formula 1) Following general procedure F and 6-ethynyl-3,4-dihydro-4,4- dimethylsρiro[2H-l -benzopyran-2, 1 '-cyclopropane] (Intermediate 38, 0.050g, 0.23mmol), methyl-2-fluoro-4-iodo-benzoate (Reagent G, 0.069g, 0.24mmol), triethyl amine (5mL), tetiahyάj-ofiιran(5mL), copper(I)iodide(0.013g, 0.07mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.049g, 0.07mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5-10 % ethyl acetate in hexane as the eluent, the title compound was obtained (0.080g, 100%). Η NMR (300 MHz, CDC13): δ 7.90 (t, IH, J= 7.9Hz), 7.63 (d, IH, J= 1.8Hz), 7.32 (dd, 1H, J= 1.5, 8.2Hz), 7.26 (dd, 1H, J= 1.5,11.4Hz), 7.24 (dd, IH, J= 2.1, 8.5Hz), 6.71 (d, IH, J= 8.5Hz), 1.97 (s, 2H), 1.44 (s, 6H), 0.98- 0.94 (m, 2H), 0.76-0.71 (m, 2H). 2-Fluoro-benzoic acid. 4- [(3.4-dihydro-4.4-dimethylspiro[2H- 1 -benzopyran- 2.1 '-cvclopropane]-6-yl)ethynyl]- (Compound 44, General Formula 1) Following general procedure L and using 2-fluoro-benzoic acid, 4- [(3 ,4-dihydro-4,4-dimethylspiro[2H- 1 -benzopyran-2, 1 ' -cyclopropane] -6- yl)ethynyl]-methyl ester (Compound 43, 0.08g, 0.23mmol), 5mL of methanol and 2M sodium hydroxide solution (ImL) followed by flash column chromatography over silica gel (230-400 mesh) using ethyl acetate as the eluent, the title compound was obtained (0.020g, 25%). Η NMR (300 MHz, CD3COCD3): δ 7.99 (t, IH, J= 7.9Hz), 7.63 (d, IH, J= 2.1Hz), 7.44 (dd, 1H, J= 1.5, 7.9Hz), 7.37 (dd, 1H, J= 1.5, 11.4Hz), 7.31 (dd, 1H, J= 2.1, 8.5Hz), 6.75 (d, 1H, J= 8.2Hz), 1.97 (s, 2H), 1.44 (s, 6H), 0.98- 0.94 (m, 2H), 0.76-0.71 (m, 2H). GENERAL PROCEDURE R: 2.2.4.4-Tetramethyl-chroman-6-carboxylic acid (Intermediate 39) A stirred, cooled (-78°C) solution of 6-bromo-2,2,4,4-tetramethyl chroman ( 1.2g, 4.47mmol) in 15mL of anhydrous tetrahydrofuran was treated with a 1.7M solution of tert-butyl lithium solution in pentane ( 5.27mL, 8.9mmol). After 10 minutes at -78°C, carbon dioxide (generated from dry ice) was bubbled into the reaction mixture. The reaction mixture was allowed to warm to ambient temperature. The reaction mixture was diluted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using ethyl acetate as the eluent to afford the title compound as a white solid (l.lg, 92%) . Η NMR (300 MHz, CDC13): δ 12.17 (br s, IH), 8.09 (d, IH, J= 2.1Hz), 7.85 (dd, IH, .7= 2.1, 8.5Hz), 6.83 (d, 1H, J= 8.2Hz), 1.87 (s, 2H), 1.39 (s, 6H), 1.37 (s, 6H). 2.2.4.4-Tetramethyl-chroman-6-carboxylic acid 4-(tert- butoxycarbonylmethyDphenyl ester (Compound 45, General Formula 8) A solution of 2,2,4,4-tetramethyl chroman-6-carboxylic acid (O.lg, 0.43mmol) in thionyl chloride (lOmL) was refluxed for 2h. The thionyl chloride was evaporated under reduced pressure and the residue was dissolved in 5mL of dichloromethane and treated with triethyl amine (5mL) followed by tert-butyl-4-hydroxy phenyl acetate (Reagent E, 0.088g, 0.427mmol). After 0.5h, the reaction mixture was subjected to flash column chromatography over silica gel (230-400 mesh) using 5-10% ethyl acetate in hexane as the eluent to afford the title compound (O.lg, 55%). Η NMR (300 MHz, CDC13): δ 8.15 (d, 1H, J= 2.1Hz), 7.93 (dd, IH, 7= 2.1, 8.5Hz), 7.33 (d, 2H, J= 8.8Hz), 7.16 (d, 2H, J= 8.8Hz), 6.88 (d, IH, J= 8.5Hz), 3.54 (s, 2H), 1.89 (s, 2H), 1.45 (s, 9H), 1.41 (s, 6H), 1.40 (s, 6H). 2.2.4.4-Tetramethyl-chroman-6-carboxylic acid 4-(carboxymethyl)phenyl ester (Compound 46, General Formula 8) A solution of 2,2,4,4-tetramethyl-chroman-6-carboxylic acid 4-(tert- butoxycarbonylmethyl)phenyl ester (Compound 45, O.lg, 0.23mmol) was treated with 5mL of trifluoroacetic acid and stirred at ambient temperature for lh. The trifluoroacetic acid was distilled off under reduced pressure and the residue was subjected to preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase to afford the title compound as a white solid (0.045g, 50%). Η NMR (300 MHz, CDC13): δ 8.13 (d, IH, = 2.1Hz), 7.92 (dd, IH, J= 2.3, 8.5Hz), 7.35 (d, 2H, J= 8.8Hz), 7.17 (d, 2H, J= 8.5Hz), 6.87 (d, IH, J= 8.5Hz), 3.68 (s, 2H), 1.89 (s, 2H), 1.41 (s, 6H), 1.39 (s, 6H). 6-Bromo-8-carbaldehyde-3.4-dihydro-4.4-dimethylspiro[2H-l-benzopyran- 2,1' -cyclopropane] (Intermediate 40) Following general procedure M and using 6-bromo-3,4-dihydro-4,4- dimethylspiro[2H- 1 -benzopyran-2, l '-cyclopropane](Intermediate 36, 2.3g, 8.65mmol), anhydrous dichloromethane (25mL), IM solution (8.65mL, 8.65mmol) of titanium tetrachloride in dichloromethane and α,α-dichloro methyl ether (1.09g, 9.52mmol) followed by flash column chromatography using 10% ethyl acetate in hexane as the eluent, the title compound was obtained as a yellow solid (2.06g, 81 %). 'Η NMR (300 MHz, CDC13): δ 10.20 (s, IH), 7.69 (d, IH, J= 2.6Hz), 7.58 (d, IH, J= 2.6Hz), 1.92 (s, 2H), 1.40 (s, 6H), 1.09-1.04 (m, 2H), 0.73-0.69 (m, 2H). 6-Bromo-3.4-dihydro-4.4-dimethyl-8-vinylspiro[2H-l-benzopyran-2, - cyclopropane] (Intermediate 41) Following general procedure N and using A solution of methylidene triphenyl phosphorane [generated from methyl triphenylphosphonium bromide (7g, 20mmol) and 1.6M solution of n-butyl lithium in hexanes (11.8mL, 19mmol) ], 6-bromo-8-carbonyl-3,4-dihydro-4,4-dimethylsρiro[2H-l- benzoρyran-2, 1 '-cyclopropane](Intermediate 40, 2.06g, 7mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 1-2% ethyl acetate in hexane as the eluent, the title compound was obtained as a clear oil (1.36g, 66%). Η NMR (300 MHz, CDC13): δ 7.36 (d, IH, J= 2.3Hz), 7.28 (d, IH, /= 2.6Hz), 6.80 (dd, 1H, J= 11.1, 17.9Hz), 5.63 (dd, IH, J= 1.2, 17.9Hz), 5.19 (dd, IH, J= 1.2, 11.1Hz), 1.84 (s, 2H), 1.35 (s, 6H), 0.97 (t, 2H, J= 6.3Hz), 0.62 (d, IH, J= 5.3Hz), 0.60 (d, IH, J= 6.2Hz). 6-Bromo-8-cyclopropyl-3.4-dihvdro-4.4-dimethylspiro[2H-l-benzopyran- 2.1 ' -cyclopropane] (Intermediate 42) Following general procedure O and using A 6-bromo-3,4-dihydro-4,4- dimethyl-8-vinylsρiro[2H-l -benzopyran-2, 1 '-cyclopropane] (Intermediate 41, 1.36g, 4.6mmol), a solution of diazomethane in diethyl ether and palladium (IΙ)acetate (~30mg) followed by flash column chiOmatography over silica gel (230-400 mesh) using hexane as the eluent, the title compound was obtained as a clear oil ( 1.38g, 100%) . Η NMR (300 MHz, CDC13): δ 7.19 (d, IH, J= 2.2Hz), 6.71 (d, IH, J= 2.2Hz), 1.99-1.92 (m, IH), 1.87 (s, 2H), 1.35 (s, 6H), 1.00-0.95 (m, 2H), 0.90- 0.82 (m, 2H), 0.65-0.54 (m, 4H). 8-Cyclopropyl-3.4-dihydro-4.4-dimethyl-6-(trimethylsilanyl ethynylspiro[2H- 1 -benzopyran-2.1 '-cyclopropane] (Intermediate 43) Following general procedure D and 6-bromo-8-cyclopropyl-3,4- dihydro-4,4-dimethylspiro[2H- 1 -benzopyran-2, 1 ' -cyclopropane] (Intermediate 42, 0.74g, 2.4mmol), (trimethylsilyl)acetylene (4mL, 28mmol), triethyl amine (8mL), anhydrous tetrahydrofuran , copper(I)iodide (0.050g, 0.26mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.15g, 0.22mmol), followed by flash column chromatography over silica gel (230- 400 mesh) using 1-2% ethyl acetate in hexane as the eluent, the title compound was obtained as an oil (0.62g, 80%). *Η NMR (300 MHz, CDC13): δ 7.28 (d, IH, J= 1.9Hz), 6.77 (d, IH, J= 1.9Hz), 2.03-1.94 (m, IH), 1.91 (s, 2H), 1.40 (s, 6H), 1.05-0.98 (m, 2H), 0.95- 0.83 (m, 2H), 0.69-0.59 (m, 4H), 0.27 (s, 9H). 8-Cyclopropyl-6-ethynyl-3.4-dihydro-4.4-dimethylspiro[2H- 1 -benzopyran- 2. -cyclopropane] (Intermediate 44) Following general procedure E, and 8-cyclopropyl-3,4-dihydro-4,4- dimethyl-6-(trimethylsilanyl)ethynylspiro[2H-l-benzopyran-2, - cyclopropane] (Intermediate 43, 0.62g, 1.9mmol), methanol and potassium carbonate (0.5g, 3.6mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 1-2% ethyl acetate in hexane as the eluent, the title compound was obtained as an oil (0.5g, 100%). Η NMR (300 MHz, CDC13): δ 7.30 (d, IH, J= 1.8Hz), 6.80 (d, IH, J= 2.0Hz), 2.97 (s, IH), 2.04-1.95 (m, IH), 1.91 (s, 2H), 1.39 (s, 6H), 1.20-0.90 (m, 2H), 0.90-0.84 (m, 2H), 0.75-0.58 (m, 4H). Benzeneacetic acid. 4-[ 8-cvclopropyl-3.4-dihvdro-4.4-dimethylspiror2H-l- benzopyran-2.1 '-cyclopropane]-6-yl)ethynyl]-methyl ester (Compound 47, General Formula 1) Following general procedure F and using 8-cyclopropyl-6-ethynyl-3,4- dihydro-4,4-dimethylspiro[2H- 1 -benzopyran-2, 1 ' -cyclopropane] (Intermediate 44, 0.1 lg, 0.43mmol), methyl-4-iodo phenyl acetate (Reagent B, 0.114g, 0.41mmol), triethyl amine (5mL), tetrahydrofuran (3mL), copper(I)iodide (0.025g, 0.13mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.075g, 0.1 lmmol), the title compound was obtained as a clear oil (0.096g, 56%). Η NMR (300 MHz, CDC13): δ 7.46 (d, 2H, J= 8.0Hz), 7.31 (d, IH, J= 1.9Hz), 7.24 (d, 2H, /= 8.2Hz), 6.81 (d, IH, /= 1.9Hz), 3.69 (s, 3H), 3.62 (s, 2H), 2.04-1.95 (m, IH), 1.90 (s, 2H), 1.39 (s, 6H), 1.03-0.99 (m, 2H), 0.90- 0.83 (m, 2H), 0.68-0.59 (m, 4H). Benzeneacetic acid. 4- (8-cvclopropyl-3.4-dihvdro-4.4-dimethylspiro[2H-l- benzopyran-2.1 '-cyclopropane]-6-yl ethynyl]- (Compound 48, General Formula 1) Following general procedure L and using benzeneacetic acid, 4-[(8- cyclopropyl-3 ,4-dihydro-4,4-dimethylspiro[2H- 1 -benzopyran-2, 1 ' - cycloρropane]-6-yl)ethynyl]-methyl ester (Compound 47, 0.96g, 0.24mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by flash column chromatography over silica gel (230-400 mesh) using 15% methanol in dichloromethane as the eluent, the title compound was obtained as a solid (0.084g, 91%). Η NMR (300 MHz, CDC13): δ 10.27 (br s, IH), 7.46 (d, 2H, /= 8.2Hz), 7.30 (d, IH, J= 1.8Hz), 7.23 (d, 2H, /= 8.2Hz), 6.80 (d, IH, J= 1.5Hz), 3.63 (s, 2H), 2.07-1.94 (m, IH), 1.89 (s, 2H), 1.39 (s, 6H), 1.03-0.98 (m, 2H), 0.89- 0.82 (m, 2H), 0.73-0.59 (m, 4H). 4- [(8-Cvclopropyl-3.4-dihvdro-4.4-dimethylspiro 2H- 1 -benzopyran-2.1 ' - cyclopropane]-6-yl)ethynyl]-2-fluoro-benzeneacetic acid methyl ester (Compound 49, General Formula 1) Following general procedure F and using 8-cycloρropyl-6-ethynyl-3,4- dihydro-4,4-dimethylspiro[2H- 1 -benzopyran-2, 1 ' -cyclopropane] (Intermediate 44, 0.125g, 0.5mmol), methyl-2-fluoro-4-iodo phenyl acetate (Reagent Η, 0.14g, 0.5mmol), triethyl amine (3mL), tetrahydrofuran (3mL), copper(I)iodide (0.020g, 0. lmmol) and dichlorobis(triphenylphosphine)palladium(II) (0.060g, 0.085mmol) followed by preparative normal phase ΗPLC using 10% ethyl acetate in hexane as the mobile phase, the title compound was obtained (0.096g, 46%). lH NMR (300 MHz, CDC13): o 7.30 (d, IH, J= 2.1Hz), 7.26-7.18 (m, 3H), 6.80 (d, 1H, J= 1.8Hz), 3.71 (s, 3H), 3.67 (s, 2H), 2.04-1.94 (m, IH), 1.90 (s, 2H), 1.40 (s, 6H), 1.18-0.99 (m, 2H), 0.90-0.83 (m, 2H), 0.68-0.59 (m, 4H). 4- (8-Cyclopropyl-3.4-dihvdro-4.4-dimethylspiro[2H-l-benzopyran-2. - cyclopropane]-6-yl)ethynyl]-2-fluoro-benzeneacetic acid (Compound 50, General Formula 1) Following general procedure L and using 4-[(8-cyclopropyl-3,4- dihydro-4,4-dimethylspiro[2H- 1 -benzopyran-2, 1 '-cyclopropane]-6- yl)ethynyl]-2-fluoro-benzeneacetic acid methyl ester (Compound 49, 0.096g, 0.23mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by flash column chromatography over silica gel (230-400 mesh) - using 15% methanol in dichloromethane as the eluent, the title compound was obtained as a solid (0.093g, 100%). Η NMR (300 MHz, CDC13): δ 9.50 (br s, IH), 7.27 (d, IH, J= 2.1Hz), 7.24- 7.15 (m, 3H), 6.77 (d, IH, J= 1.5Hz), 3.67 (s, 2H), 2.01-1.91 (m, IH), 1.87 (s, 2H), 1.36 (s, 6H), 1.01-0.96 (m, 2H), 0.87-0.80 (m, 2H), 0.65-0.56 (m, 4H). Benzoic acid. 4-[(y8-cvclopropyl-3.4-dihvdro-4.4-dimethylspiro[2H- 1- benzopyran-2.1 '-cyclopropane]-6-yl ethvnyl]-ethyl ester (Compound 51, General Formula 1) Following general procedure F and using 8-cyclopropyl-6-ethynyl-3,4- dihydro-4,4-dimethylspiro[2H-l -benzopyran-2, 1 '-cyclopropane] (Intermediate 44, 0.05g, 0.2mmol), ethyl-4-iodo-benzoate (Reagent A, 0.055g, 0.2mmol), triethyl amine (3mL), tetrahydrofuran(3mL), copper(I)iodide(0.020g, 0. lmmol) and dichlorobis(triphenylphosphine)palladium(II) (0.060g, 0.085mmol), the title compound was obtained (0.06g, 75%). 'Η NMR (300 MHz, CDC13): δ 8.00 (d, 2H, J= 8.2Hz), 7.55 (d, 2H, J= 8.2Hz), 7.33 (d, IH, J= 1.8Hz), 6.83 (d, IH, J= 2.1Hz), 4.38 (q, 2H, J = 7.1Hz), 2.04-1.95 (m, IH), 1.91 (s, 2H), 1.40 (s, 6H), 1.40 (t, 3H, J= 7.0Hz), 1.05-0.95 (m, 2H), 0.91-0.84 (m, 2H), 0.69-0.61 (m, 4H). Benzoic acid. 4-[(8-cyclopropyl-3.4-dihydro-4.4-dimethylspiro[2H-l- benzopyran-2.1 '-cycloρropane]-6-yDethynyl]- (Compound 52, General Formula 1) Following general procedure L and using benzoic acid, 4-[(8- cyclopropyl-3 ,4-dihydro-4,4-dimethylspiro[2H- 1 -benzopyran-2, 1 '- cyclopropane]-6-yl)ethynyl]-ethyl ester (Compound 51, 0.06g, 0.15mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by preparative reverse phase ΗPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a solid (0.040g, 72%). Η NMR (300 MHz, CDC13): δ 8.08 (d, 2H, J= 8.8Hz), 7.60 (d, 2H, J= 8.8Hz), 7.34 (d, IH, J= 1.9Hz), 6.84 (d, IH, J= 1.9Hz), 2.05-1.96 (m, IH), 1.92 (s, 2H), 1.41 (s, 6H), 1.05-0.95 (m, 2H), 0.92-0.83 (m, 2H), 0.75-0.60 (m, 4H). 4-[(8-Cyclopropyl-3.4-dihydro-4.4-dimethylspiro[2H- l-benzopyran-2.1 '- cyclopropane]-6-yl)ethynyl]-2-fluoro-benzoic acid methyl ester (Compound 53, General Formula 1) Following general procedure F and using 8-cyclopropyl-6-ethynyl-3,4- dihydro-4,4-dimethylspiro[2H-l -benzopyran-2, 1 '-cyclopropane] (Intermediate 44, 0.03g, 0.1 lmmol), methyl-2-fluoro-4-iodo-benzoate (Reagent G, 0.025g, 0.09mmol), triethyl amine (3mL), tetrahydrofuran(3mL), copper(I)iodide(0.020g, O.lmmol) and dichlorobis(triphenylphosphine)palladium(II) (0.06g, 0.085mmol) followed by preparative normal phase ΗPLC using 10% ethyl acetate in hexane as the mobile phase, the title compound was obtained as a white solid (0.019g, 40%). Η NMR (300 MHz, CDC13): δ 7.97 (t, IH, J= 7.8Hz), 7.34 (d, IH, J= 1.9Hz), 7.32-7.25 (m, 2H), 6.83 (d, IH, = 1.9Hz), 3.95 (s, 3H), 2.06-1.96 (m, IH), 1.93 (s, 2H), 1.42 (s, 6H), 1.06-1.02 (m, 2H), 0.91-0.86 (m, 2H), 0.71- 0.61 (m, 4H). 4-[(8-Cyclopropyl-3.4-dihvdro-4.4-dimethylspiro[2H-l-benzopyran-2. - cyclopropane]-6-yl)ethynyl]-2-fluoro-benzoic acid (Compound 54, General Formula 1) Following general procedure L and using 4-[(8-cyclopropyl-3 ,4- dihydro-4,4-dimethylspiro[2H- l-benzopyran-2, 1 '-cyclopropane] -6- yl)ethynyl]-2-fluoro-benzoic acid methyl ester (Compound 53, 0.019g, 0.047mmol), 5mL of methanol and IM sodium hydroxide solution (2mL) followed by preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a solid (0.0 lg, 56%). Η NMR (300 MHz, CDC13): δ 7.99 (t, IH, J= 8.0Hz), 7.36 -7.28 (m, 3H), 6.83 (d, IH, J- 1.9Hz), 2.18-1.95 (m, IH), 1.92 (s, 2H), 1.41 (s, 6H), 1.06- 1.01 (m, 2H), 0.96-0.83 (m, 2H), 0.76-0.60 (m, 4H). 8-Acetyl-6-bromo-2.2.4.4-tetramethyl chroman (Intermediate 45) A stirred, cooled (ice bath) suspension of aluminum chloride (0.99g, 7.46mmol) in anhydrous dichloromethane (20 mL) was treated with acetyl chloride (0.58g, 7.46mmol). After 5 minutes, a solution of 6-bromo-2,2,4,4- tetramethyl chroman (lg, 3.73mmol)in dichloromethane was added. The reaction was allowed to warm to ambient temperature and stirred for 2h. The reaction mixture was then poured into ice containing 10% hydrochloric acid and extracted with diethyl ether (x2). The combined organic phase was washed with saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent to afford the title compound as a pale yellow oil (0.95g, 83%). It was used as such for the next step without any characterization. 6-Bromo-8-ethyl-2.2.4.4-tetramethyl chroman (Intermediate 46) A stirred, cooled (ice bath) solution of 8-acetyl-6-bromo-2,2,4,4- tetramethyl chroman (Intermediate 45, 0.95g, 3. lmmol) in trifluoroacetic acid ( 1 OmL) was treated with triethy lsilane ( 1 OmL) and the resulting reaction mixture was allowed to warm to ambient temperature and stirred overnight. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with hexane (x2). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using hexane as the eluent to afford the title compound as a clear oil, contaminated with a small amount to triethylsilane (0.51 g, 56%) . lR NMR (300 MHz, CDC13): δ 7.23 (d, IH, J= 2.3Hz), 7.08 (d, IH, = 2.3Hz), 2.58 (q, 2H, J= 7.6Hz), 1.81 (s, 2H), 1.34 (s, 6H), 1.33 (s, 6H), 1.17 (t, 3H, J= 7.6Hz). 8-Ethyl-6-trimethylsilanylethvnyl-2.2.4.4-tetramethyl chroman (Intermediate 47) Following general procedure D and using 6-bromo-8-ethyl-2,2,4,4- tetramethyl chroman (Intermediate 46, 0.5g, 1.6 lmmol), (trimethylsilyl)acetylene (1.57g, 16. lmmol), triethyl amine (8mL), anhydrous tetrahydrofuran (lOmL), copper(I)iodide (0.025g, 0.13mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.075g, 0.1 lmmol), followed by flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent, the title compound was obtained as an oil (0.137g, 27%). 'H NMR (300 MHz, CDC13): δ 7.27 (d, IH, J= 2.1Hz), 7.10 (d, IH, J= 2.1Hz), 2.55 (q, 2H, J= 7.6Hz), 1.81 (s, 2H), 1.33 (s, 6H), 1.32 (s, 6H), 1.15 (t, 3H, J = 7.6Hz), 0.24 (s, 9H). 8-Ethyl-6-ethvnyl-2.2.4.4-tetramethyl chroman (Intermediate 48) Following general procedure E and using 8-ethyl-6- trimethylsilanylethynyl-2,2,4,4-tetramethyl chroman (Intermediate 47, 0.137g, 0.44mmol), methanol and potassium carbonate (O.lg, 0.72mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent, the title compound was obtained as an oil (0.066g, 62%). Η NMR (300 MHz, CDC13): δ 7.33 (d, IH, J= 2.2Hz), 7.15 (d, IH, J= 1.6Hz), 2.99 (s, IH), 2.59 (q, 2H, J= 7.6Hz), 1.84 (s, 2H), 1.37 (s, 6H), 1.35 (s, 6H), 1.19 (t, 3H, J= 7.6Hz). 4-f 8-Ethyl-2.2.4.4-tetramethyl-chroman-6-yl-ethynyl phenyl] acetic acid methyl ester (Compound 55, General Formula 8) Following general procedure F and using 8-ethyl-6-ethynyl-2,2,4,4- tetramethylchroman (Intermediate 48, 0.033g, 0.136mmol), methyl-4-iodo phenyl acetate (Reagent B, 0.034g, 0.12mmol), triethyl amine (2mL), tetrahydrofuran (2mL), coρper(I)iodide (0.025g, 0.13mmol) and dichlorobis(triphenylphosρhine)ρalladium(II) (0.075g, 0.1 lmmol) the title compound was obtained (0.035g, 73%). Η NMR (300 MHz, CDC13): δ 7.49 (d, 2H, J= 7.9Hz), 7.35 (d, IH, J= 1.8Hz), 7.26 (d, 2H, J= 7.9Hz), 7.18 (d, IH, J= 1.9Hz), 3.72 (s, 3H), 3.65 (s, 2H), 2.61 (q, 2H, J= 7.5Hz), 1.85 (s, 2H), 1.38 (s, 12H), 1.21 (t, 3H, J = 7.5Hz). 4-("8-Ethyl-2.2.4.4-tetramethyl-chroman-6-yl-ethynv phenyl] acetic acid (Compound 56, General Formula 8) Following general procedure L and using [4-(8-ethyl-2,2,4,4- tetramethyl-chroman-6-ylethynyl) phenyl] acetic acid methyl ester (Compound 55, 0.035g, 0. lmmol), 5mL of methanol and IM sodium hydroxide solution (ImL) followed by preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a solid (0.1 lg, 25%). *H NMR (300 MHz, CDC13): δ 7.48 (d, 2H, J= 8.0Hz), 7.33 (d, IH, J= 1.9Hz), 7.25 (d, 2H, J= 8.0Hz), 7.15 (d, IH, J= 1.9Hz), 3.65 (s, 2H), 2.59 (q, 2H, J= 7.5Hz), 1.83 (s, 2H), 1.35 (s, 12H), 1.18 (t, 3H, J= 7.4Hz). Spiro[2H-l -benzopyran-2.1 '-cyclopropane]-6-carboxylic acid. 8-cyclopropyl- 3.4-dihydro-4.4-dimethyl- (Intermediate 49) Following general procedure R and using 6-bromo-8-cyclopropyl-3,4- dihydro-4,4-dimethylspiro[2H-l -benzopyran-2, 1 '-cyclopropane] (Intermediate 42, 0.45g, 1.48mmol), anhydrous tetrahydrofuran (5mL), 1.7M solution of tert-butyl lithium solution in pentane ( 1.74mL, 2.96mmol) and carbon dioxide generated from dry ice, followed by flash column chromatography over silica gel (230-400 mesh) using 50%> ethyl acetate in hexane as the eluent, the title compound was obtained as a white solid (0.34g, 85%). Η NMR (300 MHz, CDC13): δ 12.43 (br s, IH), 7.94 (d, IH, J= 2.1Hz), 7.42 (d, IH, J= 1.8Hz), 2.06-1.96 (m, IH), 1.92 (s, 2H), 1.42 (s, 6H), 1.12-0.97 (m, 2H), 0.95-0.81 (m, 2H), 0.77-0.60 (m, 4H). Spiro|"2H-l-benzopyran-2.1 '-cvclopropane]-6-carboxylic acid. 8-cvclopropyl- 3.4-dihvdro-4.4-dimethyl-. 4-(tert-butoxycarbonylmethvDphenyl ester (Compound 57, General Formula 1) A solution of spiro[2H-l-benzopyran-2,l'-cyclopropane]-6-carboxylic acid, 8-cyclopropyl-3,4-dihydro-4,4-dimethyl- (Intermediate 49, 0.06g, 0.22mmol) in anhydrous dichloromethane (5mL) was treated with tert-butyl-4- hydroxy phenyl acetate (Reagent E, 0.05g, 0.22mmol) followed by l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.11 g, 0.22mmol) and 4-dimethylaminopyridine (0.028g, 0.22mmol). The resulting solution was stirred at ambient temperature overnight. The reaction mixture was subjected to flash column chromatography over silica gel (230-400 mesh) using 7% ethyl acetate in hexane as the eluent to afford the title compound as a clear oil that solidified on standing (0.048g, 48%). Η NMR (300 MHz, CDC13): δ 7.91 (d, IH, J- 2.1Hz), 7.41 (d, IH, J= 1.8Hz), 7.24 (d, 2H, J= 8.8Hz), 7.05 (d, 2H, J= 8.5Hz), 3.46 (s, 2H), 1.97- 1.90 (m, IH), 1.87 (s, 2H), 1.37 (s, 9H), 1.36 (s, 6H), 1.04-0.90 (m, 2H), 0.87- 0.75 (m, 2H), 0.65-0.56 (m, 4H). Spiro[2H-l -benzopyran-2.1 '-cyclopropane]-6-carboxylic acid. 8-cyclopropyl- 3.4-dihvdro-4.4-dimethyl-. 4-(carboxymethvPιphenyl ester (Compound 58, General Formula 1) A solution of spiro[2H-l-benzopyran-2,l'-cyclopropane]-6-carboxylic acid, 8-cyclopropyl-3,4-dihydro-4,4-dimethyl-, 4-(tert- butoxycarbonylmethyl)phenyl ester (Compound 57, 0.048g, 0.105mmol) was treated with 2mL of trifluoroacetic acid and stirred at ambient temperature for 2h. The trifluoroacetic acid was distilled off under reduced pressure and the residue was subjected to preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase to afford the title compound as a white solid (0.029g, 55%). Η NMR (300 MHz, CDC13): δ 7.99 (d, IH, J= 2.2Hz), 7.48 (d, IH, J= 1.9Hz), 7.34 (d, 2H, J= 8.5Hz), 7.16 (d, 2H, J= 8.5Hz), 3.67 (s, 2H), 2.07- 1.97 (m, IH), 1.95 (s, 2H), 1.44 (s, 6H), 1.09-1.04 (m, 2H), 0.93-0.85 (m, 2H), 0.79-0.64 (m, 4H). Spiro[2H-l-benzopyran-2.1 '-cvclopropane]-6-carboxylic acid. 8-cvclopropyl- 3.4-dihydro-4.4-dimethyl-. 3-(t6rt-butoxycarbonylmethyl phenyl ester (Compound 59, General Formula 1) A solution of spiro[2H- 1 -benzopyran-2, 1 '-cyclopropane]-6-carboxylic acid, 8-cyclopropyl-3,4-dihydro-4,4-dimethyl- (Intermediate 49, 0.05g, 0.18mmol) in anhydrous dichloromethane (5mL) was treated with tert-butyl-3- hydroxy phenyl acetate (Reagent F, 0.04g, 0.18mmol) followed by 1 -(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.029g, 0. lmmol) and 4-dimethylaminopyridine (0.022g, 0.18mmol). The resulting solution was stirred at ambient temperature overnight. The reaction mixture was subjected to flash column chromatography over silica gel (230-400 mesh) using 7% ethyl acetate in hexane as the eluent to afford the title compound as a clear oil that solidified on standing (0.020g, 23%). Η NMR (300 MHz, CDC13): δ 7.98 (d, IH, J= 1.9Hz), 7.48 (d, IH, J= 2.2Hz), 7.38 (t, IH, J= 7.7Hz), 7.19-7.11 (m, 3H), 3.68 (s, 2H), 2.05-1.94 (m, IH), 1.95 (s, 2H), 1.44 (s, 15H), 1.09-1.04 (m, 2H), 0.96-0.82 (m, 2H), 0.73- 0.64 (m, 4H). Spiror2H-l-benzopyran-2.1 '-cyclopropane]-6-carboxylic acid. 8-cyclopropyl- 3.4-dihydro-4.4-dimethyl-. 3-(carboxymethyl)phenyl ester (Compound 60, General Formula 1) A solution of spiro[2H- 1 -benzopyran-2, 1 '-cycloρroρane]-6-carboxylic acid, 8-cycloρroρyl-3,4-dihydro-4,4-dimethyl-, 3-(tert- butoxycarbonylmethyl)phenyl ester (Compound 59, 0.020g, 0.04mmol) was treated with 2mL of trifluoroacetic acid and stirred at ambient temperature for 2h. The trifluoroacetic acid was distilled off under reduced pressure and the residue was subjected to preparative reverse phase ΗPLC using 10% water in acetonitrile as the mobile phase to afford the title compound as a white solid (0.0125g, 62%). Η NMR (300 MHz, CDC13): δ 7.99 (d, IH, J= 2.1Hz), 7.49 (d, IH, J= 2.1Hz), 7.36 (t, IH, J= 7.8Hz), 7.18-7.08 (m, 3H), 3.56 (s, 2H), 2.06-1.95 (m, IH), 1.95 (s, 2H), 1.45 (s, 6H), 1.09-1.05 (m, 2H), 0.96-0.84 (m, 2H), 0.74- 0.65 (m, 4H). 6-Bromo-4,4-dimethyl- 1.2.3.4-tetrahydro-quinoline- 1 -carbaldehyde (Intermediate 50) A solution of 6-bromo-4,4-dimethyl- 1 ,2,3 ,4-tetrahydroquinoline, available in accordance with United States Patent No. 5,089,509, the specification of which is incoφorated herein by reference (1.8g, 7.5mmol) in 1 OmL of formic acid was refluxed for 3h. The reaction mixture was then cooled to ambient temperature and poured into ice-cold saturated aqueous sodium bicarbonate solution and extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using 15-25% ethyl acetate in hexane as the eluent to afford the title compound as a pale yellow solid (1.8g, 90%). »H NMR (300 MHz, CDC13): δ 8.71 (s, IH), 7.45 (d, IH, J= 2.2Hz), 7.28 (dd, IH, J= 2.2, 8.5Hz), 6.98 (d, IH, J= 8.5Hz), 3.78 (t, 2H, J= 6.3Hz), 1.74 (t, 2H, J= 6.3Hz), 1.28 (s, 6H). 6-Bromo- 1 -cycloρropyl-4.4-dimethyl- 1.2.3.4-tetrahvdroquinoline (Intermediate 51) A stirred, cooled (0°C) solution of 6-bromo-4,4-dimethyl- 1 ,2,3 ,4- tetrahydro-quinoline-1-carbaldehyde (Intermediate 50, 21.8, 6.7mmol) in anhydrous tetrahydrofuran (20mL) under argon was treated with titanium tetra--5O-ρropoxide (2.15mL, 7.39mmol) followed by 3M solution of ethyl magnesium bromide in diethyl ether (5.6mL, 16.8mmol) and the reaction mixture was then heated at 50°C overnight. It was then cooled in an ice-bath, quenched with saturated aqueous ammonium chloride solution and extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous sodium sulfate, filtered over celite and evaporated in vacuo to residue which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5% ethyl acetate in hexane as the eluent to afford the title compound as an oil (1.2g, 64%). Η NMR (300 MHz, CDC13): δ 7.24 (d, IH, J= 2.5Hz), 7.12 (dd, IH, J= 2.2, 8.8Hz), 7.01 (d, IH, J= 8.8Hz), 3.20 (t, 2H, J= 6.0Hz), 2.27-2.20 (m, IH), 1.68 (t, 2H, J= 5.9Hz), 1.24 (s, 3H), 1.23 (s, 3H), 0.83-0.77 (m, 2H), 0.60- 0.55 (m, 2H). 1 -CvcloρroDyl-6-trimethylsilanylethvnyl-4.4-dimethyl- 1.2.3.4-tetrahvdro- quinoline (Intermediate 52) Following general procedure D and using 6-bromo- 1 -cyclopropyl-4,4- dimethyl- 1, 2,3, 4-tetrahydro quinoline (Intermediate 51, 0.8g, 2.86mmol), (trimethylsilyl)acetylene (5mL, 35mmol), triethyl amine (lOmL), anhydrous tetrahydrofuran, copρer(I)iodide (0.080g, 0.42mmol) and dichlorobis(friphenylρhosphine)ρalladium(II) (0.240g, 0.34mmol), the title compound was obtained as an oil (0.67g, 79%). Η NMR (300 MHz, CDC13): δ 7.33 (d, IH, J= 1.8Hz), 7.22 (dd, IH, J= 2.1, 8.5Hz), 7.06 (d, IH, J= 8.5Hz), 3.27 (t, 2H, J= 5.9Hz), 2.37-2.31 (m, IH), 1.70 (t, 2H, J= 6.0Hz), 1.28 (s, 6H), 0.89-0.82 (m, 2H), 0.66-0.60 (m, 2H), 0.28 (s, 9H). 1 -Cvcloρropyl-6-ethynyl-4.4-dimethyl- 1.2.3.4-tetrahvdroquinoline: (Intermediate 53) Following general procedure E and using l-cyclopropyl-6- trimethylsilanylethynyl-4,4-dimethyl- 1 ,2,3 ,4-tetrahydroquinoline (Intermediate 52, 0.40g, 1.34mmol), methanol and potassium carbonate (0.2g, 1.47mmol) followed by flash column cliromatography over silica gel (230-400 mesh) using 2% ethyl acetate in hexane as the eluent, the title compound was obtained as an oil (0.17g, 56%). Η NMR (300 MHz, CDC13): δ 7.38 (d, IH, J= 2.1Hz), 7.27 (dd, IH, J= 2.1, 8.5Hz), 7.11 (d, IH, J= 8.5Hz), 3.30 (t, 2H, J- 6.0Hz), 3.02 (s, IH), 2.40- 2.34 (m, IH), 1.74 (t, 2H, J- 6.0Hz), 1.30 (s, 6H), 0.93-0.85 (m, 2H), 0.70- 0.63 (m, 2H). 4-( 1 -Cyclopropyl-4.4-dimethyl- 1.2.3.4-tetrahydro-quinolin-6-yl-ethynyl)- benzoic acid ethyl ester (Compound 61. General Formula 7) Following general procedure F and using l-cyclopropyl-6-ethynyl-4,4- dimethyl- 1, 2,3, 4-tetrahydro quinoline (Intermediate 53, 0.1 lg, 0.43mmol), ethyl-4-iodo-benzoate (Reagent A, 0.1 lg, 0.9mmol), triethyl amine (3mL), tefrahydrofuran(3mL), copρer(I)iodide(0.02g, 0. lmmol) and dichlorobis(triρhenylphosphine)palladium(II) (0.060g, 0.085mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 5-10% ethyl acetate in hexane as the eluent, the title compound was obtained (0.05g, 31%). Η NMR (300 MHz, CDC13): δ 7.99 (d, 2H, J= 8.2Hz), 7.54 (d, 2H, J= 8.2Hz), 7.37 (d, IH, J= 2.1Hz), 7.26 (dd, IH, J= 2.1, 8.5Hz), 7.10 (d, IH, J= 8.8Hz), 4.37 (q, 2H, J= 7.1Hz), 3.28 (t, 2H, J= 6.0Hz), 2.40-2.33 (m, IH), 1.71 (t, 2H, J= 5.8Hz), 1.40 (t, 3H, J= 7.0Hz), 1.27 (s, 6H), 0.94-0.82 (m, 2H), 0.65-0.60 (m, 2H). 4-( 1 -Cyclopropyl-4.4-dimethyl- 1.2.3.4-tetrahvdroquinolin-6-yl-ethvnyl - benzoic acid (Compound 62, General Formula 7) Following general procedure L and using 4-( 1 -cy cloρropyl-4,4- dimethyl- 1 ,2,3 ,4-tetrahydro-quinolin-6-ylethynyl)-benzoic acid ethyl ester (Compound 61, 0.05g, 0.13mmol), 5mL of ethanol and 5M sodium hydroxide solution (2mL) followed by recrystallization from hot ethyl acetate, the title compound was obtained as a solid (0.030g, 64%). Η NMR (300 MHz, DMSO-d6): δ 7.92 (d, 2H, J= 8.2Hz), 7.57 (d, 2H, J= 8.2Hz), 7.33 (d, IH, J= 1.9Hz), 7.23 (dd, IH, J= 1.9, 8.5Hz), 7.06 (d, IH, J = 8.8Hz), 3.25 (t, 2H, J= 5.8Hz), 2.41-2.34 (m, IH), 1.64 (t, 2H, J= 5.6Hz), 1.21 (s, 6H), 0.87-0.81 (m, 2H), 0.59-0.54 (m, 2H). [4-(l-Cyclopropyl-4.4-dimethyl-1.2.3.4-tetrahydro-quinolin-6-yl- ethynyDphenyl] acetic acid methyl ester (Compound 63. General Formula 7) Following general procedure F and using l-cyclopropyl-6-ethynyl-4,4- dimethyl- 1, 2,3, 4-tetrahydro quinoline (Intermediate 53, 0.05g, 0.22mmol), methyl-4-iodo-phenyl acetate (Reagent B, 0.055g, 0.2mmol), triethyl amine (5mL), tetrahydrofuran, copper(I)iodide(0.025g, 0.13mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.75g, 0.1 lmmol) followed preparative normal phase HPLC using 10 % ethyl acetate in hexane as the mobile phase, the title compound was obtained (0.089g, 100%). Η NMR (300 MHz, CDC13): δ 7.47 (d, 2H, J= 8.8Hz), 7.45 (d, IH, J= 1.8Hz), 7.35-7.22 (m, 2H), 7.10 (d, 2H, J= 8.8Hz), 3.70 (s, 3H), 3.63 (s, 2H), 3.27 (t, 2H, J= 6.0Hz), 2.37-2.31 (m, IH), 1.71 (t, 2H, J= 6.0Hz), 1.27 (s, 6H), 0.89-0.81 (m, 2H), 0.65-0.60 (m, 2H). |"4-d-Cyclopropyl-4.4-dimethyl-1.2.3.4-tetrahydro-quinolin-6-yl-ethynyl -2- fluoro-phenyl] acetic acid ethyl ester (Compound 64, General Formula 7) Following general procedure F and using l-cyclopropyl-6-ethynyl-4,4- dimethyl- 1,2,3, 4-tetrahydro quinoline (Intermediate 53, 0.1 lg, 0.49mmol), ethyl-2-fluoro-4-iodo-ρhenyl acetate (Reagent C, 0.11 g, 0.9mmol), triethyl amine (3mL), tetiahyckofuran(3mL), copper(I)iodide(0.06g, 0.32mmol) and dichlorobis(triphenylphosphine)ρalladium(II) (0.25g, 0.36mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 10 % ethyl acetate in hexane as the eluent, the title compound was obtained (0.1 g, 51 %). Η NMR (300 MHz, CDC13): δ 7.34 (d, IH, J= 2.1Hz), 7.25-7.17 (m, 3H), 7.09 (d, 2H, J= 8.8Hz), 4.17 (q, 2H, J= 7.1Hz), 3.65 (s, 2H), 3.27 (t, 2H, J = 6.0Hz), 2.38-2.31 (m, IH), 1.69 (t, 2H, J= 6.0Hz), 1.27 (s, 6H), 1.25 (t, 3H, J = 7.1Hz), 0.88-0.81 (m, 2H), 0.65-0.59 (m, 2H). N-(4-BromoρhenylVN-methyl-3-methyl-2-butenamide (Intermediate 54) 3,3-Dimethylacryloyl chloride (3mL, 27mmol) was added to a solution of 4-bromo-N-methyl-aniline (4.55g, 25mmol) in 150mL of dichloromethane followed after 5 minutes by triethyl amine (5mL, 33mmol). After 2.5h at ambient temperature, the reaction mixture was washed with water and the organic phase was dried over anhydrous sodium sulfate and evaporated in vacuo to afford the title product as a brown oil in quantitative yield. Η-NMR (300 MHz, CDC13): d 1.71 (s, 3H), 2.1 l(s, 3H), 3.28(s, 3H), 5.47(s, IH), 7.05(4 J = 8.5Hz, 2H), 7.50(4 J = 8.2Hz, 2H). 6-Bromo- 1.4.4-trimethyl-2-oxo- 1.2.3 ,4-tetrahydroquinoline (Intermediate 55) N-(4-bromophenyl)-N-methyl-3-methyl-2-butenamide (Intermediate 54, 6.42g, 24mmol) was heated to 130°C and aluminum chloride (5g, 37.4mmol) was added in portions over 0.5h. The reaction mixture was stirred for 1 hour at the same temperature and then cooled to room temperature. Ice was added cautiously to the solid, followed by ~200mL of iced water. The reaction mixture was then extracted with ether (x2) and dichloromethane (xl) and the combined organic phase was dried over anhydrous magnesium sulfate and evaporated in vacuo to yield a brown solid. The solid was treated with hexane-dichloromethane and filtered to afford 1.7g of product. The mother liquor was evaporated and purified by flash column chromatography on silica gel (230-400 mesh) to afford 2.9g of the title compound as a solid (total 72%). Η-NMR (300 MHz, CDC13): δl.29(s, 6H), 2.49(s, 2H), 3.36(s, 3H), 6.87(d, J = 8.2Hz, IH), 7.36(dd, J = 2.0, 8.5Hz, IH), 7.39(4 = 2.0Hz, IH). 6-Bromo-l .4.4-trimethylsρiror2H-l-l .2.3.4-tefrahvdroquinoline-2.1 '- cyclopropane] (Intermediate 56) A stirred, cooled (-78°C) 3M solution of ethyl magnesium bromide in ether (8. ImL, 24.25mmol) under argon was treated with anhydrous tetrahydrofuran (20mL) followed by a solution of titanium tetra-wo-propoxide (3.15mL, 10.2mmol) in tetrahydrofuran (lOmL). A solution of 6-bromo- 1,4,4- trimethyl-2-oxo- 1 ,2,3 ,4-tetrahydroquinoline (Intermediate 55, 2.6g, 9.7mmol) was cannulated into the reaction mixture and the solution was allowed to warm to room temperature overnight. It was then cooled in an ice- bath, quenched with saturated aqueous ammonium chloride solution, filtered over celite and the aqueous phase was extracted with diethyl ether (x2). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to afford an orange oil. Flash column chromatography over silica gel (230-400 mesh) using 2-4% ethyl acetate in hexane as the eluent afforded the title compound as an oil which was -70% pure (1.7g, 63%) and 0.5g of recovered starting material. Η-NMR (300 MHz, CDC13): δ 0.58(t, J= 6.0Hz, 2H), 0.91(t, J= 6.0Hz, 2H), 1.35 (s, 6H), 1.70(s, 2H), 2.68 (s, 3H), 6.59 (d, /= 8.8Hz, IH), 7.16(dd, J= 2.3, 8.8Hz, IH), 7.33(d, J= 2.3Hz, IH). 1.4.4-Trimethyl-6-(trimethylsilanyl^ethynylspiro[2H- 1 - 1.2.3.4- tetrahydroquinoline-2.1 '-cyclopropane] (Intermediate 57) Following general procedure D and using 6-bromo- 1 ,4,4- trimethylspiro[2H- 1 - 1 ,2,3 ,4-tetrahydroquinoline-2, 1 '-cyclopropane] (Intermediate 56, 0.56g, 2mmol), (trimethylsilyl)acetylene (1.13mL, δmmol), triethyl amine (4mL), anhydrous tetrahydrofuran (5mL), copper(I)iodide (0.08g, 0.4mmol) and dichlorobis(triphenylphosρhine)palladium(II) (0.28g, 0.4mmol), followed by flash column chromatography over silica gel (230-400 mesh) using hexane-2% ethyl acetate in hexane as the eluent, the title compound was obtained as an oil (0.42g, 70%). Η NMR (300 MHz, CDC13): δ 0.023(s, 9H), 0.33(t, J= 6.1Hz, 2H), 0.71(t, J - 6.1Hz, 2H), 1.10(s, 6H), 1.45(s, 2H), 2.41 (s, 3H), 6.31(d, J= 8.5Hz, IH), 6.96 (dd, J= 2.1, 8.5Hz, IH), 7.10(d, J= 2.1Hz, IH). Benzoic acid. 4-[ri.4.4-trimethylspiro[2H-l-1.2.3.4-tetrahydroquinoline-2.1 '- cyclopropane]-6-yl thynyl]-ethyl ester (Compound 65, General Formula 1) Following general procedure E and using a solution of 1,4,4-trimethyl- 6-(trimethylsilanyl)ethynylspiro[2H- 1 - 1 ,2,3 ,4-tetrahydroquinoline-2, 1 '- cyclopropane] (Intermediate 57, 0.416g, 1.4mmol), methanol (lOmL), ethyl acetate (2mL) and potassium carbonate (1.08g, mmol) a silyl deprotected acetylenic intermediate was obtained which was used directly for the next step (0.25g, 79%). Following general procedure F and using part ofthe acetylenic intermediate obtained as above (0.1 lg, 0.5mmol), ethyl-4-iodo benzoate (Reagent A, 0.112g, 0.4mmol), triethyl amine (ImL), tetrahydrofuran (2.5mL), copρer(I)iodide (0.050g, 0.26mmol) and tetrakis(triphenylphosphine)palladium(0)(0.096g, 0.17mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 8% ethyl acetate in hexane as the eluent and preparative ΗPLC on Partisil 10 silica column using 10% ethyl acetate in hexane as the mobile phase, the title compound was obtained as a yellow oil (0.048g, 26%). 'Η-NMR (300 MHz, CDC13): δ 0.60 (t, J= 6.1Hz, 2H), 0.99(t, J= 6.1Hz, 2H), 1.37(s, 6H), 1.42(t, J= 7.0Hz, 3H), 1.73(s, 2H), 2.68(s, 3H), 4.40 (q, J = 7.0Hz, 2H), 6.61(d, J = δ.8Hz, IH), 7.2δ (dd, J = 2.1, 8.5Hz, IH), 7.42 (d, J = 2.1Hz, IH), 7.57(d, J = 8.2Hz, 2H), δ.01(d, = δ.2Hz, 2H). Benzoic acid. 4-[(1.4.4-trimethylspiro[2H-l-1.2.3.4-tetrahydroquinoline-2. - cyclopropane]-6-yDethynyl]- (Compound 66, General Formula 1) Following general procedure I and using benzoic acid, 4-[(l ,4,4- trimethylspiro[2H- 1 - 1 ,2,3 ,4-tetrahydroqunoline-2, 1 ' -cycloρroρane]-6- yl)ethynyl]-ethyl ester (Compound 65, 0.03g, 0.08mmol), ethanol (2mL), tetrahydrofuran (2mL) and IM aqueous sodium hydroxide solution (ImL), the title compound was obtained as a yellow solid (0.020g, 67%). Η-NMR (300 MHz, CD3COCD3): δ 0.60 (t, J= 5.8Hz, 2H), 1.03(t, J- 5.8Hz, 2H), 1.34(s, 6H), 1.74(s, 2H), 2.69(s, 3H), 6.60(d, J = 8.5Hz, IH), 7.23 (dd, J = 2.0, δ.4Hz, IH), 7.39 (d, J = 2.0Hz, IH), 7.58(4 J = 8.2Hz, 2H), 8.01(4 J = 8.2Hz, 2H). Esterification Methods: Method A: The carboxylic acid was combined with a solution ofthe desired alcohol and concentrated sulfuric acid (20 to 1 v/v) and the resulting mixture or solution (0.75 to 1.0 M) heated to reflux overnight. The solution was cooled to room temperature, diluted with EtjO, and washed with H20, saturated aqueous NaHC03, and saturated aqueous NaCl before being dried over MgS04. Concentration ofthe dry solution under reduced pressure afforded the desired carboxylic ester of sufficient purity to be used directly in the next reaction. Method B: To a solution (0.67 to 1 ,0M) ofthe carboxylic acid in acetone was added 1.1 equivalents of the desired alkyl halide and 1.0 equivalents of solid potassium carbonate. The resulting mixture was heated to reflux for 2h and then allowed to stir at room temperature overnight. The mixture was filtered and the filtrate concentrated under reduced pressure. The product was isolated from the residue by column chromatography using silica gel as the solid phase. Method C: A solution (IM) ofthe carboxylic acid in thionyl chloride was heated at reflux until analysis of a reaction aliquot by IR spectroscopy showed the absence ofthe aryl carboxylic acid carbonyl band ( 1705 - 1680 cm"1). The solution was cooled to room temperature and concentrated under reduced pressure to give the crude acyl chloride. The acyl chloride was dissolved in CH2C12 and the resulting solution (0.5 to 0.75M) treated with 1.1 equivalents the desired alcohol and 2.0 equivalents of pyridine. After stirring overnight at room temperature the solution was diluted with Et^O and washed with H20, 10% aqueous HCl, saturated aqueous NaHC03, and saturated aqueous NaCl before being dried over Na2S04. Concentration ofthe dry solution under reduced pressure followed by column chromatography afforded the desired ester. GENERAL PROCEDURE 1 (preparation of Enol ethers : A solution (0.35 M) ofthe aryl ester in anhydrous THF was cooled to 0 °C and treated with 1.0 equivalents of Tebbe's Reagent ([μ-chloro-μ- methylene[bis(cyclopentadienyl)titanium]-dimethylaluminum] 0.5 M in toluene). After 30 minutes the solution was warmed to room temperature and stirred for 30 minutes before being carefully added to a 0.1 N NaOH solution at 0 °C. This mixture was treated with hexanes and the solids removed by filtration through a pad of Celite. The solids were washed with hexanes and the filtrate passed through a second pad of Celite to remove any newly formed solids. The organic layer was dried (Na2S04) and concentrated under reduced pressure. The desired enol ether was isolated from the residue by column chromatography using 1-2% of Et3N added to the eluant. (note: prolonged exposure ofthe product to the column can result in hydrolysis and formation of the corresponding methyl ketone.) GENERAL PROCEDURE 2 (cvclopropanation ofthe enol ethers): To a solution (0.3 M) ofthe enol ether in anhydrous Et20 was added 2.0 equivalent of Et2Zn (as a solution in hexanes) and 2.0 equivalents of CH2I2. The resulting solution was heated to reflux until analysis of a reaction aliquot (by TLC or 'H NMR) indicated that all of the starting enol ether had been consumed, (note: Additional equal amounts of EtjZn and CH2I2 can be added to drive the reaction to completion.) Upon cooling to room temperature the reaction was carefully quenched by the addition of saturated aqueous NH4C1. The resulting mixture is extracted with Et20 and the combined organic layers washed with H20 and saturated aqueous NaCl before being dried over Na2S04 and concentrated under reduced pressure. The product is isolated from the residue by column chromatography. 1 -Bromo-4-( 1 -methoxwinylVbenzene: (Intermediate 58) Using General Procedure 1 ; methyl 4-bromo-benzoate (600.0 mg, 2.78 mmols), and 5.6 mL of Tebbe's Reagent (794.0 mg, 2.78 mmols) afforded 420.0 mg (70%) ofthe title compound as a colorless oil after column chromatography (100% hexanes) . Η NMR (CDC13) δ: 7.48 - 7.45 (4H, m), 4.64 (IH, d, J = 2.9 Hz), 4.23 (IH, d, J = 2.9 Hz), 3.73 (3H, s). 1 -Bromo-4-( 1 -methoxycyelopropyl)-benzene (Intermediate 59) Using General Procedure 2; l-bromo-4-(l-methoxyvinyl)-benzene (Intermediate 58, 410. 0 mg, 1.92 mmols), Et n (711.3 mg, 5.76 mmols), and CH2I2 (1.54 g, 5.76 mmols) in 4.0 mL Et20 afforded 300.0 mg (69%) of the title compound as a colorless oil after chromatography (0-3% EtOAc - hexanes). Η NMR (CDCI3) δ: 7.46 (2H, d, J = 8.5 Hz), 7.18 (2H, d, J = 8.5 Hz), 3.21 (3H, s), 1.19 (2H, m), 0.94 (2H, m). [4-(l-MethoxycyclopropylVphenylethynyl]-trimethylsilane (Intermediate 60) Using General Procedure D; l-bromo-4-(l-methoxycyclopropyl)- benzene (Intermediate 59, 300.0 mg, 1.32 mmol) in triethylamine (4 mL) and anhydrous tetrahydrofuran (4 mL) was treated with coρper(I)iodide (93.0 mg, 0.13 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (1.39 g, 14.2 mmols) was then added followed by dichlorobis(triρhenylρhosphine)ρalladium(II) (93.0 mg, 0.13 mmol). The resulting reaction mixture was heated to 70 °C for 60h. The title compound (286.0 mg, 90%) was isolated by chromatography (0 - 3% EtOAc - hexanes). Η NMR (CDC13) δ: 7.35 (2H, d, J - 7.2 Hz), 7.14 (2H, d, J = 7.2 Hz), 3.14 (3H, s), 1.14 (2H, m), 0.8δ (2H, m), 0.17 (9H, s). 1 -Ethynyl-4-( 1 -methoxycyclopropylVbenzene (Intermediate 61) Using General Procedure E; [4-(l-methoxycyclopropyl)- phenylethynyl]-trimethylsilane (Intermediate 60, 2δ5.0 mg, 1.18 mmols) in methanol (lOmL) was treated with potassium carbonate (100.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne (220 mg, 100%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.46 (2H, d, J = 8.2 Hz), 7.24 (2H, d, J = 8.2 Hz), 3.23 (3H, s), 3.06 (IH, s), 1.22 (2H, m), 0.98 (2H, m). Ethyl 4-[4-(l-methoxycycloρroρyl)-phenylethynyl]-benzoate (Compound 67, General Formula 2) Using General Procedure F; l-ethynyl-4-(l-methoxycyclopropyl)- benzene (Intermediate 61, 100.0 mg, 0.47 mmol) and ethyl-4-iodo benzoate (Reagent A, 141.0 mg, 0.51 mmol) in triethyl amine (6 mL) was treated with copper(I)iodide (30.0 mg, 0.16 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (109 mg, 0.16 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-5% EtOAc - hexanes) afforded 135.0 mg (90%) ofthe title compound as an orange solid. Η NMR (CDCI3) δ: 8.02 (2H, d, J = 8.2 Hz), 7.5δ (2H, d, J = 8.8 Hz), 7.52 (2H, d, J = 8.2 Hz), 7.28 (2H, d, J = 8.8 Hz), 4.39 (2H, q, J = 7.1 Hz), 3.25 (3H, s), 1.40 (3H, t, J = 7.1 Hz), 1.23 (2H, m), 1.00 (2H, m). Methyl 4-[4-(l-methoxycvcloρroρyl)-ρhenylethvnyl]-ρhenyl -acetate (Compound 68, General Formula 2) Using General Procedure F; 1 -ethynyl-4-( 1 -methoxycyclopropyl)- benzene (Intermediate 61, 120.0 mg, 0.56 mmol) and methyl-(4-iodoρhenyl)- acetate (Reagent B, 154.0 mg, 0.56 mmol) in triethyl amine (6 mL) was treated with copper(I)iodide (35.0 mg, 0.19 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (130 mg, 0.19 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-8% EtOAc - hexanes) afforded 140.0 mg (78%) ofthe title compound as an orange solid. Η NMR (CDC13) δ: 7.50 (4H, d, J = 8.1 Hz), 7.28 (4H, d, J = 8.1 Hz), 3.76 (3H, s), 3.64 (2H, s), 3.25 (3H, s), 1.22 (2H, m), 0.99 (2H, m). 4-[4-(l-Methoxycyclopropyl)-phenylethynyl]-benzoic acid (Compound 69, General Formula 2) Using General Procedure I; a solution of ethyl 4- [4-( 1 - methoxycycloproρyl)-ρhenylethynyl]-benzoate (Compound 67, 110.0 mg, 0.34 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (160.0 mg, 4.0 mmols, 2.0 mL of a 2N aqueous solution) and stirred overnight at room temperature. Work-up afforded 85.0 mg (86%) ofthe title compound as an orange solid. 'H NMR (CDCI3) δ: 8.05 (2H), 7.66 (2H), 7.56 (2H, d, J = 8.5 Hz), 7.35 (2H, d, J = 8.6 Hz), 3.22 (3H, s), 1.21 (2H, m), 1.01 (2H, m). (4- 4-(l-Methoxycyclopropyl)-phenylethynyl]-phenyll-acetic acid (Compound 70, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- methoxycyclopropyl)-phenylethynyl]-phenyl} -acetate (Compound 68, 100.0 mg, 0.31 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (160.0 mg, 4.0 mmols, 2.0 mL of a 2N aqueous solution) and stirred overnight at room temperature. Work-up afforded 80.0 mg (84%) of the title compound as an orange solid. Η NMR (CDC13) δ: 7.49 (4H), 7.27 (4H), 3.66 (2H, s), 3.25 (3H, s), 1.22 (2H, m), 0.99 (2H, m). Isopropyl 4-bromobenzoate (Intermediate 62) Using General Esterification Procedure A; 4-bromobenzoic acid (1.50 g, 7.46 mmols) was combined with isopropyl alcohol to give 1.76 g (97%) of the title compound as a colorless oil. Η NMR (CDCI3) δ: 7.90 (2H, d, J = 8.5 Hz), 7.57 (2H, d, J = 8.5 Hz), 5.24 (IH, septet, J - 6.2 Hz), 1.37 (6H, d, J = 6.2 Hz). 1 -Bromo-4-( 1 -isopropoxy vinyl)-benzene (Intermediate 63) Using General Procedure 1; isopropyl 4-bromobenzoate (Intermediate 62, 780.0 mg, 3.20 mmols) and 6.4 mL of Tebbe's Reagent (910.7 mg, 3.20 mmols) afforded 328.0 mg (43%) ofthe title compound as a colorless oil after column chromatography ( 100% hexanes) . Η NMR (CDC13) δ: 7.46 (4H, m), 4.66 (IH, d, J = 2.6 Hz), 4.40 (IH, septet, J - 6.2 Hz), 4.21 (IH, d, J = 2.6 Hz), 1.34 (6H, d, J = 6.2 Hz). 1 -Bromo-4-( 1 -isopropoxy cyclopropyD-benzene (Intermediate 64) Using General Procedure 2; l-bromo-4-(l -isopropoxy vinyl)-benzene (Intermediate 63, 328. 0 mg, 1.36 mmols), Et2Zn (335.9 mg, 2.72 mmols), and CH2I2 (728.0 mg, 2.72 mmols) in 4.0 mL Et20 afforded 240.0 mg (70%) ofthe title compound as a colorless oil after chromatography (3% EtOAc - hexanes). Η NMR (CDCI3) δ: 7.43 (2H, d, J = 8.5 Hz), 7.27 (2H, d, J = 8.5 Hz), 3.70 (IH, septet, J = 6.2 Hz), 1.18 (2H, m), 1.06 (6H, d, J = 6.2 Hz), 0.91 (2H, m). r4-(l-Isopropoxycyclopropyl)-phenylethynyl]-trimethylsilane (Intermediate 65) Using General Procedure D; l-bromo-4-(l -isopropoxy cyclopropyl)- benzene (Intermediate 64, 240.0 mg, 0.94 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (18.0 mg, 0.094 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylρhosphine)palladium(II) (66.0 mg, 0.094 mmol). The resulting reaction mixture was heated to 70 °C for 5 days. The title compound (250.0 mg, 98%) was isolated by chromatography (0 - 3% EtOAc - hexanes) as an orange oil. 'H NMR (CDC13) δ: 7.41 (2H, d, J = 7.9 Hz), 7.31 (2H, d, J = 7.9 Hz), 3.70 (IH, septet, J = 6.2 Hz), 1.18 (2H, m), 1.05 (6H, 4 1 = 6.2 Hz), 0.93 (2H, m), 0.94 (9H, s). 1 -Ethynyl-4-( 1 -isopropoxy cyclopropylVbenzene (Intermediate 66) Using General Procedure E; [4-(l-isopropoxycyclopropyl)~ phenylethynyl]-trimethylsilane (Intermediate 65, 260.0 mg, 0.96 mmol) in methanol (10 mL) was treated with potassium carbonate (100.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne (220 mg, 100%) was used directly in the next reaction. Η NMR (CDC13) δ: 7.45 (2H, d, J = 8.8 Hz), 7.35 (2H, d, J = 8.8 Hz), 3.72 (IH, septet, J - 6.2 Hz), 3.06 (IH, s), 1.20 (2H, m), 1.07 (6H, d, J = 6.2 Hz), 0.95 (2H, m). Ethyl 4-[4-( 1 -isopropoxycyclopropyl)-phenylethynyl]-benzoate (Compound 71, General Formula 2) Using General Procedure F; l-ethynyl-4-(l-isopropoxycyclopropyl)- benzene (Intermediate 66, 114.0 mg, 0.57 mmol) and ethyl-4-iodo benzoate (Reagent A, 731.0 mg, 0.63 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (36.0 mg, 0.19 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (133 mg, 0.19 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 151.0 mg (76%) of the title compound as an orange solid. 'H NMR (CDC13) δ: 8.02 (2H, d, J = 7.6 Hz), 7.58 (2H, d, J = 7.6 Hz), 7.50 (2H, d, J = 7.8 Hz), 7.39 (2H, d, J = 7.8 Hz), 4.39 (2H, q, J = 7.1 Hz), 3.74 (IH, septet, J = 6.2 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.22 (2H, m), 1.08 (6H, d, J = 6.2 Hz), 0.97 (2H, m). Methyl {4-[4-(l-isoρroρoxycvclopropylVρhenylethvnyll-ρhenyll-acetate (Compound 72, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -isopropoxy cyclopropyl)- benzene (Intermediate 66, 95.0 mg, 0.45 mmol) and methyl-(4-iodophenyl)- acetate (Reagent B, 131.0 mg, 0.45 mmol) in triethylamine (6 mL) was treated with copper(I)iodide (30.0 mg, 0.16 mmol) and sparged with argon for 5 minutes . Dichlorobis(triphenylphosphine)palladium(II) (111 mg, 0.16 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-8% EtOAc - hexanes) afforded 110.0 mg (70%) ofthe title compound as an orange oil. Η NMR (CDCI3) δ: 7.20 (4H), 7.0δ (2H, d, J = 7.0 Hz), 6.97 (2H, d, J = 7.9 Hz), 3.45 (IH, septet, J = 6.2 Hz), 3.41 (3H, s), 3.35 (2H, s), 0.91 (2H, m), 0.79 (6H, d, J = 6.2 Hz), 0.68 (2H, m). 4- [4-( 1 -Isopropoxy cyclopropylVphenylethynyl] -benzoic acid (Compound 73, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l - isopropoxy cyclopropyl)-ρhenylethynyl]-benzoate (Compound 71, 110.0 mg, 0.32 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 89.0 mg (88%) ofthe title compound as a yellow solid. Η NMR (CDCI3) δ: 8.06 (2H, d, J = 8.2 Hz), 7.66 (2H, d, J *= 8.2 Hz), 7.55 (2H, J = 8.2 Hz), 7.46 (2H, d, J = 8.2 Hz), 3.73 (IH, septet, J = 6.2 Hz), 1.18 (2H, m), 1.04 (6H, d, J = 6.2 Hz), 0.99 (2H, m). {4-[4-( 1 -IsoρroρoxycvcloρropylVρhenylethvnyl]-phenv -acetic acid (Compound 74, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- isopropoxycyclopropyl)-phenylethynyl]-phenyl} -acetate (Compound 72, 80.0 mg, 0.23 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 48.0 mg (56%) of the title compound as a solid. Η NMR (CDC13) δ: 7.20 (2H, d, J = 8.2 Hz), 7.19 (2H, d, J = 8.8 Hz), 7.09 (2H, d, J = 8.8 Hz), 6.98 (2H, d, J = 8.2 Hz), 3.46 (IH, septet, J = 6.2 Hz), 3.37 (2H, s), 0.92 (2H, m), 0.79 (6H, d, J = 6.2 Hz), 0.67 (2H, m). Benzyl 4-bromobenzoate (Intermediate 67) Using General Esterification Method B; 4-bromobenzoic acid (2.01 g, 10.0 mmols), benzyl bromide (1.89 g, 11.1 mmols), and K2C03 (1.40 g, 10.0 mmols) afforded 2.33 g (80%) ofthe title compound as a colorless solid after column chromatography (3-10% EtOAc - hexanes) . Η NMR (CDCI3) δ: 7.89 (2H, d, J = 8.5 Hz), 7.52 (2H, d, J = 8.5 Hz), 7.43 - 7.31 (5H), 5.33 (2H, s). 1 -Bromo-4-( 1 -benzyloxwinylVbenzene (Intermediate 68) Using General Procedure 1; benzyl 4-bromobenzoate (Intermediate 67, 920.0 mg, 3.16 mmols) and 6.3 mL of Tebbe's Reagent (897.0 mg, 3.16 mmols) afforded 640.0 mg (70%) ofthe title compound after column chromatography ( 100% hexanes). Η NMR (CDCI3) δ: 7.55 - 7.35 (9H), 4.95 (2H, s), 4.73 (IH, d, J = 2.9 Hz), 4.34 (IH, d, J = 2.9 Hz). 1 -Bromo-4-( 1 -benzyloxycyclopropylVbenzene (Intermediate 69) Using General Procedure 2; l-bromo-4-(l-benzyloxyvinyl)-benzene (Intermediate 68, 280. 0 mg, 0.97 mmol), Et2Zn (247.0 mg, 2.0 mmols), and CH2I2 (536.0 mg, 2.0 mmols) in 2.0 mL Et20 afforded 159.0 mg (53%) of the title compound as a colorless solid after chromatography (2-5% EtOAc - hexanes). 'H NMR (CDC13) δ: 7.49 - 7.24 (9H), 4.41 (2H, s), 1.29 (2H, m), 1.00 (2H, m). [4-( 1 -BenzyloxycvclopropylVphenylethynylj-trimethylsilane (Intermediate 70) Using General Procedure D; 1 -bromo-4-( 1 -benzyloxycyclopropyl)- benzene (Intermediate 69, 160.0 mg, 0.53 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (10.0 mg, 0.05 mmol) and then sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (37.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (150.0 mg, 83%) was isolated by chromatography (0 - 3% EtOAc - hexanes) s a pale-yellow oil. Η NMR (CDC13) δ: 7.21 (3H, m), 7.09 - 7.01 (6H, m), 4.18 (2H, s), 1.07 (2H, m), 0.79 (2H, m), 0.02 (9H, s). 1 -Ethynyl-4-( 1 -benzyloxycyclopropyl)-benzene (Intermediate 71) Using General Procedure E; [4-(l-benzyloxycyclopropyl)- phenylethynylj-trimethylsilane (Intermediate 70, 150.0 mg, 0.47 mmols) in methanol (6 mL) was treated with potassium carbonate (100.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne (115 mg, 100%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.67 - 7.50 (2H, d, J = 8.2 Hz), 7.34 - 7.26 (7H, m), 4.43 (2H, s), 3.07 (IH, s), 1.32 (2H, m), 1.04 (2H, m). Ethyl 4- [4-( 1 -benzyloxycyclopropylVphenylethynyl] -benzoate (Compound 75, General Formula 2) Using General Procedure F; 1 -ethynyl-4-(l -benzyloxycyclopropyl)- benzene (Intermediate 71, 60.0 mg, 0.24 mmol) and ethyl-4-iodo benzoate (Reagent A, 72.0 mg, 0.26 mmol) in triethylamine (4 mL) was treated with copρer(I)iodide (17.0 mg, 0.09 mmol) and sparged with argon for 5 minutes. Dichlorobis(triρhenylρhosphine)palladium(II) (61 mg, 0.09 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 85.0 mg (91 %) of the title compound as an orange oil. Η NMR (CDC13) δ: 8.03 (2H, d, J = 8.2 Hz), 7.62-7.54 (4H, m), 7.39-7.26 (7H, m), 4.47 (2H, s), 4.40 (2H, q, J = 7.1 Hz), 1.42 (3H, t, J = 7.1 Hz), 1.36 (2H, m), 1.07 (2H, m). Methyl {4- [4-( 1 -benzyloxy cyclopropylVphenylethynyl] -phenyl} -acetate (Compound 76, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)- benzene (Intermediate 71, 60.0 mg, 0.20 mmol) and methyl-(4-iodophenyl)- acetate (Reagent B, 66.0 mg, 0.24 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (15.0 mg, 0.08 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (56 mg, O.Oδ mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-7% EtOAc - hexanes) afforded 64.0 mg (δ 1 %) of the title compound as a yellow oil. 'H NMR (CDC13) δ: 7.52-7.47 (4H, m), 7.37-7.25 (9H, m), 4.44 (2H, s), 3.70 (3H, s), 3.64 (2H, s), 1.32 (2H, m), 1.06 (2H, m). 4-[4-(l -BenzyloxycyclopropylVphenylethynylj-benzoic acid (Compound 77, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l- benzyloxycyclopropyl)-phenylethynyl]-benzoate (Compound 75, 78.0 mg, 0.20 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 65.0 mg (89%) ofthe title compound as a solid. Η NMR (CDC13) δ: 7.97 (2H, d, J = 8.5 Hz), 7.67 (2H, d, J = 8.7 Hz), 7.58 (2H, d, J = 8.5 Hz), 7.41-7.28 (7H, m), 4.44 (2H, s), 1.33 (2H, m), 1.12 (2H, m). l4-[4-(l-BenzyloxycyclopropylVphenylethvnyll-pheny -acetic acid (Compound 78, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- benzyloxycyclopropyl)-phenylethynyl]-phenyl} -acetate (Compound 76, 45.0 mg, 0.11 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 35.0 mg (81%) of the title compound as a pale-yellow solid. 'H NMR (CDC13) δ: 7.49 (4H, m), 7.37-7.25 (9H, m), 4.44 (2H, s), 3.66 (2H, s), 1.32 (2H, m), 1.05 (2H, m). Benzyl 4-bromo-2-methylbenzoate (Intermediate 72) Using General Esterification Method C; 2-methyl-4-bromo-benzoic acid (2.15 g, 10.0 mmols) was refluxed for 3h with 10 mL SOCl2. The resulting solution concentrated under reduced pressure and the crude acyl chloride was combined with benzyl alcohol (1.08 g, lO.Ommols) and pyridine (1.6 mL, 20.0 mmols) to give the title compound (2.4 g, 80%) after work-up and column chromatography (2-5% EtOAc - hexanes) as a colorless oil. Η NMR (CDC13) δ: 7.81 (IH, d, J = 8.5 Hz), 7.41-7.33 (7H, m), 5.32 (2H, s), 2.57 (3H, s). 4-Bromo- 1 -( 1 -benzyloxyvinyl)-2-methylbenzene (Intermediate 73) Using General Procedure 1; benzyl 4-bromo-2-methylbenzoate (Intermediate 72, 840.0 mg, 2.77 mmols) and 5.4 mL of Tebbe's Reagent (788.0 mg, 2.77 mmols) afforded 640.0 mg (76%) ofthe title compound after column chromatography (100% hexanes) . Η NMR (CDC13) δ: 7.38-7.19 (8H, m), 4.88 (2H, s), 4.45 (IH, d, J = 2.6 Hz), 4.25 (2H, d, J = 2.6 Hz), 2.35 (3H, s). 4-Bromo- 1 -( 1 -benzyloxycvcloproρylV2-methyl-benzene (Intermediate 74) Using General Procedure 2; 4-bromo- 1 -(1 -benzyloxyvinyl)-2-methyl- benzene (Intermediate 73, 400. 0 mg, 1.32 mmols), Et2Zn (325.0 mg, 2.63 mmols), and CH2I2 (704.0 mg, 2.63 mmols) in 4 mL Et20 afforded 380.0 mg (90%) ofthe title compound as a colorless oil after chromatography (2-5% EtOAc - hexanes). 'H NMR (CDC13) δ: 7.42-7.20 (8H, m), 4.31 (2H, s), 2.58 (3H, s), 1.25 (2H, m), 0.94 (2H, m). [4-( 1 -Benzyloxy cyclopropyl)-3 -methyl-phenylethynyl] -trimethylsilane (Intermediate 75) Using General Procedure D; 4-bromo- 1 -( 1 -benzyloxycyclopropyl)-2- methyl-benzene (Intermediate 74, 320.0 mg, 1.00 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (19.0 mg, 0.1 mmol) and then sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (70.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (300.0 mg, 89%) was isolated by chromatography (0 - 2% EtOAc - hexanes). Η NMR (CDC13) δ: 7.34-7.13 (8H, m), 4.24 (2H, s), 2.52 (3H, s), 1.20 (2H, m), 0.88 (2H, m), 0.25 (9H, s). 4-Ethynyl- 1 -( 1 -benzyloxycyclopropyl)-2-methyl-benzene (Intermediate 76) Using General Procedure E; [4-(l-benzyloxycyclopropyl)-3-methyl- phenylethynylj-trimethylsilane (Intermediate 75, 300.0 mg, 0.95 mmols) in methanol (6 mL) was treated with potassium carbonate (120.0 mg, 0.87 mmol) and stirred overnight at ambient temperature. The crude alkyne (185 mg, 79%) was used directly in the next reaction. Η NMR (CDC13) δ: 7.37-7.16 (8H, m), 4.27 (2H, s), 3.07 (IH, s), 2.55 (3H, s), 1.21 (2H, m), 0.92 (2H, m). Ethyl 4-[4-(l-benzyloxycvclopropylV3-methyl-phenylethynyl]-benzoate (Compound 79, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)-3- methyl-benzene (Intermediate 76, 90.0 mg, 0.34 mmol) and ethyl-4-iodo benzoate (Reagent A, 95.0 mg, 0.34 mmol) in triethylamine (6 mL) was treated with copper(I)iodide (23.0 mg, 0.12 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (80 mg, 0.11 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 68.0 mg (54%) of the title compound. Η NMR (CDC13) δ: 8.03 (2H, d, J = 8.2 Hz), 7.58 (2H, d, J = 8.2 Hz), 7.33- 7.16 (8H, m), 4.39 (2H, q, J = 7.1 Hz), 4.29 (2H, s), 2.57 (3H, s), 1.40 (3H, t, J = 7.1 Hz), 1.22 (2H, m), 0.93 (2H, m). Methyl {4-[4-(l-benzyloxycyclopropyl)-3-methyl-phenylethynyl]-phenyl}- acetate (Compound 80, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)-3- methyl-benzene (Intermediate 76, 90.0 mg, 0.34 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 95.0 mg, 0.34 mmol) in triethylamine (5 mL) was treated with copρer(I)iodide (22.0 mg, 0.11 mmol) and sparged with argon for 5 minutes. Dichlorobis(triρhenylρhosphine)ρalladium(II) (80 mg, 0.11 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 90.0 mg (71%) ofthe title compound as a pale-yellow oil. Η NMR (CDC13) δ: 7.49 (2H, d, J = 8.2 Hz), 7.32-7.16 (10H, m), 4.28 (2H, s), 3.70 (3H, s), 3.64 (2H, s), 2.56 (3H, s), 1.22 (2H, m), 0.92 (2H, m). 4-[4-(l-BenzyloxycvcloρroρylV3-methyl-ρhenylethvnyl]-benzoic acid (Compound 81, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l- benzyloxycyclopropyl)-3-methyl-phenylethynyl]-benzoate (Compound 79, 68.0 mg, 0.17 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (360.0 mg, 9.0 mmols, 3.0 mL of a 3N aqueous solution) and stirred overnight at room temperature. Work-up afforded 48.0 mg (76%) of the title compound as a solid. 'H NMR (CDCI3) δ: 8.10 (2H, d, J = 8.1 Hz), 7.63 (2H, d, J = 8.1 Hz), 7.44- 7.16 (8H, m), 4.29 (2H, m), 2.58 (3H, s), 1.24 (2H, m), 0.94 (2H, m). {4-[4-(l-Benzyloxycyclopropyl)-3-methyl-phenylethynyl]-phenyl} -acetic acid (Compound 82, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- benzyloxycyclopropyl)-3-methyl-phenylethynyl]-phenyl} -acetate (Compound 80, 75.0 mg, 0.18 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 30.0 mg (40%) ofthe title compound. Η NMR (CDCI3) δ: 7.51 (2H, d, J = 8.2 Hz), 7.42 (IH, s), 7.33-7.17 (9H, m), 4.36 (2H, s), 3.67 (2H, s), 2.57 (3H, s), 1.23 (2H, m), 0.94 (2H, m). Isopropyl 3 -methyl-4-bromobenzoate (Intermediate 77) Using General Esterification Procedure A; 4-bromo-2-methylbenzoic acid (1.6 g, 7.4 mmols) was combined with isopropyl alcohol to give 1.5 g (79%) ofthe title compound as a colorless oil. Η NMR (CDCI3) δ: 7.76 (IH, d, J = 8.2 Hz), 7.40 (IH, d, J = 7.4 Hz), 7.37 (IH, dd, J = 1.4, 8.2 Hz), 5.23 (IH, septet, J = 6.2 Hz), 2.57 (3H, s), 1.37 (6H, d, J = 6.2 Hz). 4-Bromo- 1 -( 1 -isopropoxwinylV 2-methyl-benzene (Intermediate 78) Using General Procedure 1; isopropyl 2-methyl-4-bromobenzoate (Intermediate 77, 800.0 mg, 3.11 mmols) and 6.2 mL of Tebbe's Reagent (885.2 mg, 3.11 mmols) afforded 595.0 mg (75%) ofthe title compound as a colorless oil after column chromatography (100% hexanes). Η NMR (CDC13) δ: 7.31-7.25 (2H, m), 7.16 (IH, d, J = 8.2 Hz), 4.34 (IH, septet, J = 6.0 Hz), 4.31 (IH, d, J = 2.1 Hz), 4.18 (IH, d, J = 2.1 Hz), 2.33 (3H, s), 1.31 (6H, d, J = 6.0 Hz). 4-Bromo- 1 -( 1 -isoproρoxycycloρropyl)-2-methyl-benzene (Intermediate 79) Using General Procedure 2 ; 4-bromo- 1 -( 1 -isopropoxyvinyl)-2-methyl- benzene (Intermediate 78, 389. 0 mg, 1.53 mmols), Et2Zn (376.6 mg, 3.05 mmols), and CH2I2 (817.0 mg, 3.05 mmols) in 3.0 mL Et20 afforded 340.0 mg (84%) ofthe title compound as a colorless oil after chromatography (3% EtOAc - hexanes). !H NMR (CDC13) δ: 7.33 (IH, d, J = 2.3 Hz), 7.24 (IH, dd, J = 2.3, 8.2 Hz), 7.13 (IH, d, J = 8.2 Hz), 3.57 (IH, septet, J = 6.1 Hz), 2.49 (3H, s), 1.00 (2H, m), 0.97 (6H, d, J = 6.1 Hz), 0.82 (2H, m). r4-(l-Isoproρoxycycloρroρyl -3-methyl-ρhenylethvnyl]-trimethylsilane (Intermediate 80) Using General Procedure D; 4-bromo- 1-(1 -isopropoxy cyclopropyl)-2- methyl-benzene (Intermediate 79, 250.0 mg, 0.95 mmol) in triethylamine (8 mL) was treated with coρρer(I)iodide (19.0 mg, 0.10 mmol) and then sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylρhosphine)ρalladium(II) (70.0 mg, 0.1 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (250.0 mg, 91%) was isolated by chromatography (0 - 3% EtOAc - hexanes). ]H NMR (CDC13) δ: 7.32-7.17 (3H, m), 3.56 (IH, septet, J = 6.2 Hz), 2.48 (3H, s), 1.00 (2H, m), 0.95 (6H, d, J = 6.2 Hz), 0.83 (2H, m), 0.24 (9H, s). 4-Ethynyl- 1 -(1 -isoρroρoxycvcloproρylV2-methyl-benzene (Intermediate 81) Using General Procedure E; [4-(l-isoρroρoxycycloproρyl)-3-methyl- phenylethynylj-trimethylsilane (Intermediate 80, 250.0 mg, 0.87 mmol) in methanol (10 mL) was treated with potassium carbonate (100.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne (180 mg, 98%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.32 (IH, s), 7.23 (2H, m), 3.57 (IH, septet, J = 6.2 Hz), 3.05 (IH, s), 2.50 (3H, s), 1.11 (2H, m), 0.96 (6H, d, J = 6.2 Hz), 0.83 (2H, m). Ethyl 4-[4-( 1 -isopropoxycyclopropyl)-3-methyl-phenylethynyl]-benzoate (Compound 83, General Formula 2) Using General Procedure F; 4-ethynyl- 1 -( 1 -isopropoxy cyclopropyl)-3 - methyl-benzene (Intermediate 81, 80.0 mg, 0.13 mmol) and ethyl-4-iodo benzoate (Reagent A, 100.0 mg, 0.36 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (25.0 mg, 0.13 mmol) and sparged with argon for 5 minutes. Dichlorobis(triρhenylphosphine)-palladium(II) (91 mg, 0.13 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 75.0 mg (56%) ofthe title compound as an orange solid. 'H NMR (CDCI3) δ: 8.02 (2H, d, J = 8.2 Hz), 7.57 (2H, d, J = 8.2 Hz), 7.39 (IH, s), 7.29-7.20 (2H, m), 4.39 (2H, q, J = 7.1 Hz), 3.60 (IH, septet, J = 6.2 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.13 (2H, m), 0.97 (6H, d, J = 6.2 Hz), 0.87 (2H, m). Methyl (4-r4-(l-isopropoxycyclopropylV3-methyl-phenylethvnyl]-phenyll- acetate (Compound 84, General Formula 2) Using General Procedure F; l-ethynyl-4-(l-isopropoxycyclopropyl)-3- methyl-benzene (Intermediate 81, 100.0 mg, 0.47 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 129.0 mg, 0.45 mmol) in triethylamine (6 mL) was treated with copper(I)iodide (30.0 mg, 0.16 mmol) and sparged with argon for 5 minutes. Dichlorobis(triρhenylρhosρhine)palladium(II) (110 mg, 0.1 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 120.0 mg (71%.) ofthe title compound. Η NMR (CDC13) δ: 7.48 (2H, d, J = 8.5 Hz), 7.36 (IH, s), 7.29-7.22 (4H, m), 3.70 (3H, s), 3.63 (2H, s), 3.60 (IH, septet, J = 6.2 Hz), 2.52 (3H, s), 1.09 (2H, m), 0.97 (6H, d, J = 6.2 Hz), 0.86 (2H, m). 4-[4-(l-Isopropoxycyclopropyl)-3-methyl-phenylethynyl]-benzoic acid (Compound 85, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l- isopropoxycyclopropyl)-3-methyl-phenylethynyl]-benzoate (Compound 83, 60.0 mg, 0.17 mmol) in ethanol (2 mL) and tetrahydrofuran (2 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 38.0 mg (69%) ofthe title compound as a colorless solid. Η NMR (d6-acetone) δ: 8.06 (2H, d, J = 8.5 Hz), 7.66 (2H, d, J = 8.5 Hz), 7.42 (IH, s), 7.35 (2H, m), 3.59 (IH, septet, J = 6.2 Hz), 2.52 (3H, s), 1.07 (2H, m), 0.93 (6H, d, J = 6.2 Hz), 0.88 (2H, m). {4- 4-(l-Isopropoxycyclopropyl)-3-methyl-phenylethynyl]-phenyl} -acetic acid (Compound 86, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- isopropoxycycloproρyl)-3-methyl-phenylethynyl]-phenyl}-acetate (Compound 84, 100.0 mg, 0.28 mmol) in ethanol (3 mL) and tefrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 60.0 mg (62%) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 7.48 (2H, d, J = 7.6 Hz), 7.36 (IH, s), 7.25 (4H, m), 3.65 (2H, s), 3.60 (IH, septet, J = 6.2 Hz), 2.51 (3H, s), 1.12 (2H, m), 0.97 (6H, d, J = 6.2 Hz), 0.86 (2H, m). 2.2-Dimethylρropyl 2-methyl-4-bromobenzoate (Intermediate 82) Using General Esterification Method C; 2-methyl-4-bromo-benzoic acid (1.82 g, 8.47 mmols) was refluxed for 3h with 10 mL SOCl2. The resulting solution was concentrated under reduced pressure and the crude acyl chloride combined with 2,2-dimethylρroρanol (0.75 g, 8.47 mmols) and pyridine (1.4 mL, 16.9 mmols) to give the title compound (1.64 g, 68%) after work-up and column chromatography (2-5% EtOAc - hexanes) as a colorless oil. Η NMR (CDC13) δ: 7.81 (IH, d, J = 8.2 Hz), 7.42 (IH, d, J = 2.0 Hz), 7.39 (IH, dd, J = 2.0, 8.2 Hz), 3.99 (2H, s), 2.60 (3H, s), 1.03 (9H, s). 4-Bromo- 1 -[ 1 -(2.2-dimethylpropyloxy)-vinyl]-2-methyl-benzene (Intermediate 83) Using General Procedure 1; 2,2-dimethylpropyl 2-methyl-4- bromobenzoate (Intermediate 82, 820.0 mg, 2.87 mmols) and 5.8 mL of Tebbe's Reagent (817.0 mg, 2.87 mmols) afforded 800.0 mg (98%) ofthe title compound as a colorless oil after column chromatography (100% hexanes). Η NMR (CDCI3) δ: 7.32 (IH, d, J = 2.0 Hz), 7.28 (IH, dd, J = 2.0, 8.2 Hz), 7.18 (IH, J = 8.2 Hz), 4.27 (IH, d, J = 2.1 Hz), 4.10 (IH, J = 2.1 Hz), 3.43 (2H, s), 2.33 (3H, s), 0.98 (9H, s). 4-Bromo- 1 - 1 -(2.2-dimethylpropyloxyV cyclopropyl] -2-methyl-benzene (Intermediate 84) Using General Procedure 2; 4-bromo- 1 -[ 1 -(2,2-dimethylpropyloxy)- cyclopropyl]-2-methyl-benzene (Intermediate 83, 400. 0 mg, 1.43 mmols), Et2Zn (353.2 mg, 2.86 mmols), and CH2I2 (760.0 mg, 2.86 mmols) in 3.0 mL Et20 afforded 370.0 mg (87%) ofthe title compound as a colorless oil after chromatography (3% EtOAc - hexanes). Η NMR (CDC13) δ: 7.36 (IH, s),7.27 (IH, d, J = 8.5 Hz), 7.09 (IH, d, J = 7.9 Hz), 2.86 (2H, s), 2.52 (3H, s), 1.08 (2H, m), 0.83 (2H, m), 0.80 (9H, s). [4-[l-[l-(2.2-DimethylproρyloxyVcvcloρropyl1-3-methyl-ρhenylethynyl11- trimethylsilane (Intermediate 84a) Using General Procedure D; 4-bromo-l-[l-(2,2-dimethylproρyloxy)- cycloρroρyl]-2-methyl-benzene (Intermediate 84, 255.0 mg, 0.86 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (17.0 mg, 0.09 mmol) and then sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis- (triphenylphosphine)palladium(II) (63.0 mg, 0.09 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (220.0 mg, 81%) was isolated by chromatography ( 1 -2% EtOAc - hexanes) . Η NMR (CDCI3) δ: 7.30 (IH, s), 7.21 (IH, d, J = 7.6 Hz), 7.12 (IH, d, J = 8.6 Hz), 2.80 (2H, s), 2.47 (3H, s), 1.05 (2H, m), 0.82 (2H, m), 0.75 (9H, s), 0.24 (9H, s). 4-Ethynyl-l-[l-(2.2-dimethylpropyloxy)-cyclopropyl]-2-methyl-benzene (Intermediate 85) Using General Procedure E; [4-[l-[l-(2,2-dimethylpropyloxy)- cyclopropyl]]-3-methyl-ρhenylethynyl]-trimethylsilane (Intermediate 84a, 220.0 mg, 0.83 mmol) in methanol (10 mL) was treated with potassium carbonate (80.0 mg, 0.58 mmol) and stirred overnight at ambient temperature. The crude alkyne (155 mg, 76%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.32 (IH, s), 7.24 (IH, d, J = 7.1 Hz), 7.15 (IH, d, J = 7.1 Hz), 3.04 (IH, s), 2.83 (2H, s), 2.49 (3H, s), 1.06 (2H, m), 0.83 (2H, m), 0.76 (9H, s). Ethyl 4-[4-[l-(2.2-dimethylpropyloxy)-cyclopropyl]-3-methyl-phenylethynyl]- benzoate (Compound 87, General Formula 2) Using General Procedure F; 4-ethynyl-l-[l-(2,2-dimethylpropyloxy)- cyclopropyl]-3-methyl-benzene (Intermediate 85, 75.0 mg, 0.31 mmol) and ethyl-4-iodo benzoate (Reagent A, 86.0 mg, 0.31 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (21.0 mg, 0.11 mmol) and sparged with argon for 5 minutes. Dichlorobis(triρhenylρhosphine)-ρalladium(II) (78 mg, 0.11 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 60.0 mg (50%) ofthe title compound as an orange solid. ]H NMR (CDC13) δ: 8.02 (2H, J = 8.4 Hz), 7.56 (2H, d, J = 8.4 Hz), 7.38 (IH, s), 7.30 (IH, dd, J = 1.1, 8.0 Hz), 7.20 (IH, d, J = 8.0 Hz), 4.38 (2H, q, J = 7.1 Hz), 2.84 (2H, s), 2.52 (3H, s), 1.40 (3H, t, J = 7.1 Hz), 1.07 (2H, m), 0.84 (2H, m), 0.77 (9H, s). Methyl l4- 4-ri-(2.2-dimethylpropyloxyVcyclopropyll-3-methyl- phenylethynyl]-phenyl} -acetate (Compound 88, General Formula 2) Using General Procedure F; 4-ethynyl- 1 -[ 1 -(2,2-dimethylpropyloxy)- cycloρropyl]-3-methyl-benzene (Intermediate 85, 75.0 mg, 0.31 mmol) and methyl-(4-iodophenyl)-acetate (Reagent B, 86.0 mg, 0.31 mmol) in triethylamine (6 mL) was treated with copper(I)iodide (21.0 mg, 0.11 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (78 mg, 0.11 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 100.0 mg (83%) ofthe title compound. 'H NMR (CDCI3) δ: 7.48 (2H, d, J = 7.9 Hz), 7.36-7.24 (4H, m), 7.18 (IH, d, J = 7.9 Hz), 3.70 (3H, s), 3.63 (2H, s), 2.84 (2H, s), 2.51 (3H, s), 1.07 (2H, m), 0.83 (2H, m), 0.77 (9H, s). 4-[4-[l-(2.2-Dimethylpropyloxy)-cyclopropyl]-3-methyl-phenylethynyl]- benzoic acid (Compound 89, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-[l -(2,2- dimethylpropyloxy)-cyclopropyl]-3-methyl-phenylethynyl]-benzoate (Compound 87, 60.0 mg, 0.15 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 24.0 mg (43%) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 8.06 (2H, d, J = 7.9 Hz), 7.65 (2H, d, J = 7.9 Hz), 7.42 (IH, s), 7.33 (2H, m), 2.89 (2H, s), 2.53 (3H, s), 1.07 (2H, m), 0.90 (2H, m), 0.77 (9H, s). {4-[4-[l-(2.2-DimethylρroρyloxyVcvcloproρyl]-3-methyl-ρhenylethvnyll- phenvU -acetic acid (Compound 90, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-[l-(2,2- dimethylpropyloxy)-cyclopropyl]-3-methyl-phenylethynyl]-phenyl} -acetate (Compound 88, 95.0 mg, 0.24 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 49.0 mg (53%) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 7.49 (2H, d, J = 8.2 Hz), 7.36 (IH, s), 7.27 (3H, m), 7.18 (IH, d, J = 7.9 Hz), 3.66 (2H, s), 2.84 (2H, s), 2.51 (3H, s), 1.07 (2H, m), 0.83 (2H, m), 0.77 (9H, s). Benzyl 4-bromo-2-ethyl-benzoate (Intermediate 86) Using General Esterification Method B; 4-bromo-2-ethyl-benzoic acid (0.98 g, 4.25 mmols), benzyl bromide (0.80 g, 4.68 mmols), and K2C03 (0.64 g, 4.68 mmols) afforded 1.0 g (74%) ofthe title compound after column chromatography (0-3% EtOAc - hexanes). Η NMR (CDC13) δ: 7.76 (IH, d, J = 8.5 Hz), 7.41-7.33 (7H, m), 5.32 (2H, s), 2.95 (2H, q, J = 7.6 Hz), 1.20 (3H, t, J = 7.6 Hz). 4-Bromo- 1 -( 1 -benzyloxyvinylV 2-ethyl-benzene (Intermediate 87) Using General Procedure 1 ; benzyl 4-bromo-2-ethylbenzoate (Intermediate 86, 1.20 g, 3.78 mmols) and 7.6 mL of Tebbe's Reagent (1.08 g, 3.78 mmols) afforded 800.0 mg (66%) of the title compound after column cliromatography (100% hexanes). Η NMR (CDC13) δ: 7.37-7.17 (8H, m), 4.88 (2H, s), 4.43 (IH, d, J = 2.1 Hz), 4.25 (IH, d, J = 2.1 Hz), 2.71 (2H, q, J = 7.6 Hz), 1.18 (3H, t, J = 7.6 Hz). 4-Bromo- 1 -( 1 -benzyloxycvclopropylV 2-ethyl-benzene (Intermediate 88) Using General Procedure 2 ; 4-bromo- 1 -( 1 -benzyloxyvinyl)-2-ethyl- benzene (Intermediate 87, 330. 0 mg, 1.04 mmols), Et2Zn (257.0 mg, 2.08 mmols), and CH2I2 (557.0 mg, 2.08 mmols) in 4 mL Et20 afforded 241.0 mg (70%) ofthe title compound as a colorless oil after chromatography (2-5% EtOAc - hexanes). Η NMR (CDCI3) δ: 7.43-7.15 (8H, m), 4.27 (2H, s), 3.00 (2H, q, J = 7.6 Hz), 1.29-1.21 (5H, m), 0.90 (2H, m). [4-(l-Benzyloxycyclopropyl)-3-ethyl-phenylethynyl]-trimethylsilane (Intermediate 89) Using General Procedure D; 4-bromo- 1 -( 1 -benzyloxycyclopropyl)-2- ethyl-benzene (Intermediate 88, 220.0 mg, 0.66 mmol) in triethylamine (8 mL) was treated with coρper(I)iodide (14.0 mg, 0.07 mmol) and then sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(friρhenylphosρhine)ρalladium(II) (50.0 mg, 0.07 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound was isolated by chromatography (0 - 2% EtOAc - hexanes). Η NMR (CDCI3) δ: 7.41-7.13 (8H, m), 4.24 (2H, s), 2.98 (2H, q, J = 7.6 Hz), 1.25 (3H, t, J = 7.6 Hz), 1.20 (2H, m), 0.90 (2H, m), 0.26 (9H, s). 4-Ethynyl- 1 -( 1 -benzyloxycyclopropylV 2-ethyl-benzene (Intermediate 90) Using General Procedure E; [4-(l-benzyloxycyclopropyl)-3-ethyl- phenylethynylj-trimethylsilane (Intermediate 89, 240 mg, 0.69 mmol) in methanol (6 mL) was treated with potassium carbonate (10.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne (190 mg, 99%) was used directly in the next reaction. 'H NMR (CDC13) δ: 7.43-7.15 (8H, m), 4.27 (2H, s), 3.08 (IH, s), 3.01 (2H, q, J = 7.6 Hz), 1.26 (3H, t, J = 7.6 Hz), 1.22 (2H, m), 0.92 (2H, m). Ethyl 4-[4-(l-benzyloxycycloproρylV3-ethyl-phenylethynyl]-benzoate (Compound 91, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)-3- ethyl-benzene (Intermediate 90, 90.0 mg, 0.33 mmol) and ethyl-4-iodo benzoate (Reagent A, 100.0 mg, 0.36 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (21.0 mg, 0.11 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (77 mg, 0.11 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 100.0 mg (72%) of the title compound. Η NMR (CDC13) δ: 8.03 (2H, d, J = 7.9 Hz), 7.59 (2H, d, J = 7.9 Hz), 7.49 (IH, s), 7.36-7.16 (7H, m), 4.38 (2H, q, J = 7.1 Hz), 4.28 (2H, s), 3.04 (2H, q, J = 7.6 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.29 (3H, t, J = 7.6 Hz), 1.23 (2H, m), 0.94 (2H, m). Methyl {4-[4-( 1 -benzyloxycvclopropyl)-3-ethyl-phenylethynyl]-phenyll - acetate (Compound 92, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -benzyloxy cyclopropyl)-3- ethyl-benzene (Intermediate 90, 107.0 mg, 0.39 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 110.0 mg, 0.39 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (25.0 mg, 0.13 mmol) and sparged with argon for 5 minutes. Dichlorobis(triρhenylphosphine)palladium(II) (91 mg, 0.13 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 130.0 mg (79%) ofthe title compound as a pale-yellow oil. Η NMR (CDC13) δ: 7.49 (3H, m), 7.32-7.16 (9H, m), 4.28 (2H, s), 3.71 (3H, s), 3.64 (2H, s), 3.03 (2H, q, J = 7.6 Hz), 1.32-1.23 (5H, m), 0.94 (2H, m). 4-[4-(l-BenzyloxycyclopropylV3-ethyl-ρhenylethvnyll-benzoic acid (Compound 93, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l- benzyloxycyclopropyl)-3-ethyl-phenylethynyl]-benzoate (Compound 91, 100.0 mg, 0.24 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up and purification by HPLC (Partisil 10-pac, 10% H20/CH3CN) afforded the title compound as a colorless solid. 'H NMR (CDC13) δ: 8.10 (2H, d, J = 8.5 Hz), 7.64 (2H, d, J = 8.5 Hz), 7.50 (IH, s), 7.35-7.16 (7H, m), 4.29 (2H, s), 3.04 (2H, q, J = 7.6 Hz), 1.30 (3H, t, J = 7.6 Hz), 1.25 (2H, m), 0.95 (2H, m). l4- 4-(l-Benzyloxycvclopropyl -3-ethyl-phenylethvnyl]-phenyl -acetic acid (Compound 94, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- benzyloxycyclopropyl)-3-ethyl-phenylethynyl]-phenyl} -acetate (Compound 92, 130.0 mg, 0.31 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up and purification by HPLC (Partisil 10-pac, 10% H20/CH3CN) afforded the title compound. Η NMR (CDCI3) δ: 7.49 (3H, m), 7.31-7.16 (9H, m), 4.28 (2H, s), 3.66 (2H, s), 3.02 (2H, q, J = 7.6 Hz), 1.29 (3H, t, J = 7.6 Hz), 1.23 (2H, m), 0.94 (2H, m). Isopropyl 2-ethyl-4-bromobenzoate (Intermediate 91) Using General Esterification Procedure A; 4-bromo-2-ethyl-benzoic acid (2.25 g, 9.9 mmols) was combined with isopropyl alcohol to give the title compound as a colorless oil after column chromatography (2% EtOAc- hexanes). Η NMR (CDC13) δ: 7.69 (IH, d, J = 8.5 Hz), 7.41 (IH, s), 7.36 (IH, d, J = 8.5 Hz), 5.23 (IH, septet, J = 6.2 Hz), 2.95 (2H, q, J = 7.6 Hz), 1.37 (6H, d, J = 6.2 Hz), 1.23 (3H, t, J = 7.6 Hz). 4-Bromo- 1 -( 1 -isoρroρox inyD-2-ethyl-benzene (Intermediate 92) Using General Procedure 1; isopropyl 2-ethyl-4-bromobenzoate (Intermediate 91, 1.21 g, 4.46 mmols) and 8.9 mL of Tebbe's Reagent (1.27 g, 4.46 mmols) afforded 570.0 mg (75%) ofthe title compound after column chromatography (100% hexanes) . Η NMR (CDCI3) δ: 7.36 (IH, d, J = 2.0 Hz), 7.28 (IH, dd, J = 2.0, 8.0 Hz), 7.17 (IH, d, J = 8.0 Hz), 4.39 (IH, septet, J = 6.2 Hz), 4.31 (IH, d, J = 2.1 Hz), 4.26 (IH, d, J = 2.1 Hz), 2.73 (2H, q, J = 7.6 Hz), 1.35 (6H, d, J = 6.2 Hz), 1.24 (3H, t, J = 7.6 Hz). 4-Bromo- 1 -( 1 -isopropoxy cyclopropyl -2-ethyl-benzene (Intermediate 93) Using General Procedure 2; 4-bromo- l-(l-isopropoxyvinyl)-2-ethyl- benzene (Intermediate 92, 570. 0 mg, 2.11 mmols), Et2Zn (521.0 mg, 4.22 mmols), and CH2I2 (1.13 g, 4.22 mmols) in 7.0 mL Et20 afforded 500.0 mg (85%) ofthe title compound as a colorless oil after chromatography (3% EtOAc - hexanes). Η NMR (CDCI3) δ: 7.39 (IH, d, J = 2.1 Hz), 7.25 (IH, dd, J = 2.1, 8.1 Hz), 7.15 (IH, J = 8.1 Hz), 3.59 (IH, septet, J = 6.2 Hz), 2.97 (2H, q, J = 7.6 Hz), 1.27 (3H, t, J = 7.6 Hz), 1.11 (2H, m), 0.97 (6H, d, J = 6.2 Hz), 0.83 (2H, m). [4-( 1 -Isopropoxy cy clopropyl)-3 -ethyl-phenylethynyl]-trimethylsilane (Intermediate 94) Using General Procedure D; 4-bromo- 1 -( 1 -isopropoxycy clopropyl)-2- ethyl-benzene (Intermediate 93, 300.0 mg, 1.07 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (20.0 mg, 0.11 mmol) and then sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triρhenylρhosρhine)ρalladium(II) (75.0 mg, 0.11 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound (320.0 mg, 99%) was isolated by chromatography (0 - 2% EtOAc - hexanes) as an orange oil. 'H NMR (CDC13) δ: 7.37-7.21 (3H, m), 3.56 (IH, septet, J = 6.2 Hz), 2.96 (2H, q, J = 7.6 Hz), 1.27 (3H, t, J = 7.6 Hz), 1.10 (2H, m), 0.94 (6H, d, J = 6.2 Hz), 0.84 (2H, m), 0.25 (9H, s). 4-Ethynyl- 1 -( 1 -isopropoxycvclopropylV 2-ethyl-benzene (Intermediate 95) Using General Procedure E; [4-(l-isopropoxycyclopropyl)-3-ethyl- phenylethynylj-trimethylsilane (Intermediate 94, 330.0 mg, 1.10 mmols) in methanol (10 mL) was treated with potassium carbonate (150.0 mg, 1.10 mmol) and stirred overnight at ambient temperature. The crude alkyne (238 mg, 95%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.40-7.22 (3H, m), 3.59 (IH, septet, J = 6.2 Hz), 3.07 (IH, s), 2.97 (2H, q, J = 7.6 Hz), 1.28 (3H, t, J = 7.6 Hz), 1.12 (2H, m), 0.96 (6H, d, J = 6.2 Hz), 0.85 (2H, m). Ethyl 4-[4-(l-isopropoxycyclopropyl)-3-ethyl-phenylethynyl]-benzoate (Compound 95, General Formula 2) Using General Procedure F; 4-ethynyl- 1 -( 1 -isopropoxy cy clopropyl)-3 - ethyl-benzene (Intermediate 95, 108.0 mg, 0.47 mmol) and ethyl-4-iodo benzoate (Reagent A, 130.0 mg, 047 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (30.0 mg, 0.16 mmol) and sparged with argon for 5 minutes . Dichlorobis(triphenylphosphine)-palladium(II) (110 mg, 0.16 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 125.0 mg (71%o) ofthe title compound as an oil. 'H NMR (CDC13) δ: 8.02 (2H, d, J = 8.2 Hz), 7.59 (2H, d, J = 8.2 Hz), 7.46 (IH, s), 7.33-7.26 (2H, m), 4.39 (2H, q, J = 7.1 Hz), 3.62 (IH, septet, J = 6.2 Hz), 3.01 (2H, q, J = 7.6 Hz), 1.41 (3H, t, J = 7.1 Hz), 1.31 (3H, t, J = 7.1 Hz), 1.14 (2H, m), 0.97 (6H, d, J = 6.2 Hz), 0.88 (2H, m). Methyl (4- [4-( 1 -isopropoxy cy clopropyl>3-ethyl-phenylethynvH -phenyl I - acetate (Compound 96, General Formula 2) Using General Procedure F; l-ethynyl-4-(l -isopropoxy cyclopropyl)-3- ethyl-benzene (Intermediate 95, 130.0 mg, 0.57 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 157.0 mg, 0.57 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (36.0 mg, 0.19 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (133 mg, 0.19 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-5% EtOAc - hexanes) afforded 150.0 mg (70%) of the title compound as an orange oil. Η NMR (CDCI3) δ: 7.50-7.44 (3H, m), 7.27 (4H, m), 3.70 (3H, s), 3.64 (2H, s), 3.62 (IH, septet, J = 6.2 Hz), 3.00 (2H, q, J = 7.6 Hz), 1.30 (3H, t, J = 7.6 Hz), 1.13 (2H, m), 0.97 (6H, d, J = 6.2 Hz), 0.87 (2H, m). 4-f4-(l-IsopropoxycvclopropylV3-ethyl-phenylethynyl]-benzoic acid (Compound 97, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-( 1 - isoρropoxycycloρropyl)-3-ethyl-phenylethynyl]-benzoate (Compound 95, 110.0 mg, 0.29 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was freated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up and isolation by HPLC (partisil 10-pac, 10%> H20/CH3CN) afforded the title compound as a colorless solid. Η NMR (d6-acetone) δ: 8.06 (2H, d, J = 8.2 Hz), 7.67 (2H, d, J = 8.2 Hz), 7.49 (IH, s), 7.40-7.34 (2H, m), 3.61 (IH, septet, J = 6.2 Hz), 3.01 (2H, q, J = 7.6 Hz), 1.29 (3H, t, J = 7.6 Hz), 1.08 (2H, m), 0.93 (6H, d, J = 6.2 Hz), 0.88 (2H, m). (4-[4-(l-Isopropoxycvcloρropy -3-ethyl-phenylethvnyll-ρhenyl>-acetic acid (Compound 98, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- isopropoxycycloproρyl)-3-ethyl-ρhenylethynyl]-phenyl} -acetate (Compound 96, 156.0 mg, 0.41 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up and isolation by HPLC (partisil 10-pac, 10% H20/CH3CN) afforded 85.0 mg (57%) of the title compound. Η NMR (CDC13) δ: 7.54-7.48 (3H, m), 7.34-7.27 (4H, m), 3.68 (2H, s), 3.66 (IH, septet, J = 6.2 Hz), 3.03 (2H, q, J = 7.6 Hz), 1.33 (2H, t, J = 7.6 Hz), 1.17 (2H, m), 1.01 (6H, d, J = 6.2 Hz), 0.90 (2H, m). (4-Bromo-3-isopropyl-phenoxy)-triisopropyl-silane (Intermediate 96) To a solution of 4-bromo-3-isopropylphenol (880.0 mg, 4.09 mmols) and imidazole (417.0 mg, 6.13 mmols) in 10 mL DMF was added chloro- triisopropylsilane (946.0 mg, 4.90 mmols). After stirring overnight at room temperature the solution was diluted with H20 and extracted with EtOAc. The combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound, 1.30 g (92%.), was isolated by column chromatography (1-2% EtOAc-hexanes) as a colorless oil. 'H NMR (CDC13) δ: 7.34 (IH, d, J = 8.5 Hz), 6.81 (IH, d, J = 2.9 Hz), 6.59 (IH, dd, J = 2.9, 8.5 Hz), 3.31 (IH, septet, J = 7.0 Hz), 1.33-1.21 (3H, m), 1.24 (6H, d, J = 7.0 Hz), 1.13 (18H, d, J = 7.0 Hz). Ethyl 2-isopropyl-4-triisopropylsilanyloxy-benzoate (Intermediate 97) To a solution of (4-bromo-3-isoρropyl-ρhenoxy)-friisopropyl-silane (Intermediate 96, 1.3 g, 3.8 mmols) in 15 mL Et20 cooled to -78 °C was added 4.9 mL of tert-butyllithium in pentane (532.0 mg, 8.3 mmols; 1.7 M). After stirring for 30 minutes ethyl chloroformate (832.0 mg, 7.8 mmols) was added. The resulting solution was warmed to room temperature and quenched by the addition of saturated aqueous NH4C1. The mixture was extracted with EtOAc and the combined organic layers dried (MgS04) concentrated under reduced pressure and the residue chromatographed (4% EtOAc-hexanes) to give 1.09 g (85%) ofthe title compound as a colorless oil. Η NMR (CDC13) δ: 7.72 (IH, d, J = 8.5 Hz), 6.87 (IH, d, J = 2.3 Hz), 6.69 (IH, dd, J = 2.3, 8.5 Hz), 3.88 (IH, septet; J = 7.1 Hz), 4.30 (2H, q, J = 7.1 Hz), 1.36 (3H, t, J = 7.1 Hz), 1.31-1.17 (9H, m), 1.09 (18H). [4-(l-EthoxyvinylV3-isopropyl-phenoxy]-triisopropyl-silane (Intermediate 98) Using General Procedure 1; ethyl 2-isopropyl-4-triisopropylsilanyloxy- benzoate (Intermediate 97, 450.0 mg, 1.34 mmols) and 2.0 mL of Tebbe's Reagent (398.0 mg, 1.40 mmols) afforded the title compound after column chromatography ( 100% hexanes) . Η NMR (CDCI3) δ: 7.11 (IH, d, J = 8.2 Hz), 6.78 (IH, d, J = 2.3 Hz), 6.63 (IH, dd, J = 2.3, 8.2 Hz), 4.23 (IH, d, J = 1.7 Hz), 4.10 (IH, d, J = 1.7 Hz), 3.86 (2H, q, J = 7.0 Hz), 3.16 (IH, septet, J = 7.0 Hz), 1.35 (3H, t, J = 7.1 Hz), 1.28-1.19 (3H, m), 1.19 (6H, d, J = 7.0 Hz), 1.11 (18H). [4-(l-Ethoxycyclopropyl)-3-isopropyl-phenoxy]-triisopropyl-silane (Intermediate 99) Using General Procedure 2; [4-(l-ethoxyvinyl)-3-isopropyl-phenoxy]- triisopropyl-silane (Intermediate 98, 300. 0 mg, 0.83 mmols), EtjZn (325.0 mg, 2.63 mmols), and CH2I2 (704.0 mg, 2.63 mmols) in 5.0 mL Et20 afforded 270.0 mg (86%>) ofthe title compound as a colorless oil after chromatography (0.5-2.5% EtOAc - hexanes). Η NMR (CDC13) δ: 7.06 (IH, d, J = 8.2 Hz), 6.81 (IH, d, J = 2.6 Hz), 6.59 (IH, dd, J = 2.6, 8.2 Hz), 3.76 (IH, septet, J = 7.0 Hz), 3.25 (2H, q, J = 7.0 Hz), 1.30-1.20 (3H, m), 1.19 (6H, d, J = 7.0 Hz), 1.15 (2H, m), 1.10 (18H), 1.02 (2H, t, J = 7.0 Hz), 0.82 (2H, m). 4-(l-EthoxycycloρroρylV3-isoρropyl-phenol (Intermediate 100) To a solution of [4-(l-ethoxycycloρroρyl)-3-isoproρyl-ρhenoxy]- triisopropyl-silane (Intermediate 99, 360.0 mg, 0.96mmol) in 3 mL THF at 0 °C was added tetrabutylammonium fluoride (625.0 mg, 2.39 mmols, 2.4 mL of a 1 M solution in THF). The solution was stirred at 0 °C for 30 minutes and then quenched by the addition of H20. The mixture was extracted with EtOAc and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound (180 mg, 86%) was isolated from the residue by column chromatography (4-10% EtOAc-hexanes) as a colorless solid. 'H NMR (CDCI3) δ: 7.13 (IH, d, J = 8.2 Hz), 6.79 (IH, d, J = 2.6 H), 6.57 (IH, dd, J = 2.6, 8.2 Hz), 5.48 (IH, s), 3.79 (IH, septet, J = 7.0 Hz), 3.32 (2H, q, J= 7.0 Hz), 1.21 (6H, d, J = 7.0 Hz), 1.12 (2H, m), 1.05 (3H, t, J = 7.0 Hz), 0.84 (2H, m). 4-( 1 -Ethoxycyclopropyl)-3-isopropyl-phenyl 1.1.1 -trifluoromethansulfonate (Intermediate 101) A solution of 4-( 1 -ethoxycyclopropyl)-3 -isopropyl-phenol (Intermediate 100, 172.0 mg, 0.78 mmol) in 5 mL of CH2C12 was cooled to 0 °C and to it was added 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5- chloropyridine (321.0 mg, 0.82 mmol) and triethylamine (240.0 mg, 2.4 mmols). The resulting solution was warmed to room temperature and stirred overnight. The reaction was quenched by the addition of H20 and the mixture extracted with EtOAc and the combined organic layers were washed with 10% aqueous HCl, saturated aqueous NaHC03, H20, and saturated aqueous NaCl. The solution was dried (MgS04) and concentrated under reduced pressure. The title compound was isolated by column chromatography (2-4% EtOAc- hexanes) as a colorless oil, 240.0 mg, 87%. Η NMR (CDC13) δ: 7.31 (IH, d, J = 8.6 Hz), 7.18 (IH, d, J = 2.6 Hz), 7.00 (IH, dd, J = 2.6, 8.6 Hz), 3.87 (IH, septet, J = 7.0 Hz), 2.38 (2H, q, J = 7.0 Hz), 1.24 (6H, d, J = 7.0 Hz), 1.15 (2H, m), 1.04 (3H, t, J = 7.0 Hz), 0.86 (2H, m). [4-(l-Ethoxycyclopropyl)-3-isopropyl-phenylethynyl]-trimethylsilane (Intermediate 102) Using General Procedure D; 4-(l-ethoxycyclopropyl)-3-isopropyl- phenyl 1,1,1-trifluoromethansulfonate (Intermediate 101, 240.0 mg, 0.68 mmol) in triethylamine (2 mL) and DMF (6 mL) was sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (38.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 95 °C for 5d. The title compound, 200.0 mg (99%), was isolated by chromatography (0 - 2% EtOAc - hexanes) as an orange oil. Η NMR (CDC13) δ: 7.43 (IH, d, J = 1.7 Hz), 7.25 (IH, dd, J = 1.7, 7.9 Hz), 7.16 (IH, d, J = 7.9 Hz), 3.80 (IH, septet, J = 6.8 Hz), 3.26 (2H, q, J = 7.0 Hz), 1.24 (6H, d, J = 6.8 Hz), 1.24-1.10 (2H, m), 1.03 (3H, t, J = 7.0 Hz), 0.87 (2H, s), 0.26 (9H, s). 1 -( 1 -Ethoxy cyclopropyl -4-ethynyl-2-isopropylbenzene (Intermediate 103) Using General Procedure E; [4-(l-ethoxycyclopropyl)-3-isopropyl- phenylethynylj-trimethylsilane (Intermediate 102, 210.0 mg, 0.70 mmol) in methanol (10 mL) was treated with potassium carbonate (100.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne was used directly in the next reaction. 'H NMR (CDC13) δ: 7.47 (IH, J = 1.7 Hz), 7.23 (IH, dd, J = 1.7, 7.6 Hz), 7.19 (IH, d, J = 7.6 Hz), 3.80 (IH, septet, J = 7.0 Hz), 3.27 (IH, q, J = 7.0 Hz), 3.07 (IH, s), 1.23 (6H, d, J = 7.0 Hz), 1.13 (2H, m), 1.03 (3H, t, J = 7.0 Hz), 0.85 (2H, m). Ethyl 4-r4-(l-ethoxycycloproρy -3-isopropyl-ρhenylethvnvn-benzoate (Compound 99, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2- isopropylbenzene (Intermediate 103, 50.0 mg, 0.22 mmol) and ethyl-4-iodo benzoate (Reagent A, 60.0 mg, 0.22 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (14.0 mg, 0.07 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)-palladium(II) (51 mg, 0.07 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (1-2% EtOAc - hexanes) afforded 28.0 mg (34%) ofthe title compound. Η NMR (CDCI3) δ: 8.01 (2H, d, J = 8.2 Hz), 7.59 (2H, d, J = 8.2 Hz), 7.51 (IH, d J = 1.7 Hz), 7.28 (IH, dd, J = 1.7, 7.9 Hz), 7.21 (IH, d, J = 7.9 Hz), 4.38 (2H, q, J = 7.1 Hz), 3.83 (IH, septet, J = 6.7 Hz), 3.29 (2H, q, J = 7.0 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.26 (6H, d, J = 6.7 Hz), 1.14 (2H, m), 1.04 (3H, t, J = 7.0 Hz), 0.87 (2H, m). Methyl 4-r4-(l-ethoxycvclopropyl -3-isoproρyl-phenylethvnyl]-phenyl}- acetate (Compound 100, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2- isopropylbenzene (Intermediate 103, 120.0 mg, 0.52 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 150.0 mg, 0.52 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (32.0 mg, 0.17 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylρhosρhine)palladium(II) (121 mg, 0.17 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-5% EtOAc - hexanes) afforded 140.0 mg (71%.) ofthe title compound as a pale-yellow oil. Η NMR (CDC13) δ: 7.53 (3H, m), 7.31-7.23 (4H, m), 3.86 (IH, septet, J = 6.7 Hz), 3.73 (3H, s), 3.67 (2H, s), 3.33 (2H, q, J = 7.0 Hz), 1.30 (6H, d, J = 6.7 Hz), 1.15 (2H, m), 1.08 (3H, t, J = 7.0 Hz), 0.90 (2H, m). 4-[4-(l-Ethoxycvcloρroρyl)-3-isoρroρyl-phenylethvnyl]-benzoic acid (Compound 101, General Formula 2) Using General Procedure I; A solution of ethyl 4-[4-(l- ethoxycyclopropyl)-3-isopropyl-phenylethynyl]-benzoate (Compound 99, 28.0 mg, 0.07 mmol) in ethanol (2 mL) and tetrahydrofuran (2 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 24 mg (92%) the title compound as a pale-yellow solid. Η NMR (d6-acetone) δ: 8.06 (2H, d, J = 8.2 Hz), 7.66 (2H, d, J = 8.2 Hz), 7.58 (IH, s), 7.33 (2H, m), 3.87 (IH, m), 2.27 (2H, q, J = 7.0 Hz), 1.26 (6H, d, J = 6.7 Hz), 1.09 (2H, m), 0.99 (3H, t, J = 7.0 Hz), 0.88 (2H, m). {4-[4-(l-Ethoxycyclopropyl)-3-isopropyl-ρhenylethynyl]-phenyl}-acetic acid (Compound 102, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- ethoxycycloproρyl)-3-isoρroρyl-phenylethynyl]-ρhenyl} -acetate (Compound 100, 130.0 mg, 0.35 mmol) in ethanol (5 mL) and tetrahydrofuran (5 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred at 50 °C for 4h. Work-up and isolation by HPLC (Partisil 10-pac, 10% H20/CH3CN) afforded 88.0 mg (70%) ofthe title compound. Η NMR (CDC13) δ: 7.50 (3H, m), 7.28-7.19 (4H, m), 3.82 (IH, m), 3.65 (2H, s), 3.29 (2H, q, J = 7.0 Hz), 1.25 (6H, d, J = 6.7 Hz), 1.14 (2H, m), 1.04 (3H, t, J = 7.0 Hz), 0.86 (2H, m). 4-Bromo-3-tβrt-butylphenol (Intermediate 104) To a mixture of 3-tert-butyl-methoxy benzene (1.00 g, 6.09 mmols) in CC14 (20 mL), molecular sieves, and silica gel was added N-bromosuccinimide (1.19 g, 6.70 mmols). This mixture was stirred at 55 °C for 48h. The resulting mixture was cooled to room temperature, filtered to remove the solids, and the filtrate diluted with EtOAc. This solution was washed with H20, 10% aqueous HCl, H20, saturated aqueous NaHC03 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. Column chromatography (2.5% EtOAc-hexanes) afforded 1.15 g (78%) of a 3 to 1 mixture of l-bromo-2-tert-butyl methoxy benzene and l-bromo-2- methoxy ~4-tert-butyl benzene as a colorless oil. A solution of the isomeric methoxy compounds in 10 mL of CH2C12 was cooled to 0 °C and treated with a solution (18.5 mL) of BBr3 in CH2C12 (4.63 g, 18.5 mmols). After 10 minutes the solution was warmed to room temperature, stirred for lh, and then quenched with H20. The mixture was extracted with EtOAc and the combined organic layers washed with saturated aqueous NaCl, dried (MgS04), and concentrated under reduced pressure. The title compound was isolated, 1.17 g (59%), by column chromatography (2.5- 5% EtOAc-hexanes). 'H NMR (CDC13) δ: 7.39 (IH, d, J = 8.5 Hz), 6.96 (IH, d, J = 2.9 Hz), 6.54 (IH, dd, J = 2.9, 8.5 Hz), 1.46 (9H, s). (4-Bromo-3-tert-butyl-phenoχyVtτiisopropyl-silane (Intermediate 105) To a solution of 4-bromo-3-tert-butylρhenol (Intermediate 104, 1.17 g, 5.10 mmols) and imidazole (520.0 mg, 7.65 mmols) in 10 mL DMF was added chloro-triisopropylsilane (1.18 g, 6.10 mmols). After stirring overnight at room temperature the solution was diluted wirth H20 and extracted with EtOAc. The combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound, 1.80 g (92%), was isolated by column cliromatography (0-1.5% EtOAc-hexanes) as a colorless oil. Η NMR (CDC13) δ: 7.38 (IH, d, J = 8.0 Hz), 6.97 (IH, d, J = 2.9 Hz), 6.56 (IH, dd, J = 2.9, 8.5 Hz), 1.47 (9H, s), 1.29-1.24 (3H, m), 1.09 (18H, d, J = 6.7 Hz). Ethyl 2-tgrt-butyl-4-triisopropylsilanyloxy-benzoate (Intermediate 106) To a solution of (4-bromo-3-tert-butyl-phenoxy)-triisoproρyl-silane (Intermediate 105, 1.00 g, 2.60 mmols) in 15 mL Et20 cooled to -78 °C was added 3.6 mL of tert-butyllithium, 1.7 M in pentane (395.0 mg, 6.2 mmols). After stirring for 30 minutes ethyl chloroformate (607.6 mg, 5.6 mmols) was added. The resulting solution was warmed to room temperature and quenched by the addition of saturated aqueous NH4C1. The mixture was extracted with EtOAc and the combined organic layers dried (MgS04) concentrated under reduced pressure The residue was chromatographed (2-5% EtOAc-hexanes) to give 1.23 g (88%) ofthe title compound as a colorless oil. 'H NMR (CDCI3) δ: 7.24 (IH, d, J = 8.2 Hz), 6.97 (IH, d, J = 2.6 Hz), 6.69 (IH, dd, J = 2.6, 8.2 Hz), 4.33 (2H, q, J = 7.1 Hz), 1.39 (9H, s), 1.37 (3H, t, J = 7.1 Hz), 1.29-1.21 (3H, m), 1.10 (18H, d, J = 6.7 Hz). 4-(l-EthoxwinylV3-tgrt-butyl-phenoxy]-triisopropyl-silane (Intermediate 107) Using General Procedure 1; ethyl 2-tert-butyl-4-triisopropylsilanyloxy- benzoate (Intermediate 106, 1.30 g, 3.44 mmols) and 7.2 mL of Tebbe's Reagent (1.03 g, 3.61 mmols) were reacted. The reaction required 7 days at room temperature to go to completion. The standard work-up afforded 1.29 g (78%) ofthe title compound after column chromatography (1-2% EtOAc- hexanes). Η NMR (CDCI3) δ: 7.05 (IH, d, J = 8.2 Hz), 6.94 (IH, d, J = 2.6 Hz), 6.63 (IH, dd, J = 2.6, 8.2 Hz), 4.20 (IH, d, J = 1.7 Hz), 4.08 (IH, d, J = 1.7 Hz), 3.83 (2H, q, J = 7.1 Hz), 1.37 (9H, s), 1.36 (3H, t, J = 7.1 Hz), 1.27-1.20 (3H, m), 1.10 (18H, d, J = 6.7 Hz). [4-(l-EthoxycvclopropylV3-tert-butyl-phenoxy]-triisopropyl-silane (Intermediate 108) Using General Procedure 2; [4-(l-ethoxyvinyl)-3-tert-butyl-phenoxy]- triisopropyl-silane (Intermediate 107, 320. 0 mg, 0.85 mmols), Et2Zn (325.0 mg, 2.63 mmols), and CH2I2 (704.0 mg, 2.63 mmols) in 5.0 mL Et20 afforded 257.0 mg (66%>) ofthe title compound as a colorless oil after chromatography (1-2.5% EtOAc - hexanes). Η NMR (CDC13) δ: 7.24 (IH, d, J = 8.5 Hz), 7.06 (IH, d, J = 2.6 Hz), 6.60 (IH, dd, J = 2.6, 8.5 Hz), 3.24 (2H, q, J = 7.1 Hz), 1.50 (9H, s), 1.29-1.21 (3H, m), 1.11 (18H, d, J = 6.7 Hz), 1.04 (3H, t, J = 7.1 Hz). 4-(l-EthoxycyclopropylV3-tert-butyl-phenol (Intermediate 109) To a solution of [4-(l-ethoxycyclopropyl)-3-tert-butyl-phenoxy]- triisopropyl-silane (Intermediate 108, 600.0 mg, 1.54 mmol) in 3 mL THF at 0 °C was added tetrabutylammonium fluoride (802.8.0 mg, 3.07 mmols; 3.1 mL of a 1 M solution in THF). The solution was stirred at 0 °C for 30 minutes and then quenched by the addition of H20. The mixture was extracted with EtOAc and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound (400 mg, 88%) was isolated from the residue by column chromatography (4-10% EtOAc-hexanes) as a colorless solid. Η NMR (CDC13) δ: 7.29 (IH, d, J = 8.2 Hz), 7.01 (IH, d, J = 2.6 Hz), 6.57 (IH, dd, J = 2.6, 8.2 Hz), 3.29 (2H, q, J = 7.1 Hz), 1.59 (9H, s), 1.08-1.04 (7H, m). 4-( 1 -Ethoxy cvclopropyD-3 -tβrt-butyl-phenyl 1.1.1 -trifluoromethansulfonate (Intermediate 110) A solution of 4-(l-ethoxycyclopropyl)-3-tert-butyl-ρhenol (Intermediate 109, 400.0 mg, 1.71 mmol) in 10 mL of CH2C12 was cooled to 0 °C and to it was added 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5- chloropyridine (705.0 mg, 1.79 mmol) and triethylamine (522.0 mg, 5.1 mmols). The resulting solution was warmed to room temperature and stirred overnight. The reaction was quenched by the addition of H20 and the mixture extracted with EtOAc and the combined organic layers were washed with 10% aqueous HCl, saturated aqueous NaHC03, H20, and saturated aqueous NaCl. The solution was dried (MgS04) and concentrated under reduced pressure. The title compound was isolated by column chiOmatography (2-4% EtOAc- hexanes) as a colorless oil, 542.0 mg (87%). 'H NMR (CDC13) δ: 7.48 (IH, d, J = 8.5 Hz), 7.39 (IH, d, J = 2.6 Hz), 7.01 (IH, dd, J = 2.6, 8.5 Hz), 3.26 (2H, q, J = 7.1 hz), 1.52 (9H, s), 1.12 (2H, bs), 1.08-1.04 (5H, m). [4-(l-Ethoxycyclopropyl)-3-tert-butyl-phenylethynyl]-trimethylsilane (Intermediate 111) Using General Procedure D; 4-(l-ethoxycyclopropyl)-3-tert-butyl- phenyl 1,1,1-trifluoromethansulfonate (Intermediate 110, 260.0 mg, 0.71 mmol) in triethylamine (4 mL) and DMF (6 mL) was sparged with argon for 5 minutes. Trimethylsilylacetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (40.0 mg, 0.06 mmol). The resulting reaction mixture was heated to 95 °C for 18 hours. The title compound, 215.0 mg (96%), was isolated by chromatography (0 - 2% EtOAc - hexanes) as an orange oil. Η NMR (CDCI3) δ: 7.63 (IH, d, J = 1.7 Hz), 7.32 (IH, d, J = 7.9 Hz), 7.19 (IH, dd, J = 1.7, 7.9 Hz), 3.24 (2H, q, J = 7.1 Hz), 1.51 (9H, s), 1.10 (2H, bs), 1.06-1.01 (5H, m), 0.25 (9H, s). 1 -( 1 -Ethoxycvclopropyl)-4-ethynyl-2-tert-butylbenzene (Intermediate 112) Using General Procedure E; [4-(l-ethoxycyclopropyl)-3-tert-butyl- phenylethynyl]-trimethylsilane (Intermediate 111, 215.0 mg, 0.69 mmol) in methanol (10 mL) was treated with potassium carbonate (80.0 mg, 0.58 mmol) and stirred overnight at ambient temperature. The crude alkyne, 169 mg, was used directly in the next reaction. 'H NMR (CDC13) δ: 7.68 (IH, d, J = 1.8 Hz), 7.36 (IH, d, J = 7.9 Hz), 7.23 (IH, dd, J = 1.8, 7.9 Hz), 3.26 (2H, q, J = 7.1 Hz), 3.06 (IH, s), 1.51 (9H, s), 1.11 (2H, bs), 1.07-1.02 (5H, m). Ethyl 4- 4-(l-ethoxycycloρropylV3-tert-butyl-phenylethynyll-benzoate (Compound 103, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2-tert- butylbenzene (Intermediate 112, 70.0 mg, 0.30 mmol) and ethyl-4-iodo benzoate (Reagent A, 85.0 mg, 0.30 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (19.0 mg, 0.01 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)-palladium(II) (70 mg, 0.01 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (1-2% EtOAc - hexanes) afforded 70.0 mg (73%) ofthe title compound. Η NMR (CDC13) δ: 8.02 (2H, d, J = 8.8 Hz), 7.72 (IH, d, J = 1.7 Hz), 7.59 (2H, d, J = 8.8 Hz), 7.40 (IH, d, J = 7.9 Hz), 7.28 (IH, dd, J = 1.7, 7.9 Hz), 4.39 ( 2H, q, J = 7.1 Hz), 3.28 (2H, q, J = 7.1 Hz), 1.55 (9H, s), 1.40 (3H, t, J = 7.1 Hz), 1.12 (2H, bs), 1.08-1.04 (5H, m). Methyl (4-r4-(l-ethoxycvclopropylV3-tert-butyl-ρhenylethynyl]-phenyll- acetate (Compound 104, General Formula 2) Using General Procedure F; l-(l-ethoxycyclopropyl)-4-ethynyl-2-tert- butylbenzene (Intermediate 112, 95.0 mg, 0.39 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 108.0 mg, 0.39 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (25.0 mg, 0.13 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (91 mg, 0.13 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-5% EtOAc - hexanes) afforded 100.0 mg (72%) ofthe title compound. 'H NMR (CDC13) δ: 7.70 (IH, d, J = 1.5 Hz), 7.50 (2H, d, J = 7.9 Hz), 7.38 (IH, d, J = 7.9 Hz), 7.27 (3H, m), 3.70 (3H, s), 3.64 (2H, s), 3.28 (2H, q, J = 7.1 Hz), 1.54 (9H, s), 1.12 (2H, bs), 1.08-1.03 (5H, m). 4- 4-( 1 -EthoxycvcloρropylV3-tert-butyl-ρhenylethvnyl]-benzoic acid (Compound 105, General Formula 2) Using General Procedure I; a solution of ethyl 4- [4-( 1 - ethoxycyclopropyl)-3-tert-butyl-phenylethynyl]-benzoate (Compound 103, 70.0 mg, 0.18 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (240.0 mg, 6.0 mmols, 3.0 mL of a 2N aqueous solution) and stirred overnight at room temperature. Work-up afforded 40 mg (62%) the title compound as a pale-yellow solid. Η NMR (d6-acetone) δ: 8.06 (2H, d, J = 8.7 Hz), 7.76 (IH, d, J = 1.8 Hz), 7.67 (2H, d, J = 8.7 Hz), 7.50 (IH, d, J = 7.9 Hz), 7.33 (IH, dd, J = 1.8, 7.9 Hz), 3.28 (2H, q, J = 7.3 Hz), 1.54 (9H, s), 1.13 (2H, bs), 1.10 (2H, m), 1.02 (3H, t, J = 7.3 Hz). (4-[4-(l-EthoxycyclopropylV3-tert-butyl-phenylethvnyll-phenyll-acetic acid (Compound 106, General Formula 2) Using General Procedure I; a solution of methyl {4-[4-(l- ethoxycycloproρyl)-3-tert-butyl-ρhenylethynyl]-phenyl} -acetate (Compound 104, 100.0 mg, 0.26 mmol) in ethanol (4 mL) and tetrahydrofuran (4 mL) was treated with NaOH (240.0 mg, 6.0 mmols, 3.0 mL of a 2N aqueous solution) and stirred at 50 °C for 4h. Work-up and isolation by HPLC (Partisil 10-pac, 10% H20/CH3CN) afforded 70.0 mg (73%) of the title compound. Η NMR (CDC13) δ: 7.73 (IH, d, J = 1.3 Hz), 7.53 (2H, d, J = 7.9 Hz), 7.41 (IH, d, J = 7.9 Hz), 7.28 (3H, m), 3.69 (2H, s), 3.31 (2H, q, J = 7.1 Hz), 1.56 (9H, s), 1.15 (2H, bs), 1.11-1.05 (5H, m). l-(4-BromophenylVcvclopropanecarbonitrile (Intermediate 113) To a 50%) aqueous NaOH solution (40.0 g, wt/wt) was added benzyl triethylammonium chloride ( 1.0 g, 4.4 mmols), 4-bromobenzonitrile ( 19.6 g, 0.10 mol), and 1 ,2-dibromoethane (56.4 g, 0.30 mol). The mixture was stirred overnight at room temperature and then diluted with 100 mL of H20. This mixture was extracted with EtOAc and the combined extracts were washed with saturated aqueous NaHS203, H20, and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. Bulb-to-bulb distillation afforded 18.8 g (85%) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 7.48 (2H, d, J = 8.6 Hz), 7.17 (2H, d, J = 8.6 Hz), 1.75 (2H, dd, J = 5.2, 7.6 Hz), 1.39 (2H, dd, J = 5.2, 7.6 Hz). 1 -(4-Bromoρhenyl)-cycloproρanecarboxylic acid (Intermediate 114) To a solution of KOH (6.06 g, 0.11 mol) in 10 mL of H20 was added 40 mL of ethylene glycol and l-(4-bromophenyl)-cyclopropanecarbonitrile (Intermediate 113, 10.0 g, 0.45 mol). This solution was heated to 135-140 °C for 4h, cooled to room temperature, and then poured into a mixture of 100 mL ice and 10% aqueous HCl. The resulting mixture was allowed to stand overnight at 5 °C, the solid was collected by filtration and washed with H20. The colorless solid was dried under reduced pressure to give 10.6 g (97%) of the title compound. Η NMR (CDC13) δ: 7.43 (2H, d, J = 8.5 Hz), 7.21 (2H, d, J = 8.5 Hz), 1.68 (2H, dd, J = 4.0, 7.1 Hz), 1.24 (2H, dd, J = 4.0, 7.1 Hz). Tert-butyl T 1 -(4-bromophenviy cvclopropyU-carbarnate (Intermediate 115) A solution of l-(4-bromophenyl)-cyclopropanecarboxylic acid (Intermediate 114, 2.32 g, 9.62 mmols), diphenylphosphoryl azide (2.65 g, 9.62 mmols), triethylamine (973.0 mg, 9.62 mmols) in 40 mL tert-BuOH (distilled from Na°) was heated to reflux for 17h. The solution was concentrated under reduced pressure and the residue dissolved in EtOAc and washed with 5% aqueous HCl, H20, saturated aqueous NaHC03, and saturated aqueous NaCl before being dried over MgS04. Concentration of the dry solution under reduced pressure and column chromatography (5-10% EtOAc - hexanes) afforded 2.01 g (67%>) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 7.39 (2H, d, J = 8.3 Hz), 7.08 (2H, d, J = 8.3 Hz), 5.35 (IH, bs), 1.43 (9H, s), 1.26 (2H, m), 1.17 (2H, m). l-(4-BromoρhenylVcycloproρylamine (Intermediate 116) To a solution of tert-butyl [ 1 -(4-bromoρhenyl)-cycloρropyl]-carbamate (Intermediate 115, 1.08 g, 3.40 mmols) in 20 mL MeOH and 20 mL THF was added 20 mL of 3M aqueous HCl. The solution was warmed to 35 °C for 3 hours and then stirred for 17h at 25 °C. The reaction was quenched by adjusting the pH ofthe solution to 12 with 3M aqueous NaOH. The mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound 613 mg (85%) was used without further purification. Η NMR (CDCI3) δ: 7.43 (2H, d, J = 8.3 Hz), 7.17 (2H, d, J = 8.3 Hz), 1.89 (2H, bs), 1.07 (2H, m), 0.95 (2H, m). 7V-[l-(4-bromophenyl)-cyclopropyl]-propionamide (Intermediate 117) To a solution of l-(4-bromophenyl)-cycloρroρylamine (Intermediate 116, 84 mg, 0.4 mmol) in 4 mL CH2C12 at room temperature was added propionyl chloride (43.0 mg, 0.47 mmol) and pyridine (56.0 mg, 0.71 mmol). After stirring 17 hours at room temperature the reaction was quenched by the addition of H20 and extracted with EtOAc. The combined extracts were washed with 10% aqueous HCl, saturated aqueous NaHC03, and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound 85.0 mg (67%), was isolated by column chromatography (20-50% EtOAc-hexanes) as a colorless solid. 'H NMR (CDC13) δ: 7.48 (2H, d, J = 8.5 Hz), 7.09 (2H, d, J = 8.5 Hz), 6.40 (IH, s), 2.19 (2H, q, J = 7.2 Hz), 1.18-1.24 (4H, m), 1.12 (3H, t, J = 7.2 Hz). [l-(4-BromoρhenylVcvcloρroρyl]-ρroρylamine (Intermediate 118) To a solution of N-[l-(4-bromophenyl)-cyclopropyl]-propionamide (Intermediate 117, 85.0 mg, 0.32 mmol) in THF (5 mL) at 0 °C was added BH3-Me2S (48.0 mg, 0.63 mmol; 0.31 mL of a 2M solution in THF). The solution was heated to 55 °C for 17 hours, cooled to room temperature, saturated aqueous NaHC03 was added and the resulting mixture was stirred for 2 hours. This mixture was extracted with EtOAc and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound was isolated by column chromatography (10-30% EtOAc-hexanes). Η NMR (CDC13) δ: 7.42 (2H, d, J = 8.5 Hz), 7.19 (2H, d, J = 8.5 Hz), 2.46 (2H, t, J = 7.3 Hz), 1.40 (2H, m), 0.98 (2H, m), 0.86 (5H, m). Propyl-[l-(4-trimethylsilanylethynyl-phenyl)-cyclopropyl]-amine (Intermediate 119) Using General Procedure D; [l-(4-bromophenyl)-cyclopropyl]- propylamine (Intermediate 118, 100.0 mg, 0.39 mmol) in triethylamine (8 mL) was treated with coρper(I)iodide (13.0 mg, 0.06 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis(triphenylρhosphine)ρalladium(II) (48.0 mg, 0.06 mmol). The resulting reaction mixture was heated to 70 °C for 5days. The title compound (80.0 mg, 75%) was isolated by chromatography (0 - 10% EtOAc - hexanes) as an orange oil. Η NMR (CDCI3) δ: 7.41 (2H, d, J = 8.5 Hz), 7.21 (2H, d, J = 8.5 Hz), 2.45 (2H, t, J = 7.3 Hz), 1.39 (2H, m), 0.98 (2H, m), 0.87 (2H, m), 0.84 (3H, t, J = 7.3 Hz), 0.24 (9H, s). [ 1 -(4-Ethynylphenyl)-cyclopropyl]-ρropylamine (Intermediate 120) Using General Procedure E; propyl- [ 1 -(4-frimethylsilanylethynyl- phenyl)-cycloρroρyl]-amine (Intermediate 119, 80.0 mg, 0.30 mmols) in methanol (8 mL) was treated with potassium carbonate (80.0 mg, 0.59 mmol) and stirred overnight at ambient temperature. The crude alkyne (58 mg, 100%) was used directly in the next reaction. Η NMR (CDC13) δ: 7.44 (2H, d, J = 8.5 Hz), 7.24 (2H, d, J = 8.5 Hz), 3.05 (IH, s), 2.46 (2H, t, J = 7.3 Hz), 1.41 (2H, m), 1.00 (2H, m), 0.90 (2H, m), 0.86 (3H, t, J = 7.3 Hz). Ethyl 4-[4-(l-propylamino-cyclopropyl)-phenylethvnyl]-benzoate (Compound 107, General Formula 2) Using General Procedure F; [l-(4-ethynylρhenyl)-cycloρroρyl]- propylamine (Intermediate 120, 38.0 mg, 0.19 mmol) and ethyl-4-iodo benzoate (Reagent A, 58.0 mg, 0.21 mmol) in triethyl amine (6 mL) was treated with copper(I)iodide (8.0 mg, 0.04 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (27 mg, 0.04 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (5-15% EtOAc - hexanes) afforded 40.0 mg (61%) ofthe title compound as an orange oil. Η NMR (CDCI3) δ: 8.01 (2H, d, J = 8.5 Hz), 7.57 (2H, d, J = 8.5 Hz), 7.49 (2H, d, J = 8.5 Hz), 7.28 (2H, d, J = 8.5 Hz), 4.39 (2H, q, J = 7.1 Hz), 2.49 (2H, t, J = 7.3 Hz), 1.46 (2H, m), 1.41 (3H, t, J = 7.1 Hz), 1.01 (2H, m), 0.89 (2H, m), 0.87 (3H, t, J = 7.3 Hz). 4-[4-( 1 -Propylamino-cyclopropyl)-phenylethynyl]-benzoic acid (Compound 108, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l-propylamino- cycloρropyl)-phenylethynyl]-benzoate (Compound 107, 40.0 mg, 0.12 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (160.0 mg, 4.0 mmols, 2.0 mL of a 2N aqueous solution) and stirred overnight at room temperature. Work-up afforded 25.0 mg (69%) of the title compound as a solid. Η NMR (d6-DMSO) δ: 7.97 (2H, d, J = 8.5 Hz), 7.65 (2H, d, J = 8.5 Hz), 7.50 (2H, d, J = 8.5 Hz), 7.36 (2H, d, J = 8.5 Hz), 2.39 (2H, t, J = 7.3 Hz), 1.37 (2H, m), 1.00 (2H, m), 0.93 (2H, m), 0.84 (3H, t, J = 7.3 Hz). [ 1 -(4-BromoρhenylV cvcloρroρyl]-diρropylamine (Intermediate 121) To a solution of l-(4-bromoρhenyl)-cycloρroρylamine (Intermediate 116) in CH3CN / HO Ac (5 mL, 9:1 , v/v) and THF 3 mL at 0 °C was added propionaldehyde (277.0 mg, 4.95 mmols) and NaCNBH3 (153.0 mg, 2.47 mmols). The reaction was warmed to room temperature and after 5hours quenched with H20. The pH ofthe solution was adjusted to 8-9 using aqueous NaOH and extracted with EtOAc. The combined extracts were washed with H20 and saturated aqueous NaCl, dried (MgS04) and concentrated under reduced pressure. The title compound, 190.0 mg (56%), was isolated by column chromatography (2-5% EtOAc-hexanes). 'H NMR (CDC13) δ: 7.42 (2H, d, J = 8.3 Hz), 7.18 (2H, d, J = 8.3 Hz), 2.39 (4H, t, J = 7.3 Hz), 1.62-1.40 (4H, m), 0.96 (2H, m), 0.86 (6H, t, J = 7.3 Hz), 0.80 (2H, m). Dipropyl-[l-(4-trimethylsilanylethynyl-phenyl -cvclopropyll-amine (Intermediate 122) Using General Procedure D; [l-(4-bromophenyl)-cycloproρyl]- dipropylamine (Intermediate 121, 150.0 mg, 0.50 mmol) in triethylamine (5 mL) was treated with copρer(I)iodide (10.0 mg, 0.05 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (35.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound was isolated by chromatography (0 - 3% EtOAc - hexanes). 'H NMR (CDC13) δ: 7.35 (2H, d, J = 8.3 Hz), 7.24 (2H, d, J = 8.3 Hz), 2.39 (4H, t, J = 7.3 Hz), 1.55-1.42 (4H, m), 0.96 (2H, m), 0.88-0.79 (8H, m), 0.25 (9H, s). [ 1 -(4-EthynylρhenylVcvclopropyll-diρroρylamine (Intermediate 123) Using General Procedure E; diρroρyl-[l-(4-frimethylsilanylethynyl- ρhenyl)-cycloρroρyl]-amine (Intermediate 122, 45.0 mg, 0.14 mmols) in methanol (5 mL) was treated with potassium carbonate (50.0 mg, 0.37 mmol) and stirred overnight at ambient temperature. The crude alkyne (34 mg, 100%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.42 (2H, d, J = 8.3 Hz), 7.28 (2H, d, J = 8.3 Hz), 2.40(4H, t, J = 7.3 Hz), 1.53-1.40 (4H, m), 0.96 (2H, m), 0.90-0.79 (8H, m). Ethyl 4-[4-(l-dipropylamino-cyclopropyl)-phenylethynyl]-benzoate (Compound 109, General Formula 2) Using General Procedure F; [l-(4-ethynylphenyl)-cyclopropyl]- dipropylamine (Intermediate 123, 34.0 mg, 0.16 mmol) and ethyl-4-iodo benzoate (Reagent A, 59.0 mg, 0.21 mmol) in triethyl amine (6 mL) was treated with copρer(I)iodide (13.0 mg, 0.07 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylρhosphine)palladium(II) (49 mg, 0.07 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded the title compound as a yellow oil. <H NMR (CDCI3) δ: 8.03 (2H, d, J = 8.2 Hz), 7.58 (2H, d, J = 8.2 Hz), 7.49 (2H, d, J = 8.2 Hz), 7.30 (2H, d, J = 8.2 Hz), 4.39 (2H, q, J = 7.1 Hz), 2.43 (4H, t, J = 7.3 Hz), 1.52-1.42 (4H, m), 1.41 (3H, t, J = 7.1 Hz), 0.99 (2H, m), 0.88-0.83 (8H, m). 4-[4-(l-Dipropylamino-cyclopropyl)-phenylethynyl]-benzoic acid (Compound 110, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l -dipropylamino- cycloproρyl)-phenylethynyl]-benzoate (Compound 109, 51.0 mg, 0.13 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 32.0 mg (70%) ofthe title compound as a colorless solid. 'H NMR (d6-DMSO) δ: 7.98 (2H, d, J = 8.3 Hz), 7.67 (6H, m), 3.05-2.89 (4H, m), 1.98 (2H, m), 1.72 (4H, m), 1.23 (2H, m), 0.88 (6H, t, J = 7.3 Hz). Benzyl-[l-(4-bromophenyl)-cyclopropyl]-amine (Intermediate 124) and Dibenzyl- 1 -(4-bromophenylVcyclopropyl]-amine (Intermediate 125) A solution of l-(4-bromophenyl)-cyclopropylamine (Intermediate 116, 244.0 mg, 1.15 mmols) and benzyl bromide (255.0 mg, 1.50 mmols) in 4 mL DMF was stirred at 85 °C for 6 hours, cooled to room temperature and stirred overnight. The solution was diluted with H20 and the pH adjusted to 8-9 with aqueous NaOH. The solution was extracted with EtOAc and the combined organic layers were washed with H20 and saturated aqueous NaCl, dried (MgS04) and concentrated under reduced pressure. Column chromatography (5-10% EtOAc-Hexanes) afforded 110 mg (32%) ofthe N-benzyl amine. 'H NMR (CDC13) δ: 7.48 (2H, d, J = 8.4 Hz), 7.30-7.23 (7H, m), 3.68 (2H, s), 1.07 (2H, m), 0.93 (2H, m); and 100 mg (22%) ofthe NN-dibenzyl amine, Η NMR (CDCI3) δ: 7.55 (2H, d, J = 8.3 Hz), 7.40-7.19 (12H, m), 3.61 (4H, s), 0.87 (2H, m), 0.71 (2H, m). Benzyl-[l-(4-trimethylsilanylethynyl-phenylVcvcloρroρyl]-amine (Intermediate 126) Using General Procedure D; benzyl-[l-(4-bromophenyl)-cyclopropyl]- amine (Intermediate 124, 110.0 mg, 0.36 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (10.0 mg, 0.05 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (38.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 70 °C for 5 d. The title compound 85 mg (74%) was isolated by chromatography (1 - 10% EtOAc - hexanes). Η NMR (CDC13) δ: 7.46 (2H, d, J = 8.3 Hz), 7.31 -7.22 (7H, m), 3.67 (2H, s), 1.06 (2H, m), 0.94 (2H, m), 0.26 (9H, s). Benzyl-ι rl-(4-ethynylρhenylVcvcloρroρyl]-amine (Intermediate 127) Using General Pocedure E; benzyl-[l-(4-trimethylsilanylethynyl- phenyl)-cyclopropyl]-amine (Intermediate 126, 85.0 mg, 0.27 mmol) in methanol (5 mL) was treated with potassium carbonate (50.0 mg, 0.37 mmol) and stirred overnight at ambient temperature. The crude alkyne (65 mg, 100%) was used directly in the next reaction. >H NMR (CDCI3) δ: 7.49 (2H, d, J = 7.9 Hz), 7.32 (2H, d, J = 7.9 Hz), 7.23 (5H, m), 3.68 (2H, s), 3.08 (IH, s), 1.07 (2H, m), 0.95 (2H, m). Ethyl 4- [4-( 1 -benzylamino-cyclopropyl)-phenylethynyl] -benzoate (Compound 111, General Formula 2) Using General Procedure F; benzyl-[l-(4-ethynylphenyl)-cyclopropyl]- amine (Intermediate 127, 65.0 mg, 0.27 mmol) and ethyl-4-iodo benzoate (Reagent A, 68.0 mg, 0.27 mmol) in triethyl amine (8 mL) was treated with copper(I)iodide (16.0 mg, 0.08 mmol) and sparged with argon for 5 minutes. Dichlorobis (triphenylphosρhine)ρalladium(II) (58 mg, 0.08 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-5% EtOAc - hexanes) afforded 90 mg (90%) of the title compound as an orange solid. Η NMR (CDCI3) δ: 8.05 (2H, d, J = 8.3 Hz), 7.61 (2H, d, J = 8.3 Hz), 7.55 (2H, d, J = 8.1 Hz), 7.43 (2H, d, J = 8.1 Hz), 7.32-7.22 (5H, m), 4.40 (2H, q, J = 7.1 Hz), 3.72 (2H, s), 1.42 (2H, t, J = 7.1 Hz), 1.01 (2H, m), 0.99 (2H, m). 4-[4-(l-Benzylamino-cyclopropyl)-phenylethynyl]-benzoic acid (Compound 112, General Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l -benzylamino- cycloproρyl)-phenylethynyl]-benzoate (Compound 111, 75.0 mg, 0.19 mmol) in ethanol (4 mL) and tetrahydrofuran (4 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 35.0 mg (50%) of the title compound as a colorless solid. Η NMR (CD3OD) δ: 7.93 (2H, d, J = 8.3 Hz), 7.61-7.51 (6H, m), 7.32-7.23 (5H, m), 3.98 (2H, s), 1.33(2H, m), 1.19 (2H, m). Dibenzyl-fl-(4-trimethylsilanylethvnyl-pheny -cvclopropyl]-amine (Intermediate 128) Using General Procedure D; dibenzyl-[l-(4-bromophenyl)- cyclopropyl]-amine (Intermediate 125, 45.0 mg, 0.11 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (10.0 mg, 0.05 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.35 g, 3.6 mmols) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (35.0 mg, 0.05 mmol). The resulting reaction mixture was heated to 70 °C for 5d. The title compound 40 mg (88%) was isolated by chromatography (hexanes). Η NMR (CDCI3) δ: 7.52 (2H, d, J = 8.3 Hz), 7.36-7.24 (12H, m), 3.60 (4H, s), 0.87 (2H, m), 0.67 (2H, m), 0.29 (9H, s). Dibenzyl-[l-(4-ethynylρhenylVcyclopropyl]-amine (Intermediate 129) Using General Procedure E; dibenzyl-[l-(4-trimethylsilanylethynyl- phenyl)-cyclopropyl]-amine (Intermediate 128, 100.0 mg, 0.26 mmol) in methanol (5 mL) was treated with potassium carbonate (60.0 mg, 0.44 mmol) and stirred overnight at ambient temperature. The crude alkyne (80 mg, 99%) was used directly in the next reaction. 'H NMR (CDCI3) δ: 7.53 (2H, d, J = 7.9 Hz), 7.36 (2H, d, J = 7.9 Hz), 7.28- 7.25 (10H, m), 3.62 (4H, s), 3.11 (IH, s), 0.88 (2H, m), 0.68 (2H, m). Ethyl 4T4-( 1 -dibenzylamino-cvcloρropylVphenylethvnyl]-benzoate (Compound 113, General Formula 2) Using General Procedure F; dibenzyl-[l-(4-ethynylρhenyι)- cycloproρyl]-amine (Intermediate 129, 40.0 mg, 0.12 mmol) and ethyl-4-iodo benzoate (Reagent A, 60.0 mg, 0.22 mmol) in triethylamine (5 mL) was treated with coρper(I)iodide (8.0 mg, 0.04 mmol) and sparged with argon for 5 minutes. Dichlorobis (triphenylphosphine)palladium(II) (27 mg, 0.04 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-5% EtOAc - hexanes) afforded the title compound as an oil. Η NMR (CDC13) δ: 8.04 (2H, d, J = 8.5 Hz), 7.79 (4H, m), 7.42 (2H, d, J = 7.9 Hz), 7.29-7.17 (10H, m), 4.40 (2H, q, J = 7.1 Hz), 3.63 (4H, s), 1.42 (3H, t, J = 7.1 Hz), 0.88 (2H, m), 0.73 (2H, m). 4-[4-(l-Dibenzylamino-cycloproρyl)-phenylethynyl]-benzoic acid (Compound 114, Formula 2) Using General Procedure I; a solution of ethyl 4-[4-(l-dibenzylamino- cycloρropyl)-phenylethynyl]-benzoate (Compound 113, 48.0 mg, 0.10 mmol) in ethanol (2 mL) and tetrahydrofuran (2 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 42.0 mg (93%) ofthe title compound as a colorless solid. Η NMR (d6-DMSO) δ: 7.98 (2H, d, J = 8.2 Hz), 7.67 (2H, d, J = 8.2 Hz), 7.64 (2H, d, J = 7.9 Hz), 7.47 (2H, d, J = 7.9 Hz), 7.28-7.20 (10H, m), 3.57 (4H, s), 0.84 (2H, m), 0.69 (2H, m). Benzyl-[ 1 -(4-bromophenylVcvclopropyl]-methylamine (Intermediate 130) To a solution of benzyl-[l-(4-bromophenyl)-cyclopropyl]-amine (Intermediate 124, 100.0 mg, 0.33 mmol) in 5 mL of acetone was added K2C03 (91 mg, 0.66 mmol) and iodomethane (2.28 g, 16.1 mmols). The resulting mixture was stirred at 25 °C for 20 hours, diluted with Et20, and washed with H20 and saturated aqueous NaCl. The solution was dried (MgS04) and concentrated under reduced pressure to give 90 mg (86%) of the title compound. Η NMR (CDC13) δ: 7.47 (2H, d, J = 8.5 Hz), 7.29-7.18 (7H, m), 3.53 (2H, s), 2.07 (3H, s), 1.07 (2H, m), 0.86 (2H, m). Benzyl- l-(4-trimethylsilanylethvnyl-phenylVcvcloρroρyl]-methylamine (Intermediate 131) Using General Procedure D; benzyl-[l-(4-bromophenyl)-cycloproρyl]- methylamine (Intermediate 130, 90.0 mg, 0.28 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (6.0 mg, 0.03 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.70 g, 7.1 mmols) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (20.0 mg, 0.03 mmol). The resulting reaction mixture was heated to 70 °C for 5 days. The title compound 80 mg (84%) was isolated by chromatography (0- 2% EtOAc-hexanes). Η NMR (CDC13) δ: 7.46 (2H, d, J = 8.2 Hz), 7.32-7.18 (7H, m), 3.52 (2H, s), 2.06 (3H, s), 1.06 (2H, m), 0.87(2H, m), 0.26 (9H, s). Benzyl- 1 -(4-ethvnylρhenylV cyclopropyl]-methylamine (Intermediate 132) Using General Procedure E; benzyl- [ 1 -(4-trimethylsilanylethynyl- ρhenyl)-cyclopropyl]-methylamine (Intermediate 131, 80.0 mg, 0.24 mmol) in methanol (5 mL) was treated with potassium carbonate (80.0 mg, 0.59 mmol) and stirred overnight at ambient temperature. The crude alkyne (60 mg, 99%) was used directly in the next reaction. Η NMR (CDC13) δ: 7.49 (2H, d, J = 8.2 Hz), 7.33-7.21 (7H, m), 3.55 (2H, s), 3.08 (IH, s), 2.08 (3H, s), 1.07 (2H, m), 0.89 (2H, m). Ethyl 4- {4-f 1 -(benzyl-methylamino -cyclopropyl]-ρhenylethynyl} -benzoate (Compound 115, General Formula 2) Using General Procedure F; benzyl-[l -(4-ethynylρhenyl)-cyclopropyl]- methylamine (Intermediate 132, 70.0 mg, 0.28 mmol) and ethyl-4-iodo benzoate (Reagent A, 77.0 mg, 0.28 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (18.0 mg, 0.10 mmol) and sparged with argon for 5 minutes. Dichlorobis (triphenylphosphine)ρalladium(II) (65 mg, 0.10 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column cliromatography (2-5% EtOAc - hexanes) afforded 86 mg (75%) of the title compound as an oil. Η NMR (CDC13) δ: 8.03 (2H, d, J = 8.5 Hz), 7.59 (2H, d, J = 8.5 Hz), 7.53 (2H, d, J = 8.2 Hz), 7.36 (2H, d, J = 8.2 Hz), 7.25 (5H, m), 4.39 (2H, q, J = 7.1 Hz), 3.57 (2H, s), 2.10 (3H, s), 1.41 (3H, t, J = 7.1 Hz), 1.10 (2H, m), 0.92 (2H, m). 4- [4-( 1 -Benzylmethylamino-cvclopropylVphenylethvnyl] -benzoic acid (Compound 116, General Formula 2) Using General Procedure I; a solution of ethyl 4- {4- [ 1 -(benzyl- methylamino)-cycloproρyl]-phenylethynyl}-benzoate (Compound 115, 65.0 mg, 0.16 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 45.0 mg (75%) of the title compound as a solid. Η NMR (d6-DMSO) δ: 7.96 (2H, d, J = 8.3 Hz), 7.66 (2H, d, J = 8.3 Hz), 7.58 (2H, d, J = 8.2 Hz), 7.42 (2H, d, J = 8.2 Hz), 7.29-7.18 (5H, m), 3.52 (2H, s), 2.00 (3H, s),1.02 (2H, m), 0.87 (2H, m). (4-Bromo-2-methyl-phenyl)-methanol (Intermediate 133) A solution of methyl 4-bromo-2-methyl-benzoate (1.05 g, 4.58 mmols) in 10 mL of Et20 was cooled to 0 °C and treated with LiAlH4 (177.0 mg, 4.58 mmols), stirred for 3 hours, and then carefully quenched with H20. The mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl, dried (MgS04), and concentrated under reduced pressure. The title compound, 830.0 mg (90%), was isolated by column chromatography (10-30% EtOAc-hexanes) as a colorless oil. 'H NMR (CDC13) δ: 7.30 (2H, m), 7.18 (IH, d, J = 8.8 Hz), 4.57 (2H, d, J = 5.5 Hz), 2.27 (3H, s), 2.13 (IH, t, J = 5.5 Hz). (4-Bromo-2-methyl-benzyloxy -trimethylsilane (Intermediate 134) To a solution of (4-bromo-2-methyl-ρhenyl)-methanol (Intermediate 133, 500.0 mg, 2.48 mmols), in 10 mL THF was added triethylamine (374.0 mg, 3.70 mmols) and chlorotrimethylsilane (297.0 mg, 2.70 mmols). The resulting solution was stirred for 17 hours at 25 °C and then treated with H20 and extracted with Et20. The combined organic layers were washed with H20, 10% aqueous HCl, saturated NaHC03, and saturated NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound, 550.0 mg (81%)), was isolated by column chromatography (5% EtOAc-hexanes) as a colorless oil. Η NMR (CDC13) δ: 7.35-7.28 (3H, m), 4.64 (2H, s), 2.29 (3H, s), 0.20 (9H, s). 2-Methyl-4-trimethylsilanylethynyl-l-trimethylsilanyloxymethyl-benzene (Intermediate 135) Using General Procedure D; (4-bromo-2-methyl-benzyloxy)- trimethylsilane (Intermediate 134, 550.0 mg, 2.01 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (38.0 mg, 0.20 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (1.05 g, 10.6 mmols) was then added followed by dichlorobis(triphenylρhosρhine)palladium(II) (142.0 mg, 0.20 mmol). The resulting reaction mixture was heated to 70 °C for 5 days. The title compound (380.0 mg, 65%) was isolated by chromatography (0 - 2% EtOAc - hexanes) as an orange oil. 'H NMR (CDC13) δ: 7.31 (3H, m), 4.64 (2H, s), 2.24 (3H, s), 0.24 (9H, s), 0.15 (9H, s). (4-Ethvnyl-2-methyl-phenylVmethanol (Intermediate 136) Using General Procedure E; 2-methyl-4-trimethylsilanylethynyl- 1 - trimethylsilananyloxymethyl-benzene (Intermediate 135, 380.0 mg, 1.30 mmols) in methanol (10 mL) was treated with potassium carbonate (180.0 mg, 1.3 mmol) and stirred overnight at ambient temperature. The crude alkyne was purified by column chromatography (5-20% EtOAc-hexanes) to give 100.0 mg (34%.) ofthe title compound. Η NMR (CDCI3) δ: 7.06 (3H, m), 4.42 (2H, d, J = 5.2 Hz), 2.81 (IH, s), 2.05 (3H, s), 1.59 (IH, t, J = 5.2 Hz). Ethyl 4-(4-hydroxymethyl-3-methyl-phenylethynyl -benzoate (Compound 117, General Formula 6) Using General Procedure F; (4-ethynyl-2-methyl-phenyl)-methanol (Intermediate 136, 100.0 mg, 0.44 mmol) and ethyl-4-iodo benzoate (Reagent A, 125.0 mg, 0.45 mmol) in triethyl amine (4 mL) was treated with copper(I)iodide (29 mg, 0.15 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (102 mg, 0.15 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (20-40% EtOAc - hexanes) afforded 130.0 mg (99%) of the title compound as an orange solid. 'H NMR (CDCI3) δ: 7.98 (2H, d, J = 8.2 Hz), 7.56 (2H, d, J = 8.2 Hz), 7.36 (3H, m), 4.65 (2H, s), 4.36 (2H, q, J = 7.1 Hz), 2.40 (IH, s), 2.30 (3H, s), 1.39 (3H, t, J = 7.1 Hz). Ethyl 4-(4-bromomethyl-3-methyl-phenylethynylVbenzoate (Intermediate 137) A solution of ethyl 4-(4-hydroxymethyl-3-methyl-phenylethynyl)- benzoate (Compound 117, 130.0 mg, 0.44 mmol) and triphenylphosphine (150.0 mg, 0.57 mmol) in 5 mL CH2C12 was cooled to 0 °C and N- bromosuccinimide (101.0 mg, 0.57 mmol) was added in 5 portions over 20 minutes. The solution was warmed to 25 °C and stirred for 17 hours. The reaction was quenched by the addition of dilute aqueous NaHC03. The resulting mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (Na2S04) and concentrated under reduced pressure. The title compound, 120.0 mg (76%), was isolated by column chromatography (2-5% EtOAc-hexanes) as a colorless solid. 'H NMR (CDC13) δ: 8.01 (2H, d, J = 8.1 Hz), 7.56 (2H, d, J = 8.1 Hz), 7.32 (3H, m), 4.48 (2H, s), 4.38 (2H, q, J = 7.1 Hz), 2.40 (3H, s), 1.39 (3H, t, J = 7.1 Hz). Ethyl 4-(4-imidazol- 1 -yl-methyl-3-methyl-phenylethynyl -benzoate (Compound 118, General Formula 6) A solution of imidazole (30.0 mg, 0.44 mmol) in 2 mL DMF was treated with NaH (11.0 mg, 0.44 mmol) and heated to 90 °C. After lh a solution of ethyl 4-(4-bromomethyl-3 -methyl-phenylethynyl)-benzoate (Intermediate 137, 120.0 mg, 0.34 mmol) in 2 mL DMF was added and stirring at 90 °C continued for 1 hour. The solution was cooled to room temperature and concentrated under reduced pressure. The title compound, 90.0 mg (71 %) was isolated by column cliromatography (20- 100% EtOAc- hexanes) as a colorless solid. Η NMR (CDC13) δ: 8.02 (2H, d, J = 8.5 Hz), 7.57 (2H, d, J = 8.5 Hz), 7.51 (IH, s), 7.40 (IH, s), 7.36 (IH, dd, J = 1.2, 7.9 Hz), 7.10 (IH, s), 6.93 (IH, d, J = 7.9 Hz), 6.88 (IH, t, J = 1.7 Hz), 5.12 (2H, s), 4.38 (2H, q, J = 7.1 Hz), 2.27 (3H, s), 1.40 (3H, t, J = 7.1 Hz). 4-(4-Imidazol- 1 -yl-methyl-3-methyl-phenylethynyl)-benzoic acid (Compound 119, General Formula 6) Using General Procedure I; a solution of ethyl 4-(4-imidazol- 1 - ylmethyl-3-methyl-phenylethynyl)-benzoate (Compound 118, 82.0 mg, 0.24 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 51.0 mg (68%) of the title compound as a solid. Η NMR (d6-DMSO) δ: 9.20 (IH, s), 7.97 (2H, d, J = 8.2 Hz), 7.73 (2H, m), 7.65 (2H, d, J = 8.2 Hz), 7.52 (IH, s), 7.46 (IH, d, J = 7.9 Hz), 7.13 (IH, d, J = 7.9 Hz), 5.50 (2H, s), 2.32 (3H, s). 4-Bromo- 1 -bromomethyl-2-methyl-benzene (Intermediate 138) A solution of (4-bromo-2-methyl-ρhenyl)-methanol (Intermediate 133, 319.0 mg, 1.58 mmol) and tiiphenylphosphine (466.0 mg, 1.74 mmol) in 5 mL CH2C12 was cooled to 0 °C and Λ^-bromosuccinimide (309.0 mg, 1.74 mmol) was added in 5 portions over 20 minutes. The solution was warmed to 25 °C and stirred for 17 hours. The reaction was quenched by the addition of dilute aqueous NaHC03. The resulting mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (Na2S0 ) and concentrated under reduced pressure. The title compound, 350.0 mg (84%), was isolated by column chromatography (2- 3% EtOAc-hexanes) as a colorless oil. Η NMR (CDC13) δ: 7.32 (IH, d, J = 2.0 Hz), 7.29 (IH, dd, J = 2.0, 7.9 Hz), 7.15 (IH, d, J = 7.9 Hz), 4.43 (2H, s), 2.37 (3H, s). 1 -(4-Bromo-2-methyl-benzyiy lH-imidazole (Intermediate 139) A solution of imidazole (58.0 mg, 0.86 mmol) in 3 mL DMF was treated with NaH (20.0 mg, 0.86 mmol) and heated to 90 °C. After lh a solution of 4-bromo- l-bromomethyl-2-methyl-benzene (Intermediate 138, 190.0 mg, 0.72 mmol) in 3 mL DMF was added and stirring at 90 °C continued for lhour. The solution was cooled to room temperature and concentrated under reduced pressure. The title compound, 160.0 mg (88%) was isolated by column chromatography (5% MeOH-EtOAc) as a colorless solid. !H NMR (CDC13) δ: 7.46 (IH, s), 7.34 (IH, dd, J = 1.8 Hz), 7.30 (IH, dd, J = 1.8, 8.2 Hz), 7.08 (IH, t, J = 1.2 Hz), 6.83 (IH, t, J = 1.2 Hz), 6.80 (IH, d, J = 8.2 Hz), 5.03 (2H, s), 2.23 (3H, s). 1 -(2-Methyl-4-trimethylsilanylethvnyl-benzylV IH-imidazole (Intermediate 140) Using General Procedure D; l-(4-bromo-2-methyl-benzyl)-lH- imidazole (Intermediate 139, 160.0 mg, 0.64 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (12.0 mg, 0.07 mmol) and then sparged with argon for 5 minutes. Trimethylsilyl acetylene (0.70 g, 0.71 mmols) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (45.0 mg, 0.07 mmol). The resulting reaction mixture was heated to 70 °C for 5 days. The title compound (140.0 mg, 82%) was isolated by chromatography (5% MeOΗ-EtOAc ) as an orange oil. 'Η NMR ^DCy δ: 7.53 (1Η, s), 7.38 (1Η, s), 7.34 (1Η, d, J = 8.0 Ηz), 7.15 (1Η, s), 6.94 (1Η, s), 6.91 (1Η, d, J = 8.0 Ηz), 5.14 (2Η, s), 2.29 (3H, s), 0.31 (9H, s). 1 -(4-Ethynyl-2-methyl-benzylV IH-imidazole (Intermediate 141) Using General Procedure E; l-(2-methyl-4-trimethylsilanylethynyl- benzyl)- IH-imidazole (Intermediate 140, 140.0 mg, 0.53 mmols) in methanol (5 mL) was treated with potassium carbonate (100.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne (105 mg, 100%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.49 (1Η, s), 7.35 (1Η, s), 7.31 (1Η, dd, J = 1.7, 7.9 Ηz), 7.10 (1Η, s), 6.69 (1Η, d, J = 7.9 Ηz), 6.85 (1Η, t, J = 1.2 Ηz), 5.14 (2Η, s), 3.08 (IH, s), 2.26 (3H, s). Methyl [4-(4-imidazol-l-yl-methyl-3-methyl-phenylethvnylVρhenyl]-acetate (Compound 120, General Formula 6) Using General Procedure F; l-(4-ethynyl-2-methyl-benzyl)-lH- imidazole (Intermediate 141, 101.0 mg, 0.53 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 145.0 mg, 0.53 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (34.0 mg, 0.18 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (124 mg, 0.18 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (5% MeOΗ-EtOAc) afforded 45.0 mg (25%>) ofthe title compound as an orange oil. 'Η NMR (CDC13) δ: 7.47 (3Η, m), 7.35 (3H, m), 7.27 (3H, m), 6.91 (IH, d, J = 7.3 Hz), 5.11 (2H, s), 3.70 (3H, s), 3.64 (2H, s), 2.26 (3H, s). [4-(4-Imidazol- 1 -yl-methyl-3-methyl-phenylethynyl)-phenyl]-acetic acid (Compound 121, General Formula 6) Using General Procedure I; a solution of methyl [4-(4-imidazol- 1 - ylmethyl-3-methyl-ρhenylethynyl)-ρhenyl]-acetate (Compound 120, 45.0 mg, 0.13 mmol) in ethanol (2 mL) and tetrahydrofuran (2 mL) was treated with NaOH (80.0 mg, 2.0 mmols, 2.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 30.0 mg (70%) of the title compound as a pale-orange solid. 'H NMR (d4-MeOH) δ: 8.97 (IH, s), 7.60 (2H, d J = 8.8 Hz), 7.47 (3H, m), 7.41 (IH, d, J = 7.9 Hz), 7.30 (2H, d, J = 7.9 Hz), 7.23 (IH, d, J = 7.9 Hz), 5.51 (2H, s), 3.64 (2H, s), 2.33 (3H, s). 1 -Isoρroρyl-3-methoxy-benzene (Intermediate 142) To a solution of 3-isopropyl-ρhenol (5.00 g, 36.2 mmols) in 50 mL of acetone was added K2C03 (7.50 g, 54.3 mmols) and iodomethane (10.3 g, 72.5 mmols). The resulting solution was heated to 50 °C and stirred for 18 hours, cooled to room temperature, and concentrated under reduced pressure. The residual oil was dissolved in Et20 and washed with H20, saturated aqueous NaHC03, and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The crude methyl ether was used without further purification. Η NMR (CDC13) δ: 7.22 (IH, t, J = 8.1 Hz), 6.84-6.72 (3H, m), 3.81 (3H, s), 2.88 (IH, septet, J = 7.0 Hz), 1.25 (6H, d, J = 7.0 Hz). l-Bromo-2-isoρropyl-4-methoxy-benzene (Intermediate 143) A mixture of l-isopropyl-3-methoxy-benzene (Intermediate 142, 3.50 g, 23.3 mmols), molecular sieves, and silica gel in 150 mL CC14 was treated with N-bromosuccinimide (4.98 g, 28.0 mmols) at 35 °C for 18 hours. An additional portion of N-bromosuccinimide (830.0 mg, 4.46 mmols) was added and stirring continued for 6 hours. The mixture was cooled to room temperature, H20 was added, and the mixture was filtered to remove the solids. The mixture was extracted with E20 and the combined organic layers were washed with 10% aqueous HCl, H20, saturated aqueous ΝaHC03, and saturated NaCl before being dried (MgS04) and concentrated under reduced pressure. Column chromatography (2.5% EtOAc-hexanes) afforded 4.34 g (81 %) of the title compound as a pale-yellow oil. Η NMR (CDCI3) δ: 7.41 (IH, d, J = 8.8 Hz), 6.82 (IH, d, J = 2.6 Hz), 6.61 (IH, dd, J - 2.6, 8.8 Hz), 3.79 (3H, s), 3.31 (IH, septet, J = 6.7 Hz), 1.23 (6H, d, J = 6.7 Hz). 4-Bromo-3-isopropyl-phenol (Intermediate 144) To a solution of l-bromo-2-isopropyl-4-methoxy-benzene (Intermediate 143, 2.20 g, 9.60 mmols) in 50 mL CH2C12 at -78 °C was added BBr3 (4.81 g, 19.2 mmols; 19.2 mL of a IM solution in CH2C12). After stirring for 3 hours at -78 °C the solution was warmed to 0 °C for 3 hours and then at 25 °C for 1 hour before being quenched with H20. The mixture was diluted with Et20 and washed with H20 and saturated aqueous NaCl, dried (Na2S04) and concentrated under reduced pressure. Column chromatography (2.5-10% EtOAc-hexanes) afforded the title compound as a colorless oil. 'H NMR (CDC13) δ: 7.38 (IH, d, J = 8.5 Hz), 6.79 (IH, d, J = 2.9 Hz), 6.57 (IH, dd, J = 2.9, 8.5 Hz), 3.31 (IH, septet, J = 7.0 Hz), 1.22 (6H, d, J = 7.0 Hz). (4-Bromo-3-isoproρyl-phenoxyVtert-butyl-dimethyl-silane (Intermediate 145) A solution of 4-bromo-3-isoproρyl-ρhenol (Intermediate 144, 1.13 g, 5.25 mmols), chloro-tert-butyl-dimethylsilane (0.95 g, 6.30 mmols), and imidazole (428.0 mg, 6.3 mmols) in 10 mL DMF was stirred at 25 °C for 3 hours. The solution was diluted with H20 and extracted with Et20 and the combined organic layers were washed with H20, saturated aqueous NaCl, and dried (MgS04) before being concentrated under reduced pressure. Column chromatography (1-2% EtOAc-hexanes) afforded 1.50 g (87%) ofthe title compound as a colorless oil. Η NMR (CDC13) δ: 7.32 (IH, d, J = 8.8 Hz), 6.73 (IH, d, J = 3.0 Hz), 6.52 (IH, dd, J = 3.0, 8.8 Hz), 3.26 (IH, septet, J = 6.7 Hz), 1.19 (6H, d, J = 6.7 Hz), 0.96 (9H, s), 0.17 (6H, s). 4-(rgrt-butyl-dimethyl-silanyloxy)-2-isopropyl-benzaldehyde (Intermediate 146) A solution of (4-bromo-3-isopropyl-phenoxy)-tert-butyl-dimethyl- silane (Intermediate 145, 1.03 g, 3.13 mmols) in 25 mL E20 was cooled to - 78 °C and treated with tert-butyllithium (401.0 mg, 6.26 mmols; 3.7 mL of a 1.7M solution in pentane). After 30 minutes the reaction was quenched with DMF (913.0 mg, 12.5 mmols) and warmed to room temperature. The solution was diluted with H 0, extracted with Et20 and the combined organic layers washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. Column chromatography (2% EtOAc- hexanes) afforded 480.0 mg (55%) of the title compound as a colorless oil. Η NMR (CDC13) δ: 10.19 (IH, s), 7.72 (IH, d, J = 8.5 Hz), 6.85 (IH, d, J = 2.3 Hz), 6.77 (IH, dd, J = 2.3, 8.5 Hz), 3.97 (IH, septet, J = 6.7 Hz), 1.27 (6H, d, J = 6.7 Hz), 1.00 (9H, s), 0.25 (6H, s). 4-Hydroxy-2-isoρroρyl-benzaldehvde (Intermediate 147) To a solution of 4-(tert-butyl-dimethyl-silanyloxy)-2-isoρroρyl- benzaldehyde (Intermediate 146, 880.0 mg, 3.17 mmols) in 6 mL THF at 0 °C was added tetrabutylammonium fluoride (1.66 g, 6.33 mmols; 6.3 mL of a IM solution in THF). The pale-yellow solution was stirred for 30 minutes and quenched by the addition of ice cold H20. The mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (Na2S0 ) and concentrated under reduced pressure. Column chromatography (20% EtOAc-hexanes) afforded 500.0 mg (96%) ofthe title compound as a colorless solid. Η NMR (CDCI3) δ: 10.15 (IH, s), 7.79 (IH, d, J = 8.5 Hz), 6.95 (IH, d, J = 2.3 Hz), 6.86 (IH, dd, J = 2.3, 8.5 Hz), 3.96 (IH, septet, J = 6.7 Hz), 1.29 (6H, d, J = 6.7 Hz). 4-Formyl-3-isoproρyl-ρhenyl 1.1.1 -trifluoro-methansulfonate (Intermediate 148) A solution of 4-hydroxy-2-isopropyl-benzaldehyde (Intermediate 147, 300.0 mg, 1.83 mmol) in 10 mL of CH2C12 was cooled to 0 °C and to it was added 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine (754.0 mg, 1.92 mmol) and triethylamine (592.0 mg, 5.85 mmols). The resulting solution was warmed to room temperature and stirred for 4.5 hours. The reaction was quenched by the addition of H20 and the mixture extracted with EtOAc and the combined organic layers were washed with 10% aqueous HCl, saturated aqueous NaHC03, H20, and saturated aqueous NaCl. The solution was dried (MgS04) and concentrated under reduced pressure. The title compound was isolated by column chromatography (5-10% EtOAc-hexanes) as a colorless oil, 470.0 mg (87%). Η NMR (CDC13) δ: 10.37 (IH, s), 7.94 (IH, d, J = 8.5 Hz), 7.33 (IH, d, J = 2.3 Hz), 7.26 (IH, dd, J = 2.3, 8.5 Hz), 4.00 (IH, septet, J = 6.7 Hz), 1.33 (6H, d, J = 6.7 Hz), ' 4-Hvdroxymethyl-3-isopropyl-phenyl 1.1.1 -trifluoro-methansulfonate (Intermediate 149) To a solution of 4-formyl-3-isopropyl-phenyl 1,1,1 -trifluoro- methansulfonate (Intermediate 148, 540.0 mg, 1.82 mmols) in 7 mL MeOH at 0 °C was added NaBH4 (72.0 mg, 1.91 mmols). After stirring 2 hours at 0 °C the reaction was carefully quenched with H20 and extracted with Et20. The combined organic layers were washed with H20 and saturated aqueous NaCl, dried (MgS04), and concetrated under reduced pressure. The title compound was isolated by column chromatography (5-10% EtOAc-hexanes) as a colorless oil, 355.0 mg (90%). 'H NMR (CDCI3) δ: 7.45 (IH, d, J = 8.5 Hz), 7.17 (IH, d, J = 2.7 Hz), 7.08 (IH, dd, J = 2.7, 8.5 Hz), 4.74 (2H, d, J = 5.3 Hz), 3.21 (IH, septet, J = 7.0 Hz), 2.12 (IH, t, J = 5.3 Hz), 1.24 (6H, d, J = 7.0 Hz). 4-(rgrt-butyl-dimethyl-silanyloχymethylV3 -isopropyl-phenyl 1.1.1 -trifluoro- methansulfonate (Intermediate 150) A solution of 4-hydroxymethyl-3 -isopropyl-phenyl 1,1,1 -trifluoro- methansulfonate (Intermediate 149, 760.0 mg, 2.55 mmols), chloro-tert- butyl-dimethylsilane (470.0 mg, 3.18 mmols), and imidazole (225.0 mg, 3.25 mmols) in 6 mL DMF was stirred at 25 °C for 17 hours. The solution was diluted with H20 and extracted with Et20 and the combined organic layers were washed with 10% aqueous HCl, saturated aqueous NaHC03, H20, and saturated aqueous NaCl, and dried (MgS04) before being concentrated under reduced pressure. Column chromatography (2-5% EtOAc-hexanes) afforded 970.0 mg (92%) ofthe title compound as a colorless oil. Η NMR (CDC13) δ: 7.49 (IH, d, J = 8.5 Hz), 7.10 (IH, d, J = 2.3 Hz), 7.06 (IH, dd, J = 2.3, 8.5 Hz), 4.75 (2H, s), 3.10 (IH, septet, J = 6.7 Hz), 1.21 (6H, d, J = 6.7 Hz), 0.93 (9H, s), 0.10 (6H, s). l-(rert-butyl-dimethyl-silanyloxymethylV2-isoproρyl-4- trimethylsilanylethynyl-benzene (Intermediate 151) To a solution of 4-(tert-butyl-dimethyl-silanyloxymethyl)-3 -isopropyl- phenyl 1,1,1-trifluoro-methansulfonate (Intermediate 150, 970.0 mg, 2.35 mmols) in triethylamine (2 mL) and 6 mL DMF was sparged with argon for 15 minutes. Trimethylsilyl acetylene (1.00 g, 10.6 mmols) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (66.0 mg, 0.09 mmol). The resulting reaction mixture was heated to 95 °C for 20 hours. The solution was cooled to room temperature and concentrated under reduced pressure. The title compound (200.0 mg, 78%) was isolated by chromatography (0-25% EtOAc-hexanes) as an orange oil. Η NMR (CDCI3) δ: 7.37-7.25 (3H, m), 4.75 (2H, s), 3.08 (IH, septet, J = 7.0 Hz), 1.21 (6H, d, J = 7.0 Hz), 0.92 (9H, s), 0.25 (9H, s), 0.09 (6H, s). rert-butyl-(4-ethynyl-2-isopropyl-benzyloxy)-dimethyl-silane (Intermediate 152) Using General Procedure E; l-(tert'-butyl-dimethyl-silanyloxymethyl)- 2-isoproρyl-4-trimethylsilanylethynyl-benzene (Intermediate 151, 850.0 mg, 2.36 mmols) in methanol (25 mL) was treated with potassium carbonate (250.0 mg, 1.81 mmols) and stirred overnight at ambient temperature. The crude alkyne (650 mg, 95%) was used directly in the next reaction. Η NMR (CDCI3) δ: 7.41-7.25 (3H, m), 4.77 (2H, s), 3.07 (IH, septet, J = 7.0 Hz), 3.05 (IH, s), 1.22 (6H, d, J = 7.0 Hz), 0.94 (9H, s), 0.11 (6H, s). Ethyl 4-[4-(tgr -butyl-dimethyl-silanyloxymethyl -3-isopropyl- phenylethynylj-benzoate (Intermediate 153) Using General procedure F; terz!-butyl-(4-ethynyl-2-isoρroρyl- benzyloxy)-dimethyl-silane (Intermediate 152, 300.0 mg, 1.04 mmols) and ethyl-4-iodo benzoate (Reagent A, 287.0 mg, 1.04 mmols) in triethylamine (8mL) was treated with copper(I)iodide (50.0 mg, 0.26 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (182 mg, 0.26 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-4% EtOAc - hexanes) afforded 310.0 mg (68%) ofthe title compound as an orange solid. . Η NMR (CDC13) δ: 8.03 (2H, d, J = 8.5 Hz), 7.60 (2H, d, J = 8.5 Hz), 7.48- 7.37 (3H, m), 4.80 (2H, s), 4.39 (2H, q, J = 7.1 Hz), 3.14 (IH, septet, J = 6.8 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.27 (6H, d, J = 6.8 Hz), 0.96 (9H, s), 0.12 (6H, s). Methyl {4-[4-(tert-butyl-dimethyl-silanyloxymethyl)-3-isopropyl- phenylethynyl]-phenyl} -acetate (Intermediate 154) Using General Procedure F; tert-butyl-(4-ethynyl-2-isopropyl- benzyloxy)-dimethyl-silane (Intermediate 152, 355.0 mg, 1.26 mmols) and methyl-(4-iodophenyl)-acetate (Reagent B, 349.0 mg, 1.26 mmols) in triethylamine (8 mL) was treated with copper(I)iodide (60.0 mg, 0.32 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (222 mg, 0.32 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (2-5% EtOAc-hexanes) afforded 288.0 mg (66%) of the title compound as an orange oil. Η NMR (CDCI3) δ: 7.49 (2H, d, J = 8.5 Hz), 7.43-7.35 (3H, m), 7.25 (2H, d, J = 8.5 Hz), 4.77 (2H, s), 3.69 (3H, s), 3.63 (2H, s), 3.11 (IH, septet, J = 6.7 Hz), 1.25 (6H, d, J = 6.7 Hz), 0.94 (9H, s), 0.10 (6H, s). Ethyl [4-(4-hydroxymethyl-3-isoρroρyl-phenylethvnyl)-benzoate (Compound 122, General Formula 6) To a solution of ethyl 4-[4-(tert-butyl-dimethyl-silanyloxymethyl)-3- isoρroρyl-ρhenylethynyl]-benzoate (Intermediate 153, 310.0 mg, 0.71 mmol) in 4 mL THF at 0 °C was added tetrabutylammonium fluoride (371.0 mg, 1.42 mmols; 1.4 mL of a IM solution in THF). The pale-yellow solution was stirred for 10 minutes and quenched by the addition of ice cold H20. The mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (Na2S04) and concentrated under reduced pressure. Column chromatography (20-30% EtOAc-hexanes) afforded 200.0 mg (87%) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 7.98 (2H, d, J = 8.5 Hz), 7.58 (2H, d, J = 8.5 Hz), 7.48 (IH, s), 7.35 (2H, m), 4.71 (2H, s), 4.35 (2H, q, J = 7.1 Hz), 3.19 (IH, septet, J = 7.0 Hz), 2.51 (IH, s), 1.39 (3H, t, J = 7.1 Hz), 1.25 (6H, d, J = 7.0 Hz). Methyl [4-(4-hydroxymethyl-3-isopropyl-phenylethynyl)-phenyl]-acetate (Compound 123, General Formula 6) To a solution of methyl {4-[4-(tert-butyl-dimethyl-silanyloxymethyl)- 3-isopropyl-phenylethynyl]-phenyl}-acetate (Intermediate 154, 288.0 mg, 0.66 mmol) in 5 mL THF at 0 °C was added tetrabutylammonium fluoride (471.0 mg, 1.80 mmols; 1.8 mL of a IM solution in THF). The pale-yellow solution was stirred for 15 minutes and quenched by the addition of ice cold H20. The mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (Na2S04) and concentrated under reduced pressure. Column chromatography (5- 10% EtOAc-hexanes) afforded 180.0 mg (85%) of the title compound as a colorless solid. Η NMR (CDC13) δ: 7.48 (3H, m), 7.32 (2H, m), 7.24 (2H, d, J = 8.5 Hz), 4.69 (2H, s), 3.68 (3H, s), 3.62 (2H, s), 3.18 (IH, septet, J = 7.0 Hz), 2.21 (IH, s), 1.25 (6H, d, J = 7.0 Hz). Ethyl [4-(4-bromomethyl-3-isoproρyl-ρhenv1ethynylVbenzoate (Intermediate 155) A solution of ethyl [4-(4-hydroxymethyl-3-isoρroρyl-ρhenylethynyl)- benzoate (Compound 122, 200.0 mg, 0.62 mmol) and triphenylphosphine (211.0 mg, 0.81 mmol) in 5 mL CH2C12 was cooled to 0 °C and 7Y- bromosuccinimide (144.0 mg, 0.81 mmol) was added in 5 portions over 20 minutes. The solution was warmed to 25 °C and stirred for 17 hours. The reaction was quenched by the addition of dilute aqueous NaHC03. The resulting mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (Na2S04) and concentrated under reduced pressure. The title compound, 220.0 mg (93%), was isolated by column chromatography (5%> EtOAc-hexanes) as a pale-yellow solid. Η NMR (CDC13) δ: 8.03 (2H, d, J = 8.2 Hz), 7.59 (2H, d, J = 8.2 Hz), 7.48 (IH, s), 7.31 (2H, m) 4.55 (2H, s), 4.39 (2H, q, J = 7.1 Hz), 3.29 (IH, septet, J = 7.0 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.30 (6H, d, J = 7.0 Hz). Methyl [4-(4-bromomethyl-3-isopropyl-phenylethynv -phenyl]-acetate (Intermediate 156) A solution of methyl [4-(4-hydroxymethyl-3-isoρroρyl- ρhenylethynyl)-phenyl]-acetate (Compound 123, 180.0 mg, 0.56 mmol) and triphenylphosphine (190.0 mg, 0.73 mmol) in 5 mL CH2C12 was cooled to 0 °C and N-bromosuccinimide (130.0 mg, 0.73 mmol) was added in 5 portions over 20 minutes. The solution was warmed to 25 °C and stirred for 17 hours. The reaction was quenched by the addition of dilute aqueous ΝaHC03. The resulting mixture was extracted with Et20 and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (Na2S04) and concentrated under reduced pressure. The title compound, 212.0 mg (98%.), was isolated by column chromatography (5-10% EtOAc-hexanes) as a pale-yellow oil. 'H NMR (CDC13) δ: 7.48 (3H, m), 7.28 (4H, m), 4.55 (2H, s), 3.69 (3H, s), 3.63 (2H, s), 3.28 (IH, septet, J = 7.0 Hz), 1.30 (6H, d, J = 7.0 Hz). Ethyl [4-(4-imidazol-l-yl-methyl-3-isopropyl-phenylethynyl)-phenyl1- benzoate (Compound 124, General Formula 6) A solution of ethyl [4-(4-bromomethyl-3-isopropyl-phenylethynyl)- benzoate (Intermediate 155, 120.0 mg, 0.31 mmol) and 1-acetylimidazole (36.0 mg, 0.33 mmol) in 5 mL CH3CN was heated at 65 °C for 4 hours and then at 55 °C for 16 hours. The solution was cooled to room temperature, diluted with H20 and made basic by addition of Na2C03, and extracted with EtOAc. The combined organic layers were washed with H20 and saturated aqueous NaCl, dried (MgS04), and concentrated under reduced pressure. Column chromatography (1% Et3N in 5% MeOH-EtOAc) afforded 75.0 mg (65%) ofthe title compound as a colorless solid. Η NMR (CDCI3) δ: 8.03 (2H, d, J = 8.5 Hz), 7.60 (2H, d, J = 8.5 Hz), 7.53 (IH, d, J = 1.5 Hz), 7.49 (IH, s), 7.35 (IH, dd, J = 1.5, 7.9 Hz), 7.09 (IH, bs), 6.98 (IH, d, J = 7.9 Hz), 6.85 (IH, bs), 5.19 (2H, s), 4.39 (2H, q, J = 7.1 Hz), 3.08 (IH, septet, J = 6.8 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.20 (6H, d, J = 6.8 Hz). Methyl [4-(4-imidazol-l-yl-methyl-3-isopropyl-phenylethynylVphenyl]- acetate (Compound 125, General Formula 6) A solution of methyl [4-(4-bromomethyl-3-isopropyl-phenylethynyl)- phenyl]-acetate (Intermediate 156, 72.0 mg, 0.19 mmol) and 1- acetylimidazole (22.0 mg, 0.20 mmol) in 5 mL CH3CN was heated at 65 °C for 8h and then at 55 °C for 16 hours. The solution was cooled to room temperature, diluted with H20 and made basic by addition of Na2C03, and extracted with EtOAc. The combined organic layers were washed with H20 and saturated aqueous NaCl, dried (MgS04), and concentrated under reduced pressure. Column chromatography (0.5% Et3N in 5% MeOH-EtOAc) afforded 40.0 mg (58%) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 7.49 (4H, m), 7.33 (IH, dd, J = 1.5, 7.9 Hz), 7.28 (2H, d, J = 8.5 Hz), 7.08 (IH, t, J = 1.2 Hz), 6.95 (IH, d, J = 7.9 Hz), 6.84 (IH, t, J = 1.2 Hz), 5.17 (2H, s), 3.70 (3H, s), 3.64 (2H, s), 3.06 (IH, septet, J = 6.8 Hz), 1.20 (6H, d, J = 6.8 Hz). [4-(4-Imidazol-l-yl-methyl-3-isopropyl-phenylethynyl -phenyl]-benzoic acid (Compound 126, General Formula 6) Using General Procedure I; a solution of ethyl [4-(4-imidazol-l- ylmethyl-3-isopropyl-phenylethynyl)-phenyl]-benzoate (Compound 124, 75.0 mg, 0.20 mmol) in ethanol (4 mL) and tetrahydrofuran (1 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 68.0 mg (88%>) of the title compound as a colorless solid. 'H NMR (d4-MeOH) δ: 9.01 (IH, s), 8.01 (2H, d, J = 8.2 Hz), 7.63-7.57 (5H, m), 7.44 (IH, d, J = 7.9 Hz), 7.29 (IH, d, J = 7.9 Hz), 5.59 (2H, s), 3.17 (IH, septet, J = 6.8 Hz), 1.20 (6H, d, J = 6.8 Hz). [4-(4-Imidazol- 1 -yl-methyl-3-isopropyl-phenylethynyl -phenyl]-acetic acid (Compound 127, General Formula 6) Using General Procedure I; a solution of methyl [4-(4-imidazol-l- ylmethyl-3-isopropyl-phenylethynyl)-phenyl]-acetate (Compound 125, 40.0 mg, 0.11 mmol) in ethanol (4 mL) and tetrahydrofuran (1 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 22.0 mg (52%) of the title compound as a colorless solid. Η NMR (d4-MeOH) δ: 9.02 (IH, bs), 7.62 (IH, t, J = 1 A Hz), 7.58 (2H, m), 7.49 (2H, d, J = 8.2 Hz), 7.43 (IH, dd, J = 1.5, 7.9 Hz), 7.31 (3H, m), 5.58 (2H, s), 3.68 (2H, s), 3.16 (IH, septet, J = 6.7 Hz), 1.18 (6H, d, J = 6.7 Hz). 4-Bromo-7V-cyclopropyl-2-methyl-benzamide (Intermediate 157) A solution of 4-bromo-2-methylbenzoic acid and SOCl2 was refluxed for 3 hours, cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in 30 mL CH2C12 and combined with cyclopropyl amine (810.0 mg, 14.3 mmols) and pyridine (2.05 g, 26.0 mmols). The solution was stirred for 18 hours and then diluted with EtOAc before being washed with 5% aqueous HCl, saturated NaHC03, and saturated aqueous NaCl. The solution was dried (MgS04) and concentrated under reduced pressure leaving the title compound as a colorless solid. Η NMR (CDC13) δ: 7.34 (IH, d, J = 2.3 Hz), 7.28 (IH, dd, J = 2.3, 8.2 Hz), 7.13 (IH, d, J = 8.2 Hz), 6.10 (IH, bs), 2.85 (IH, m), 2.37 (3H, s), 0.85 (2H, m), 0.59 (2H, m). (4-Bromo-2-methyl-benzylVcvclopropyl-amine (Intermediate 158) To a solution of 4-bromo-N-cyclopropyl-2-methyl-benzamide (Intermediate 157, 1.81 g, 7.12 mmols) in THF (12 mL) was added BH3«SMe2 (1.08 g, 14.24 mmols). The solution was heated to 60 °C for 6 hours, cooled to room temperature and carefully treated with saturated aqueous Na2C03 (30 mL) and stirred for 17 hours. This mixture was extracted with EtOAc and the combined organic layers were washed with H20, saturated aqueous NaCl before being dried (MgS0 ) and concentrated under reduced pressure. The title compound was isolated by column chromatography (10- 15% EtOAc-hexanes). Η NMR (CDC13) δ: 7.26 (2H, m), 7.12 (IH, d, J = 7.9 Hz), 3.76 (2H, s), 2.31 (3H, s), 2.14 (IH, m), 0.44 (2H, m), 0.36 (2H, m). (4-Bromo-2-methyl-benzyl)-cyclopropyl-ethyl-amine (Intermediate 159) A mixture of (4-bromo-2-methyl-benzyl)-cyclopropyl-amine (Intermediate 158, 600.0 mg, 2.49 mmols), ethyl iodide (1.56 g, 10.0 mmols), and K2C03 (690.0 mg, 5.00 mmols) in 10 mL acetone was heated at 60 °C for 18 hours. The mixture was cooled to room temperature, diluted with H20, and extracted with EtOAc. The combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. The title compound was isolated by column chromatography (2.5% EtOAc-hexanes). 'H NMR (CDC13) δ: 7.23 (2H, m), 7.12 (IH, d, J = 7.6 Hz), 3.62 (2H, s), 2.56 (2H, q, J = 7.3 Hz), 2.29 (3H, s), 1.75 (IH, m), 1.04 (3H, t, J = 7.3 Hz), 0.39 (2H, m), 0.30 (2H, m). Cyclopropyl-ethyl-(2-methyl-4-trimethylsilanylethynyl-benzyl)-amine (Intermediate 160) Using General Procedure D; (4-bromo-2-methyl-benzyl)-cyclopropyl- ethyl-amine (Intermediate 159, 620.0 mg, 2.31 mmols) in triethylamine (8 mL) was treated with copper(I)iodide (44.0 mg, 0.23 mmol) and then sparged with argon for 15 minutes. Trimethylsilylacetylene (1.04 g, 10.6 mmols) was then added followed by dichlorobis-(triphenylphosphine)palladium(II) (162.0 mg, 0.23 mmol). The resulting reaction mixture was heated to 70 °C for 5 days. The title compound (650.0 mg, 98%) was isolated by chromatography (1-4% EtOAc - hexanes). 'H NMR (CDCI3) δ: 7.32 (IH, s), 7.20 (2H, m), 3.65 (2H, s), 2.55 (2H, q, J = 7.3 Hz), 2.28 (3H, s), 1.74 (IH, m), 1.03 (3H, t, J = 7.3 Hz), 0.36 (2H, m), 0.27 (2H, m), 0.24 (9H, s). Cyclopropyl-ethyl-(4-ethynyl-2-methyl-benzyl)-amine (Intermediate 161) Using General Procedure E; cyclopropyl-ethyl-(2-methyl-4- trimethylsilanylethynyl-benzyl)-amine (Intermediate 160, 650.0 mg, 2.30 mmols) in methanol (lOmL) was treated with potassium carbonate (100.0 mg, 0.72 mmol) and stirred overnight at ambient temperature. The crude alkyne (495 mg, 99%) was used directly in the next reaction. Η NMR (CDC13) δ: 7.32 (IH, s), 7.21 (2H, m), 3.66 (2H, s), 3.01 (IH, s), 2.56 (2H, q, J = 7.3 Hz), 2.29 (3H, s), 1.76 (IH, m), 1.04 (3H, t, J = 7.3 Hz), 0.40 (2H, m), 0.29 (2H, m). Ethyl 4-{4-[(cyclopropyl-ethyl-amino)-methyl]-3-methyl-phenylethynyl}- benzoate (Compound 128, General Formula 6) Using General Procedure F; cyclopropyl-ethyl-(4-ethynyl-2-methyl- benzyl)-amine (Intermediate 161, 190.0 mg, 0.89 mmol) and ethyl-4-iodo benzoate (Reagent A, 245.0 mg, 0.89 mmol) in triethylamine (5 mL) was treated with copper(I)iodide (56.0 mg, 0.30 mmol) and sparged with argon for 15 minutes. Dichlorobis(triphenylphosphine)-palladium(II) (208 mg, 0.30 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (3-5% EtOAc - hexanes) afforded the title compound. Η NMR (CDC13) δ: 8.01 (2H, d, J = 8.2 Hz), 7.56 (2H, d, J = 8.2 Hz), 7.31- 7.24 (3H, m), 4.38 (2H, q, J = 7.1 Hz), 3.68 (2H, s), 2.58 (2H, q, J = 7.3 Hz), 2.32 (3H, s), 1.77 (IH, m), 1.39 (3H, t, J = 7.1 Hz), 1.05 (3H, t, J = 7.3 Hz), 0.39 (2H, m), 0.3 l (2H, m). Methyl (4- {4-[(cyclopropyl-ethyl-amino)-methyl]-3-methyl-phenylethynyll - phenvD-acetate) (Compound 129, General Formula 6) Using General Procedure F; cyclopropyl-ethyl-(4-ethynyl-2-methyl- benzyl)-amine (Intermediate 161, 300.0 mg, 1.41 mmols) and methyl-(4- iodophenyl)-acetate (Reagent B, 388.0 mg, 1.41 mmols) in triethylamine (8 mL) was treated with copper(I)iodide (67.0 mg, 0.35 mmol) and sparged with argon for 15 minutes. Dichlorobis(triphenylphosphine)palladium(II) (246 mg, 0.35 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (5-7% EtOAc - hexanes) afforded 270.0 mg (53%) ofthe title compound as a pale-yellow oil. Η NMR (CDCI3) δ: 7.47 (2H, d, J = 7.9 Hz), 7.30-7.22 (5H, m), 3.70 (3H, s), 3.68 (2H, s), 3.63 (2H, s), 2.58 (2H, q, J = 7.3 Hz), 2.32 (3H, s), 1.77 (IH, m), 1.05 (3H, t, J = 7.3 Hz), 0.39 (2H, m), 0.30 (2H, m). 4-{4-[(Cyclopropyl-ethyl-aminoVmethyl]-3-methyl-phenylethynyl}-benzoic acid: (Compound 130, General Formula 6) Using General Procedure I; a solution of ethyl 4- {4-[(cyclopropyl- ethyl-amino)-methyl]-3-methyl-phenylethynyl} -benzoate (Compound 128, 130.0 mg, 0.36 mmol) in ethanol (5 mL) and tetrahydrofuran (5 mL) was treated with NaOH (360.0 mg, 9.0 mmols, 3.0 mL of a 3N aqueous solution) and stirred overnight at room temperature. Work-up afforded 115.0 mg (96%) ofthe title compound as a colorless solid. 'H NMR (d6-acetone) δ: 8.05 (2H, d, J = 8.2 Hz), 7.64 (2H, d, J = 8.2 Hz), 7.32 (3H, m), 3.73 (2H, s), 2.59 (2H, q, J = 7.3 Hz), 2.35 (3H, s), 1.83 (IH, m), 1.05 (3H, t, J = 7.3 Hz), 0.38 (2H, m), 0.27 (2H, m). (4-{4-[(Cyclopropyl-ethyl-aminoVmethyl]-3-methyl-phenylethynyl}-phenyl)- acetic acid (Compound 131, General Formula 6) Using General Procedure I; a solution of methyl (4-{4-[(cyclopropyl- ethyl-amino)-methyl]-3-methyl-phenylethynyl} -phenyl)-acetate (Compound 129, 140.0 mg, 0.39 mmol) in ethanol (5 mL) and tetrahydrofuran (5 mL) was treated with NaOH (360.0 mg, 9.0 mmols, 3.0 mL of a 3N aqueous solution) and stirred overnight at room temperature. Work-up followed by HPLC (Partisil- 10 pac 10% H20-CH3CN) afforded the title compound. Η NMR (CDC13) δ: 7.45 (2H, d, J = 8.2 Hz), 7.25 (5H, m), 4.16 (2H, m), 3.82 (2H, s), 3.56 (2H, s), 2.75 (2H, q, J = 7.3 Hz), 2.30 (3H, s), 1.86 (IH, m), 1.14 (3H, t, J = 7.3 Hz), 0.54 (2H, m), 0.46 (2H, m). Ethyl {4-(4-cyclopropylaminomethyl-3-isopropyl-phenylethynyl}-benzoate (Compound 132, General Formula 6) A solution of ethyl [4-(4-bromomethyl-3-isopropyl-phenylethynyl)- benzoate (Intermediate 155, 110.0 mg, 0.29 mmol) and cyclopropylamine (420.0 mg, 7.4 mmols) in EtOH (5 mL) was stirred at 25 °C for 6 hours and then concentrated under reduced pressure. The residue was dissolved in EtOAc and washed with saturated aqueous NaHC03, H20 and saturated aqueous NaCl. The solution was dried (MgS04) and concentrated under reduced pressure to give 103 mg (99%) ofthe title compound as an orange oil. IH NMR (CDC13) δ: 8.01 (2H, d, J = 8.5 Hz), 7.59 (2H, d, J = 8.5 Hz), 7.47 (IH, s), 7.30 (2H, m), 4.38 (2H, q, J = 7.1 Hz), 3.89 (2H, s), 3.26 (IH, septet, J = 7.0 Hz), 2.17 (IH, m), 1.40 (3H, t, J = 7.1 Hz), 1.26 (6H, d, J = 7.0 Hz), 0.45 (2H, m), 0.39 (2H, m). Ethyl 4- {4-[(cyclopropyl-ethyl-amino)-methyl]-3-isopropyl-phenylethynyl} - benzoate (Compound 133, General Formula 6) To a solution of ethyl {4-(4-cyclopropylaminomethyl-3-isopropyl- phenylethynyl} -benzoate (Compound 132, 103.0 mg, 0.29 mmol) in 6 mL of acetone was added ethyl iodide (67.0 mg, 0.43 mmol) and K2C03 (79.0 mg, 0.57 mmol). The mixture was stirred at 60 °C for 6 hours, cooled to room temperature and quenched by the addition of H20. The mixture was extracted with EtOAc and the combined organic layers were washed with H20 and saturated aqueous NaCl before being dried (MgS04) and concentrated under reduced pressure. Column chromatography (4-5%. EtOAc - hexanes) afforded 68.0 mg (59%) ofthe title compound. Η NMR (CDCI3) δ: 8.01 (2H, d, J = 8.6 Hz), 7.58 (2H, d, J = 8.6 Hz), 7.44 (IH, s), 7.28 (2H, m), 4.39 (2H, q, J = 7.1 Hz), 3.73 (2H, s), 3.55 (IH, septet, J = 6.6 Hz), 2.57 (2H, q, J = 7.3 Hz), 1.75 (IH, m), 1.40 (3H, t, J = 7.1 hz), 1.22 (6H, d, J = 6.6 Hz), 1.05 (3H, t, J = 7.3 Hz), 0.37 (2H, m), 0.28 (2H, m). 4-{4-[(Cyclopropyl-ethyl-amino)-methyl]-3-isopropyl-phenylethynyl|- benzoic acid (Compound 134, General Formula 6) Using General Procedure I; a solution of ethyl 4- {4-[(cyclopropyl- ethyl-amino)-methyl]-3-isopropyl-phenylethynyl} -benzoate (Compound 133, 68.0 mg, 0.17 mmol) in ethanol (3 mL) and tefrahydrofuran (3 mL) was treated with NaOH (600.0 mg,15.0 mmols, 3.0 mL of a 5N aqueous solution) and stirred overnight at room temperature and then at 55 °C for 9 hours. Work-up followed by crystallization ofthe solid residue from hot CH3CN afforded 45.0 mg (72%) ofthe title compound as a pale-yellow solid. Η NMR (d6-acetone) δ: 8.05 (2H, d, J = 8.1 Hz), 7.66 (2H, d, J = 8.1 Hz), 7.49 (IH, s), 7.32 (2H, m), 3.78 (2H, s), 3.44 (IH, septet, J = 6.7 Hz), 2.59 (2H, q, J = 7.3 Hz), 1.80 (IH, m), 1.21 (6H, d, J = 6.7 Hz), 1.05 (3H, t, J = 7.3 Hz), 0.40 (2H, m), 0.26 (2H, m). Methyl [4-(8.8-dimethyl-5-oxo-5.6.7.8-tetrahydro-naphthalen-2-yl-ethynyl - phenylj-acetate (Compound 4, General Formula 8) Using General Procedure F; 6-ethynyl-4,4-dimethyl-3,4-dihydro-2H- naρhthalen-1-one (Intermediate 13, 190.0 mg, 0.96 mmol) and methyl-(4- iodophenyl)-acetate (Reagent B, 245.0 mg, 0.96 mmol) in triethyl amine (8 mL) was treated with copper(I)iodide (46 mg, 0.24 mmol) and sparged with argon for 15 minutes. Dichlorobis(triphenylphosphine)palladium(II) (168 mg, 0.24 mmol) was added and the reaction mixture was stirred overnight at room temperature. Column chromatography (10-20% EtOAc - hexanes) afforded 250.0 mg (75%) ofthe title compound as a pale-yellow solid. Η NMR (CDC13) δ: 7.99 (1Η, d, J = 7.9 Ηz), 7.57 (1Η, d, J = 1.5 Ηz), 7.51 (2Η, d, J = 8.5 Hz), 7.43 (IH, dd, J = 1.5, 7.9 Hz), 7.29 (2H, d, J = 8.5 Hz), 3.70 (3H, s), 3.65 (2H, s), 2.73 (2H, t, J = 7.0 Hz), 2.04 (2H, t, J = 7.0 Hz), 1.41 (6H, s). Methyl [4-(5-hvdroxy-8.8-dimethyl-5.6.7.8-tetrahydro-naρhthalen-2-yl- ethynyl)-phenyl]-acetate (Compound 135, General Formula 4) To a solution of methyl [4-(8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro- naphthalen-2-yl-ethynyl)-phenyl]-acetate (Compound 4) in 5 mL MeOH at 0 °C was added NaBH4 (18.0 mg, 0.48 mmol). The reaction was stirred at 0 °C for 2 hours and then quenched by the addition of H20. The solution was diluted with Et20 and washed with H20 and saturated aqueous NaCl before being dried (MgS04) and the solvents were removed under reduced pressure. Column chromatography (20-40% EtOAc-hexanes) afforded 140.0 mg (87%) ofthe title compound as a colorless oil. 'H NMR (CDC13) δ: 7.49 (3H, m), 7.39 (IH, d, J = 7.9 Hz), 7.31 (IH, dd, J = 1.5, 7.9 Hz), 7.25 (2H, d, J = 8.2 Hz), 4.58 (IH, bs), 3.68 (3H, s), 3.62 (2H, s), 2.05 (IH, m), 1.79 (2H, m), 1.60 (IH, m), 1.33 (3H, s), 1.26 (3H, s). Methyl [4-(5-imidazol-l-yl-8.8-dimethyl-5.6.7.8-tetrahydro-naphthalen-2- ylethynyl)-phenyl]-acetate (Compound 136, General Formula 4) A solution of methyl [4-(5-hydroxy-8,8-dimethyl-5,6,7,8-tetrahydro- naphthalen-2-ylethynyl)-ρhenyl]-acetate (Compound 135, 140.0 mg, 0.40 mmol) and carbonyldiimidazole (136.0 mg, 0.84 mmol) in 5 mL THF was heated to 65 °C for 48 hours. The solution was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in Et20 and washed with 5% aqueous NaOH, H20, and saturated aqueous NaCl before being dried (Na2S04) and concentrated under reduced pressure. Column chromatography (5% MeOH-CH2Cl2) afforded 50.0 mg (31 %) of the title compound as a colorless solid. Η NMR (CDCI3) δ: 7.57 (IH, d, J = 1.5 Hz), 7.52-7.45 (3H, m), 7.27 (3H, m), 7.08 (IH, s), 6.81 (2H, m), 5.30 (IH, t, J = 5.8 Hz), 3.71 (3H, s), 3.65 (2H, s), 2.20 (2H, m), 1.75 (2H, m), 1.40 (3H, s), 1.36 (3H, s). [4-(5-Imidazol-l-yl-8.8-dimethyl-5.6.7.8-tetrahydro-naphfhalen-2-yl-ethvnylV phenyl] -acetic acid (Compound 137, General Formula 4) Using General Procedure I; a solution of methyl [4-(5-imidazol-l-yl- 8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-ethynyl)-phenyl]-acetate (Compound 136, 50.0 mg, 0.13 mmol) in ethanol (4 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 40.0 mg (83%) ofthe title compound as a pale-orange solid. Η NMR (d4-MeOH) δ: 8.93 (IH, s), 7.68 (IH, s), 7.61 (IH, s), 7.54 (IH, s), 7.47 (2H, d, J = 8.2 Hz), 7.31 (3H, m), 6.95 (IH, d, J = 8.2 Hz), 5.83 (1H, t, J = 5.8 Hz), 3.68 (IH, s), 3.63 (IH, s), 2.38 (IH, m), 2.26 (IH, m), 1.76 (2H, m), 1.45 (3H, s), 1.36 (3H, s). Ethyl r4-(5-imidazol-l-yl-8.8-dimethyl-5.6.7.8-tetrahvdro-naρhthalen-2-yl- ethynylVbenzoate (Compound 138, General Formula 4) A solution of ethyl [4-(5-hydroxy-8,8-dimethyl-5,6,7,8-tetrahydro- naphthalen-2-yl-ethynyl)-benzoate (180.0 mg, 0.52 mmol) and carbonyldiimidazole (176.0 mg, 1.08 mmol) in 5 mL THF was heated to 65 °C for 21 hours. The solution was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in Et20 and washed with 55 aqueous NaOH, H20, and saturated aqueous NaCl before being dried (Na2S04) and concentrated under reuced pressure. Column chromatography (5% MeOH-CH2Cl2) afforded 50.0 mg (24%) ofthe title compound as a colorless solid. Η NMR (CDC13) δ: 8.03 (2H, d, J = 7.9 Hz), 7.59 (3H, m), 7.46 (IH, s), 7.29 (IH, dd, J = 1.5, 8.3 Hz), 7.09 (IH, s), 6.82 (IH, d, J = 8.2 Hz), 6.81 (IH, s), 5.31 (IH, t, J = 5.8 Hz), 4.39 (2H, q, J = 7.1 Hz), 2.20 (2H, m), 1.75 (2H, m), 1.40 (9H, m). [4-(5-Imidazol-l-yl-8.8-dimethyl-5.6.7.8-tetrahydro-naphthalen-2-yl-ethynylV benzoic acid (Compound 139, General Formula 4) Using General Procedure I; a solution of ethyl [4-(5-imidazol-l-yl-8,8- dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-ethynyl)-benzoate (Compound 138, 50.0 mg, 0.13 mmol) in ethanol (3 mL) and tetrahydrofuran (1 mL) was treated with NaOH (120.0 mg, 3.0 mmols, 3.0 mL of a IN aqueous solution) and stirred overnight at room temperature. Work-up afforded 40.0 mg (87%) ofthe title compound as a colorless solid. Η NMR (d4-MeOH) δ: 8.92 (IH, s), 8.04 (2H, d, J = 8.2 Hz), 7.74 (IH, d, J = 1.5 Hz), 7.62 (3H, m), 7.57 (IH, t, J = 1.5 Hz), 7.38 (IH, dd, J = 1.5, 7.9 Hz), 6.97 (IH, d, J = 7.9 Hz), 5.83 (IH, t, J = 5.8 Hz), 2.33 (2H, m), 1.78 (2H, m), 1.47 (3H, s), 1.39 (3H, s). 2-Isopropyl-4-trifluoromethanesulfonyloxy-benzyl acetate (Intermediate 162) To a solution of 4-hydroxymethyl-3 -isopropylphenyl 1,1,1- trifluoromethanesulfonate (Intermediate 149, 190.0 mg, 0.64 mmol) in 5 mL CH2C12 was added acetyl chloride (75.0 mg, 0.96 mmol) and pyridine( 101.0 mg, 1.38 mmols). After stirring for 3 hours at 25 °C the reaction was quenched by the addition of H20 and the resulting mixture extracted with EtOAc. The combined organic layers were washed with H20 and saturated aqueous NaCl, dried (MgS0 ) and concentrated under reduced pressure. The title compound, 182 mg (84%), was isolated from the residual oil by column chromatography (5 - 10% EtOAc-hexanes) as a colorless oil. Η NMR (CDC13) δ: 7.43 (IH, d, J = 8.7 Hz), 7.19 (IH, d, J = 2.7 Hz), 7.09 (IH, dd, J = 2.7, 8.5 Hz), 5.17 (2H, s), 3.18 (IH, septet, J = 6.7 Hz), 2.10 (3H, s), 1.26 (6H, d, J = 6.7 Hz). 4-Isopropenyloxymethyl-3 -isopropyl-phenyl 1.1.1 -trifluoromethanesulfonate (Intermediate 163) Using General Procedure 1; 2-isopropyl-4- trifluoromethanesulfonyloxy-benzyl acetate (Intermediate 162, 182.0 mg, 0.54 mmols), and 1.1 mL of Tebbe's Reagent (159.0 mg, 0.56 mmols) afforded 130.0 mg (72%.) ofthe title compound as a colorless oil after column chromatography (2-5% EtOAc-hexanes). Η NMR (CDC13) δ: 7.43 (IH, d, J = 8.5 Hz), 7.18 (IH, d, J = 2.6 Hz), 7.09 (IH, dd, J = 2.6, 8.5 Hz), 4.75 (2H, s), 3.98 (2H, s), 3.12 (IH, septet, J = 6.7 Hz), 1.88 (3H, s), 1.25 (6H, d, J = Hz). 3 -Isopropyl-4-( 1 -methyl-cy clopropoxymethyD-phenyl 1.1,1- trifluoromethanesulfonate (Intermediate 164) Using General Procedure 2; 4-isopropenyloxymethyl-3-isopropylphenyl 1,1,1 -trifluoromethanesulfonate (Intermediate 163, 130. 0 mg, 0.39 mmol), Et2Zn (272.0 mg, 2.2 mmols), and CH2I2 (702.0 mg, 2.6 mmols) in 3.0 mL EtjO afforded 120.0 mg (89%) ofthe title compound as a colorless oil after column chromatography (4-5% EtOAc - hexanes). Η NMR (CDC13) δ: 7.39 (IH, d, J = 8.5 Hz), 7.13 (IH, d, J = 2.7 Hz), 7.05 (IH, dd, J = 2.7, 8.5 Hz), 4.54 (2H, s), 3.16 (IH, septet, J = 6.7 Hz), 1.47 (3H, s), 1.24 (6H, d, J = 6.7 Hz), 0.86 (2H, m), 0.48 (2H, m). [3-Isopropyl-4-(l-methyl-cyclopropoxymethyl)-phenylethynyl]- trimethylsilane (Intermediate 165) Using General Procedure D; 3 -isopropyl-4-( 1 -methyl- cyclopropoxymethyl)-phenyl 1,1,1 -trifluoromethanesulfonate (Intermediate 164, 120.0 mg, 0.34mmol) in triethylamine (2 mL) and anhydrous DMF (5 mL) was sparged with argon for 5 minutes. Trimethylsilyl acetylene (700.0 mg, 0.71 mmol) was then added followed by dichlorobis(triphenylphosphine)palladium(II) (24.0 mg, 0.03 mmol). The resulting reaction mixture was heated to 95 °C for 60 hours. The title compound 110.0 mg, (99%) was isolated by chromatography (0-1% EtOAc - hexanes). Η NMR (CDC13) δ: 7.36 (IH, s), 7.24 (2H, bs), 4.53 (2H, s), 3.11 (IH, septet, J = 6.7 Hz), 1.45 (3H, s), 1.22 (6H, d, J = 6.7 Hz), 0.85 (2H, m), 0.44 (2H, m), 0.25 (9H, s). 4-Ethynyl-2 -isopropyl- 1 -( 1 -methyl-cyclopropoxymethyD-benzene (Intermediate 166) Using General Procedure E; [3-isopropyl-4-(l-methyl- cyclopropoxymethyl)-phenylethynyl]-trimethylsilane (Intermediate 165, 110.0 mg, 0.37 mmol) in methanol (6 mL) was treated with potassium carbonate (80.0 mg, 0.58 mmol) and stirred overnight at ambient temperature. The crude alkyne (84 mg, 100%) was used directly in the next reaction. Η NMR (CDC13) δ: 7.55 (IH, s), 7.41 (2H, m), 4.68 (2H, s), 3.26 (IH, septet, J = 6.8 Hz), 3.18 (IH, s), 1.60 (3H, s), 1.37 (6H, d, J = 6.8 Hz), 0.99 (2H, m), 0.59 (2H, m). Methyl {4-[3-isopropyl-4-( 1 -methyl-cyclopropoxymethyD-phenylethynyl]- phenyl} -acetate (Compound 140, General Formula 6) Using General Procedure F; 4-ethynyl-2-isopropyl- 1 -( 1 -methyl- cyclopropoxymethyl)-benzene (Intermediate 166, 78.0 mg, 0.34 mmol) and methyl-(4-iodophenyl)-acetate (Reagent B, 94.0 mg, 0.34 mmol) in triethylamine (8 mL) was treated with copper(I)iodide (22.0 mg, 0.11 mmol) and sparged with argon for 5 minutes. Dichlorobis(triphenylphosphine)palladium(II) (79 mg, 0.11 mmol) was added and the reaction mixture was stirred at room temperature for 3.5 hours. Column chromatography (2-5% EtOAc - hexanes) afforded 77.0 mg (60%) of the title compound as a yellow oil. Η NMR (CDCI3) δ: 7.49 (2H, d, J = 8.2 Hz), 7.43 (IH, d, J = 1.5 Hz), 7.33- 7.24 (4H, m), 4.55 (2H, s), 3.70 (3H, s), 3.63 (2H, s), 3.14 (IH, septet, J = 6.8 Hz), 1.47 (3H, s), 1.25 (6H, d, J = 6.8 Hz), 0.86 (2H, m), 0.46 (2H, m). {4-[3-Isopropyl-4-(l-methyl-cyclopropoxymethyl)-phenylethynyl]-phenyl}- acetic acid (Compound 141, Formula 6) Using General Procedure I; a solution methyl {4-[3-isopropyl-4-(l- methyl-cyclopropoxymethyl)-phenylethynyl]-phenyl} -acetate (Compound 140, 70.0 mg, 0.19 mmol) in ethanol (3 mL) and tetrahydrofuran (3 mL) was treated with NaOH (240.0 mg, 6.0 mmols, 2.0 mL of a 3N aqueous solution) and stirred overnight at room temperature. Work-up and purification by HPLC (Partisil 10-pac, 10% H20/CH3CN) afforded of the title compound as a colorless solid. Η NMR (CDCI3) δ: 7.50 (2H, d, J = 8.2 Hz), 7.43 (IH, s), 7.33-7.24 (4H, m), 4.55 (2H, s), 3.65 (2H, s), 3.14 (IH, septet, J = 6.7 Hz), 1.47 (3H, s), 1.25 (6H, d, J = 6.7 Hz), 0.87 (2H, m), 0.46 (2H, m). 2.6-Di-tert-butyl-4-trimethylsilanylethynyl-phenol: (Intermediate 167) Following General Procedure D and using 4-bromo-2,6-di-t-butyl- phenol (1.43g, 5mmol), triethyl amine (15mL), anhydrous tetrahydrofuran ( 15mL), copρer(I)iodide (0.06g, 0.3 lmmol), trimethylsilyl acetylene (4.9g, 50mmol) and dichlorobis(triphenylphosphine)palladium(II) (0.18g, 0.26mmol) followed by flash column chromatography over silica gel (230-400 mesh) using hexane as eluent, the title compound was obtained (1.35g, 90%). Η NMR (300 MHz, CDC13): δ 7.29 (s, 2H), 5.35 (s, IH), 1.42 (s, 18H), 0.24 (s, 9H). (3.5-Di-tβrt-butyl-4-methoχy-phenylethynyl -trimethyl-silane: (Intermediate 168) A solution 2,6-di-tert-butyl-4-trimethylsilanylethynyl-phenol (Intermediate 167, 0.302g, lmmol) in acetone (5mL) was treated with potassium carbonate (0.138g, lmmol) and methyl iodide (0.142g, lmmol) and stirred overnight at room temperature. The volatiles were distilled off in vacuo and the residue was purified by flash column chromatography on silica gel (230-400 mesh) using ethyl acetate as the eluent to afford the title compound as a white solid (0.28g, 90%). Η NMR (300 MHz, CDC13): δ 7.41 (s, 2H), 3.70 (s, 3H), 1.49 (s, 18H), 0.30 (s, 9H). 1.3-Di-tgrt-butyl-5-ethynyl-2-methoxy-benzene: (Intermediate 169) Following General Procedure E and (3,5-di-tgrt-butyl-4-methoxy- phenylethynyl)-trimethyl-silane (Intermediate 168, 0.28g, 0.9mmol), potassium carbonate (0.98g, 7. lmmol) and methanol (lOmL) followed by flash column chromatography over silica gel (230-400 mesh) using hexane as the eluent, the title compound was obtained (0.23g, 100%). Η NMR (300 MHz, CDC13): δ 7.46 (s, 2H), 3.75 (s, 3H), 3.05 (s, IH), 1.49 (s, 18H). [4-(3.5-Di-tgrt-butyl-4-methoxy-phenylethynyl)-phenyl]-acetic acid methyl ester: (Compound 142, General Formula 5) Following General Procedure F and using l,3-di-tert-butyl-5-ethynyl-2- methoxy-benzene (Intermediate 169, 0.094g, 0.36mmol), methyl-4-iodo phenyl acetate (Reagent B, 0.09g, 0.32mmol), triethyl amine (5mL), anhydrous tetrahydrofuran (5mL), copper(I)iodide (0.02g, 0. lmmol) and dichlorobis(triphenylphosphine)palladium(II) (0.06g, 0.085mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 10 % ethyl acetate in hexane as the eluent, the title compound (0.114g, 81%) was obtained as an oil. 'H NMR (300 MHz, CDC13): δ 7.52 (d, 2H, J= 8.0Hz), 7.46 (s, 2H), 7.28 (d, 2H, J= 8.2Hz), 3.72 (s, 3H), 3.71(s, 3H), 3.66 (s, 2H), 1.47 (s, 18H). [4-(3.5-Di-tgrt-butyl-4-methoxy-phenylethynyl)-phenyl]-acetic acid: (Compound 143, General Formula 5) Following General Procedure I and using [4-(3,5-di-tgrt-butyl-4- methoxy-phenylethynyl)-phenyl]-acetic acid methyl ester (Compound 142, 0.114g, 0.29mmol), 5M aqueous sodium hydroxide solution (2mL) and ethanol (4mL), followed by preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a white solid (0.097g, 88%). 'H NMR (300 MHz, CDC13): δ 7.55(d, 2H, J= 8.0Hz), 7.48 (s, 2H), 7.30 (d, 2H, J= 8.2Hz), 3.74 (s, 3H), 3.69 (s, 2H), 1.49 (s, 18H). [4-(3.5-Di-tgrt-butyl-4-methoxy-phenylethynyl)-2-fluoro-phenyl]-acetic acid methyl ester: (Compound 144, General Formula 5) Following General Procedure F and using 1 ,3-di-tgrt-butyl-5-ethynyl-2- methoxy-benzene (Intermediate 169, 0.087g, 0.33mmol), methyl-2-fluoro-4- iodo phenyl acetate (Reagent H, 0.088g, 0.30mmol), triethyl amine (5mL), anhydrous tetrahydrofuran (lOmL), copper(I)iodide (0.02g, 0. lmmol) and dichlorobis(triphenylphosphine)ρalladium(II) (0.06g, 0.085mmol) followed by flash column chromatography over silica gel (230-400 mesh) using 10 % ethyl acetate in hexane as the eluent, the title compound (0.122g, 89%) was obtained. Η NMR (300 MHz, CDC13): δ 7.46 (s, 2H), 7.33-7.24 (m, 3H), 3.75 (s, 3H), 3.73(s, 3H), 3.72 (s, 2H), 1.48 (s, 18H). [4-(3.5-Di-tert-butyl-4-methoxy-phenylethynyl)-2-fluoro-phenyl]-acetic acid: (Compound 145, General Formula 5) Following General Procedure I and using [4-(3,5-di-tgrt-butyl-4- methoxy-phenylethynyl)-2-fluoro-phenyl]-acetic acid methyl ester (Compound 144, 0.122g, 0.29mmol), 5M aqueous sodium hydroxide solution (ImL) and ethanol (4mL), followed preparative reverse phase HPLC using 10% water in acetonitrile as the mobile phase, the title compound was obtained as a white solid (0.077g, 65%). 'H NMR (300 MHz, CDC13): δ 7.42 (s, 2H), 7.29-7.19 (m, 3H), 3.71 (s, 2H), 3.69 (s, 3H), 1.43 (s, 18H).

Claims

WHAT IS CLAIMED IS: 1. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound of the formula
Figure imgf000246_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X is O, S or NR where R is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I;
Z is -C≡C-,
Figure imgf000246_0002
where n' is an integer having the value 1 - 5,
-CO-NRr,
Figure imgf000246_0003
-CO-0-,
-0-CO-,
-CS-NRr,
NRrCS-,
-CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 4; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substimted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 2; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
2. A method in accordance with Claim 1 wherein the compound has the formula
Figure imgf000247_0001
where X is O or CH3N; Y is H or cyclopropyl; Z is -C≡C- or -CO-0-; R2 is H or F; n is 0 or 1, and R8 is H, alkyl of 1 to 6 carbons, or a cation of a pharmaceutically acceptable base.
3. A method in accordance with Claim 2 wherein the compound is selected from the group consisting of: benzoic acid, 4-[(3,4-dihydro-4,4-dimethylspiro[2H-l-benzopyran-2,l '- cyclopropane]-6-yl)ethynyl]-, benzeneacetic acid, 4-[(3,4-dihydro-4,4- dimethylspiro[2H- 1 -benzopyran-2, 1 '-cyclopropane]-6-yl)ethynyl]- and 2- fluoro-benzoic acid, 4-[(3,4-dihydro-4,4-dimethylspiro[2H-l-benzopyran-2,l '- cyclopropane]-6-yl)ethynyl]- or a salt with a pharmaceutically acceptable base or a C 6 alkyl ester of said compound. 4. A method in accordance with Claim 2 wherein the compound is selected from the group consisting of: benzeneacetic acid, 4-[(8-cyclopropyl-3,4-dihydro-4,4- dimethyIspiro[2H-l-benzopyran-2,l '-cyclopropane]-6-yl)ethynyl]-, 4-[(8- cyclopropyl-3 ,4-dihydro-4,4-dimethylspiro [2H- 1 -benzopyran-2, 1 ' - cyclopropane]-6-yl)ethynyl]-2-fluoro-benzeneacetic acid , benzoic acid, 4-[(8- cyclopropyl-3,4-dihydro-4,4-dimethylspiro[2H-l-benzopyran-2,l '- cyclopropane]-6-yl)ethynyl]- and 4-[(8-cyclopropyl-3,4-dihydro-4,
4- dimethylspiro[2H-l-benzopyτan-2, -cycloproρane]-6-yl)ethynyl]-2-fluoro- benzoic acid or a salt with a pharmaceutically acceptable base or a C]_6 alkyl ester of said compound.
5. A method in accordance with Claim 2 wherein the compound is spiro[2H- 1 -benzopyran-2, 1 '-cyclopropane] -6-carboxylic acid, 8-cyclopropyl- 3,4-dihydro-4,4-dimethyl-, 4-(carboxymethyl)phenyl ester or a salt with a pharmaceutically acceptable base or a C^ alkyl ester of said compound.
6. A method in accordance with Claim 2 wherein the compound is spiro[2H- 1 -benzopyran-2, 1 '-cyclopropane] -6-carboxylic acid, 8-cycloproρyl- 3,4-dihydro-4,4-dimethyl-, 3-(carboxymethyl)phenyl ester or a salt with a pharmaceutically acceptable base or a C g alkyl ester of said compound.
7. A method in accordance with Claim 2 wherein the compound is benzoic acid, 4-[(l,4,4-trimethylspiro[2H-l-l,2,3,4-tetrahydroquinoline-2,l '- cycloρropane]-6-yl)ethynyl]- or a salt with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
8. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound ofthe formula
Figure imgf000249_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups;
X is O, S or NR where R is H, alkyl of 1 to 6 carbons or benzyl; Z is -C≡C-,
Figure imgf000249_0002
where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rx is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 4; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 4; Rs is H, alkyl of 1 to 6 carbons, fluorosubstituted alkyl of 1 to 6 carbons, benzyl, or lower alkyl or halogen substituted benzyl; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base.
9. A method in accordance with Claim 8 wherein the compound has the formula
Figure imgf000250_0001
where X is O, NR where R is H, n-propyl or benzyl; R3 is H or lower alkyl of 1 to 6 carbons; R5 is benzyl or lower alkyl of 1 to 6 carbons; n is 0 or 1, and R8 is H, alkyl of 1 to 6 carbons, or a cation of a pharmaceutically acceptable base.
10. A method in accordance with Claim 9 wherein the compound is selected from the group consisting of 4-[4-(l-propylamino-cyclopropyl)- phenylethynyl] -benzoic acid and 4-[4-(l-benzylamino-cycloproρyl)- phenylethynylj-benzoic acid or a salt with a pharmaceutically acceptable base or a C g alkyl ester of said compound.
11. A method in accordance with Claim 9 wherein the compound is selected from the group consisting of 4-[4-(l-dibenzylamino-cyclopropyl)- phenylethynyl] -benzoic acid and 4- [4-( 1 -benzylmethylamino-cy clopropyl)- phenylethynyl] -benzoic acid or a salt with a pharmaceutically acceptable base or a C _6 alkyl ester of said compound.
12. A method in accordance with Claim 9 wherein the compound is selected from the group consisting of 4-[4-(l-benzyloxycyclopropyl)- phenylethynyl]-benzoic acid, 4- [4-(l -benzyloxy cyclopropyl)-3 -methyl- phenylethynyl] -benzoic acid and 4-[4-(l-benzyloxycyclopropyl)-3-ethyl- phenylethynylj-benzoic acid or a salt with a pharmaceutically acceptable base or a C . alkyl ester of said compound.
13. A method in accordance with Claim 9 wherein the compound is selected from the group consisting of {4- [4-(l -benzyloxy cyclopropyl)- ρhenylethynyl]-phenyl} -acetic acid, {4-[4-(l-benzyloxycycloρroρyl)-3- methyl-phenylethynyl] -phenyl} -acetic acid and {4-[4-(l- benzyloxycyclopropyl)-3-ethyl-phenylethynyl]-phenyl} -acetic acid or a salt with a pharmaceutically acceptable base or a C^ alkyl ester of said compound.
14. A method in accordance with Claim 9 wherein the compound is selected from the group consisting of 4-[4-(l-methoxycycloρropyl)- ρhenylethynyl]-benzoic acid, 4-[4-(l-isoproρoxycyclopropyl)-ρhenylethynyl]- benzoic acid, 4-[4-(l-isopropoxycyclopropyl)-3-methyl-phenylethynyl]- benzoic acid, 4-[4-[l-(2,2-dimethylpropyloxy)-cyclopropyl]-3-methyl- phenylethynylj-benzoic acid and 4-[4-(l-ethoxycyclopropyl)-3-tgrt-butyl- phenylethynylj-benzoic acid or a salt with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
15. A method in accordance with Claim 9 wherein the compound is selected from the group consisting of {4- [4-(l -methoxy cyclopropyl) - phenylethynyl]-phenyl} -acetic acid, {4- [4-(l -isopropoxy cyclopropyl)- phenylethynyl]-phenyl} -acetic acid, {4- [4-(l -isopropoxy cyclopropyl)-3- methyl-phenylethynyl]-phenyl}-acetic acid, {4-[4-[l-(2,2- dimethylpropyloxy)-cyclopropyl]-3-methyl-phenylethynyl]-phenyl}-acetic acid, {4-[4-(l-benzyloxycyclopropyl)-3-ethyl-phenylethynyl]-phenyl}-acetic acid, {4-[4-(l-isopropoxycyclopropyl)-3-ethyl-phenylethynyl]-phenyl}-acetic acid and {4-[4-(l-ethoxycyclopropyl)-3-tgrt-butyl-phenylethynyl]-phenyl}- acetic acid or a salt with a pharmaceutically acceptable base or a C^ alkyl ester of said compound.
16. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound ofthe formula
Figure imgf000253_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 1 to 6 carbons, Cl, Br, or I;
Z is -C≡C-,
-(CR^CR^j.^ where n' is an integer having the value 1 - 5,
-CO-NRr,
NRrCO-,
-CO-0-,
-0-CO-,
-CS-NRr,
NRrCS-,
-CO-S-,
-S-CO-,
-N=N-; Rj is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 5; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
17. A method in accordance with Claim 16 wherein the compound has the formula
Figure imgf000254_0001
where R2 is H or halogen; n is 0 or 1 and R8 is H, alkyl of 1 to 6 carbons, or a cation of a pharmaceutically acceptable base.
18. A method in accordance with Claim 17 wherein the compound is [4-(2-cyclopropyl-4,4-dimethyl- 1 ,2,3 ,4-tetrahydro-isoquinolin-6-yl-ethynyl)- 2-fluoro-ρhenyl]-acetic acid or a salt with a pharmaceutically acceptable base.
19. A method in accordance with Claim 17 wherein the compound is [4-(2-cyclopropyl-4,4-dimethyl- 1 ,2,3,4-tetrahydro-isoquinolin-6-yl-ethynyl)- phenyl]-acetic acid or a salt with a pharmaceutically acceptable base.
20. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound ofthe formula
Figure imgf000255_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; Xj is 1 -imidazolyl, or lower alkyl or halogen substituted 1 -imidazolyl, OR, SR, NRRg where R is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I; Z is -C≡C-, -(CR^CRi)-.* where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; R6 is H, lower alkyl, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, with the proviso that when Y is H, A is phenyl and Xj is OH then n is 1 to 4.
21. A method in accordance with Claim 20 wherein the compound has the formula
Figure imgf000257_0001
wherein Xj is 1 -imidazolyl, or dialkyl-N or alkyl,cycloproρyl-N where the alkyl group has 1 to 6 carbons;
R2 is H or halogen; n is 0 or 1, and
R8 is H, alkyl of 1 to 6 carbons, or a cation of a pharmaceutically acceptable base.
22. A method in accordance with Claim 21 where the compound is selected from the group consisting of 4-[(5-cyclopropyl-methyl-amino)-8,8- dimethyl-5,6,7,8-tetrahydro-naphthalene-2yl-ethynyl]-benzoic acid and 4-[5- (cyclopropyl-methyl-amino)-8,8-dimethyl- 5,6,7,8-tetrahydro-naphthalene-2- yl-ethynyl]-2-fluoro benzoic acid or a salt with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
23. A method in accordance with Claim 21 where the compound is selected from the group consisting of 4-[(5-(cyclopropyl-methyl-amino)-8,8- dimethyl- 5,6,7,8-tetrahydro-naphthalene-2-yl-ethynyl)-ρhenyl]-acetic acid and [4-(5-(cycloρroρyl-methyl-amino)-8,8-dimethyl- 5 ,6,7,8-tetrahydro- naphthalene-2-yl-ethynyl)-2-fluoro-phenyl]-acetic acid or a salt with a pharmaceutically acceptable base or a Cj_6 alkyl ester of said compound.
24. A method in accordance with Claim 21 where the compound is 4- [5-(wc>-propyl-methyl-amino)-8,8-dimethyl-5,6,7,8-tetrahydro-naρhthalene-2- yl-ethynyl)]-benzoic acid or a salt with a pharmaceutically acceptable base or a C _6 alkyl ester of said compound.
25. A method in accordance with Claim 21 where the compound is [4- (5-imidazol-l-yl-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-ethynyl)- benzoic acid or a salt with a pharmaceutically acceptable base or a C _6 alkyl ester of said compound.
26. A method in accordance with Claim 21 where the compound is [4- (5-imidazol-l-yl-8,8-dimethyl-5,6,7,8-tetrahydro-naρhthalen-2-yl-ethynyl)- ρhenyl]-acetic acid or a salt with a pharmaceutically acceptable base or a Cμg alkyl ester of said compound.
27. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound ofthe formula
Figure imgf000258_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X is O, S or NR where R is H, alkyl of 1 to 6 carbons,
Figure imgf000258_0002
or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 o 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I; Z is -C≡C-, -(CR^CRj)-.. where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rx is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 3; R7 is H, alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons or lower alkyl substituted cycloalkyl of 1 to 6 carbons; n is an integer having the values of 1 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
28. A method in accordance with Claim 27 wherein the compound has the formula
Figure imgf000260_0001
wherein Y is branched-chain alkyl of 3 to 6 carbons; R2 is H or F;
R3 is branched-chain alkyl of 3 to 6 carbons; R7 is lower alkyl of 1 to 6 carbons, and
R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
29. A method in accordance with Claim 27 where the compound is selected from the group consisting of [4-(3,5-di-tgrt-butyl-4-methoxy- phenylethynyl)-phenyl]-acetic acid and [4-(3,5-di-tgrt-butyl-4-methoxy- phenylethynyl)-2-fluoro-phenyl]-acetic acid or a salt of said compound with a pharmaceutically acceptable base.
30. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound ofthe formula
Figure imgf000260_0002
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X2 is 1 -imidazolyl, lower alkyl or halogen substituted 1 -imidazolyl, OR7, SR7 or NRR7 where R is H, alkyl of 1 to 6 carbons or benzyl; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, Cl, Br, or I; Z is -C≡C-, -(CR^CRj)-.' where n' is an integer having the value 1 - 5, -CO-NR1 -, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRrCS-, -CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is alkyl of 1 to 6 carbons, F, Cl, Br, I, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 3 ; R7 is H, alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons or
Figure imgf000262_0001
n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
31. A method in accordance with Claim 30 where the compound has the formula
Figure imgf000262_0002
wherein R3 is alkyl of 1 to 6 carbons; X2 is 1 -imidazolyl, OR7, or NRR7 where R is alkyl of 1 to 6 carbons or cyclopropyl, and R7 is alkyl of 1 to 6 carbons, cyclopropyl or lower alkyl substituted cyclopropyl; n is O or l, and R8 is H, alkyl of 1 to 6 carbons, or a cation of a pharmaceutically acceptable base.
32. A method in accordance with Claim 31 wherein the compound is selected from the group consisting of 4-(4-imidazol-l-yl-methyl-3-methyl- phenylethynyl)-benzoic acid and [4-(4-imidazol-l-yl-methyl-3-isopropyl- phenylethynyl)-phenyl]-benzoic acid or a salt of said compound with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
33. A method in accordance with Claim 31 where the compound is selected from the group consisting of [4-(4-imidazol-l-yl-methyl-3-methyl- ρhenylethynyl)-ρhenyl]-acetic acid and [4-(4-imidazol- 1 -yl-methyl-3 - isopropyl-phenylethynyl)-phenyl]-acetic acid or a salt of said compound with a pharmaceutically acceptable base or a C^ alkyl ester of said compound.
34. A method in accordance with Claim 31 where the compound is selected from the group consisting of 4-{4-[(cycloproρyl-ethyl-amino)- methyl]-3-methyl-ρhenylethynyl} -benzoic and 4- {4-[(cycloρropyl-ethyl- amino)-methyl]-3-isopropyl-phenylethynyl}-benzoic acid or a salt of said compound with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
35. A method in accordance with Claim 31 where the compound is (4- {4-[(cyclopropyl-ethyl-amino)-methyl]-3-methyl-phenylethynyl}-phenyl)- acetic acid or a salt of said compound with a pharmaceutically acceptable base or a C1-6 alkyl ester of said compound.
36. A method in accordance with Claim 31 where the compound is {4- [3-isopropyl-4-(l-methyl-cyclopropoxymethyl)-phenylethynyl]-phenyl}-acetic acid or a salt of said compound with a pharmaceutically acceptable base or a C j „6 alkyl ester of said compound.
37. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal as effective dose of a pharmaceutical composition comprising a compound of the formula
Figure imgf000263_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; Y is H, alkyl of 1 to 10 carbons, benzyl, lower alkyl or halogen substituted benzyl, fluoro-substituted alkyl of 1 to 10 carbons, cycloalkyl of 3 to 6 carbons, lower alkyl substituted cycloalkyl of 3 to 6 carbons, F, Cl, Br, or I; Z is -C≡C-, -(CR1=CR1)n' where n' is an integer having the value 1 - 5, -CO-NRr, NRrCO-, -CO-0-, -0-CO-, -CS-NRr, NRj-CS-, -CO-S-, -S-CO-, -N=N-; Rj is independently H or alkyl of 1 to 6 carbons; p is an integer having the values of 0 to 5; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; n is an integer having the values of 0 to 4, and
R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
38. A method in accordance with Claim 37 where the compound has the formula
Figure imgf000265_0001
wherein R2 is hydrogen, alkyl of 1 to 6 carbons, or halogen n is 0 or 1 , and
R8 is H, alkyl of 1 to 6 carbons, or a cation of a pharmaceutically acceptable base.
39. A method in accordance with Claim 38 where the compound is 4- ( 1 -cycloproρyl-4,4-dimethyl- 1 ,2,3,4-tetrahydroquinolin-6-yl-ethynyl)-benzoic acid or a salt of said compound with a pharmaceutically acceptable base or a Cλ_6 alkyl ester of said compound.
40. A method in accordance with Claim 38 where the compound is [4-(l-cycloproρyl-4,4-dimethyl-l,2,3,4-tetrahydro-quinolin-6-yl- ethynyl)phenyl] acetic acid methyl ester.
41. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound ofthe formula
Figure imgf000266_0001
wherein A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R2 groups; X3 is S, or O, C(R1)2, or CO; Yj is H, lower alkyl of 1 to 3 carbons, cycloalkyl of 3 to 6 carbons, benzyl, lower alkyl substituted cycloalkyl of 3 to 6 carbons;
Z is -CsC-,
-(CR1=CR1)n> where n' is an integer having the value 1 - 5,
-CO-NRr,
NRrCO-,
-CO-0-,
-0-CO-,
-CS-NRr,
Figure imgf000266_0002
-CO-S-,
-S-CO-,
-N=N-; Rj is independently H or alkyl of 1 to 6 carbons; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; R3 is independently alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, alkylthio of 1 to 6 carbons or benzyl; m is an integer having the values 0 to 2; R4 is independently H, alkyl of 1 to 6 carbons, or F; fluorosubstituted alkyl of 1 to 6 carbons, or halogen; o is an integer having the values of 0 to 4; n is an integer having the values of 0 to 4, and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base, the compound meeting at least one ofthe provisos selected from the group consisting of: Yj is cycloalkyl, when Yj is not cycloalkyl then X3 is O or S and n is 1, when Yj is not cycloalkyl then X3 is CO, and n is 1 , when Yj is not cycloalkyl then X3 is CO and the moiety A is substituted with at least one F group.
42. A method in accordance with Claim 41 where the compound has the formula
Figure imgf000267_0001
wherein R2 is H or F; R3 is H or lower alkyl of 1 to 6 carbons; X3 is O or CO; Yx is H, alkyl of 1 to 6 carbons, or cyclopropyl; Z is -C≡C- or -CO-0-; n is 0 or l, and R8 is H, alkyl of 1 to 6 carbons, or a cation of a pharmaceutically acceptable base, the compound meeting at least one ofthe provisos selected from the group consisting of: Yx is cyclopropyl, when j is not cyclopropyl then X3 is O and n is 1 , when Yl is not cyclopropyl then X3 is CO, and n is 1, when x is not cyclopropyl then X3 is CO and the moiety A is substituted with at least one F group.
43. A method in accordance with Claim 42 where the compound is 2- fluoro-4-(8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro-naphthalen-2yl-ethynyl)- benzoic acid or a salt of said compound with a pharmaceutically acceptable base or a C^g alkyl ester of said compound.
44. A method in accordance with Claim 42 where the compound is selected from the group consisting of 4-[(8,8-dimethyl-5-oxo-5,6,7,8- tetrahydro-naphthalene-2-yl-ethynyl)-ρhenyl]-acetic acid and [2-fluoro-4- (8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro-naρhthalene-2-yl-ethynyl)ρhenyl]- acetic acid or a salt of said compound with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
45. A method in accordance with Claim 42 where the compound is 2- fluoro-4-(2,2,4,4-tetramethyl-chroman-6-yl-ethynyl)-benzoic acid or a salt of said compound with a pharmaceutically acceptable base or a C^ alkyl ester of said compound.
46. A method in accordance with Claim 42 where the compound is selected from the group consisting of [4-(2,2,4,4-tetramethyl-chroman-6-yl- ethynyl) phenyl] acetic acid, [2-fluoro-4-(2,2,4,4-tetramethyl-chroman-6-yl- ethynyl) phenyl] acetic acid and [4-(8-ethyl-2,2,4,4-teframethyl-chroman-6-yl- ethynyl) phenyl] acetic acid or a salt of said compound with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
47. A method in accordance with Claim 42 where the compound is 4- (8-cycloproρyl-2,2,4,4-tetramethyl-chroman-6-yl-ethynyl)-benzoic acid or a salt of said compound with a pharmaceutically acceptable base or a Cμ6 alkyl ester of said compound.
48. A method in accordance with Claim 42 where the compound is selected from the group consisting of [4-(8-cycloρroρyl-2,2,4,4-tetramethyl- chroman-6-yl-ethynyl) phenyl] acetic acid and [4-(8-cyclopropyl-2,2,4,4- tetramethyl-chroman-6-yl-ethynyl)-2-fluorophenyl] acetic acid or a salt of said compound with a pharmaceutically acceptable base or a C^ alkyl ester of said compound.
49. A method in accordance with Claim 42 where the compound is 8,8-dimethyl-5-oxo-5,6,7,8-tetrahydro-naphthalene-2 -carboxylic acid-4- (carboxymethyl)phenyl ester or a salt of said compound with a pharmaceutically acceptable base or a Cj_6 alkyl ester of said compound.
50. A method in accordance with Claim 42 where the compound is 2,2,4,4-tetramethyl-chroman-6-carboxylic acid 4-(carboxymethyl)phenyl ester or a salt of said compound with a pharmaceutically acceptable base or a Cι_6 alkyl ester of said compound.
51. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000270_0001
X5 is O, X6 is CH, n is 0 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; X5 is S, X6 is CH, n is 1 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C!.6-alkyl), or a cation of a pharmaceutically acceptable base; X5 is S, X6 is CH, n is 2 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; X5 is S, X6 is CH, n is 0 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; and X5 is S, X6 is N, n is 0 and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1. 6-alkyl), or a cation of a pharmaceutically acceptable base.
52. A method in accordance with Claim 51 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows: X5 is O, X6 is CH, n is 0 and R8 is H or a cation of a pharmaceutically acceptable base; Xs is S, X6 is CH, n is 1 and R8 is H or a cation of a pharmaceutically acceptable base; X5 is S, X6 is CH, n is 2 and R8 is H or a cation of a pharmaceutically acceptable base; X5 is S, X6 is CH, n is 0 and R8 is H or a cation of a pharmaceutically acceptable base; and X5 is S, X6 is N, n is 0 and R8 is H or a cation of a pharmaceutically acceptable base.
53. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound shown by the formula
Figure imgf000271_0001
wherein the variable R8 is H, alkyl of 1 to 6 carbons, -CH^Cμg- alkyl), or a cation of a pharmaceutically acceptable base.
54. A method in accordance with Claim 53 wherein in the formula of the compound R8 is H or a cation of a pharmaceutically acceptable base.
55. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000271_0002
R10 is CH3; Rπ is Cl, R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base;
R10 is CH3j Rn is cyclopropyl, R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH^Cμg-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3; Ru is CF3, R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3CH2, Rn is Br, R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3; Rπ is CH3> R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C!_6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3j Rπ is Cl, R12 is F, X6 is N and R8 is H, alkyl of 1 to 6 carbons, -CH20(Ci_6-alkyl), or a cation of a pharmaceutically acceptable base; Rj0 is CH3 Rπ is pheny^ R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CTL ^.g-alkyl), or a cation of a pharmaceutically acceptable base; R10 is H Rn is Br R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3j Rπ is OCH3; R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3) Ru is CH3> R12 is H, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3; Ru is Hj R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3> Ru is Br, R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3? Rn is CF3CF2, R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a phaπnaceutically acceptable base; R10 is CH3) Rn is CH3 CH2, R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C _6-alkyι), or a cation of a pharmaceutically acceptable base; R10 is CH3) Rn is tso-propyl R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C j.g-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3 Rπ is (l-methyl)cyclopropyl5 R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C}.6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3) Rn is
Figure imgf000273_0001
R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base; R10 is CH3) Rπ is (2,2-difluoro)cycloρropyl R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a phaπnaceutically acceptable base and R10 is CH3 Rπ is (cyclopropyl)methyl; R12 is F, X6 is CH and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
56. A method in accordance with Claim 55 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows: R10 is CH3> Rπ is Cl, Ri2 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3; Rn is cyclopropyl, R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3) Rn is CF3, R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3CH2, Rπ is Br, R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3) Rπ is CH3 R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3> Rπ is Cl, R12 is F, X6 is N and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3 Rn is phenyl, R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is H Rπ is Br R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3; Ru is OCH3) R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3> Ru is CH3 R12 is H, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3) Rπ is H R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3 Ru is Br R12 is F X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3> Rn is CF3CF2, R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3; Rπ is CH3 CH2, R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base; R10 is CH3> Rπ is iso-propyl, R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base;
R10 is CH3; RX1 is (l-methyl)cyclopropyl; R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base;
R10 is CH3) Ru is
Figure imgf000275_0001
R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base;
R10 is CH3 Rn is (2,2-difluoro)cyclopropyl5 R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base, and
R10 is CH3j Rπ is (cyclopropyl)methyl R12 is F, X6 is CH and R8 is H or a cation of a pharmaceutically acceptable base.
57. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000275_0002
R12 is H, the two R13 groups jointly represent an oxo (=0) function and R14 is CH3 and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base;
R12 is H, R13 is H, R14 is CH3 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base;
R12 is H, R13 is CH3> R14 is CH3 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R12 is H, R13 is CH3> R14 is H and R8 is H, alkyl of 1 to 6 carbons, - CH20(C μg-alkyl), or a cation of a pharmaceutically acceptable base; R12 is F, R13 is CH3> R14 is CH3 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, and Ri2 is H, one ofthe R13 groups is H, the other is OH, R14 is CH3 and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
58. A method in accordance with Claim 57 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows: R12 is H, the two R13 groups jointly represent an oxo (=0) function and R14 is CH3 and R8 is H or a cation of a pharmaceutically acceptable base; R12 is H, R13 is H, R14 is CH3 and R8 is H or a cation of a pharmaceutically acceptable base; R12 is H, R13 is CH3 R14 is CH3 and R8 is H or a cation of a pharmaceutically acceptable base; R12 is H, R13 is CH3> R14 is H and R8 is H or a cation of a pharmaceutically acceptable base; R12 is F, R13 is CH3) R14 is CH3 and R8 is H or a cation of a pharmaceutically acceptable base, and R12 is H, one ofthe R13 groups is H, the other is OH, R14 is CH3 and R8 is H or a cation of a pharmaceutically acceptable base.
59. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000277_0001
R12 is H, R15 is tgrttαry-butyl, R16 is OH, R17 is Cl and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R12 is H, R15 is tertiatγ-butyl, R16 is OCH3j R17 is tgrt αr -butyl and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R12 is H, R15 is 1-adamantyl, R16 is OCH3> R17 is H and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base; R12 is H, R15 is tertiary-butyl, R16 is OH, R17 is tertian-butyl and R8 is H, alkyl of 1 to 6 carbons, -CH20(Cμ6-alkyl), or a cation of a pharmaceutically acceptable base, and R12 is F, R15 is tertiary-butyl, R16 is OH, R17 is H and R8 is H, alkyl of 1 to 6 carbons, -CH^Cμg-alkyl), or a cation of a pharmaceutically acceptable base.
60. A method in accordance with Claim 59 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows: R12 is H, R15 is tgrtiαry-butyl, R16 is OH, R17 is Cl and R8 is H or a cation of a pharmaceutically acceptable base; R12 is H, R15 is tertiary-butyl, R16 is OCH3; R17 is tertiary-butyl and R8 is H or a cation of a pharmaceutically acceptable base; R12 is H, R15 is 1-adamantyl, R16 is OCH3; R17 is H and R8 is H or a cation of a pharmaceutically acceptable base;
R12 is H, R15 is tertiary-butyl, R16 is OH, R17 is tertiary-butyl and R8 is H or a cation of a pharmaceutically acceptable base, and
R12 is F, R15 is tertiary-butyl, R16 is OH, R17 is H and R8 is H or a cation of a pharmaceutically acceptable base.
61. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000278_0001
R12 is F, R15 is tgrttαry-butyl, R16 is CH3CH20, R17 is I and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, and
R12 is F, R15 is tertiary-butyl, R16 is CH3CH20, R17 is Br and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
62. A method in accordance with Claim 61 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows:
R12 is F, R15 is tertiary-butyl, R16 is CH3CH20, R17 is I and R8 is H or a cation of a pharmaceutically acceptable base, and R12 is F, R15 is tertiary-butyl, R16 is CH3CH20, R17 is Br and R8 is H or a cation of a pharmaceutically acceptable base.
63. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000279_0001
R12 is H, X6 is CH, X7 is (CH3)2C and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base; R12 is H, X6 is CH, X7 is CH2 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C 2 _6-alkyl), or a cation of a pharmaceutically acceptable base; R12 is H, X6 is CH, X7 is S and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1_6-alkyl), or a cation of a pharmaceutically acceptable base; R12 is F, X6 is CH, X7 is CH2 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C 2 _6-alkyl), or a cation of a pharmaceutically acceptable base, and R12 is H, X6 is N, X7 is CH2 and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
64. A method in accordance with Claim 63 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows: R12 is H, X6 is CH, X7 is (CH3)2C and R8 is H or a cation of a pharmaceutically acceptable base; R12 is H, X6 is CH, X7 is CH2 and R8 is H or a cation of a pharmaceutically acceptable base;
R12 is H, X6 is CH, X7 is S and R8 is H or a cation of a pharmaceutically acceptable base;
R12 is F, X6 is CH, X7 is CH2 and R8 is H or a cation of a pharmaceutically acceptable base, and
R12 is H, X6 is N, X7 is CH2 and R8 is H or a cation of a pharmaceutically acceptable base.
65. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound shown by the formula
wherein the variable R8 is H, alkyl of 1 to 6 carbons, -CH20(C _6- alkyl), or a cation of a pharmaceutically acceptable base.
66. A method in accordance with Claim 65 wherein in the formula of the compound R8 is H or a cation of a pharmaceutically acceptable base.
67. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound shown by the formula
Figure imgf000280_0002
wherein the variable R8 is H, alkyl of 1 to 6 carbons, -CH20(C1_6- alkyl), or a cation of a pharmaceutically acceptable base.
68. A method in accordance with Claim 67 wherein in the formula of the compound R8 is H or a cation of a pharmaceutically acceptable base.
69. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000281_0001
R12 is F, R18 is H, R19 is H and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base, and R12 is H, R18 is OH, R19 is F and R8 is H, alkyl of 1 to 6 carbons, - CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
70. A method in accordance with Claim 69 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows: R12 is F, R18 is H, R19 is H and R8 is H or a cation of a pharmaceutically acceptable base, and R12 is H, R18 is OH, R19 is F and R8 is H or a cation of a pharmaceutically acceptable base.
71. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound shown by the formula
Figure imgf000282_0001
wherein the variable R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6- alkyl), or a cation of a pharmaceutically acceptable base.
72. A method in accordance with Claim 71 wherein in the formula of the compound R8 is H or a cation of a pharmaceutically acceptable base.
73. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound shown by the formula
Figure imgf000282_0002
wherein the variable R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6- alkyl), or a cation of a pharmaceutically acceptable base.
74. A method in accordance with Claim 73 wherein in the formula of the compound R8 is H or a cation of a pharmaceutically acceptable base.
75. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound selected from the group of compounds wherein the variables for each compound are defined as follows with reference to the formula below:
Figure imgf000283_0001
R15 is 1-adamantyl, R16 is OH and R8 is H, alkyl of 1 to 6 carbons, - CH20(C!,6-alkyl), or a cation of a pharmaceutically acceptable base, and
R15 is 1-adamantyl, R16 is OCH3 and R8 is H, alkyl of 1 to 6 carbons, CH20(C1.6-alkyl), or a cation of a pharmaceutically acceptable base.
76. A method in accordance with Claim 75 wherein the compound is selected from the group of compounds wherein the variables for each compound are defined as follows:
R15 is 1-adamantyl, R16 is OH and R8 is H or a cation of a phaπnaceutically acceptable base, and
R15 is 1-adamantyl, R16 is OCH3 and R8 is H or a cation of a pharmaceutically acceptable base.
77. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound shown by the formula
Figure imgf000283_0002
wherein the variable R8 is H, alkyl of 1 to 6 carbons, -CH20(C1.6- alkyl), or a cation of a pharmaceutically acceptable base.
78. A method in accordance with Claim 77 wherein in the formula of the compound R8 is H or a cation of a pharmaceutically acceptable base.
79. A method of inhibiting the enzyme cytochrome P450RAI in a mammal by administering to said mammal an effective dose of a pharmaceutical composition comprising a compound shown by the formula
Figure imgf000284_0001
wherein the variable R8 is H, alkyl of 1 to 6 carbons, -CH20(C2_6- alkyl), or a cation of a pharmaceutically acceptable base.
80. A method in accordance with Claim 79 wherein in the formula of the compound R8 is H or a cation of a pharmaceutically acceptable base.
81. A method of providing a compound which is an inhibitor ofthe enzyme cytochrome P450RAI, the method comprising: identifying a compound that has activity as a retinoid in an art recognized assay which demonstrates retinoid-like activity, the retinoid compound having a formula such that it includes a benzoic acid, benzoic acid ester, naphthoic acid, naphthoic acid ester or heteroaryl carboxylic acid or ester moiety, with a partial structure of -A(R2)-(CH2)n-COOR8 where n is 0, A is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl, naphthyl and heteroaryl groups being optionally substituted with one or two R2 groups; R2 is independently H, alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons and R8 is H, alkyl of 1 to 6 carbons, -CH20(C1,6-alkyl), or a cation of a pharmaceutically acceptable base, and selecting a compound that is a homolog of the previously identified retinoid compound where in the formula ofthe homolog n is 1 or 2.
82. A method in accordance with Claim 81 wherein a homolog is selected where in the formula of the homolog n is 1.
83. A method in accordance with Claim 81 further comprising the step of synthesizing the selected homolog.
84. A method in accordance with Claim 83 wherein a homolog is synthesized where in the formula of the homolog n is 1.
85. A method in accordance with Claim 83 wherein the step of synthesizing the homolog utilizes a homologation procedure wherein a chain of a carboxylic acid or of carboxylic ester of the partial formula -A(R2)- (CH2)n-COOR8 is lengthened by adding one or two (CH2) units.
86. A method in accordance with Claim 85 wherein the step of synthesizing the homolog utilizes Arndt-Eistert method of synthesis.
87. A method in accordance with Claim 84 where the step of synthesizing the homolog includes a reaction with a reagent selected from the formulas
l
Figure imgf000285_0001
sCOOEt
Figure imgf000285_0002
PCT/US2001/025465 2000-09-28 2001-08-14 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai WO2002026727A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001286478A AU2001286478B2 (en) 2000-09-28 2001-08-14 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome P450RAI
JP2002531111A JP2004509955A (en) 2000-09-28 2001-08-14 Methods for providing and using compounds (retinoids) having activity as cytochrome P450 RAI inhibitors
EP01965927A EP1322631A2 (en) 2000-09-28 2001-08-14 Methods of providing and using compounds ( retinoids ) having activity as inhibitors of cytochrome p450rai
AU8647801A AU8647801A (en) 2000-09-28 2001-08-14 Methods of providing and using compounds having activity as inhibitors of cytochrome p450rai
CA002423919A CA2423919A1 (en) 2000-09-28 2001-08-14 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/672,751 2000-09-28
US09/672,751 US6313107B1 (en) 2000-08-29 2000-09-28 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI

Publications (2)

Publication Number Publication Date
WO2002026727A2 true WO2002026727A2 (en) 2002-04-04
WO2002026727A3 WO2002026727A3 (en) 2002-05-16

Family

ID=24699854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025465 WO2002026727A2 (en) 2000-09-28 2001-08-14 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai

Country Status (6)

Country Link
US (4) US6313107B1 (en)
EP (1) EP1322631A2 (en)
JP (1) JP2004509955A (en)
AU (2) AU2001286478B2 (en)
CA (1) CA2423919A1 (en)
WO (1) WO2002026727A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087219A1 (en) * 2004-03-10 2005-09-22 Research Foundation Itsuu Laboratory Memory fixation accelerator
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US8013001B2 (en) 2001-12-21 2011-09-06 Exelixis, Inc. Modulators of LXR

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642885B1 (en) * 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US6740676B2 (en) 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2004032848A2 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US6683092B1 (en) 2003-04-09 2004-01-27 Allergan, Inc. [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
EP1696899A1 (en) * 2003-12-17 2006-09-06 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
US7932366B2 (en) 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
JP2008523145A (en) * 2004-12-13 2008-07-03 イーライ リリー アンド カンパニー Spiro derivatives as lipoxygenase inhibitors
RU2007135224A (en) * 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) PGD2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATORY DISEASES
US7811261B2 (en) 2008-06-02 2010-10-12 Sta-Med, Llc Needle cover assembly for a syringe
JP2012503595A (en) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ Compounds for the treatment of metabolic diseases
US8162882B2 (en) 2010-06-23 2012-04-24 Sta-Med, Llc Automatic-locking safety needle covers and methods of use and manufacture
US20130310419A1 (en) 2011-02-03 2013-11-21 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
WO2012166746A1 (en) 2011-05-31 2012-12-06 Sta-Med, Llc Blood collection safety devices and methods of use and manufacture
EP2910549A1 (en) 2011-09-15 2015-08-26 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University 1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene derivatives useful as rxr modulators for treating alzheimer's disease and cancer
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
CN107176945B (en) * 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 Retinoid compound, preparation method, intermediate and application thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011755A1 (en) * 1991-12-18 1993-06-24 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US6252090B1 (en) * 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) * 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6303785B1 (en) * 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
WO2002018361A2 (en) * 2000-08-29 2002-03-07 Allergan, Inc. Compounds having activity as inhibitors of cytochrome p450rai

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
CH651034A5 (en) 1982-05-12 1985-08-30 Hoffmann La Roche CHROMAN, THIOCHROMAN OR 1,2,3,4-TETRAHYDROCHINOLIN DERIVATIVES AND THEIR USE AS MEDICINAL ACTIVE SUBSTANCES.
DK158947C (en) 1982-07-06 1991-01-21 Hoffmann La Roche TETRAHYDRONAPHTHALIN, BENZOFURAN AND BENZOTHIOPHENDER DERIVATIVES, PREPARATION AND USE THEREOF, AND RODENTICID CONTAINING SUCH DERIVATIVES
US4539154A (en) 1983-06-15 1985-09-03 Hoffmann-La Roche Inc. Polyene compounds
ATE38835T1 (en) 1983-07-05 1988-12-15 Pfizer CARBONIC ACID DERIVATIVES USEFUL IN PREVENTING DECOMPOSITION OF CARTILAGE.
WO1985000806A1 (en) 1983-08-08 1985-02-28 Sri International Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues
FR2562539B1 (en) 1984-04-06 1987-04-17 Chauvin Blache Lab NOVEL VINYL-4 BENZOIC ACID DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC APPLICATIONS THEREOF AND AS LIGANDS
US4826984A (en) 1984-04-09 1989-05-02 The Board Of Regents For The Oklahoma Agricultural And Mechanical College Acting For And On Behalf Of Oklahoma State University Heteroarotinoid compounds as anticancer agents
JPS6122046A (en) 1984-07-07 1986-01-30 Koichi Shiyudo Stilbene derivative
DE3580134D1 (en) 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem BENZOESAEUR DERIVATIVES.
LU85544A1 (en) 1984-09-19 1986-04-03 Cird AROMATIC HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE THERAPEUTIC AND COSMETIC FIELDS
DE3434946A1 (en) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen DIARYLACETYLENE, THEIR PRODUCTION AND USE
LU85849A1 (en) 1985-04-11 1986-11-05 Cird BENZONAPHTHALENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE PHARMACEUTICAL AND COSMETIC FIELDS
IL80270A0 (en) 1985-10-11 1987-01-30 Cird Naphthalene derivatives,their preparation and pharmaceutical compositions containing them
DE3602473A1 (en) 1986-01-28 1987-07-30 Basf Ag VINYLPHENOL DERIVATIVES, THEIR PRODUCTION AND USE
LU86351A1 (en) 1986-03-12 1987-11-11 Oreal BENZOPYRANNYL AND BENZOTHIOPYRANNYL BENZOIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN COSMETICS AND HUMAN AND VETERINARY MEDICINE
DE3615157A1 (en) 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-ARYLALKYL-4-ALKOXY-2 (5H) -FURANONE, INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS THERAPEUTIC ACTIVE SUBSTANCES
ZW6587A1 (en) 1986-05-13 1987-12-02 Hoffmann La Roche Tetrahydro naphthanline derivatives
ZW7487A1 (en) 1986-05-23 1987-12-16 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
ZW10287A1 (en) 1986-07-15 1988-01-13 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
FR2601670B1 (en) 1986-07-17 1988-10-07 Cird NOVEL AROMATIC BICYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS
US4739098A (en) 1986-09-22 1988-04-19 Allergan, Inc. Ethynylphenyl-containing retinoic acid derivatives
US4923884A (en) 1986-12-24 1990-05-08 Allergan, Inc. Ethynylheteroaromatic-acids having retinoic acid-like activity
US5149705A (en) 1987-03-13 1992-09-22 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5602130A (en) 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4810804A (en) 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
IL85896A (en) 1987-04-06 1993-01-14 Riker Laboratories Inc Substituted di-tert.- butylphenols and pharmaceutical compositions containing them
ZA885192B (en) 1987-08-19 1989-04-26 Hoffmann La Roche Pharmaceutical preparations
KR0139216B1 (en) 1988-04-11 1998-05-01 제임스 엠. 캐내지 Tetralin esters of phenols or benzoic acids having retinoic like activity
US5015658A (en) 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US4992468A (en) 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5399561A (en) 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5023341A (en) 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5013744B1 (en) 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
US5006550A (en) 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
US5202471A (en) 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
CA2080581A1 (en) 1990-04-16 1991-10-17 Alfred P. Spada Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
LU87821A1 (en) 1990-10-12 1992-05-25 Cird Galderma BI-AROMATIC COMPOUNDS, AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS
US5563292A (en) 1990-10-17 1996-10-08 Schering Corporation Lipoxygenase inhibitors
EP0571546B1 (en) 1991-02-13 1996-10-16 Allergan, Inc. Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity
US5134159A (en) 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
JP3157523B2 (en) 1991-03-26 2001-04-16 アラーガン、インコーポレイテッド Chromans and thiochromans having a heteroarylethynyl substituent at position 7 with retinoid-like biological activity
FR2676440B1 (en) 1991-05-15 1993-07-30 Cird Galderma NOVEL AROMATIC COMPOUNDS DERIVED FROM IMINE, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS.
CA2129831A1 (en) 1992-02-11 1993-08-19 Roshantha A. S. Chandraratna Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity
US5326898A (en) 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
EP0617020A1 (en) 1992-04-02 1994-09-28 Shudo, Koichi, Prof. Dr. Carboxylic acid derivatives having retinoic acid-like activity
JPH0672866A (en) 1992-07-02 1994-03-15 Chugoku Igakuka Gakuin Yakubutsu Kenkyusho Differentiation inducing agent
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
AU5664294A (en) 1993-01-11 1995-02-28 Ligand Pharmaceuticals, Inc. Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5426118A (en) 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
CA2138000A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
DE69510203T2 (en) 1994-08-10 1999-12-23 Hoffmann La Roche RETINOIC ACID X RECEPTOR LIGANDS
CA2208844A1 (en) * 1994-12-29 1996-07-11 Alan T. Johnson Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5534641A (en) 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5599967A (en) 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5559248A (en) 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5616712A (en) 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5688957A (en) 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US6063606A (en) * 1996-06-21 2000-05-16 Queen's University Kingston Retinoid metabolizing protein
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5723666A (en) 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US6048873A (en) 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6369225B1 (en) * 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) * 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6369261B1 (en) * 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en) * 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011755A1 (en) * 1991-12-18 1993-06-24 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US6252090B1 (en) * 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) * 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6303785B1 (en) * 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
WO2002018361A2 (en) * 2000-08-29 2002-03-07 Allergan, Inc. Compounds having activity as inhibitors of cytochrome p450rai

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LEO M A ET AL: "RETINOIC ACID METABOLISM BY A SYSTEM RECONSTITUTED WITH CYTOCHROME P-450" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 234, no. 1, 1 October 1984 (1984-10-01), pages 305-312, XP002040075 ISSN: 0003-9861 *
MARTINI R ET AL: "PARTICIPATION OF P450 3A ENZYMES IN RAT HEPATIC MICROSOMAL RETINOICACID 4-HYDROXYLATION" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 303, no. 1, 15 May 1993 (1993-05-15), pages 57-66, XP002040076 ISSN: 0003-9861 *
NJAR V C O ET AL: "Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 17, September 2000 (2000-09), pages 1905-1908, XP004214134 ISSN: 0960-894X *
TOMITA S ET AL: "CHARACTERISTIC PROPERTIES OF A RETINOIC ACID SYNTHETIC CYTOCHROME P-450 PURIFIED FROM LIVER MICROSOMES OF 3-METHYLCHOLANTHRENE- INDUCED RATS" BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1290, no. 3, 1996, pages 273-281, XP002040080 ISSN: 0006-3002 *
WHITE J A ET AL: "IDENTIFICATION OF THE RETINOIC ACID-INDUCIBLE ALL-TRANS-RETINOIC ACID 4-HYDROXYLASE" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 47, 22 November 1996 (1996-11-22), pages 29922-29927, XP002040079 ISSN: 0021-9258 *
WHITE JAY A ET AL: "Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 12, 6 June 2000 (2000-06-06), pages 6403-6408, XP002168088 ISSN: 0027-8424 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US8013001B2 (en) 2001-12-21 2011-09-06 Exelixis, Inc. Modulators of LXR
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7507754B2 (en) 2003-01-29 2009-03-24 Asterand Uk Limited EP4 receptor antagonists
US7528157B2 (en) 2003-01-29 2009-05-05 Asterand Uk Limited EP4 receptor antagonists
US7858644B2 (en) 2003-01-29 2010-12-28 Asterand Uk Limited EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists
US7569602B2 (en) 2003-10-16 2009-08-04 Asterand Uk Limited Furan derivatives as EP4 receptor antagonists
WO2005087219A1 (en) * 2004-03-10 2005-09-22 Research Foundation Itsuu Laboratory Memory fixation accelerator
US8198329B2 (en) 2004-03-10 2012-06-12 Research Foundation Itsuu Laboratory Memory consolidation promoting agent and method of use
US8431613B2 (en) 2004-03-10 2013-04-30 Research Foundation Itsuu Laboratory Memory fixation accelerator

Also Published As

Publication number Publication date
US6387892B1 (en) 2002-05-14
AU2001286478B2 (en) 2007-11-01
US6855512B2 (en) 2005-02-15
US6495552B2 (en) 2002-12-17
WO2002026727A3 (en) 2002-05-16
US20020132796A1 (en) 2002-09-19
US6313107B1 (en) 2001-11-06
CA2423919A1 (en) 2002-04-04
US20030078270A1 (en) 2003-04-24
AU8647801A (en) 2002-04-08
EP1322631A2 (en) 2003-07-02
JP2004509955A (en) 2004-04-02

Similar Documents

Publication Publication Date Title
US6495552B2 (en) Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
AU2001286478A1 (en) Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome P450RAI
EP1366036B1 (en) Compounds having activity as inhibitors of cytochrome p450rai
AU2001286471A1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6359135B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6303785B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6369261B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US7351737B2 (en) 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
US6603019B2 (en) 1-imidazolyl substituted tetrahydronaphthalene derivatives as inhibitors of eytochrome P450RAI
US6369225B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US20040077721A1 (en) Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
AU2006249248A1 (en) Pharmaceutical compositions having activity as inhibitors of cytochrome P450RAI

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2423919

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001965927

Country of ref document: EP

Ref document number: 2001286478

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002531111

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001965927

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2001286478

Country of ref document: AU

Date of ref document: 20010814

Kind code of ref document: B